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Abstract 
 
Type 1 diabetes mellitus (T1DM) is characterised by an increased risk of cardiovascular 
disease (CVD). Metformin has been shown to have cardio-protective properties in type 
2 diabetes. We aimed to determine if the cardio-protective effect of metformin is 
mediated by modulating circulatory biomarkers in T1DM whilst maintaining unchanged 
glycemic control. 
 
Twenty-three T1DM patients without overt CVD were treated with metformin for eight 
weeks (treatment group-TG). They were matched with nine T1DM patients on standard 
treatment (SG) and twenty-three age- and sex-matched healthy volunteers (HC). 
Insulin dose was adjusted to keep unchanged glycaemic control in TG. We evaluated 
endothelial progenitor cells (cEPCs-CD45dimCD34+VEGFR2+), circulatory endothelial 
cells (cECs-CD45dimCD133−CD34+CD144+), , microRNAs (miR), cytokines (all groups), 
microparticles (MP) and peripheral mononuclear cells (PBMC) (except SG). 
 
 
At baseline, TG had lower cEPCs, Pro-angiogenic cells (PACs), (Colony forming Unit) 
CFU-Hills’ colonies, and PACs adhesion and higher cECs, Endothelial-MPs(EMP-
AnnexinV+CD31+CD41-) and Platelet-MPs (PMP-AnnexinV+CD31+CD41+) versus HC. 
Metformin improved cEPCs, PACs, CFU-Hills’ colonies, cECs number and PACs 
adhesion in TG to levels seen in HC whilst EMPs and PMPs levels did not change. 
 
 
miR-21, miR-222, miR-195, miR-210, miR-223 and miR-320 levels were higher in TG 
when compared to HC. In TG, miR-21, miR-222, miR-195 and miR-210 levels reduced 
significantly after metformin treatment. Inflammatory cytokines and tissue inhibitors of 
metalloproteinase-1 (TIMP-1) were higher in T1DM when compared to HC. Vascular 
injury markers were not raised in T1DM when compared to HC. After metformin 
treatment, TIMP-1, IL-6 and thrombomodulin levels reduced significantly. 
 
 
In TG, metformin treatment significantly modulated eleven genes in PBMC. These 
genes were involved in MAP signalling kinase pathway, inflammatory response, cell 
movement, death, signalling and survival. 
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We have demonstrated that metformin can potentially shift the balance towards 
vascular repair. This can be mediated via improvement in EPC mobilisation, survival, 
inflammatory status and proangiogenic miRs. independent of metformin’s glucose 
lowering effect. However further long-term cardiovascular outcome studies in T1DM 
are still required. 
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1.1 Diabetes mellitus  
 
Diabetes mellitus (DM) is one of the most common metabolic syndromes characterised 
by hyperglycaemia (Nathan et al., 1997). In addition to disturbance in glucose 
metabolism, protein and fat metabolism is affected. The main pathological abnormality 
is either reduced insulin secretion or decreased insulin sensitivity. The metabolic 
disturbance observed in diabetes results in the development of long term complications 
(Alberti et al., 2004). Of major concern is that the burden of disease is increasing. It 
was estimated that, in 2015, approximately 415 million people of the world population 
have diabetes mellitus. This is estimated to increase to 642 million by the year 2030 
(DiabetesUK, 2015). The prevalence of diabetes among adults in England in 2011 was 
6 % and the cost to the National Health Service (NHS) in 2015 was £10 billion 
(DiabetesUK, 2016). 
 
Common symptoms at presentation are related to hyperglycaemia. Patients usually 
present with classical symptoms, including polyuria, polydipsia and weight loss despite 
increased appetite and tiredness (Kasper et al. 2008). Current diagnostic criteria for 
diabetes mellitus are based on World Health Organisation (WHO)/ International 
Diabetes Federation (IDF) (2006) criteria: “fasting plasma glucose ≥ 7.0mmol/l and/or 
2–h plasma glucose ≥ 11.1mmol/l”. 
 
Depending on the pathogenesis DM can be classified into different categories. Two 
major classifications are type 1 DM (T1DM) and type 2 DM (T2DM) 
(AmericanDiabetesAssociation, 2010). T2DM is characterised by insulin resistance 
and abnormal glucose metabolism. T2DM is more prevalent, and the current epidemic 
is putting the NHS under huge pressure. By contrast, T1DM by recent estimates 
accounts for 10% and 15% of all cases of diabetes mellitus. However, it presents 
earlier than T2DM. This results in patients having a metabolic abnormality for a longer 
duration of time.  This results in serious consequence in both short and long terms 
(Daneman, 2006). 
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1.1.1 Type 1 diabetes mellitus 
 
T1DM is characterised by the absolute lack of insulin due to pancreatic β-cell 
destruction. There are two types of T1DM: Type 1A, which is associated with 
autoimmune destruction of pancreatic β-cells and Type 1B, which is idiopathic in origin. 
However, both have a similar problem of insulin deficiency. The pathogenesis of T1DM 
is multifactorial. In addition to genetic susceptibility, exposure to environmental factors, 
triggers an immune response in the at risk individual, resulting in the destruction of 
pancreatic β-cells (Kasper DL, 2008). There is a gradual decline in β-cell numbers. 
However, most patients only become symptomatic when there is depletion of 
pancreatic β-cells by 80% (Kasper DL, 2008).  
 
1.1.1.1 Epidemiology of type 1 diabetes 
 
T1DM usually occurs in young individuals. Around 50-60% of the patients are younger 
than 16-18 years old at the time of the onset of disease (Devendra et al., 2004). It 
appears that there are two peaks of presentation of T1DM: one between the ages of 5 
to 7 years old and a second at or near puberty (Harjutsalo et al., 2008). It is one of most 
the common chronic diseases in children (Karvonen et al., 2000). Incidence of T1DM 
is much lower in adults. Approximately 25% of diagnosis of T1DM is made in adults 
(Haller et al., 2005). Around 5 to 10% of adults with T2DM diagnosis are found to have 
T1DM (Palmer et al., 2005). Patients present with short duration of symptoms between 
3 to 4 weeks and 7 to 8 weeks for children and adults respectively.   Most of the patients 
usually present with the classical symptoms described above. However, few patients 
have diabetic ketoacidosis at the first presentation (Devendra et al., 2004).  
 
The incidence of T1DM is higher during autumn and winters (Moltchanova et al., 2009). 
Both genders are affected equally by T1DM (Soltesz et al., 2007). However, there are 
reports suggesting that more males are affected as adults than females, especially in 
European populations (Gale, 2001; Kyvik et al., 2004). In areas of high incidence of 
T1DM, more males appear to be diagnosed with T1DM. Whereas, in areas of lower 
incidence more females are affected by T1DM (Karvonen et al., 1998).  
The worldwide incidence of T1DM is roughly 2-5% (Onkamo et al., 2000; DIAMOND 
Project Group, 2006; Patterson et al., 2009). In the United Kingdom, approximately 20 
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in 100000 people present with T1DM per year (Karvonen et al., 2000). The UK has the 
fifth highest incidence of type 1 diabetes under the age of 14 years (28.2 per 100,0000) 
(IDF Atlas, 2015). The incidence of T1DM varies considerably depending on 
geographical location (Figure 1). The incidence increases as we move north of the 
equator (Karvonen et al., 2000). Scandinavian countries having the highest incidence 
of T1DM. India, China and Venezuela has the lowest incidence in the world (0.1 per 
100000) (Maahs et al., 2010). It is particularly of concern that the age of presentation 
of T1DM is decreasing (Dahlquist and Mustonen, 2000). Finland has an annual rise in 
the incidence of T1DM of 2.4%, whereas Sweden and Norway have risen in the 
incidence of 3.3% (Patterson et al., 2009).  
 
 
 
 
 
Figure 1: Incidence of T1DM under 15 years old per 100000 children per year (2015).  
(IDF Atlas, 2015) 
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1.1.1.2 Natural history of type 1 diabetes 
 
The pathophysiology of T1DM includes a combination of genetic, environmental and 
immunological factors acting synergistically leading to destruction of pancreatic β cells. 
At birth, individuals at risk of developing T1DM have normal pancreatic β cell function 
and mass. Exposure to environmental trigger in a genetically susceptible individual will 
lead to the development of autoimmune response against pancreatic β cells. 
Immunological markers are present in individuals before clinical development in T1DM. 
There is a loss of pancreatic β cells. The rate of loss is variable depending on many 
factors. Clinical symptoms of diabetes develop when there is a loss of ~80% of 
pancreatic β cells. Recent studies have suggested that in some individual symptoms 
may develop with loss of 40 to 50% of β cells (Akirav et al., 2008). In some individuals, 
pancreatic β cell function persists for a prolonged period. (Figure 2).  
 
 
Figure 2: Pathogenesis of T1DM. Adapted from (Atkinson, 2012) 
 
T1DM does not follow any specific inheritance pattern. There is a 2% risk of developing 
T1DM in children with T1DM mothers, whereas children of T1DM fathers have a risk 
of 7% (Redondo et al., 2001). 83% of newly diagnosed T1DM do not have any family 
history of T1DM. The background risk of becoming T1DM in the general population is 
around 1 in 300. This is increased to one in twenty for individuals with first degree 
relatives of T1DM (Redondo et al 2001). The concordance rate for monozygotic twins 
is around 30-50%. For diazygotic twins, this is reduced to around 6 to 10% (Atkinson, 
2012). 
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1.1.1.3  Cardiovascular complication in diabetes  
 
Cardiovascular disease (CVD) remains the main cause of mortality and morbidity in 
patients with diabetes despite controlling for traditional factors such as hypertension, 
smoking, and hypercholesterolemia (Kannel and McGee, 1979; Stamler et al., 1993). 
DM is linked with 24000 more deaths each year, and up to half of these are due to CVD 
(The Health and Social Care Information Centre 2011). The rates of CVD are 3-5 fold 
higher with T1DM patients than in the general population. In addition, poorer outcomes 
in diabetes have been observed for treatment of acute coronary syndromes (ACS) and 
coronary revascularisation (Malmberg et al., 2000; Lloyd-Jones et al., 2003; Gurm et 
al., 2004; Pell et al., 2004). Furthermore, data has shown that patients with diabetes on 
standard treatment for secondary prevention have significantly worse outcome when 
compared to non-diabetic individuals ('Collaborative meta-analysis of randomised trials 
of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high 
risk patients,' 2002).  
 
There is ample evidence from population based studies that there is an increased risk 
of CVD and mortality in T1DM. Roy et al. (2012) showed CVD rate of 15.5% over 6 
year follow up in T1DM (Roy et al., 2012). Waden et al. (2009) showed CVD rate of 
8.6% over 5.7 years in T1DM (Wadén et al., 2009).  The reason for high CVD rate in 
Roy et al. (2012) could be due to a very high HbA1c of 13.5% (vs 8% in Waden et al. 
2009). In a large UK population based trial, it was demonstrated that patients with 
T1DM were more likely to develop acute coronary heart disease (CHD) when compared 
to healthy controls (HR in males and female was 3 and 7.6 respectively).. Overall, it is 
estimated that CVD events will occur 10 to 15 years earlier in T1DM individual when 
compared to non-diabetic individuals (Soedamah-Muthu et al., 2006). Incidence rate of 
CHD in T1DM varies between 2.1% to 19% (Schram et al., 2003a; Conway et al., 2009). 
On average, the incidence of CHD is around 15% over 15 years period (de Ferranti et 
al., 2014). The mortality rate from CHD has been reported to be high as well. Conway 
et al. (2009) demonstrated a fatal CHD rate of 8.39 over 15 year follow up. Shankar et 
al. (2007) and Stettler et al. (2006) showed a CHD mortality rate of 15% and 17% 
respectively after more than 10 years follow up (Stettler et al., 2006; Shankar et al., 
2007). Mortality from CHD is higher in males than females and in patients of age more 
than 40 years (Liang et al 2013).  
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Incidence of CVA is lower than IHD in T1DM. The rate of CVA in T1DM varies between 
0.3% to 0.74% (background population rate of 0.2 to 0.3%-(Schram et al., 2003a; Klein 
et al., 2004; Roger et al., 2012). Peripheral vascular disease is a very common 
complication in T1DM. Moss et al. (1999) demonstrated that the incidence of lower limb 
amputation was 7.2% (Moss et al., 1999). In Swedish population based study, it was 
observed that the probability of lower limb amputation was 20% in males and 11% in 
females in patients with T1DM who areolder than 65 years. Patients with T1DM are 86 
times more likely to undergo amputations when compared to the background 
population (Jonasson et al., 2008).  
 
The patients with T1DM have been shown to develop CVD much earlier than non-
diabetic population (Figure 3). CVD usually develops within around two decades of 
diagnosis of T1DM. This could then occur potentially when the patients are in their 30s 
if they were diagnosed with T1DM in early teens (de Ferranti et al., 2014). CVD has 
been shown to be a major cause of mortality in T1DM after 20 years of diagnosis. This 
occurs at a rate of 3% per year (Secrest et al., 2010). The life expectancy of adults at 
the age of 20 with type 1 diabetes is reduced by up to 13 years with CVD being the 
leading cause of premature death (Livingstone et al., 2015). 
 
It has been shown that young patients (mean age of 25 years) with T1DM without any 
co-morbidities including macrovascular disease or microalbuminuria, show features of 
early cardiovascular disease, such as increased carotid intima media thickness (CIMT) 
and endothelial dysfunction as compared with age matched healthy controls (Sibal et 
al., 2009a). Other studies have also demonstrated increased CIMT in T1DM when 
compared to healthy volunteers (Yamasaki et al., 1994; Järvisalo et al., 2002; Dalla 
Pozza et al., 2007; Margeirsdottir et al., 2010). Similarly, T1DM is associated with 
coronary artery calcifications (Dabelea et al., 2003). All these are makers of early 
atherosclerosis.  Angiographic evidence suggests that T1DM patients have increased 
coronary artery burden than non-diabetic population (Valsania et al., 1991). This could 
be 4-fold higher (Pajunen et al., 2000).  
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Figure 3:10-year CVD risk in T1DM according to age and gender compared to non-diabetic 
individuals. Adapted from (Soedamah-Muthu et al., 2006) 
 
1.1.1.4 Management of T1DM 
 
The primary aim of the management of T1DM is to improve glycaemic control (HbA1c 
<7). This is achieved by insulin replacement and structured education of the patient 
e.g. DAFNE (Dose Adjustment for Normal Eating). The availability of structured 
education programme is still limited to the small number of patients with T1DM. 
However, there is a drive to increase the availability of education to all T1DM. Insulin 
pump therapy, which delivers insulin as a constant infusion, is also now available, but 
its use in the United Kingdom is below the recommended level.  
 
The benefits of good glycaemic control are well documented. The Diabetes Control and 
Complications Trial (DCCT) (between 1982–1993) and Epidemiology of Diabetes 
Interventions and Complications (EDIC) (between 1994-2006) have both shown 
benefits of intensive diabetes control. This (DCCT, 1986) was a landmark, multi-centre 
randomised control trial (RCT) which compared intensive diabetes control with 
conventional control in T1DM patients. It showed that diabetes-related complications 
are reduced by as much as 76% (DCCT, 1993). EDIC is a post randomisation study of 
DCCT (EDIC, 1999a). It showed that good glycaemic control has long term benefits. 
There was 42% risk reduction in all cause cardiovascular outcomes (myocardial 
infarction, cardiac catheterisation, etc.) (EDIC, 1999b). It also demonstrated that the 
intensively treated group had slower progression of atherosclerosis markers (Nathan 
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et al., 2003) (carotid intima-medial wall thickness progressed slowly and less coronary 
calcification). A 1% increment in HbA1c has been shown to be associated with an 
increase (6.4%) in coronary artery stenosis (Larsen et al., 2002). In a large Swedish 
observation study, it has been shown that a 1% increase in HbA1c was associated with 
an increase in the risk of CVD (approximately 30% increase) (Eeg-Olofsson et al., 
2010).  
 
Based on these studies, good glycaemic control is defined as HbA1c of ≤ 7% (53 
mmol/mol). However, in clinical practice this has been difficult to achieve. The national 
paediatric audit (2012) showed that only 16% of patients under the age of 25 year 
achieved HbA1c of 7.5% (58 mmol/mol).  Median reported HbA1c in Europe and 
Australia is around 8.5% (Pambianco et al., 2007; Saunders et al., 2008; Donovan and 
McIntyre, 2010). In EDIC, mean HbA1c was around 8% (63 mmol/mol) (EDIC, 2003; 
Nathan DM, 2005). If glucose levels are tightly controlled than there is an increased 
incidence of hypoglycaemia (DCCT: 2.50 – 3 times more common in the intensive 
group) (DCCT, 1991). A major barrier against achieving good glycaemic control is fear 
of hypoglycaemia. The recent work by the EURODIAB Prospective Complications 
Study has demonstrated a U-shaped association between the all-cause mortality and 
HbA1c (Figure 4). That is, the all-cause mortality is highest at low (5.6%; 37.7mmol/L) 
and high (11.8%; 105.5mmol/mol) HbA1c (Schoenaker et al., 2014). Even with good 
glycaemic control the CVD risk remains more than twice that of non-diabetic individuals 
(Figure 5)(Lind et al., 2014; Snell-Bergeon and Maahs, 2015). 
 
Based on all the available evidence, additional strategies need to be developed to 
reduce the CV risk in T1DM without causing significant hypoglycaemia. 
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Figure 4: Association between HbA1c and all-cause mortality risk in T1DM patients. 
‘Restricted cubic spline regression with three knots located at the fifth, 50th, and 95th percentiles 
(HbA1c 5.6%, 8.1%, and 11.8%). The y-axis represents adjusted HRs for all-cause mortality for any 
value of HbA1c compared with a reference HbA1c of 8.1%. HRs are adjusted for age and sex (P for 
overall effect of HbA1c = .008; P for nonlinearity = .03). Dashed lines indicate 95% CIs.’  
(Schoenaker et al., 2014) 
 
 
 
 
Figure 5: Elevated risk of mortality in type 1 diabetes mellitus 
(Snell-Bergeon and Maahs, 2015) 
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1.2 Circulatory markers of vascular repair and damage in diabetes mellitus 
 
The endothelium and its functions play a major role in the maintenance of vascular 
homeostasis. Damage to the endothelium and subsequent impairment of endothelial 
function is key to the early development of vascular disease and atherosclerosis. 
Vascular homeostasis is maintained by a fine balance between vascular repair and 
damage. Advancement in research has identified circulatory biomarkers which play a 
critical role in the maintenance of a balance of repair and damage. The circulatory 
biomarkers of vascular damage and repair are endothelial progenitor cells (EPCs), 
circulatory endothelial cells (cECs), microparticles (MPs), microRNA (miRNA) and 
cytokines.  
 
These markers are discussed briefly in this section and in more details in Chapter 4, 
Chapter 5, Chapter 6 and Chapter 7.  
 
1.2.1 Endothelial progenitor cells 
 
In response to vascular damage, vascular repair is promoted by local endothelial cells 
and bone-marrow derived cells, called endothelial progenitor cells (EPCs). EPCs were 
first described in 1997 (Asahara et al., 1997). These cells have the ability to home in 
on the site of vascular injury, proliferate and contribute to endothelial repair (Urbich 
and Dimmeler, 2004a), thereby maintaining endothelial health. 
Circulatory endothelial progenitor cells (cEPCs) are a heterogeneous population of 
cells characterised by the expression of surface antigen CD34+, VEGFR-2+ and/or 
CD133+ identified by flow cytometry. CD34+ and CD133+ are haematopoietic stem 
cell markers (Timmermans et al., 2009; Yoder, 2012). VEGFR-2 is a surface marker of 
endothelial lineage. Progenitor cells undergo various stages of maturation. The CD133 
marker is lost as cEPCs mature. Thus, more mature cEPCs are positive for CD34 and 
VEGFR-2 (Hristov et al., 2003). VEGFR-2 plays an important role in angiogenesis by 
promoting endothelial cell growth and cell permeability (Collet et al., 2014). cEPC 
levels are reduced in T1DM.  
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Proangiogenic cells (PACs), previously known as early EPCs are the cultured 
peripheral blood mononuclear cells (PBMNC) whereas colonies derived from replated 
PBMNC are known as colony-forming units (CFU-Hill’s colonies) (Hill et al., 2003a). 
PACs and CFU-Hill’s colonies are reduced in both type 1 and type 2 diabetes. 
1.2.2 Circulatory Endothelial Cells 
 
Vascular damage results in the release of circulatory endothelial cells (cECs) from the 
vascular intima. cECs are mature endothelial cells characterised by presence of 
endothelial cell surface markers like CD144 and absence of haematopoietic (e.g. 
CD45) and progenitor cell markers (e.g. CD133). CD144 is important for maintaining 
endothelium integrity through cell-to-cell adhesion (Goon et al., 2006). 
cECs are formed through detachment from vascular intima due to irreversible loss of 
integrity as a response to endothelial activation by mechanical stress, inflammatory 
cytokines, growth factors, infectious agents, lipoprotein, and oxidative stress (Goon et 
al., 2006; Burger and Touyz, 2012). cECs are elevated in type 1 and type 2 diabetes 
(McClung et al., 2005; Asicioglu et al., 2010). The cEC count (a marker of vascular 
damage) is directly related to HbA1c in type 1 diabetes (Asicioglu et al., 2010). 
1.2.3 Microparticle 
 
Microparticles (MPs) are submicron (0.1-1 micron) fragments which are released by 
cells (endothelial cells, platelets, leukocytes etc.), either through activation or apoptosis 
in response to various stimuli (Jimenez et al., 2003).  MPs are identified by surface 
antigens on their bilayer membrane which they inherit from the cells they originate from 
(for example; endothelial microparticles (EMPs) are characterised by the presence of 
CD144, CD62e, CD146, CD51 and CD31). In addition, they also have 
phosphatidylserine on the outer leaflet of the bilayer membrane (Piccin et al., 2006).  
MPs are present in small numbers in healthy controls (Berckmans et al., 2001). 
However, levels of circulatory MPs increase in patients with CVD risk factors including 
diabetes mellitus. Levels of MP phenotypes have been shown to be altered in both, 
type 1 and type 2 diabetes (Dignat-George et al., 2002; Salem et al., 2015). This will 
be discussed further in Chapter 4.  
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It is hypothesised that altered glucose levels in diabetes leads to generation of reactive 
oxygen species and lipid peroxidation. This mechanism plays a role in the generation 
of MPs (Curtis et al., 2010). MPs are not only a biomarker of vascular damage but also 
plays a vital role in cell-to-cell communication (Trummer et al., 2013). Cell-to-cell 
communication can be carried by MPs via membrane or cytoplasmic protein or nuclear 
material like miRNA (Lozito and Tuan, 2014).  
 
1.2.4 MicroRNA 
 
MicroRNA (miRNA) is a family of small highly conserved endogenous non-coding 
single-stranded RNA that is produced in every animal and plant cells (Ambros, 2004; 
David et al., 2004). They are approximately 22 (19-24) nucleotides in length (David et 
al., 2004; Bhaskaran and Mohan, 2014). They play a significant role in the regulating 
post-transcriptional gene expression. miRNA binds the complementary target on 
messenger RNA leading to their degradation on inhibition of transcription. This results 
in dysregulation of subsequent protein production. However, the exact mechanism is 
unknown (Bhaskaran and Mohan, 2014).  miRNAs are thought to regulate 
approximately 30% of mRNA (Filipowicz et al., 2008).  
 
With advances in the miRNA field, we are now able to detect miRNA in plasma (Mitchell 
et al., 2008). The role of miRNA in diabetes has been acknowledged recently. miRNA 
has been recognised as a potential marker to predict the future development of 
diabetes mellitus (Zampetaki et al., 2010). Various studies have shown that miRNA 
levels are altered in patients with diabetes. Therefore, there is immense potential in 
exploring the role of miRNA in developing complications related to diabetes mellitus. 
Furthermore, new treatments could be developed which can target specific miRNA to 
reduce the development of diabetes related complications. The MERIT Study is novel 
as we explored the effect of metformin on selected miRNAs linked with the 
development of CVD.  
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1.2.5 Cytokines and peripheral blood mononuclear cell  
 
Cytokines are small glycoproteins that are released by endothelial cells and circulatory 
cells like peripheral blood mononuclear cells (PBMCs) (Kofler et al., 2004). PBMCs 
play an important role in the maintenance of inflammatory signals and the development 
of vascular damage and atherosclerosis (Moore and Tabas, 2011; Hedrick, 2015).  
Cytokines are involved in many physiological and pathological functions including 
immunity (innate and/or acquired) (Dinarello). They also play an important role in 
generating an inflammatory response leading to vascular damage or repair (Ait-Oufella 
et al., 2011). Each cytokine has an important role in the process of vascular 
homeostasis. For example, IL-6, IL-8 and TNF-α are potent inflammatory cytokines, 
whereas IL-10 is a potent anti-inflammatory cytokine (Han and Boisvert, 2014). Chronic 
inflammatory response in diabetes plays an important role in the development of 
diabetes related complication. Inflammatory cytokines act on the endothelium, leading 
to the activation and generation of adhesion molecules, E-Selectin, ICAM-1 and 
VCAM-1 (Wang and Huo, 2010). Inflammatory cytokines and adhesion molecules 
initiate an interaction between leukocytes and the endothelium, leading to development 
of vascular dysfunction and atherosclerosis in diabetes (Weber et al., 2007). bFGF and 
VEGF plays an important role in vascular repairs (Lindner et al., 1991). However, an 
exaggerated response in diabetes leads to the development of proliferative retinopathy 
(Alon et al., 1995).  
 
Circulatory cytokines, growth factors and adhesion molecule levels have been studied 
in both, type 1 and type 2 diabetes. Levels of these markers have been shown to 
predict the onset and progression of diabetes related complication. This is further 
discussed in chapter 6.  
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1.3 Metformin 
 
Metformin is the most commonly used oral drug for the treatment of T2DM. It has 
become the first line oral therapy as per major guidelines for treatment of T2DM 
(American Diabetes Association (ADA), European Association for the Study of 
Diabetes (EASD) and National Institute for Health and Clinical Excellence (NICE) 
2008). Metformin is currently the only biguanide used in clinical practice (Kaztung et al 
2007 p-741).  
 
The active component of metformin is guanidine, a compound that has been in use for 
centuries to treat “intense urination” (Witters, 2001). Guanidine is extracted from a 
plant called Galega officinalis (French Lilac) (Figure 6). Metformin was created by 
Sterne and colleague in mid 1950s and found to have glucose lowering effect, but 
needs a pancreas for its action (Sterne, 1957). At the same time, (Ungar et al., 1957) 
discovered a more potent biguanide called phenformin.  The usual effective dose of 
phenformin is 20 times lower than metformin (100mg vs 2000mg). However, 
phenformin was reported to cause lactic acidosis and increased cardiovascular 
mortality in type 2 diabetes patients (Walker and Linton, 1959). This resulted in 
biguanide falling out of favour. However, the less potent biguanide, metformin gained 
acceptance among clinicians in Europe. With time, it was clear that metformin-induced 
acidosis occurred at a very low frequency. In 1995, metformin was approved by the 
Food and Drug Administration (FDA) for use in the United States. In 1998, metformin 
was shown to have cardio-protective effect in individuals with type 2 diabetes (UKPDS, 
1998). Since then metformin has become an integral part of the management of T2DM.  
 
1.3.1 Structure of biguanide 
 
Three biguanides have been discovered so far; metformin, phenformin and Buformin 
(Bridges et al., 2014) (Figure 7). Biguanide contains two linked guanidine (Pernicova 
and Korbonits, 2014). Metformin has two methyl groups attached to the guanidine side 
chain. Phenformin has a loss of an ammonia group from the two guanidine linked 
groups. In addition, phenformin contains a phenyl-ethyl ring attached to the guanidine 
side chain (Pernicova and Korbonits, 2014).  In Buformin, butyl ring is attached to the 
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guanidine side chain (Bailey and Day, 2004). Buformin and phenformin are not used 
in clinical practice due to an increased risk of lactic acidosis (Schafer, 1983).  
 
 
 
Figure 6: Galega officinalis (French Lilac). 
Picture taken from Flore-bis. 
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Figure 7: Structure of metformin, phenformin and Buformin. 
 
Adapted from (Holleman, 2014) 
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1.3.2 Pharmacokinetic profile of metformin 
 
Metformin is entirely absorbed via the small intestine. The stomach and large intestine 
are not involved in metformin absorption. Bioavailability of metformin is approximately 
40-60%. Absorption of metformin finishes at about 6-10 hours after oral administration 
(Scheen, 1996). The rate of absorption or bioavailability does not increase with an 
increasing dose of metformin. There is an inverse correlation between metformin dose 
and absorption (Scheen, 1996). In circulation, metformin does not bind to plasma 
protein (Papanas et al., 2009). Metformin is not metabolised by liver. It is excreted by 
the kidney. Half-life is approximately 1.5 to 6.5 hours (Tucker et al., 1981)(Tucker et 
al. 1981). It can be prolonged in case of renal impairment (Papanas et al., 2009). 
Metformin concentration in plasma is below 5ug/ml or 10-30 umol/L (FDA, 2002; 
Diamanti-Kandarakis et al., 2009)(Figure 8).  
 
 
Figure 8: Metformin pharmacokinetic. 
Adapted from (Gong Li, 2012)  
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1.3.3 General action of metformin 
 
Metformin is mainly used to lower blood glucose levels in type 2 diabetes individuals. 
Metformin reduces hepatic gluconeogenesis and lipogenesis. This effect is speculated 
to be mediated by several mechanisms. Activation of adenosine monophosphate 
kinase-activated protein Kinase (AMPK) pathway plays a vital role in action of 
metformin in liver (Diamanti-Kandarakis et al., 2009). Metformin reduces insulin 
resistance. This is mediated via its actions in liver, skeletal muscles and the small 
intestine (Hundal et al., 2000; Viollet et al., 2012; McCreight et al., 2016). This effect is 
mediated via AMPK pathway activation and recruitment of GLUT4. It is important to 
note that metformin has been shown to accentuate the insulin mediated glycogen 
synthesis at physiological relevant doses (Al-Khalili et al., 2005). In addition, metformin 
inhibits lipogenesis and increases fatty acid oxidation in skeletal muscles (Diamanti-
Kandarakis et al., 2009). 
 
Concentration of metformin was 30 to 300 time higher in mucosa of small intestine 
compared to plasma (Bailey et al., 2008). Metformin may diminish glucose absorption 
from intestine (Bailey  and Turner 1996). This has been demonstrated by Fineman and 
colleagues, where gut released metformin has been demonstrated to lower glucose 
absorption. This effect was mediated mainly in the lower part of the small intestine 
(Buse et al., 2016). Metformin may increase the secretion of GLP-1 and also cause a 
reduction in appetite (Bailey  and Turner 1996; Rotella et al., 2001).  
 
1.3.4 Efficacy of metformin in type 2 diabetes mellitus 
 
Metformin is an anti-hyperglycaemic agent which has been shown to improve 
glycaemic control, both in monotherapy and in combination with oral hypoglycaemic 
and injectable agents. In a meta-analysis, metformin has been shown to improve 
HbA1c by 12 mmol/mol (1.12%) reduction when compared with placebo. As an add-
on with oral hypoglycaemic agent and insulin, metformin reduced HbA1c by 
11mmol/mol (0.95%) and 9 mmol/mol (0.83%). The reduction has been shown to be 
maintained in trials with duration of more than 24 weeks (Hirst et al., 2012). Metformin 
has shown to have dose dependent glucose lowering effect (Garber et al., 1998; 
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Fujioka et al., 2005). Improvement in glycaemic control has been observed in both 
obese and non-obese (normal BMI) individuals (Ito et al., 2010).  
 
The effect of metformin on body weight is of great interest as the majority of T2DM 
individuals are either overweight or obese (Daousi et al., 2006). Unfortunately, data on 
the effect of metformin on weight is not consistent. The (UKPDS, 1998), one of the 
longest running trials showed that type 2 diabetes patients on metformin as 
monotherapy gained 1.5kg in weight. The reviews of other studies does demonstrate 
a modest effect on weight loss (up to a maximum of 3.8kg) (DeFronzo  et al., 1995; 
Golay, 2007).  
 
Metformin has shown to reduce total cholesterol, LDL cholesterol and triglyceride 
significantly (-0.26mmol/L, -0.22mmol/L and -0.13 mmol/L respectively). However, 
metformin has no effect on blood pressure (Wulffele et al., 2004).  
 
1.3.5 Efficacy of metformin in type 1 diabetes mellitus 
 
Metformin has now been recommended in overweight type 1 diabetes patients as an 
addition to insulin therapy (NICE, 2015). However, the addition of metformin has shown 
to have no effect on glycaemic control (Vella et al., 2010). It was speculated that the 
dose of insulin was adjusted toward baseline HbA1c. Indeed, insulin dose has been 
demonstrated to be reduced by 20%. Metformin has shown a modest reduction of 
weight in type 1 diabetes (Moon et al., 2007; Vella et al., 2010; Pitocco et al., 2013a; 
Libman et al., 2015). Furthermore, the reduction of lipid profile has been shown to be 
of similar magnitude as in type 2 diabetes (Vella et al., 2010).   
 
1.3.6 Action on AMPK pathway 
The mechanism of action of metformin is unclear. It has been proposed that metformin 
primarily acts on an enzyme (AMPK) (Figure 9) (Katzung et al., 2007 page 741).  
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Metformin is a powerful activator of AMPK. At supra-pharmacological concentrations 
(1-10 mM), metformin inhibits complex I of the respiratory chain, leading to a reduction 
in intracellular ATP, which in turn triggers the activation of AMPK (Owen et al., 2000). 
More importantly, at pharmacologically relevant concentrations (10-20 µM), it has been 
proposed that metformin phosphorylates and thereby activates AMPK in human 
endothelial cells (Its upstream kinase, LKB1 is not a direct target of metformin but 
required in the process of AMPK activation) (Hardie, 2006)  Upon activation, AMPK 
directly promotes the expression of peroxisome proliferator- activated receptor-γ 
coactivator-1α (PGC-1α) and increases mitochondrial function (Iwabu et al., 2010). Its 
expression has been reported to decline during ageing, (Petersen et al., 2003; Ling et 
al., 2004)  and is down-regulated in the failing heart (Arany et al., 2005) thus correlating 
with impairment of mitochondrial function. Both gain and loss-of-function studies 
indicate that PGC-1α plays a key role in regulating mitochondrial biogenesis (Lin et al., 
2002) and is essential for mitochondrial function in all cells, including EPCs. PGC-1α 
also acts as a transcriptional co-activator. It positively regulates expression of the pro-
angiogenic factor like vascular endothelial growth factor (VEGF) leading to 
angiogenesis in vivo (Arany et al., 2008a; Jung et al., 2010). PGC-1α knockout mice 
show a striking failure to reconstitute normal blood flow to the ischaemic limb. 
Increased PGC-1α expression in skeletal muscle is protective (Arany et al., 2008b). 
Since direct activation of PGC-1α might not be amenable to pharmacological 
intervention, an attractive approach would be the activation of its upstream regulators, 
such as AMPK. 
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Figure 9: Proposed mechanism of metformin action through AMPK/PGC-1α pathway. 
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1. Metformin in supraphysiological doses inhibits complex I of the respiratory chain, leading to the reduction 
of intracellular ATP and subsequent increase in AMP concentrations, key monitor of the cellular energy 
status. 2. Rising levels of AMP stimulate AMPK. 3. Metformin directly activates AMPK (via phosphorylation 
of AMPK kinases (i.e. LKB1). 4. Activation of AMPK increases eNOS production. 5. AMPK directly 
phosphorylates PGC-1α and this in turn mediates an increase in PGC-1α protein action on the PGC-1α its 
own promoter. 6. Fasting increases NAD+, substrate and an activator of sirtulin 1, NAD-dependent protein 
deacetylase (SIRT1) which activates PGC-1α through deacetylation and thus facilitates regulation of target 
gene expression. 7. Activated PGC-1α regulates target genes i.e. increased translocation of GLUT4. 
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1.3.7 Cardiovascular effect of Metformin 
 
Metformin has been shown to have vasculo-protective benefits irrespective of its 
antihyperglycaemic and lipid lowering effects (UK Prospective Diabetes Study 1988). 
The UK Prospective Diabetes Study (UKPDS) (1998) demonstrated that metformin 
significantly reduced all-cause mortality and diabetes-related mortality. This reduction 
was much more than other groups treated with sulfonylurea and insulin. Furthermore, 
there was no significant difference in the glycaemic control of metformin and insulin or 
sulphonylurea treated group. In animal models, metformin prevented the development 
of pulmonary hypertension, luminal occlusion and severe transplant coronary heart 
disease (CHD) (Verma et al., 2000; Cantin et al., 2002; Romualdi et al., 2008; Teede 
et al., 2008; Agard et al., 2009). Metformin also improved heart failure and survival in 
animals via activation of AMPK and its downstream mediators, endothelial nitric oxide 
synthase (eNOS) and PGC-1α (Gundewar et al., 2009). More recently, it has been 
demonstrated that metformin (at physiological concentration) and 5-amino-1-β-D-
ribofuranosyl-imidazole-4-carboxamide (AICAR) (another AMPK activator) normalised 
mitochondrial reactive oxygen species (mtROS) and promoted mitochondrial 
biogenesis in mature endothelial cells, also partly mediated by the AMPK and PGC-1α 
pathway (Kukidome et al., 2006; Kim et al., 2007b). Metformin has been demonstrated 
to lower mortality and morbidity in heart failure patients with type 2 diabetes (Eurich et 
al., 2005). This effect was most likely independent of glycaemic control.  
 
In chronic ischaemic post MI model, metformin has been shown to have cardio-
protective effect (Yin et al., 2011). Chronic pre-treatment of metformin in T2DM 
individuals was associated with improved outcomes after primary angioplasty for acute 
myocardial infarction (AMI) (Zhao et al., 2013b). Lexis et al. (2014) demonstrated in a 
retrospective cohort study that the use of metformin is associated with smaller infarct 
size in patients with MI (Lexis et al., 2014b). In contrast, Basnet and colleagues showed 
that in AMI patients who have undergone primary angioplasty, infarct size was not 
associated with metformin use (Basnet et al., 2015). Similarly, metformin has not 
shown any improvement in the left ventricular ejection fraction despite the 
improvement in the all-cause mortality (Lexis et al., 2014a; Abualsuod et al., 2015). 
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Metformin has been shown to improve EF in T2DM (Mather et al., 2001). Similarly, 
metformin has shown to improve EF in T1DM (Pitocco et al., 2013b). Even in non-
diabetic first degree relatives of the patient with diabetes mellitus, metformin has 
shown to improve EF (de Aguiar et al., 2006). Furthermore, metformin has 
demonstrated a reduction in CIMT in patients with type 2 diabetes (Matsumoto et al., 
2004). However, evidence in non-diabetic individuals does not compliment trials in type 
2 diabetes. Metformin did not show any effect on CIMT in high CV risk cardiovascular 
individuals (Preiss et al., 2013). However, this trial had below mentioned limitation 
which can explain the results. All participants in this trial were already taking statins. 
Statin use in previous trials in individual with diabetes was much lower (UKPDS and 
HOMA). Furthermore, compliance of metformin was less then 80%. Similarly, around 
20% of the subjects took lower doses of metformin. The initial design of the trial 
stipulated 24 months follow-up period. However, this was reduced to 18 months. In 
addition, fewer participants completed the trial than the calculated sample size. All 
these factors could have potentially limited the effect of metformin on CIMT. In contrast, 
metformin reduced CIMT in PCOS (Orio et al., 2005) and improved circulation in PVD 
patients (Sirtori et al., 1984).  
 
1.4 Conclusion 
 
From the above-mentioned discussion, we can identify that type 1 diabetes patients 
are at increased risk of developing CVD. Even with good glycaemic control, the risk of 
CVD remains higher. There is a need to develop novel treatment modalities to prevent 
CVD. 
 
Metformin has been shown to have a cardio-protective effect in type 2 diabetes 
mellitus. This effect may be mediated independent of glycaemic control. It is likely the 
cardioprotective mechanism would operate in T1DM in addition to T2DM.  
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2 Chapter 2: Study aims and hypothesis 
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2.1 Study aims 
 
Metformin was the first medication to demonstrate cardiovascular benefit in type 2 
diabetes (UK Prospective Diabetes Study 1988). Its cardio-protective effect is likely to 
be glucose independent and mediated via activation of the AMPK pathway (Katzung 
et al., 2007 page 741, UK Prospective Diabetes Study 1988). Metformin has been 
shown to reduce formation of advanced glycation product and improve endothelial 
function (Pitocco et al., 2013a). Metformin is usually added in type 1 diabetes to 
improve glycaemic control and reduce insulin requirement (Vella et al., 2010). There is 
limited information available on the cardiovascular effect of metformin in type 1 
diabetes. There was no guidance regarding the use of metformin in type 1 diabetes at 
the time of setting up of our study. In addition, at the start of our study, there was no 
randomised controlled trial published on the effect of metformin on CVD in type 1 
diabetes.  
 
Type 1 diabetes pathophysiology provided an important reason to study the effect of 
metformin on circulatory biomarkers in patients with type 1 diabetes. We could adjust 
the insulin dosage to maintain an unchanged glycaemic control. Changes in insulin 
resistance are less likely to play a major role in type 1 diabetes. This would not have 
been possible in patients with type 2 diabetes. Metformin treatment in type 2 diabetes 
would have resulted in improvement in insulin resistance, glycaemic control and 
weight. Thus, type 1 diabetes is a useful model to explore the effect of metformin.  
 
We aimed to determine if the cardio-protective effect of metformin is mediated by 
modulating circulatory biomarkers in type 1 diabetes whilst maintaining unchanged 
glycaemic control. We aimed to establish the concept of enhancing endogenous 
vascular stem cell function and a relationship between markers of vascular repair and 
damage.  
 
2.1.1 Primary aim 
 
The primary aim of our study was to evaluate the effect of metformin on cEPCs in type 
1 diabetes. 
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2.2 Hypotheses 
 
In type 1 diabetes, when changes in glycaemia are accounted for, metformin will: 
1. Improve the number and function of EPCs in T1DM  
2. Improve cEC in T1DM  
3. Improve circulatory MPs in T1DM  
4. Increase angiogenic miRNA and decreases anti-angiogenic miRNA 
5. Increase cytokines related to EPC mobilisation and angiogenesis    
6. Decrease cytokines representative of vascular injury markers and  
           inflammatory cytokines 
7. Shift the gene expression profile of PBMC in T1DM towards decreased    
           inflammation.  
 
Aims and objectives are again presented in each chapter.  
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3 Chapter 3: Clinical study 
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3.1 Clinical study design 
3.1.1 Type of study 
 
To test above-mentioned hypothesis, we desgined an observation study named 
MERIT Study. The Medicines and Healthcare Products Regulatory Agency (MHRA) 
judged our study as a Non-Clinical Trial of an Investigational Medicinal Product (non-
CITMP). 
 
3.1.2 Clinical study method 
 
We recruited 23 patients with type 1 diabetes with inclusion criteria of HbA1c <8.5% 
(69 mmol/mmol), absence of macrovascular disease or stage 3b or worse renal 
impairment (eGFR <45ml/min/1.73 m2) or active proliferative retinopathy, as the 
‘treatment group’ (TG). Nine age-, gender and duration of diabetes matched type 1 
diabetes patients were recruited as a standard group (SG).  Randomisation was not 
undertaken. Both, TG and SG did not have any new intervention during the trial except 
for metformin in TG. Patients with suspected hypoglycemia unawareness were 
excluded. The study protocol (Figure 10) included a run-in phase of 6 weeks to ensure 
stable glucose control. Following this period metformin was given for 8 weeks to TG 
with a dose titrated up to a maximum of 1 gram twice a day over 2 to 3 weeks or to the 
highest tolerated dose. The SG underwent similar follow-up except for metformin 
treatment. Participants were encouraged not to change their medication other than the 
dose of insulin therapy during the study. Patients were closely followed up and will 
attend the clinic at a regular interval. Telephone contact was also made to review the 
patient’s glycaemic control. After the end of the study, patients were given the option 
to continue Metformin therapy at the discretion of their GPs and followed up in their 
routine diabetes clinic. 
 
Furthermore, the treatment group was compared with 23 age- and gender-matched non-
diabetic healthy controls (HC).  
Inclusion and exclusion criteria for TG and SG are given Table 1.
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Inclusion Criteria Exclusion Criteria 
• Type 1 diabetes mellitus 
• Age ≥ 16 
• HbA1c ≤ 8.5% (69 mmol/mol) 
• Duration of diabetes ≥ 5 years 
• Stable diabetes control for ≥ 2 
months 
• GFR < 45 ml/ min/ 1.73m2 
• Woman of childbearing age 
planning pregnancy 
• Pregnancy and/or lactation 
• Proliferative diabetic retinopathy 
• History of CVD/IHD 
• Peripheral vascular disease 
• CVA or TIA 
• Suspected hypoglycaemia 
unawareness 
• Impaired cognitive function/ 
unable to give informed consent 
• History of lactic acidosis 
• Contraindications to metformin 
• History of alcohol problem or 
drug abuse 
 
Table 1: Inclusion and exclusion criteria 
 
All subjects gave their written informed consent and the Local Ethics Committee approved 
the study. Patients with type 1 diabetes were recruited either from, Queen Elizabeth 
Hospital, Gateshead or Royal Victoria Infirmary, Newcastle, UK. Healthy controls were 
recruited from the staff from the above or students from Newcastle University, UK. 
 
All participants were advised to attend early morning in the fasting state. The advice 
was given to avoid caffeinated drinks (tea, coffee, etc.), smoking and exercise since 
the preceding evening (previously described by Sibal et al. 2009). Women will be 
studied in the follicular phase of their menstrual cycle.  
 
Medical examination included general physical examination, blood pressure, and body 
weight and height measurement.  12-lead ECG and the Rose angina questionnaire 
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were performed. Clarke hypoglycaemic awareness questionnaire was performed to 
assess hypoglycaemia unawareness status before the start of the study. 
 
Retinopathy status was confirmed before the start of the study. If retinopathy 
screening had been done within the last six months, then this was accepted. 
 
3.1.3 Blood and other routine care 
A total of 40-mls of blood (Ethylenediaminetetraacetic acid-EDTA and citrate) was 
collected for the study of potential biomarkers at the start and end of the study for TG 
and SG. In HC, blood was collected once.  
 
In addition, blood was taken to measure HbA1c, full blood count, thyroid function test, 
U&E, and LFT as per routine clinical care. In TG, HbA1c was measured four times: at 
recruitment, the start of treatment, six weeks after the start of treatment and end of the 
study. In SG, HbA1c was evaluated at the same time points. The aim that no significant 
change of glycaemic control was observed as judged by HbA1c measurements. 
HbA1c was measured once in HC at the time of recruitment.  
 
C-peptide levels were measured if needed, before the start of the study. Subjects 
were excluded if C-peptide levels were higher than 200pmol/L (0.6ng/ml).  
 
Urine was collected to document microalbuminuria status (positive or negative).  
However, if the urine albumin-creatinine ratio had been done in the last six months 
than it was accepted. 
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3.1.4 Glycaemic control 
We aimed for unchanged glycaemic control during the study in the treatment group, 
which was assessed by HbA1c (four times points over 14 weeks) and continuous 
glucose monitoring (CGM) (Ipro2- Medtronic) (minimum of 48 hours) was performed 
in those receiving metformin to ensure unchanged glycaemic control. EasyGV Version 
8.8.2. R2 was used to calculate the glucose variability index (Hill et al., 2011). CGM 
was not undertaken in standard group. The CBG target for the duration of the study 
was 5mmol/l to 11mmol/l.  
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3.2 Statistical analysis 
 
The results are expressed as mean+/-SD (standard deviation) or mean+/-SE 
(Standard error) unless stated otherwise. Within the group (treatment or standard) 
comparison was evaluated by paired Student t-test or Wilcoxon Signed Rank test 
depending on the distribution. Between-groups, the comparison was evaluated by 
unpaired Student t test or the Mann-Whitney test. Log transformation was carried out 
for miRNAs before performing a comparison between or within groups. All the data 
were log transformed before we performed correlation. Correlation between different 
parameters were calculated by Pearson correlation.  One-way ANOVA was used to 
analyse the difference between HbA1c values. Statistical significance was accepted 
at p <0.05 (two-tailed significance) unless stated otherwise. 
 
We took advice from the statistician regarding using ANCOVA to assess the change 
in the treated group (TG) after adjusting for the change in the control group (SG). We 
were advised that it is better to use Student t-test or Wilcoxon Signed Rank test. This 
was due to the design of the study. The treatment group (TG) had more subject than 
the standard group (SG). This will make intrepretation of the result difficult.   
 
As the aim of the study was to assess the effect of metformin on cEPCs in type 1 
diabetes, therefore, a statistical power calculation was undertaken only for the TG. 
Based on our pilot work and in order to reduce CVD risk in patients with type 1 
diabetes, minimum of 20 patients were required in treatment group to show a 
difference of 0.0021 in cEPCs (% leukocytes) with α=0.05 and a power of 90%. SPSS 
v21.0 (SPSS Inc, Ill) was used to perform statistical analysis.  
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3.3 Results 
3.3.1 Clinical characteristics 
Baseline characteristics of three groups are shown in the Table 2. All groups were well 
matched for age, gender and blood pressure. TG and SG had a similar duration of 
diabetes (DOD), HbA1c, baseline insulin dose, lipid profile and creatinine. BMI was 
lower in SG in comparison to TG.  
 
In the TG, at recruitment, twelve patients took aspirin and/or ACE inhibitor and/or 
statins in addition to insulin. No new medication other than metformin was started 
during the trial (except for metformin in the TG). No medication dosage was changed 
other than the dose of insulin and metformin. The HC group took no aspirin, ACE 
inhibitors and/or statins. Five patients in the SG took aspirin or/and ACE inhibitor 
and/or statins in addition to insulin. There was no difference in medication between 
TG and SG.  
 
After treatment with metformin in the TG, BMI, total cholesterol, triglyceride, blood 
pressure and HbA1c remained unchanged. Over fourteen weeks HbA1c values were 
as follows (-6 week (56.4+/-8.3 mmol/mol, 7.3+/-3%), 0 week (56.85+/-10.5 mmol/mol, 
7.3+/-0.9%), +6 week (56.8+/-8.5 mmol/mol, 7.3+/-0.8%) and +8 week (56+/-
0.8mmol/mol, 7.3+/-0.8%); one-way ANOVA, p=0.78). The coefficient of variation of 
HbA1c over 14 weeks was 4.8%. Furthermore, continuous glucose monitoring 
confirmed unchanged glucose control and variability (Table 3). Insulin dose, HDL 
cholesterol and creatinine were significantly reduced in the TG treatment group after 
metformin treatment. There were no changes in any variables in SG. 
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 TGV1 TGV2 p value 
Average glucose 
CGM mmo/L 
9+/-3 8+/-2.3 0.17 
Blood glucose 
standard 
deviation 
3.3+/-1.1 3+/-1.2 0.3 
Mean amplitude 
of glycaemic 
excursion 
7+/-2.7 6+/-3 0.3 
Continuous 
overall net 
glycaemic action 
7.7+/-2 7.3+/-2.2 0.4 
Total area under 
curve (AUC) 
(calculated): 
12341+/-2900 11500+/-3182 0.3 
AUC above limit-
7.8 (CGM) 
1.86 1.97 0.7 
 
Table 3: Glucose variability before and after metformin treatment. TG V1: Pre-treatment; TG V2: Post-
treatment; CGM: Continous glucose monitor 
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3.3.2 Side effects 
None of the volunteers in the study suffered any side effects requiring discontinuation 
of metformin. Eighteen patients took the full recommended dose of metformin (1000mg 
BD or 500mg BD-due to low eGFR-45 to 60 ml/min/1.73 m2). Five patients had 
gastrointestinal side effects that required dose reduction (two patients took 500mg 
TDS; two took 500mg BD, and one took 500mg OD). No patient suffered any major 
episode of hypoglycaemia.  A major episode of hypoglycaemia was defined as any 
episode of low blood glucose requiring the intervention of the third party due to 
impaired conciousness to resolve the event. There was no significant effect of 
metformin on minor hypoglycaemic events (% ≤ 3.9 mmol/L and area under curve 3.9 
mmol/L on CGMS: 8.6% vs 13.3%; p=0.2 and 0.08 vs 0.1; p=0.5 respectively).  
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3.4 Discussion 
 
We designed the MERIT study to explore the effects of metformin in type 1 diabetes 
on surrogate CVD circulatory biomarkers. Almost all the studies in type 1 diabetes so 
far have only explored the effect of metformin on metabolic features rather than 
cardiovascular markers or outcomes. There is only one study which explored the effect 
of metformin on endothelial function and oxidative markers (Pitocco et al., 2013b).  
 
We recruited T1DM subject who have well-established diagnosis based on clinical and 
biochemical features. It was ensured that all patients were diagnosed for more than 
five years. This gave enough time for patients to have developed subclinical vascular 
damage without overt disease. The aim of the study was to explore the effect of 
metformin on early cardiovascular markers in type 1 diabetes. We excluded patients 
with the overt macrovascular disease.  Metformin is contraindicated in patients with 
eGFR below 30 ml/min. Furthermore, dose reduction is needed when eGFR goes 
below 45 ml/min. Therefore, we excluded patients with stage 3b CKD. Patients with 
proliferative retinopathy were excluded. Proliferative retinopathy is characterised by 
ischaemic induced vessel formation. Proliferative retinopathy will result in increased 
cEPC and angiogenic circulatory markers driven by ischemia-induced VEGF response. 
Patients with hypoglycaemic unawareness were excluded to ensure that a recruited 
cohort can be safely follow up due to the inherent risk of hypoglycaemia.  
 
Subjects in the TG had good overall diabetes control (HbA1c < 57 mmol/mol or 7.3%). 
The average duration of diabetes was more than 20 years. This made our group 
fascinating. Our group based on the duration of diagnosis would have developed a 
subclinical vascular injury. In our centre, we have shown that the young individual with 
a 10-year diagnosis of type 1 diabetes has features of vascular damage (Sibal et al. 
2009). Metabolic features were well controlled except for BMI. The cohort in TG were 
overweight when compared to SG.  Increased BMI has been reported in recent studies 
in type 1 diabetes, including a previous study conducted at our institute in young type 
1 diabetes (Age 25.4 years) (Sibal et al. 2009). In this study, BMI was 25.3 kg/m2. 
Similarly, subjects in Pitacco et al. (2013) were overweight (27.3 kg/m2). BMI can 
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affect levels of circulatory markers evaluated. Metformin treatment may influence 
insulin resistance in TG as they were overweight.  
 
TG cohort were compared with matched SG. SG underwent similar follow up and 
clinical care during the study period except for treatment with metformin. We only 
recruited nine subjects in SG. The main aim for SG was to establish that clinical care 
and follow up during the study will not result in any changes in the measured 
parameters. TG and SG were well matched for age and gender except for BMI. BMI 
was significantly lower in SG when compared to TG. This could introduce a bias which 
can influence the results. Future studies should be planned to explore the effect of 
metformin on insulin resistance and circulatory biomarkers. 
 
Twenty-three volunteers were recruited in the healthy control group. They were well 
matched with TG. HbA1c was as expected lower in HC compared to TG. Interestingly, 
triglyceride was higher in HC when compared with TG. This could be due to the good 
lifestyle in our TG. Indeed, TG group participant were motivated to improve their health. 
Our type 1 diabetes individuals had been educated by healthcare professional as a 
part of education for type 1 diabetes. Furthermore, patients in TG were on lipid lowering 
agents.  
 
TG was given metformin for eight weeks. The dose of metformin was titrated gradually 
to reduce the chance of developing of side effects. As expected, a few patients 
developed metformin-related side effects and were unable to reach the maximum 
recommended dose. This is in contrast with Pitocco et al. (2013), who reported that all 
subjects managed to take the full recommended dose of 850mg TDS. This could be 
due to the shorter duration of treatment in our study (8 weeks). By contrast the cohort 
in Pitocco et al. (2013) had more time to gradually increase the dose of metformin.  
 
We ensured adequate follow up to prevent the development of major hypoglycaemia. 
Insulin dose was reduced to maintain constant glycaemic control. CGMS was 
performed before the start of metformin and at a maximum dose of metformin. Insulin 
dose was reduced by five units per day. This was in line with previous studies (Meyer 
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et al., 2002; Lund et al., 2008a). A meta-analysis estimated a reduction of insulin dose 
of 6.6 units per day with metformin (Vella et al. 2010).  
 
We were able to achieve the aim of our study to keep the glycaemic control unchanged. 
This is evidence by stable HbA1c and CGMS reading. Furthermore, glucose variability 
also remained unchanged. It is interesting to note from previous work on metformin in 
type 1 diabetes that overall HbA1c remained unchanged after metformin treatment 
(Vella et al. 2010 and Pitocco et al. 2013). 
 
We performed CGMS in TG. CGMS was not performed in SG. This was due to 
limitation in funding. Furthermore, performing CGMS provided information which was 
used to make sure that overall glycaemic control did not change and patients’ blood 
glucose were in safe range. Therefore, we did not have data to compare glucose 
variability between TG and SG. We believe that this will not lead to significant bias as 
HbA1c remained similar between TG and SG.  
 
Eight weeks of metformin treatment did not result in any significant change in BMI. This 
is in contrast with a recent study which showed that six months of metformin in people 
with type 1 diabetes resulted in the loss of nearly 2.5 kg weight when compared to 
placebo (Pitocco et al., 2013b). However, we requested that the patients would not aim 
to improve their diabetic control whilst in the study, so it is a possible explanation for 
the lack of weight loss. Surprisingly, HDL cholesterol levels were reduced after 
metformin therapy, though, were similar to the control group and remained well within 
the normal range. Total cholesterol and triglyceride did not change with metformin 
treatment.  
 
In summary, types 1 diabetes cohorts (TG) in our study have good overall diabetes 
control. Overall metabolic parameters were in line with the previously published 
evidence. They are well matched with HC and SG. Furthermore, metformin treatment 
did not change glycaemic control and BMI.  
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4 Chapter 4: Effect of metformin on endothelial progenitor cells, 
circulatory endothelial cells and microparticles 
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4.1 Endothelial Progenitor Cells 
 
Endothelial progenitor cells (EPCs) contribute to the development of new blood vessels 
in adult (Urbich and Dimmeler, 2004b). EPCs play a pivotal role in vascular repair. 
Impairment of EPC function is an important factor in the pathogenesis of 
cardiovascular disease. This has made EPCs remarkably attractive as a biomarker of 
cardiovascular disease (Silvestre and Lévy, 2009).  
 
EPCs are defined as a group of cells that are mainly derived from bone marrow with 
an ability to multiply (clonal expansion), proliferate and have a capacity for resistance 
to stress (stemness characteristics) and can differentiate into mature endothelial cells 
(Urbich and Dimmeler, 2004b).  
 
4.1.1 Historical Perspective 
 
Before 1997, our general understanding was limited to the fact that the new blood 
vessel formation in adult (postnatal) life is limited to angiogenesis. Angiogenesis is a 
process of development of the blood vessels through proliferation, sprouting and 
migration of fully differentiated cells (endothelial) from the pre-existing vasculature 
(Risau and Flamme, 1995). Vasculogenesis, the process by which mesodermal cells 
differentiate into angioblast precursor cells and then subsequently develop into a new 
vessel like structure, was thought to occur only during embryonic development (Risau 
and Flamme, 1995; Sabin, 2002).  
 
In 1997, Asahara et al. challenged the above theory and postulated that postnatal 
vessel formation could occur not only by angiogenesis but also by vasculogenesis. 
Asahara et al. (1997) isolated cells from the adult peripheral blood that differentiated 
into endothelial cells in vitro and in vivo. These cells express cell surface markers CD34 
and VEGFR2 (KDR). In culture, these cells formed clusters consisting of round cells in 
the centre and sprouts of spindle shaped cells in the periphery. This is similar to blood 
island like clusters during embryonic life. This seminal study suggested that there are 
circulatory cells “progenitor endothelial cells”, which can contribute to new vessel 
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formation in adult life. These cells also play an important in repair of damaged 
endothelium (Asahara et al., 1997).  
 
Since 1997, more than 8000 papers have been published (Pubmed as of 12th October 
2016, using the search term endothelial progenitor cells). Even with a large number of 
literature, defining EPCs remains a matter of debate (Yoder, 2012). Isolating true EPCs 
remains difficult since they lack a specific cell surface marker and their maturation cycle 
remains unclear (Yoder, 2009). Furthermore, many circulatory cells may contribute to 
blood vessel repair and formation (Ingram et al., 2005; Yoder, 2012). Two main 
methods have been used to isolate EPCs in research (Ingram et al., 2005). 
1 Culture method 
2 Flow cytometry 
 
4.1.2 Endothelial progenitor cells isolation: Culture Characterization 
 
Endothelial progenitor cells can be cultured from peripheral blood mononuclear cells 
(PBMC) using ficoll density centrifugation or lymphoprep to separate PBMCs from 
peripheral blood. Two main methods have been extensively used in literature (Prater 
et al., 2007): 
A. Adhesion based method 
B. Colony forming assay 
 
4.1.2.1 Adhesion based method 
 
In method 1 (Figure 11), once PBMCs are separated, they are plated with culture 
medium supplemented with endothelial growth factors on a fibronectin coated tissue 
culture plate. After 4 to 7 days in culture, non-adherent cells are removed leaving 
behind adherent cells (Vasa et al., 2001b; Rehman et al., 2003). These adherent cells 
are called pro-angiogenic cells (PACs).  
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PACs have the distinct property of binding plant lectin (Ulex europaeus; Ulex) and 
ingest acetylated LDL (ac-LDL). PACs are identified and quantified by labelling with 
both ac-LDL and ulex lectin and then are counted. PACs have been used in many 
studies to define EPCs (Vasa et al., 2001b; Rehman et al., 2003). 
 
Even though ac-LDL bind’s cell surface receptors of EPCs and endothelial cells (Voyta 
et al., 1984), it is not a completely reliable marker of EPCs. ac-LDL receptors are widely 
distributed on myeloid lineage subset of hematopoietic cells (Rohde et al., 2006). In 
addition, ulex lectin binds not only vascular endothelial cells but also many circulatory 
blood cells and epithelial cells (Holthöfer H, 1982; Schwechheimer et al., 1984; Liu Sm, 
1996; Graziano et al., 2001). Thus, both LDL and lectin are not specific markers to 
identify EPCs. 
 
Another confounding factor is contamination of PBMCs with platelets (Prokopi et al., 
2009). These platelets can get fragmented in vitro culture. On occasion, platelet 
fragments can get incorporated in the cell membrane of cells in culture plates. This can 
result in cells with platelet fragment showing some features and function of platelets 
(Prokopi et al., 2009).  
 
Adhesion based method is fraught with above-mentioned problems. But it is interesting 
to note that these adherent cells (EPCs or PACs) are known to promote angiogenesis 
in animal ischaemic models like limb ischemia and myocardial ischemia (MI) (Kalka et 
al., 2000; Kawamoto et al., 2001) These cells have been shown to be directly 
associated with CVD (Vasa et al., 2001b). 
 
Vasa et al., (2001) demonstrated that PAC numbers were 40% lower in coronary artery 
disease patients and also demonstrated impaired functional capacity (PAC migration) 
as compared to healthy volunteers. In addition, there was an inverse correlation 
between numbers of risk factors and PAC numbers. Smoking was found to be the most 
important factor which lowered PAC numbers. Whereas, hypertension had the greatest 
effect on PAC function: reduced PAC migration (Vasa et al., 2001b) and endothelial 
repair capacity (Giannotti et al., 2010).  
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Figure 11: Common methods of EPC culture. Adapted from (Prater et al., 2007). 
Method 1  Method 2  Method 3 
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4.1.2.2 Colony forming assay 
 
The second method for defining EPCs uses isolated PBMCs in a colony forming assay 
(Yoder, 2012). Colony forming assay can be performed in two ways (Figure 11).  
 
In method 2, PBMCs are separated from the peripheral blood through ficoll density 
centrifugation or lymphoprep. PBMCs are plated on a fibronectin coated tissue culture 
plate. After 48 hours, non-adherent cells are collected. This is to avoid any 
contamination with other cells like monocyte, endothelial cells, etc. Collected non-
adherent cells are plated fibronectin coated tissue culture plate. The culture medium is 
changed after every 72 hours. After 5 to 7 days discrete colonies are formed. These 
colonies are characterized by a central collection of round cells surrounded by 
elongated spindle-shaped cells sprouting at the periphery (Hill et al. 2003). These 
colonies are called colony forming unit-Hills (CFU-Hills) or colony forming unit-EC 
(CFU-EC) or early EPCs. 
 
Asahara et al., (1997) initially defined the method. It was shown that these clusters of 
colonies have an endothelial phenotype as they express CD31, CD34, FLK-1 (fetal 
liver kinase; also called KDR-kinase insert domain receptor or VEGFR2), Tie-2 
(CD202B) and E-Selectin. It was thought that these colonies are likely responsible for 
vasculogenesis.  
 
The Hill colony isolation method has been modified, and the additional step of removing 
contaminating cells like monocytes or endothelial is now used (Hill et al., 2003a). An 
important feature of these colonies is the fact that they disappear within 10-14 days 
(Ingram et al., 2005). CFU-Hills express endothelial, hematopoietic and macrophage 
antigens. They show some macrophage function of expressing non-specific esterase 
and bacteria activity (phagocytosis). They have minimal proliferative potential and do 
not form vessels in vivo (Yoder et al., 2007).  
 
Even though CFU-Hills do not have a direct role in vessel formation, it has been shown 
that CFU-Hills numbers are an important predictor of cardiovascular risk. CFU-Hill 
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numbers are inversely correlated with the Framingham risk score (Hill et al., 2003a). 
Patients with CAD (Hill et al., 2003a), diabetes mellitus (Hill et al., 2003a; DiMeglio et 
al., 2010), hypertension (Hill et al., 2003a) and subclinical atherosclerosis (Cheng et 
al., 2010a) have significantly lower CFU-Hills (significantly lower in multi vessel 
coronary disease; (Kunz et al., 2006). Acute vascular injury (angioplasty, unstable 
angina, etc.) results in an increase in the number of CFU-Hills (George et al., 2004; 
Bonello et al., 2006).  
 
In method 3, isolated PBMCs are plated on type 1 collagen, and non-adherent cells 
are discarded. This is done every day until the seventh day and then every other day. 
Colonies start to form between 5 to 22 days. These colonies are well-circumscribed 
monolayer of cobblestone endothelial cells (Ingram et al., 2005). These colonies are 
called endothelial colony forming cells (ECFCs) or late EPCs.   These colonies are 
distinct from those described by Hill et al. (2003) (CFU-Hill). ECFCs do not express 
haematopoietic markers like CD45 or monocytic markers like CD14. Also, ECFCs do 
not express CD133, but they do express CD34 and KDR. If CD34+CD45- enriched 
PBMCs are plated, there is a significant improvement in numbers of ECFCs 
(Timmermans et al., 2007). These colonies have strong proliferative potential and form 
vessels in vivo (Ingram et al., 2005; Yoder et al., 2007).  
 
To date our understanding for CFU-Hill and ECFCs is limited. We are still trying to 
understand the relevance of these colonies. Evidence has shown that these colonies 
are likely to play an important part in neo-vasculogenesis, either directly or indirectly 
(Padfield Gj, 2010). In humans, both CFU-Hills and ECFCs are mobilised due to 
vascular stress (Bonello et al., 2006; Marboeuf et al., 2008; Massa et al., 2009). They 
both are believed to play an essential role in vascular repair. In a mouse model when 
CFU-Hill and ECFCs are infused together in an ischaemic limb, there is a synergistic 
improvement in the blood flow to the limb (Yoon et al., 2005).   
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4.1.3 Circulatory endothelial progenitor cells enumeration: Flow cytometry 
(FACS) 
 
An increasingly common method for identifying circulatory EPCs is through flow 
cytometry of peripheral blood. The technique is based on the fact that each cell will 
express a specific surface antigen. These surface antigens can be labelled with 
monoclonal antibodies. This means that through fluorescence-activated cell sorting 
(FACS), the specific cell population can be enumerated. A small amount of peripheral 
blood (50-150 microliter) or mononuclear cells after separation in labelled with a 
fluorescent monoclonal antibody (Vasa et al., 2001b; Xu et al., 2008; Sibal et al., 
2009a). After incubation, the cells are identified using FACS analysis.  
 
Identification of cEPCs by flow cytometry is hampered by the fact that there is a lack 
of specific markers that clearly discriminate EPCs from circulatory endothelial cells 
(cEC). Circulatory EPCs are thought to include antigens for hematopoietic and 
endothelial lineage cells (Yoder et al. 2007). In the first report (Asahara et al., 1997), 
CD34+ and VEGFR2+ (KDR) cells were identified as markers of identification. When 
cells with CD34+ or KDR+ cells were infused in an ischaemic limb, these cells promoted 
vasculogenesis and were localised in the ischaemic area (Asahara et al., 1997).  
 
However, CD34 and KDR are also expressed on endothelial cells. This makes 
delineation of cEPCs from cECs difficult. Peichev et al. (2000) added that, in addition 
to CD34 and KDR, cEPCs also express CD133, which is not expressed by endothelial 
cells (Peichev et al., 2000). Reye et al. (2002) extended this and showed that bone 
marrow derived CD133+VEGFR2+CD34- cells give rise to cells that express endothelial 
cell surface markers. They function as mature endothelial cells and promote 
angiogenesis and wound healing in vitro and in vivo (Reyes et al., 2002). However, no 
studies have been conducted on CD34+VEGFR2+CD133+ cells to see if they promote 
vasculogenesis or if they localise to new vessel sites (Yoder, 2009).  
 
Cells positive for all three markers, CD34+, VEGFR2+ and CD133+ do not form CFU-
Hill or ECFC in vitro. However, only CD34+ cell fractions which are CD45- 
demonstrated ECFC activity. Endothelial cells do not express the CD45 antigen (Case 
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et al., 2007; Timmermans et al., 2007). In addition, Timmerman et al. (2007) 
demonstrated that VEGFR2, but not CD133 was expressed by CD34+/CD45- cells. 
Similarly, CD34+/CD45+ cells expressed CD133 but not VEGFR2.  
 
From the available evidence, CD34+ cells have been used extensively to describe and 
define the EPC phenotype. In order to improve the identification of more specific 
populations of EPCs, various combinations of surface antigens like CD34+VEGFR2+ 
(Pelosi et al., 2002), CD34+CD133+ (Allanore et al., 2007), CD34+VEGFR2+CD133+ 
(Peichev et al., 2000), CD34+CD133+CD45+ (Martin et al., 2008), CD34+CD133+CD45, 
CD45-CD34+VEGFR2+ etc. have been used. Other than combinations mentioned 
above, CD144+, CD31+, CD146+ and CXCR-4+ have been used in various 
combinations to identify cEPCs. However, none of these have been studied in vitro or 
in vivo to confirm the formation of the endothelium.  
  
CD34/VEGFR2+, CD34+CD133+ and CD133+VEGFR2+ have been used in much 
clinical studied to determine cEPC role in CVD (Schmidt-Lucke et al., 2005; Chironi et 
al., 2007; Sibal et al., 2009a). CD133 is expressed more in immature cells when 
compared to CD34. Furthermore, in contrast to CD34, CD33 in not expressed on 
mature EC. Therefore, CD34+CD133+ may not be a specific marker of EPCs. Ingram 
et al. (2005) suggested using CD45- cells to define cEPCs (Ingram et al., 2005). Making 
a distinction between CD45 negative, dim and bright events have been possible with 
improvement in flow cytometry technology and methods resulting in improved 
sensitivity of rare event. CD34+VEGFR2+ cells have been shown to express CD45 
dimly (Schmidt-Lucke et al., 2010). 
 
Schmidth-Lucke et al. 2010 clarified that the CD45dim population defines the 
CD34+VEGFR2+ cells as cEPCs in relation to CVD. Current evidence defines cEPCs 
as cells which are CD45dimCD34+VEGFR2+ (Schmidt-Lucke et al., 2010). Using other 
markers like CD133+VEGFR2+ and CD34+CD133+VEGFR2+ in CD45dim fraction will 
increase variability as these events are much rarer than CD45dimCD34+VEGFR2+. 
CD34+VEGFR2+ has been shown to provide the best data with regards to cell count 
and coefficient of variation (Fadini et al., 2008) (Figure 12). 
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Figure 12: A Venn diagram demonstrating different subgroups of progenitor cells calculated relative to 
CD34+ cell count. Adapted by (Fadini et al., 2008). 
 
Vasa et al. (2001) demonstrated that CD34+KDR+ cells were reduced by 48% in 
coronary artery patients as compared to healthy individuals. This reduction was 
strongly correlated with cardiovascular risk factors (r=-0.394; P=0.02). Interestingly, 
CD34+ or CD133+ alone or CD34+CD133+ combined cells did not show a correlation 
with the number of risk factors (Vasa et al., 2001b). Schmidt-Lucke et al. (2005) 
showed similar results and added that patients with lower CD34+/VEGFR2+ cell count 
are more likely to have a cardiovascular event over 10+/-12 months follow-up 
(Schmidt-Lucke et al., 2005).  
 
Circulatory EPCs (CD34+VEGFR2+) numbers were adversely affected even in the pre-
clinical stage of atherosclerosis (Chironi et al., 2007). Furthermore, cEPC levels had 
been shown to have predictive potential in post cardiac events (Werner et al., 2005). 
In this large (519 IHD subjects) study, higher cEPC (CD34+VEGFR2+) levels at 
baseline results in good prognosis over a period of 12 months.  However, no 
association was found between cEPC levels and acute MI and death from any cause. 
This may be due to the patients not being classified on the history of acute or recent 
MI (Kim, 2005). 
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Acute MI leads to increase in cEPC numbers: CD34+ (Shintani et al., 2001), 
CD34+CXCR4+ and CD34+CD177+ (Wojakowski et al., 2004) and CD34+, CD34+KDR+, 
CD34+CD133+ and CD34+CD117+ (Grundmann et al., 2007) when compared to stable 
coronary artery disease (CAD) patients. This is likely due to mobilisation of cEPCs in 
response to growth factors and cytokine release from ischaemic tissue (Ghadge et al., 
2011). 
 
4.1.4 Mobilisation and homing 
 
In response to insult like ischaemia or endothelial damage, progenitor cells mobilise 
from bone marrow and home to the site of the stress. This is a complex but co-
ordinated multistep process (Papayannopoulou et al., 2001) which is regulated by 
factors such as: 
1. Proteases (elastase, cathepsins, and matrix metalloprotein-9) 
2. Cytokines (interleukin 8 (IL-8), IL-1, etc) 
3. Chemokines and growth factors (VEGF, stromal cell-derived factor-1 (SDF-1), 
Granulocyte colony-stimulating factor (G-CSF), erythropoietin, hypoxia-
inducible factor 1α (HIF-1α). 
VEGF and SDF-1 play a very important role in the mobilisation and homing of cEPCs 
(Asahara et al., 1999; De Falco et al., 2004). Pathological and physiological stimuli like 
hypoxia and exercise lead to induction of HIF-1α (Jiang et al., 2008; Cheng et al., 
2010b). HIF-1α is a transcription factor that promotes VEGF and SDF-1 expression 
(Ceradini et al., 2004; Jiang et al., 2008; Oladipupo et al., 2011). SDF-1 binds to the 
CXCR-4 chemokine receptor which is highly expressed in EPCs (Shiba et al., 2007) 
(Figure 13). HIF-1α increase expression of erythropoietin, a powerful mobiliser of EPCs 
(Heeschen et al., 2003a).  
 
eNOS has been shown to increase EPC mobilisation. Stimuli such as exercise and 
VEGF activate eNOS, which is needed to maintain adequate EPC mobilisation. eNOS 
is thought to act via MMP-9 (Aicher et al., 2003). 
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Figure 13: HIF-1α, VEGF and SDF-1 interaction in vascular repair.  
1.) Ischemia increases up-regulation of the HIF-1α, which then increases SDF-1α and VEGF. 2.)” These 
signals reach the bone marrow (BM). 3.) This leads to alterations in the BM microenvironment (e.g. 
induction of MMP2/9, CD26, elastase and cathepsin G) resulting in proliferation and increased CXCR4 
receptor expression of stem and progenitor cells as well as SDF-1 degradation. 4.) The changes in the 
BM SDF-1 gradient lead to the translocation of stem and progenitor cells into the PB and their homing 
towards the local SDF-1 gradient initiated in the myocardium by ischemia. 5.) BM stem and progenitor 
cells selectively home to the ischaemic myocardium where they are involved in myocardial repair 
through cardio-protective functions and induction of angiogenesis”. Adapted from (Ghadge et al., 2011).  
 
 
The initial step in mobilisation is thought to depend on proteinases like MMP-9, which 
acts on a membrane bound kit ligand and converts it to the soluble kit ligand. This is 
needed by progenitor cells to move to the vascular zone of bone marrow (Heissig et 
al., 2002). VEGF and SDF-1 activate bone marrow MMP-9 (Figure 3) (Heissig et al., 
2002; Hao et al., 2011).  
 
Powerful chemokines and cytokines like VEGF, MCP-1 and SDF-1; all play an 
important role in homing EPCs to the injury site (Chavakis et al., 2005). For cEPCs to 
adhere to damaged endothelium, the integrin receptor plays a critical role. These 
proteins are involved in the adhesion and transmigration of progenitor cells. β2-integrin 
and α4β1-integrin are two important integrins. In experimental models, it has been 
shown that blocking β2integrin prevents homing of EPCs to the site of ischaemia 
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(Chavakis et al., 2005). Furthermore, blocking of α4β1-integrin results in the reversal 
of adhesion of EPCs from vascular cell adhesion molecules-1 (VCAM-1) (Qin et al., 
2006). Once the EPCs adhere to the damaged endothelium, they need to transmigrate 
through the monolayer. This is mediated by endothelial protease like MMP-9 and 
cathepsin (Urbich et al., 2005; Iwakura et al., 2006).  
 
Above mentioned activity plays a vital role in neovascularisation. However, our 
understanding of mobilisation and homing of EPCs is limited and continues to be 
investigated (Mayr et al., 2011).  
 
4.1.5 Function of endothelial progenitor cells 
 
From extensive literature, EPCs have a positive effect on vascular function. EPCs were 
thought to play a direct role in neovascularisation (incorporation into neo-endothelium). 
It is now understood that there are different types of circulating progenitor cells in 
peripheral blood. These different types of cells act directly and indirectly (paracrine and 
autocrine) during the process of vascular repair.  
 
Rehman et al. (2003) showed that early EPCs have limited proliferation potential, but 
secrete high levels of pro-angiogenic growth factors like VEGF, G-CSF and hepatocyte 
growth factor (HGF) (Rehman et al., 2003). He et al. (2005) showed that early EPCs 
release IL-8, a powerful angiogenic cytokine. Cultured medium from early EPC 
increases proliferation of HUVEC cells. This effect is attenuated by inhibiting IL-8 (He 
et al., 2005). CD34+ cells in culture release IL-8, IL-6, macrophage inflammatory 
protein-1β (MIP-1β), MIP-1α and monocyte chemoattractant protein-1 (MCP-1) 
(Scheubel et al., 2010). Furthermore, endothelial sprout preferentially grows towards 
CD34 cells. In addition, CD34+ cells augment the growth of endothelial sprout in 
culture.  
 
Yoon et al. (2005) studied the effect of early and late EPCs in vitro and in vivo. They 
found that IL-8 and VEGF were secreted from early EPCs. Late EPCs had high levels 
of receptors for VEGF and IL-8. When late EPCs were cultured with conditioned 
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medium from early EPCs, there was significantly improved proliferation, migration, 
invasion of collagen gel and tubulisation. This effect was neutralized when VEGF and 
IL-8 were inhibited. Yoon et al. (2005) performed in vivo experiment by injecting early 
and late EPCs together in the ischaemic hind limb. This resulted in significant 
improvement in perfusion when compared to either early or late type of EPC alone 
(Yoon et al., 2005).  
 
Cytokines released from EPCs have cytoprotective effects on endothelial cells. This is 
due to the increased expression of Catalase, Cu/ZnSoD and MnSOD in endothelial 
cells. These cytokines released from cEPCs have an anti-apoptotic effect. This 
reduction in endothelial cell apoptosis is through increased Bcl-2/Bax expression ratio 
(Bcl-2; anti-apoptotic factor; Bax; pro-apoptotic factor). This effect is not reversed with 
an inhibitor of cytokines like VEGF, HGF, MM-9, IL-8 alone or in combination. 
Therefore, it is likely that there are some unidentified cytokines or factors responsible.  
(Yang et al., 2010).  
 
Recently, it has been postulated that the paracrine effect that release of exosomes or 
microparticles from EPCs may be partly responsible for the paracrine effect. These 
exosomes/microparticles are a conduit of transport, moving an important message 
from one cell to another. This could be cytokines or mRNA or microRNA (Lässer et al., 
2013). Sahoo et al. (2011) showed that CD34+ cells secrete exosomes. These 
exosomes independently increase angiogenesis in vitro and in vivo (Sahoo et al., 
2011). These exosomes are rich in pro-angiogenic miRNA (Lässer et al., 2013). The 
role of miRNA will be discussed in chapter 5.  
 
4.1.6 Effect of environmental and physiological factors on cEPCs 
 
4.1.6.1 Smoking  
Smoking is one of the major risk factors for CVD. Vasa et al. (2001) identified smoking 
as a major predictor of EPC numbers (PAC). Smokers have significantly fewer EPCs 
(CD34+KDR+ and KDR+CD133+) levels (Yue et al., 2010). In addition to lower cEPC 
numbers, their functional capacity is adversely affected. Smokers have poorer 
proliferation, migration, adhesion and tubulisation when compared to non-smokers 
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(Michaud et al., 2006). Interestingly, brief exposure (30minutes) to second-hand 
smoking results in increased cEPCs. This is likely secondary to vascular injury leading 
to the mobilisation of EPCs. Nevertheless, the functional capacity of EPCs is adversely 
affected (Heiss et al., 2008). Smoking cessation results in recovery of EPC numbers, 
but this effect is reversible. That is, when smoking is resumed, EPC numbers reduce 
(Kondo et al., 2004).  
 
4.1.6.2 Obesity 
Obesity is a common problem and associated with cardiovascular risk. Circulatory EPC 
(CD34+KDR+) numbers are reduced in healthy but obese subjects (Westerweel et al., 
2008). EPC numbers are improved with weight loss (Müller-Ehmsen et al., 2008). 
Muller-Ehmsen et al. (2008) inducted volunteers into diet and six months exercise 
program group. On average, participants lost 5.8 kgs. In addition, a decrease in BMI 
correlated with an increase in CD34+ and CD34+CD117+ cells. Heida et al. (2010) 
demonstrated that obesity had deleterious effects on EPC function (Heida et al., 2010). 
This could be reversed with weight loss. More recently, Ciuceis et al. (2012) showed 
that EPC numbers were improved after weight loss achieved by bariatric surgery (De 
Ciuceis and et al., 2012).  
 
4.1.6.3 Exercise 
Physical exercise results in an increase in cEPCs. This even occurs with a single bout 
of exercise in healthy individuals (Rehman et al., 2004). Different researchers have 
tried different exercise regimens to assess the effects of exercise on cEPCs. Cesari et 
al. (2012) demonstrated that cEPC numbers improve significantly after 3 months of 
exercise (Cesari et al., 2012). This improvement was also seen in children and 
adolescents. Walther et al. (2008) compared different durations of exercise regimens 
(2 hours/week, 5 hours/week and 12 hours/week). Maximal benefit was seen in the 
group undertaking exercise for 12 hours/week. The migratory capacity of EPCs was 
also better in this group (12 hours/week) as compared to other groups (Walther et al., 
2008).  
 
Even in ischaemic heart disease (IHD) patients, exercise has a positive effect on 
cEPCs. Again, different research groups have tried different regimen. Laufs et al. 
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(2004) showed that four weeks of controlled exercise program resulted in 78%+/-34% 
improvement in cEPC levels (Laufs et al., 2004). Steiner et al. (2005) showed similar 
results after stable CAD patients undertook 12 weeks of endurance training (Steiner et 
al., 2005).  
 
4.1.7 Effect of diabetes mellitus on endothelial progenitor cells 
  
There is an extensive body of evidence regarding alteration in EPC numbers and 
function in DM. Both culture and cytometric methods have consistently demonstrated 
the findings of decreased EPCs number and impaired function (example; adhesion, 
migration, vessel formation and proliferation) in both T1DM and T2DM compared to 
HC.  
 
PAC numbers are negatively affected in T2DM (Tepper et al., 2002) and T1DM 
(Loomans et al., 2004). Furthermore, PAC numbers are inversely correlated with 
HbA1c (Tepper et al., 2002).  
 
Circulatory EPC levels are lower in T2DM (Egan et al., 2008; Liao et al., 2010) and 
T1DM (Sibal et al., 2009a) compared to HC.  In T1DM patients without any overt CVD 
complication, cEPCs (CD34+CD144+, CD133+CD144+ and CD133+CD144+) are lower 
by 46-69% as compared to healthy controls. This correlated with markers of early 
vascular disease (endothelial function) (Sibal et al., 2009a).  EPC (CD34+VEGFR2+) 
and CD34+ cells are reduced early during the natural history of T2DM. CD34+ cells are 
reduced in patients with impaired glucose tolerance compared to HC. (Fadini et al., 
2007).  
 
Patients with DM-related complications have lower cEPC as compared to patients 
without diabetes-related complication. Patients with microalbuminuria (Dessapt et al., 
2010), peripheral vascular disease (Fadini et al., 2005) and non-proliferative 
retinopathy (Brunner et al., 2009) have lower cEPCs (CD34+ and CD34+CD133+, 
CD34+VEGFR2+, CD34+CD133+CD309+ and CD34+CD133+CD309+CD31+ 
respectively). Makino and co-workers (2009) showed that numbers of CD34+ cells 
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predictor development of microalbuminuria in T2DM patients (Makino et al., 2009). In 
proliferative retinopathy, a condition with increased vascularisation, there is an 
increase in cEPC numbers. This result in a phenomenon called diabetic paradox 
(which is characterized by increased neovascularisation in the retina but limited 
vascularisation peripherally). This is due to the diabetic related limitation of cEPC to 
function peripherally and a consequence of growth factor and cytokines released from 
ischaemic insults resulting in mobilization and homing of cEPC (Fadini et al., 2006a). 
 
The role of hyperglycaemia in reduced EPC numbers is supported by studies in T1DM. 
EPC numbers have been shown to improve significantly with improving glycaemic 
control in children with T1DM (Hörtenhuber et al., 2013).  Higher glucose variability 
has been shown to reduce EPC numbers (CD34+ and CD34+VEGFR2+CD133+) in 
T1DM (Maiorino et al., 2015). Furthermore, improvement in glucose variability has 
been shown to improve EPC numbers (Maiorino et al., 2016). In vitro studies have 
demonstrated impaired EPC function under very high glucose condition (Chen et al., 
2007; Kim et al., 2014). High glucose exposure resulted in increased cellular oxidative 
stress and mitochondrial function resulting in autophagy of EPC (Kim et al., 2014). 
Chen et al. (2007) showed that high glucose increased senescence and reduced the 
function of EPC which is not ameliorated by anti-oxidant treatment. Balestrieri et al. 
(2013) showed that levels of silent information regulator 1 (SIRT-1) are reduced 
whereas platelet activating factor (PAF) is increased in EPCs of T2DM. This is much 
more exacerbated in patients with poor control (Balestrieri et al., 2013). Human studies 
in both T1DM and T2DM have confirmed that EPC functions are in patients with DM. 
Loomans et al. (2005) observed impaired tube formation in patients with T1DM. 
Similarly, adhesion, proliferation, migratory capacity is reduced in T2DM (Tepper et al. 
2004). Table 4 present studies published on T1DM and EPC.  
 
Reduced numbers of EPC in patients with DM can occur due to three broad 
mechanisms. Firstly, the release of EPC from bone marrow of DM patients in response 
to stimuli may be impaired. Secondly, differentiation of progenitor cells in bone marrow 
can be impaired. Thirdly, decreased survival of endothelial progenitor cells.  
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4.1.8 Effect of medication on endothelial progenitor cells 
 
Since the discovery of EPCs and our understanding of their clinical significance, many 
intervention studies have been conducted to see if numbers and function of EPCs can 
be improved. As discussed above, making lifestyles changes such as smoking 
cessation and exercise has been shown to improve the numbers and function of EPCs. 
In addition, medications such as atorvastatin (Vasa et al., 2001a), ramipril (Min et al., 
2004), enalapril (Wang et al., 2006a), telmisartan (Pelliccia et al., 2010), pioglitazone 
(Werner et al., 2007), etc. have shown positive (numbers and/or function) effects on 
EPCs in uncontrolled studies. 
 
We will briefly discuss the effect of commonly used medication in diabetes on EPCs. 
The discussion is limited to statins, antihypertensive agents, oral and injectable 
hypoglycaemic agents. 
 
4.1.8.1 Statins 
 
Vasa et al. (2001) demonstrated a 3-fold increase in EPCs numbers after four weeks 
of treatment with atorvastatin. Functional capacity as measured by the Boyden 
chamber showed significant improvement. This seems to be due to increased 
expression of telomere repeat-binding factor2 (Spyridopoulos et al., 2004). Statin also 
prevents EPC telomere shortening (Satoh et al., 2008). Statins have been shown to 
increase eNOS activity. These have been shown to increase EPC mobilisation from 
bone marrow (Walter et al., 2002b). Mice myocardial infarction models have 
demonstrated increased mobilisation of EPCs after treatment with a statin when 
compared to a vehicle treated mice group (Landmesser et al., 2004). Similar results 
were observed in T1DM animal model (Mohler et al., 2009). Statin had demonstrated 
an increase in EPC numbers and function in human studies. Statin treatment during 
the acute phase of ischaemic stroke improved CFU-Hill colonies number when 
compared to a non-treated group (Sobrino et al., 2012). Similar results were noted in 
post-menopausal women after eight weeks of pravastatin (Paradisi et al., 2012).  
Atorvastatin has been shown to increase cEPC numbers in patients with CAD and 
subjects  undergoing coronary artery bypass compared to a non-statin treated group 
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(Baran et al., 2011) and (Schmidt-Lucke et al., 2010).  Statin treatment in patients with 
DM has been shown to increase EPC numbers (Jaumdally et al., 2010).  
 
Questions have been raised over the long-term effect of statins on EPC. It has been 
shown that the effect of statin on EPC seems to be lost after three months. Use of 
statins over long-term decreased EPC numbers in CVD patients (Hristov et al., 2007). 
Brief discontinuation of statins in patients with T2DM has shown to increase EPC 
numbers and their function (Fadini et al., 2015b). This was speculated to be caused by 
reverse activation of statin affected pathways. However, the effect of statin in lowering 
cholesterol far out weights the risk of CVD in patients with T2DM. 
 
4.1.8.2 Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin 
receptor blockers (ARB) 
 
Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers 
(ARB) are used extensively in patients with DM, especially with hypertension and 
microalbuminuria. Both ACEi and ARB have shown to increase EPC mobilisation and 
function in patients with CVD (Pelliccia et al., 2010; Cangiano et al., 2011). Min et al. 
(2004) demonstrated increased EPC numbers and function in patients with CAD 
treated with Ramipril (Min et al., 2004). Similarly, Bahlman et al. (2005) observed an 
increase in EPC numbers after olmesartan or irbesartan in T2DM. Both of these studies 
enumerated EPC by culture method. Bahlmann et al. (2005) also used flow cytometry 
to enumerate CD34+ cells but did not show any effect of treatments on these cells 
(Bahlmann et al., 2005). Sun et al. (2013) demonstrated increased cEPC numbers 
after perindopril in patients with type 2 diabetes after myocardial ischemia (Sun et al., 
2013). ACEi has demonstrated an inverse correlation between the increase in EPC 
numbers and vascular injury as assessed by CIMT in patients with hypertension 
(Cacciatore et al., 2011).  
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4.1.8.3 Oral and injectable hypoglycaemic medications 
 
1.1.1.1 Metformin 
 
Metformin has been shown to increase the EPCs number in patients with T2DM (Chen 
et al., 2010; Liao et al., 2010; Esposito et al., 2011). However, in these studies patients 
had lost weight and their glycaemic control had also improved. Therefore, the drug-
only effect on the improvement of EPC numbers cannot be confirmed due to the 
potential effects of improved glycaemic control and/or weight loss. No studies have 
been conducted in patients with T1DM. Metformin may exert a positive effect on EPC 
via multiple mechanisms. Briefly, the mechanism is likely to be centred around AMPK 
activation, SIRT-1, increased eNOS activity and reduced inflammation/oxidative 
stress. All these pathways can lead to increased EPC mobilisation and improved 
survival and function.   
 
1.1.1.2 Sulfonylureas 
 
Sulfonylureas are commonly used in T2DM. There is very limited literature published 
on the effect of sulfonylurea on EPCs. Chen et al. (2010) demonstrated that the EPC 
numbers increased after gliclazide treatment. However, it was not clear if this effect 
was mediated via improved glycaemic control or a direct consequence of the gliclazide.  
 
1.1.1.3 Thiazolidinedione 
 
Only pioglitazone is now used in T2DM from thiazolidinediones. Multiple studies have 
demonstrated that pioglitazone increased EPC numbers in T2DM when compared to 
the non-treated group (Wang et al., 2006b). However, this correlated with the decrease 
in fasting glucose levels in treated group. Furthermore, pioglitazone improved 
migration, adhesion, tube formation and viability (Wang et al., 2006b; Spigoni et al., 
2012). These studies have been replicated in mouse models of type 2 diabetes. 
Gensch and co-workers showed increased EPC numbers and function and reduced 
apoptosis after pioglitazone treatment (Gensch et al., 2007). Werner et al. (2007) 
showed that patients with CAD (normoglycaemic) treated with pioglitazone results in 
improvement in number and function of EPCs. This was due to the positive effect of 
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pioglitazone on serum adiponectin concentration (an increase of 322%) (Werner et al., 
2007).  
 
1.1.1.4 DPP4 inhibitors 
 
Incretin-based therapy are now increasing being used in T2DM and may have cardio-
protective effects. Animal studies have demonstrated that sitagliptin increased EPC 
numbers and function (Goncalves et al., 2011; Huang et al., 2012). Fadini and co-
worker (2010) replicated findings of animal studies in patients with T2DM. EPC 
numbers increased after four weeks of sitagliptin treatment. SDF-1α levels also 
increased significantly.  It was speculated that the increase in SDF-1α could be due to 
inhibition of DDP4 in the bone marrow, leading to increased mobilisation of EPCs 
(Fadini et al., 2010).  
 
1.1.1.5 Insulin 
 
Insulin is the mainstay of treatment in T1DM. There is limited evidence on the effect of 
insulin on EPC in patients with T1DM. Insulin treatment in mice type 1 diabetic model 
have shown to improve EPC numbers and function (Dong et al. 2011). Most of the 
evidence regarding insulin and EPCs are in T2DM. Insulin has been shown to improve 
the cEPCs number and function in type 2 diabetes (Humpert et al., 2005; Humpert et 
al., 2008; Fadini et al., 2011; Oikonomou et al., 2014).  However, the improvement in 
cEPCs number in Fadini et al. (2011) could be attributed to improvement in HbA1c. 
This was in contrast with Humpert et al. (2005), who showed that the effect of insulin 
on the cEPCs number was independent of HbA1c. The effect of insulin can be 
mediated via insulin-mediated IGF-1 and eNOS activation (Humpert et al., 2008). 
Insulin also has been shown to reduce oxidative stress (Siegelaar et al., 2009). 
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4.1.9 Methods 
 
4.1.9.1 Flow cytometry protocol for enumeration of circulatory endothelial 
progenitor cells (cEPCs) and circulatory endothelial cells (cECs) 
 
Peripheral blood sample collected in the EDTA bottle was used to flow cytometry 
analysis of cEPCs and cECs. First 4 millilitres of collected blood was not used for 
cEPCs analysis to avoid spurious result. Blood samples were processed within 4 
hours of collection.100 µl volume whole blood was added to a TruCount tube.  
 
All five antibodies mentioned in Table 5 was added to the whole blood in the Trucount 
tube. The sample was incubated for 30 minutes at room temperature in the dark. After 
incubation, 2 millilitres of Pharm Lyse (1x strength, diluted with DI water) was used to 
lyse RBCs. It was further incubated for 10 minutes in the dark to ensure complete 
lysis of RBCs. The sample was then analysed using the BD FACS Canto™ II system.  
Following antibodies were added to the whole blood in the TruCount tube (Table 5):  
 
 
 
 
 
 
 
 
Table 5: Antibodies used for EPC and cEC enumeration. 
Before analysing the study samples, optimisation was carried out. Compensation 
and gating strategy were defined with support from flow cytometry department. This 
is discussed below. 
 
Antibody Fluorochrome Volume to add 
CD34 PerCP-Cy5.5 20µl 
CD133 APC 5µl 
VEGFR2 (KDR) PE 5µl 
CD144 FITC 10µl 
CD45 V500 5ul 
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4.1.9.2 Optimising compensation strategy for enumeration of circulatory 
endothelial progenitor cells and circulatory endothelial cells 
 
First, each fluorochrome was analysed separately. Then, V500 CD45 was used to 
stain the cells. After that, each fluorochrome was added with V500 CD45 one at a 
time to enumerate the fluorescence in each channel. Compensation was done to 
make sure there is no overlap of the fluorescence channels (e.g., FITC can spill over 
into the PE channel). Once the compensation was achieved using each fluorescence 
antibody with V500 CD45 than all the fluorochromes were added and analysed 
together. Adequate compensation was deemed adequate once each fluorochrome 
fluorescence (run together) was similar to fluorochrome fluorescence run separately.  
 
4.1.9.3 Optimisation of gating strategy for flow cytometric analysis of 
circulatory endothelial progenitor cells 
 
BD FACSDiva™ software was used for flow cytometry data analysis. Forward and 
side scatter was plotted. Gate for leukocytes was drawn to exclude debris and beads. 
Subsequent analysis was done in the lymphocytic gate. Quantification of different 
cEPCs was performed by gating at the region containing lymphocyte sub-population 
of the cell. A further gate was set on CD45 vs. side scatter. This gate defined all CD45+ 
positive events. The events in CD45+ were then plotted on CD34 versus CD45. Gate 
was configured to define all events which were CD34+ and CD45+. 
 
The lymphocytic gate was set on CD45 vs. side scatter.  The gate was set to define 
all CD45dim positive events. CD45dim events were then plotted on CD34 versus CD45. 
The gate was set to define all events which were CD34+ and CD45dim positive. Then 
we plotted all CD34 and CD45dim events on CD34 versus VEGFR2. Upper right 
quadrant was defined as CD45dimCD34+VEGFR2+. Furthermore, all CD34+ and 
CD45dim events were plotted as CD34 versus CD133. Upper right quadrant was 
defined as CD45dimCD34+CD133+ (Figure 14). 
 
cEPCs are defined as CD45dimCD34+VEGFR2+. Circulating progenitor cells (CPCs) 
are defined as CD45+CD34+ and CD45dimCD34+CD133+. 
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4.1.9.4 Determination of cEPCs and CPC per 100 leukocytes 
 
Number of cEPCs and CPCs per 100 leukocytes was calculation by the following 
formula:  
 
cEPCs or CPC per 100 leukocytes =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑐𝐸𝑃𝐶 𝑜𝑟 𝐶𝑃𝐶 𝑔𝑎𝑡𝑒
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑙𝑒𝑢𝑘𝑜𝑐𝑦𝑡𝑒 𝑔𝑎𝑡𝑒
 × 100 
 
4.1.9.5 Inter-assay and intra-assay variation of cEPCs 
 
As the primary outcome of our study is the change of cEPCs, it is paramount that the 
coefficient of variation (CV%) is as low as possible (approximately 5-10%). Four 
volunteers sample were run on two separate occasions to enumerate inter-assay 
variation. Nine volunteers samples were analysed twice at the same time to assess 
intra-assay variation. Inter-assay and intra-assay variation for 
CD45dimCD34+VEGFR2+ events are < 7% and < 8% respectively. This is in 
concordance with the best available evidence (Table 6).  
 
Table 6: Evidence about intra-assay variations of cEPC. 
Published evidence Coefficient of variation % 
Jialil et al. 2010 11% 
Shmilovich et al. 2007 <10% 
Dessapt et al. 2010 <10 
Briguori et al. 2010 15.5%  
6
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4.1.9.6 Laboratory Protocol 
 
Blood volume of 40 mls was collected at the start and end (8 weeks) of the study and 
was processed within 4 hours of blood collection.  
 
4.1.9.6.1 Isolation of EPCs 
 
4.1.9.6.2 Culture Method 
 
4.1.9.6.2.1 Choice of medium 
 
EBM2 (EBM-2; Promo cell supplemented with 20% fetal calf serum and growth factors-
hEGF, HC, VEGF, hbFGF, R3IGF, AA and Hep-11) was used as a medium for our 
culture.   
 
4.1.9.6.2.2  Proangiogenic cells 
 
PACs were cultured according to the method discussed by Vasa et al. (2001) (Figure 
15). It was modified to suit our laboratory. Approximately 20 mls of venous blood was 
transferred from vacutainer tubes to a 50mL Falcon tube. Venous blood was diluted 
with Ca2+/Mg2+-free phosphate-buffered saline (PBS) (2:1) and mixed by gentle 
inversion. 13mL of Lymphoprep was added to a fresh 50mL Falcon tube. This was 
tilted approximately 45 and the dilute blood was carefully overlaid. Sample was then 
centrifuged at 800g for 15 minutes at room temperature (acceleration = 5, deceleration 
= 3). The buffy coat layer was carefully taken at the Lymphoprep/plasma interface 
using a plastic pasteur pipette, avoiding any lymphoprep, and transferred to a fresh 
50mL Falcon tube. The sample was then centrifuged at 500g for 5 minutes at room 
temperature (deceleration=3). The supernatant was discarded and washed by 
resuspending in 10mL Ca2+/Mg2+-free PBS. This was further centrifuge at 500g for 5 
minutes at room temperature (deceleration=3). The supernatant was discarded and 
the cells resuspended in 1mL of culture medium. Culture medium consisted of EBM2 
(including growth factors) with 20% fetal calf serum (FCS) and 1% 
penicillin/streptomycin.  
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The cell density was determined by diluting 10L cell suspension in 90L PBS. An 
aliquot of dilute cell suspension was added to Trypan Blue at a ratio of 1:1. 10L of 
diluted/stained cell suspension was pipetted to one chamber of the haemocytometer 
and the cells were counted in five squares. The cell count per mL was determined by: 
 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙 =
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 × 20
2 × 10−5
 
The volume of cells was determined from the stock suspension to give 1 X 106 and 5 
X 106 cells as follows: 
1000Z
V
C


 
V = volume of stock suspension containing 1 X 106 and 5 X 10
6 cells, Z = required cell 
number (1 X 106 and 5 X 106), C = cell density of stock suspension.  
 
Culture plates were coated with fibronectin and allowed to dry for 30 minutes. For each 
sample, at least 3-4 wells of a 24-well culture plate were seeded with 1 X 106 cells from 
the stock suspension. In addition 5 X 106 cells were seeded into six wells of 6 well 
culture plate. The plates were incubated at 37C in 5% CO2/air for 48 hours. 
 
After 48 hours, the supernatant containing non-adherent cells was collected and 
transferred to a fresh 50mL Falcon tube. Each well was washed twice with sterile PBS 
and retained with the supernatant. The supernatant was used for plating Hill colonies. 
 
After removing and washing culture plates, the medium was placed, and cells were 
incubated 37C in 5% CO2/air for 48 hours. After which PACs were stained with Ac-
LDL and Ulex lectin. At least three wells of 24 well plates were stained.  
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Figure 15: PAC enumeration method. 
 
Staining EPCs were done according to the method discussed by Vasa et al. (2001). 
Cells were incubated with DiLDL (1,19–dioctadecyl–3,3,39,39–
tetramethylindocarbocyanine–labeled acetylated low-density lipoprotein) (2.4 ug/mL) 
for 1 hour at 37°C.  2% paraformaldehyde was used for 10minutes to fix the cells, 
and then lectin staining was performed by incubating the cells for 1 hour with 
fluorescein isothiocyanate (FITC)–labelled Ulex europaeus agglutinin I (lectin, ten 
ug/mL; Sigma). At least 15 randomly selected high-power fields were captured by an 
inverted microscope. Cells staining for both lectin and Di-LDL (Figure 16) were classed 
as PACs, and they were counted per high power fields.  
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Figure 16: A. Pro-angiogenic cells (20X; Brightfield). B. Dil-LDL staining of EPCs (pro-angiogenic 
cells): Red. C. Ulex-Lectin staining of EPCs (pro-angiogenic cells): Green. D. Double staining of EPCs 
(superimposed image of EPCs labelled with dil-LDL and ulex-lectin). 
 
4.1.9.6.2.3 Hill colonies  
 
Characterisation of the Hill colonies was done as per protocol discussed by Hill et al. 
(2003) (Figure 17). Initial steps were similar to section 4.1.9.6.2.3 (discussed above). 
However, after 48 hours, the culture supernatant was collected. The cultured plate was 
washed twice with PBS and supernatant collected. The cell suspension collected was 
centrifuged at 500g for 5 minutes at room temperature (deceleration=3). The 
supernatant was discarded, and the cell pellet was re-suspended in 1mL of medium 
and counted. 1X106 cells were re-plated in fresh fibronectin-coated 24-well plates. At 
least three wells were re-plated. The plates were incubated at 37C in 5% CO2/air, and 
the medium was changed every three days. After seven days, Hill colonies and clusters 
were counted. 
A B 
C D 
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Figure 17: CFU-Hill Colonies enumeration method. 
Only those colonies were counted that exhibit multiple thin flat cells emanating from a 
central cluster of rounded cells as illustrated in the Figure 18. These colonies were 
called Hill colonies.  
 
 
Figure 18: Hill Colony (multiple thin flat cells radiating from a central cluster of rounded cells). 
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4.1.9.6.2.4 Functional Assay 
 
The fibronectin adhesion assay was performed as a part of the functional assay. This 
has been described by Huang et al. (2007) (Figure 20). On day 4, at least three wells 
of 6 well culture plates were washed with PBS and gently detached with 5 mmol/l 
EDTA.  
 
Detached cells were collected in a 50 ml falcon tube. The culture plates were washed 
twice with PBS and once with EBM2 containing 5% FCS. This was to make sure all 
detached cells were collected. The suspension was centrifuged at 500g for 5 min. The 
supernatant was discarded. The pellet was re-suspended in 500 ul of EBM2 containing 
5% FCS.  
 
At least four wells of the 48 well culture plate were coated with fibronectin. After drying 
for 30 minutes, identical cell numbers were plated and incubated at 37C in 5% CO2/air 
for 30 minutes. After 30 minutes, each well was washed at least twice to remove all 
non-adherent cells. Adherent cells are stained with ac-LDL and ulex-lectin, as 
described above. At least ten randomly selected high-power fields were captured. Cells 
staining positive for both lectin and Di-LDL were judged to be EPCs, and they were 
counted per high power fields (Figure 19). 
 
 
Figure 19:  Dual-stained cells positive for both lectin and Di-LDL (Adhesion assay). 
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Figure 20: PAC adhesion function method.
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4.1.10 Specific aims 
 
In this section, we aimed to evaluate if metformin improved the following in type 1 
diabetes when controlled for glycaemic changes: 
1. Number of cEPCs, 
2. Number of PACs, 
3. Adhesion function of PACs, and 
4. Number of CFU-Hill colonies. 
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4.1.11 Results 
 
4.1.11.1 CD34+  
 
Result is presented in Figure 21. 
 
4.1.11.1.1 Treatment group (Pre metformin) versus Healthy control 
 
CD34+ cells were significantly lower (57%) in TG compared with HC (Treatment group 
pre-metformin (TG V1) vs HC; median (intraquartile range (IQ): 0.047 (0.038-0.078) vs 
0.11 (0.09-0.13) % leukocytes; p<0.0001). 
 
4.1.11.1.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight weeks of metformin treatment did not result in any change in CD34+ cells; TG V1 
vs TG V2; median (IQ): 0.047 (0.038-0.078) vs 0.058 (0.04-0.074) % leukocytes; 
p=0.1. 
 
4.1.11.1.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, CD34+ cells remained significantly lower in TG V2 when 
compared with HC (TG V2 vs HC); median (IQ): 0.058 (0.04-0.074) vs 0.11 (0.09-0.13) 
% leukocytes; p<0.0001.  
 
4.1.11.1.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, CD34+ cell count was similar in TG and the SG (TG V1 vs standard group 
pre observation (SG V1); median (IQ): 0.047 (0.038-0.078) vs 0.047 (0.036-0.06); 
p=0.7. 
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4.1.11.1.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
CD34+ cells count: SG V1 and standard group post observation (SG V2): median (IQ):  
0.047 (0.036-0.06) vs. 0.048 (0.038-0.065) % leukocytes; p=0.9. 
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Figure 21: CD34+ cells are comparing all groups (mean+/-SE). Pre-treatment (TG V1) and Post-
treatment (TG V2), Healthy control and standard group: Pre observation (SG V1) and Post 
observation (SG V2). Results are given as per 100 leukocytes.  
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4.1.11.2 CD45dimCD34+CD133+ 
 
Result is presented in Figure 22. 
 
4.1.11.2.1 Treatment group (Pre metformin) versus Healthy control 
 
CD45dimCD34+CD133+ cells were significantly lower in TG compared with HC: TG V1 
vs HC; mean+/-SE: 0.019+/-0.002 vs 0.03+/-0.002 % leukocytes; p<0.0001). 
 
4.1.11.2.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight weeks of metformin treatment did not result in any change in 
CD45dimCD34+CD133+ cells (TG V1 vs TG V2; mean+/-SE: 0.0019+/-0.002 vs 0.02+/-
0.002 % leukocytes; p=0.4). 
 
4.1.11.2.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, CD45dimCD34+CD133+ cells remained significantly lower in 
TG when compared with HC (TG V2 vs HC); mean+/-SE: 0.02+/-0/002 vs 0.03+/-0.002 
% leukocytes; p=0.0001.  
 
4.1.11.2.4 Treatment group (Pre metformin) versus Standard group (Pre-
observation) 
 
At baseline, CD45dimCD34+CD133+ cell count was similar in TG and the SG: (TG V1 
vs SG V1; mean+/-SE: 0.019+/-0.002 vs 0.023+/-0.004; p=0.3). 
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4.1.11.2.5 Standard group (Pre observation) versus Standard group (Post 
observation): 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
CD45dimCD34+CD133+ cells count (SG V1 vs SG V2: mean+/-SE:  0.023+/-0.004 vs. 
0.02+/-0.0039 % leukocytes; p=0.3). 
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Figure 22: CD45dimCD34+CD133+ cells comparing all groups (mean+/-SE). Pre-treatment (TG V1) and 
Post-treatment (TG V2), Healthy control and standard group: Pre observation (SG V1) and Post 
observation (SG V2). Results are given as per 100 leukocytes. 
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4.1.11.3 CD45dimCD34+VEGFR-2+ 
 
Combined result is presented in Figure 28. 
 
4.1.11.3.1 Treatment group (Pre metformin) versus Healthy control 
 
At baseline, cEPCs (CD45dimCD34+VEGFR-2+) were significantly lower (60%) in TG 
compared with HC (TG V1 vs HC; median (IQ): 0.0028 (0.0016-0.006) vs 0.0068 
(0.006-0.009) % leukocytes; p<0.0001). 
 
4.1.11.3.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly increased cEPCs in TG by more than 
75% (TG V1 vs TG V2; median (IQ): 0.0028 (0.0016-0.006) vs 0.005 (0.0035-0.0085) 
% leukocytes; p=0.0004). 
 
4.1.11.3.3 Treatment group (Post metformin) versus Healthy control 
 
As mentioned above, metformin treatment improved cEPCs number in TG group and 
normalised the levels of cEPCs count when compared to HC (TG V2 vs HC); median 
(IQ): 0.0028 (0.0016-0.006) vs. 0.0068 (0.006-0.009) % leukocytes). After treatment, 
the cEPCs count is only 28% lower in TG when compared to HC versus 60% lower in 
TG pre-metformin treatment when compared to HC. After metformin treatment, 
significance disappeared (p=0.065).  
 
4.1.11.3.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, cEPCs count was similar in TG and the SG (TG V1 vs SG V1; median 
(IQ): 0.0028 (0.0016-0.006) vs 0.003 (0.0022-0.004); p=0.9). 
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4.1.11.3.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
the cEPCs count (SG V1 SG V2: median (IQ):  0.003 (0.0022-0.004) vs. 0.0035 (0.003-
0.005) % leukocytes; p=0.55). 
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Figure 23: cEPC-CD45dimCD34+VEGFR-2+ comparing treatment group: Pre-treatment (TG V1) and 
Post-treatment (TG V2), Healthy control and standard group: Pre observation (SG V1) and Post 
observation (SG V2). Results are given as per 100 leukocytes. Line denotes in each box as median 
and + in each box denotes mean value. 
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4.1.11.4 Effect of metformin at four weeks on cEPCs and progenitor 
phenotypes 
 
In TG, four weeks of metformin treatment did not change CD45dimCD34+VEGFR-2+ 
(Figure 29) and CD45dimCD34+CD133+ (Figure 30) cell numbers in treatment group. 
However, the CD34+ cell levels increased by 78% (Figure 31) (Table 7). 
 
 
 
N=7 
Pre-metformin (TG 
V1) 
4-week metformin 
(TG V1.5) 
Post-metformin 
(TG V2) 
CD45dimCD34+VEGFR-2+ 
median (IQ) 
0.0034 (0.002-
0.006) 
0.0039 (0.0023-
0.009) 
0.007 (0.005-
0.009) 
CD34+  
mean+/-SE 
0.06+/-0.01 0.11+/-0.01* 0.067+/-0.01^ 
CD45dimCD34+CD133+ 
mean+/-SE 
0.02+/-0.004 0.02+/-0.0045 0.02+/-0.003 
Table 7: cEPC and CPC levels at three times points (pre-metformin, 4-week metformin and post-
metformin). * and ^ denotes significance on Post hoc Bonferroni’s multiple comparison tests). 
 
Friedman test did not show significance between three-time points measurement for 
CD45dimCD34+VEGFR-2+ (p=0.0515). Levels more than doubled between TG V1 and 
TG V2.Lack of significance is likely due to small sample size. 
 
One-way ANOVA analysis was significant for CD34+ cell (p=0.0019) Post hoc 
(Bonferroni's multiple comparison tests) was significant for TG V1 vs. TG V1.5 and TG 
1.5 vs. TG 2. It was not significant between TG 1 vs. TG 2. 
 
One-way ANOVA analysis was not significant for CD45dimCD34+CD133+ cells.  
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Figure 24: cEPC levels at three-time point (TG V1, TG V1.5 and TG2) (median (IQ). 
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Figure 25: CD34+ cell levels at three-time point (TG V1, TG V1.5 and TG2) (mean+/-SE).  
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Figure 26: CD45dimCD34+CD133+ cell levels at three-time point (TG V1, TG V1.5 and TG2) (mean+/-
SE).  
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4.1.11.5 Proangiogenic cells 
 
Result is presented in Figure 32. 
 
4.1.11.5.1 Treatment group (Pre metformin) versus Healthy control 
 
At baseline, PAC numbers were significantly lower in TG when compared with HC 
(TG V1 vs. HC): mean+/-SE: 16.6+/-1.9 vs. 40.3+/-4.2 per hpf: p<0.0001). 
 
4.1.11.5.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly increased PAC number in TG; (TG V1 
vs. TG V2) mean+/-SE: 16.6+/-1.9 vs. 28.4+/-2.7 per hpf: p<0.0001). 
 
4.1.11.5.3 Treatment group (Post metformin) versus Healthy volunteer 
 
After metformin treatment, PAC numbers remained significantly different between TG 
V2 and HC (TG V2 vs. HC); mean+/-SE: 28.4+/-2.7vs 40.3+/-4.2 per hpf: p=0.008. 
 
4.1.11.5.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, PAC numbers were similar in TG and the SG (TG V1 vs. SG V1 (Pre); 
mean+/-SE; (TG V1 vs. SG V1: 16.6+/-1.9 vs. 17.6+/-4 per hpf; p=0.8). 
 
4.1.11.5.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of observation, PAC numbers remained unchanged (SG V1 and SG 
V2: mean+/-SE (SG V1 vs. SG V2: 17.6+/-4 vs. 15+/-3.7: p=0.6).  
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Figure 27: PAC comparing all the groups (mean+/-SE). Results are given as per hpf. 
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4.1.11.6 Colony forming unit (CFU-Hill colonies) 
 
Result is presented in Figure 33. 
 
4.1.11.6.1 Treatment group (Pre metformin) versus Healthy control 
 
At baseline, CFU-Hill colonies were significantly lower in TG when compared with HC 
(TG V1 vs. HC): mean+/-SE: 8.3+/-1.4 vs. 20.6+/-2.3: p<0.0001). 
 
4.1.11.6.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly increased CFU-Hill colonies in TG; (TG 
V1 vs. TG V2) mean+/-SE: 8.3+/-1.4 vs. 13.8+/-1.9: p<0.0001). 
 
4.1.11.6.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, CFU-Hill colonies number remained significantly different 
between TG V2 and HC (TG V2 vs. HC); mean+/-SE: 13.8+/-1.9 vs. 20.6+/-2.3: 
p=0.02. 
 
4.1.11.6.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, CFU-Hill colonies were similar in TG and the SG (TG V1 vs. SG V1; 
mean+/-SE; 8.3+/-1.4 vs. 10.4+/-2.2; p=0.12). 
 
4.1.11.6.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of observation, CFU-Hill colonies number remained unchanged (SG 
V1 vs. SG V2): mean+/-SE: 10.4+/-2.2 vs. 11.1+/2.1: p=0.8).  
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Figure 28: CFU-Hill colonies all the groups (mean+/-SE). Results are given as per hpf. 
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4.1.11.7 Proangiogenic cell Function-Adhesion 
 
Result is presented in Figure 34. 
 
4.1.11.7.1 Treatment group (Pre metformin) versus Healthy control 
 
At baseline, adhesion of PACs was significantly lower in TG when compared with HC 
(TG V1 vs. HC): mean+/-SE: 26.9+/-4.5 vs. 67+/-6: p<0.0001). 
 
4.1.11.7.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly increased adhesion of PACs in TG; (TG 
V1 vs. TG V2) mean+/-SE: 26.9+/-4.5 vs. 61+/-8.8: p<0.0001). 
 
4.1.11.7.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, adhesion of PACs in TG became similar to HC (TG V2 vs. 
HC); mean+/-SE: 61+/-8.8 vs. 67+/-6: p=0.6. 
 
4.1.11.7.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, adhesion of PACs number was similar in TG and the SG (TG V1 vs. SG 
V1; mean+/-SE; 8.3+/-1.4 vs. 35.9+/-5; p=0.12). 
 
4.1.11.7.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of observation, adhesion of PACs number remained unchanged (SG 
V1 and SG V2: mean+/-SE: 35.9+/-5 vs. 37.3+/-5.4: p=0.9).  
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Figure 29: PAC adhesion function comparing all the groups (mean+/-SE). Results are given as per 
hpf. 
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4.1.11.8 Subgroup analysis – Effect of metformin in smokers and patients 
taking ACE/Statins 
 
Smoking, statin and ACE inhibitors and has been shown to effect EPC numbers and 
function. This has been discussed above in section 4.1.6.1, 4.1.8.1 and 4.1.8.2. We 
explored if metformin will affect EPCs, PACs, CFU-Hill colonies numbers and PAC 
function in patients who smoked or were on statin and/or ACE inhibitors.  
 
In TG who smoked (n=4), metformin resulted in similar or higher increase in cEPC, 
PAC, CFU-Hill colonies or adhesion properties of PACs (73%; (median (IQ)) 0.0038 
(0.002-0.018 vs 0.0066 (0.0048-0.018) % leukocytes, 185%; 9.6 (2.5-13) vs 27.4 (22.6-
28.6) per hpf, 133%; 8.4 (5.8-24.8) vs 19.9 (10-37.5) per well and 137%; 18.2 (2.3-
49.9) vs 42.4 (18-64.3) per hpf respectively) or were on ACE and/or Statins (n=11) 
(122%, 69%, 111% and 81% respectively).   
 
 
4.1.11.9 Correlation 
 
Correlation is presented in Appendix A. Below, we present important correlations.  
 
At the baseline, PAC numbers were inversely related to glucose variability (CONGA: 
r=-0.56; p<0.01; AUC: r=-5; p<0.05). At the baseline, PAC adhesion function was 
inversely related to glucose variability (CONGA: r=-0.43; p<0.05). 
 
In univariate analysis in TG, there was no correlation between changes in HbA1c, BMI, 
insulin dosage, total cholesterol, HDL cholesterol, LDL cholesterol, cEPCs, PACs, 
CFU-Hill’s colonies levels and PACs adhesion.  
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4.1.12 Discussion 
 
Markers of vascular repair were assessed at baseline and after four and eight weeks 
of metformin treatment. These were compared with healthy volunteers. Similar 
markers were evaluated in T1DM cohort group to explore if any changes in above-
mentioned markers can be observed with routine follow up without any treatment with 
metformin.   
 
4.1.12.1 Decreased cEPC and progenitor cell phenotypes (CPC) in type 1 
diabetes 
 
4.1.12.1.1 Main finding 
 
cEPC and CPC levels in T1DM individuals are significantly lower than healthy controls. 
 
4.1.12.1.2 Prior work 
 
Above mentioned finding is similar to the results of previous work (Sibal et al., 2009a; 
Hernandez et al., 2014). However, in a younger group of patients with T1DM, we have 
found EPC numbers to be similar between patients and healthy controls (West et al., 
2015). Individual with T1DM in West et a (2015) was much younger, lower BMI and 
high cardio-respiratory fitness (VO2max 50 ml.kg.min-1 - average 
VO2max 42 ml.kg.min-1). It can be speculated that higher cardio-respiratory fitness can 
be a contributory factor compared to HC. 
 
4.1.12.1.3 Mechanism 
 
Our finding of decreased EPC numbers suggests impaired endothelial repair 
mechanism and the risk of future development of cardiovascular disease. We know 
that T1DM patients with CVD or peripheral vascular disease (PVD) had lower EPC 
when compared with patients without CVD and PVD (Hernandez et al., 2014). 
 
Lower EPCs and CPCs levels in our study could be due to decreased cell survival, 
increased senescence and/or decreased recruitment from the bone marrow. An animal 
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model has shown that long-term diabetes mellitus can cause bone marrow 
microangiopathy (Ferraro et al., 2011; Westerweel et al., 2013). This could be one of 
the reasons of impaired recruitment in T1DM.  
 
Furthermore, research has shown impaired mobilisation of cEPCs in response to the 
administration of the recombinant granulocyte colony-stimulating factor in patients with 
diabete (Fadini et al., 2013). We have also shown that the bone marrow release of 
cEPCs in response to an exercise is also blunted in T1DM versus healthy controls 
(West et al., 2015). 
 
We can speculate that the underlying cause of lower EPC numbers in our patients may 
be due to impaired bone marrow function. DM is known to cause bone marrow 
microangiopathy. This has been well established in animal models. Microcirculation of 
the diabetic animal model has shown evidence of rarefaction, reduced circulation and 
increased permeability. These changes are accompanied by impairment of nerve 
signalling (sympathetic and nociceptive nerve fibre) increased inflammatory cells and 
adipocytes deposition (Oikawa et al., 2010; Mangialardi et al., 2013; Albiero et al., 
2014; Albiero et al., 2015). Some of these changes in bone marrow have been 
confirmed in human studies (Spinetti et al., 2013). Fadini and co-workers (2006) 
observed that EPCs were not mobilised from bone marrow of T1DM rats in response 
to ischemia/reperfusion injury. There was suboptimal response to growth factor 
stimulation in these diabetic rats (Fadini et al., 2006b). Impaired mobilisation of 
progenitor cells due to bone marrow dysfunction was observed in a mouse model of 
diabetes (Ferraro et al., 2011; Westerweel et al., 2013). Human studies have shown 
impaired mobilisation of EPC from bone marrow. Ferraro et al. (2013) demonstrated 
reduced mobilisation of progenitor cells in response to G-CSF in patients with diabetes 
with the haematological disorder. Fadini and co-workers (2013) demonstrated impaired 
mobilisation of progenitor cells after G-CSF stimulation in patients with DM (Fadini et 
al., 2013). These findings were corroborated in a meta-analysis by the same group 
demonstrated reduced CD34+ cell response to G-CSF in CVD patients with diabetes 
(Fadini and Avogaro, 2013). It is interesting to note that HbA1c did not correlate with 
G-CSF effect on progenitor cell mobilisation (Fadini et al., 2013). Therefore, it is likely 
other mechanisms may account for an impaired response.  
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Fadini and group (2013) has demonstrated that SDF-1α gradient was affected in 
patients with diabetes. SDF-1α is a substrate of CD26/DDP-4. CD26/DDP-4 is a 
protease, and its activity is impaired in patients with diabetes. G-CSF failed to 
upregulate the activity of CD26/DDP-4 in bone marrow derived from patients with 
diabetes. As a result, SDF-1α gradient did not change (Fadini et al., 2013).  
 
There is a need to develop strategies to improve mobilisation of EPC in patients with 
diabetes. Studies in diabetic mice models have identified that CXCR4 receptor 
antagonist ameliorated impaired bone marrow mobilisation of progenitor cells (Tepper 
et al., 2010).  This finding was confirmed in a small human study (10/group). In this 
study, plerixafor (CXCR4 antagonist) was able to equally able to increase CD34+ 
mobilisation in both groups (with or without DM) after G-CSF stimulation (Fadini et al., 
2015a).  
 
4.1.12.2 Decreased PAC, CFU-Hill colonies and PAC adhesion function in 
type 1 diabetes 
 
4.1.12.2.1 Main finding 
 
Main findings were:  
1. T1DM had lower PAC numbers when compared to HC. 
2. Number and adhesion function of PACs were inversely correlated with glucose 
variability but not correlated with HbA1c. 
3. CFU-Hill colonies were lower in T1DM when compared to HC. 
 
4.1.12.2.2 Prior work 
 
Our data was consistent with a previous report by Looman et al. (2004). However, in 
contrast to Looman et al. (2004), PAC numbers in our subjects were not associated 
with HbA1c but were inversely related to glucose variability. In our study, T1DM 
patients had better diabetes control than patients in above-mentioned study (8.3+/-1.5 
vs. 7.3%). Our finding could be relevant for understanding that even with good diabetes 
control T1DM patients were at high risk of impaired vascular repair.  
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Our results corroborated findings of seminal work by Hill et al. (2003), who showed that 
the numbers of CFU-Hill colonies were significantly lower in subjects with diabetes 
compared to individuals without diabetes. Our data showing lower CFU-Hill colonies 
provide additional evidence that T1DM were at increased risk of development of future 
CVD in our patients. 
 
4.1.12.2.3 Mechanism 
 
Low levels of PAC in T1DM in our study could be due to increased cell death and 
apoptosis or poor functional capacity of PACs. It has been shown that apoptosis may 
not be involved in lower EPC numbers in patients with DM  (Jung et al., 2010).  An 
alternative mechanism could be impaired function capacity of PAC to proliferate, 
differentiate and/or adhere to culture condition. We had demonstrated that the 
adhesion function of PACs was impaired in T1DM when compared to HC. PACs 
dysfunction in adhesion in T1DM could result in impaired cEPCs homing, cell-cell 
contact and transmigration events which were necessary neovascularisation and 
vascular repair. The lower number of CFU-Hill colonies in our study could also be due 
to decreased adhesive or migratory properties of cells or due to the decreased fraction 
of PBMC capable of colony forming properties.  
 
Our data demonstrated that with good glycaemic control, HbA1c may not impact on 
PAC function. Nevertheless, glucose variability still can play some role in PAC 
dysfunction resulting in reduced vascular regenerative potential in T1DM and 
contributing to the pathogenesis of vascular complications. Glucose fluctuations had 
been shown to cause more endothelial damage than chronic hyperglycaemia (Cavalot, 
2013). It is thought that oxidative stress and damage plays an important role. This has 
been shown to be true in type 2 diabetes (Monnier et al., 2006). However, this has not 
been shown to be the case with T1DM (Wentholt et al., 2007). It has been shown that 
reducing glucose variability improved cEPC numbers (Maiorino et al., 2016). Thus, the 
effect of improved glucose variability on cEPC numbers and PAC function can be 
another way to improve the balance between vascular repair and damage. This needs 
to be confirmed by exploring if glucose variability has any effect on endothelial function.  
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4.1.12.3 Metformin treatment increases cEPC numbers 
 
4.1.12.3.1 Main finding 
 
Our main findings were: 
1. Metformin improved cEPC numbers significantly in T1DM and brought the 
number closer to HC.  
2. After four weeks of metformin treatment, CD34+ cell increased. 
CD45dimCD34+VEGFR2+ did not change after four weeks of metformin 
treatment. However, after eight weeks of metformin treatment, CD34+ cell levels 
came down to baseline and CD45dimCD34+VEGFR2+ numbers increased.  
 
4.1.12.3.2 Novelty 
 
We have shown for the first time that 8 weeks of metformin treatment increased cEPC 
numbers in T1DM without altering overall diabetes control as assessed by HbA1c and 
glucose variability. We believe that this increase was caused by metformin, not by the 
clinical care given during eight weeks of treatment. SG did not show any change in 
cEPC numbers. Our SG underwent similar clinical care without treatment with 
metformin. Other progenitor cell phenotypes did not change after metformin treatment.  
 
In addition, we have shown for the first time that metformin initially increased CD34+ 
cell numbers. This was followed by an increase in differentiation of CD34+ cells into 
more mature cEPCs.  This finding provides an important information regarding a 
possible mechanism of increased cEPC numbers after treatment with metformin.  
 
 
4.1.12.3.3 Prior work 
 
Previous work had shown that metformin improved cEPC numbers. However, all of the 
evidence is available in T2DM. There was a significant improvement in HbA1c (Chen 
et al., 2010; Liao et al., 2010; Esposito et al., 2011). Thus, the change in cEPCs 
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number could have been attributed to improved diabetic control. We have 
demonstrated that improvement in cEPC is independent of glycaemic control in TG. 
 
4.1.12.3.4 Mechanism 
 
We speculate that the observed effect of metformin on cEPCs in our study may be due 
to improved cell survival, decreased senescence, increased recruitment from the bone 
marrow and/or increased differentiation of CD34+ hematopoietic precursor cells into 
EPCs.  
 
In-vitro work has shown that metformin’s effect on improved EC survival by reducing 
premature senescence and apoptosis (Arunachalam et al., 2014b). It had been shown 
that metformin exerts its protective effect on endothelium through SIRT-1. Does 
metformin exert a similar effect on cEPC? This will need to be further studied.  
 
It had been shown that in DM, EPC mobilisation could be impaired (Fadini et al., 2013). 
Multiple mechanisms including eNOS dysfunction (Gallagher et al.)(Gallagher et al. 
2007) or alteration in cytokines has been shown to play a role in impaired EPC 
mobilisation (Fadini and Avogaro, 2013). We will discuss this further in chapter 6. 
Metformin is a potent activator of AMPK pathway. It has been shown that AMPK 
activation improved EPC mobilisation and differentiation (Li et al., 2008; Li et al., 
2012a; Yu et al., 2016).  
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4.1.12.4 Metformin treatment improves PAC, CFU-Hill colonies and PAC 
adhesion function 
 
4.1.12.4.1 Main finding 
 
Our main findings were: 
1. Metformin significantly improved PAC numbers independent of glycaemic 
control in T1DM.  
2. Metformin enhanced the function of PAC adhesion and increased the ability to 
form colonies (CFU-Hill colonies) independent of glycaemic control in T1DM.  
 
 
4.1.12.4.2 Novelty 
 
We have shown for the first time that the cell fraction of PBMC taken from patients with 
T1DM after metformin treatment continued to show significant improvement in PACs, 
CFU-Hill colonies number and PAC adhesion function in a euglycaemic culture 
environment when compared to the cells taken at the pre-treatment stage. 
 
4.1.12.4.3 Mechanism 
 
We postulate that metformin improves functional capacity of PAC to proliferate, 
differentiate and/or adhere to culture condition. We have demonstrated that adhesion 
capacity of PAC improved after metformin treatment and brought it closer to healthy 
volunteers. PACs adhesion function improvement after metformin treatment in T1DM 
can improve cEPCs homing, cell-cell contact and transmigration events for 
neovascularisation and vascular repair. AMPK activator had been shown to improve 
EPC function (Yu et al., 2016). The beneficial effect of metformin can be in part 
mediated by its activation of AMPK. It would have been ideal if we had assessed 
whether AMPK pathway inhibition would abrogate this improvement in PAC adhesion 
function and ability to form colonies. This is one of the limitations of our study.  
 
Change in PACs and CFU-Hill colonies number and PAC adhesion function were not 
correlated with changes in insulin dosage. This is interesting, as insulin has been 
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shown to improve cEPCs number (Humpert et al., 2005; Fadini et al., 2011) and 
function in type 2 diabetes (Humpert et al., 2008; Oikonomou et al., 2014).  However, 
the improvement in cEPCs number in Fadini et al. (2011) could be attributed to 
improvement in HbA1c. This is in contrast with Humpert et al. (2005), who showed that 
the effect of insulin on the cEPCs number is independent of HbA1c. If the former was 
likely, given the reduction in insulin dosage in our study, cEPCs, PACs and CFU-Hill 
colony number and PACs adhesion should have decreased, but this is not the case. 
This suggests that the insulin dose reduction did not have any effect on improving 
cEPCs or PACs function. 
 
4.1.13 Conclusion 
 
In conclusion, eight weeks of metformin treatment increased cEPC, PAC, CFU Hill 
colonies number and PAC adhesion function in T1DM independent of glycaemic 
control. Our data also corroborated findings from previous work showing lower cEPCs, 
PACs, CFU-Hill colonies number and PAC function in T1DM. Future work is needed to 
explore the mechanisms by which metformin improved cEPCs, PAC, CFU-Hill colonies 
number and PAC function in T1DM.  
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4.2 Circulatory endothelial cells (cECs) 
 
Endothelial cell (EC) lines the vasculature as a monolayer. They not only form a barrier 
but plays a vital role in vascular haemostasis (Lerman and Zeiher, 2005). In normal 
condition, EC turnover is very low (0-1% daily). These cells are very rare in the blood of 
healthy individual (between 5-10 cells/ml) (Woywodt et al., 2006). It is thought that these 
cells are cleared by the reticuloendothelial system (Boos et al., 2006). cECs are 
approximately 15-50µm in diameter (Erdbruegger et al., 2006).  Vascular damage results 
in the release of circulating endothelial cells (cECs) from the vascular intima into 
circulation. The mechanism of cECs detachment from vascular intima is complex and is 
due to irreversible loss of integrity as a response to endothelial activation by mechanical 
stress, inflammatory cytokines, growth factors, infectious agents, lipoprotein, and 
oxidative stress (Boos et al., 2006) (Figure 35). It is not clear if EC apoptosis or 
detachment occurs in which order, however, the current evidence point towards 
detachment preceding apoptosis (Erdbruegger et al., 2006).  
 
 
Figure 30: Potential mechanisms for EC detachment and microparticle formation. CEC, circulating 
endothelial cells; EMP, endothelial microparticles; sTM, soluble thrombomodulin; sE-Sel, soluble E-
selectin; vWF, von Willebrand factor. Adapted from (Goon et al., 2006). 
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4.2.1 Enumeration of cECs 
 
Accurate enumeration of cECs remains difficult due to low numbers of cECs in circulation 
Boos et al. 2006). Two major methods are used: 
 
1. Immunomagnetic separation (George et al., 1992; Blann et al., 2005) 
 
2. Flow cytometry (Mancuso et al., 2001; Khan et al., 2005)  
 
 
Immunomagnetic separation involves the use of ferrous beads bound to the anti-CD146 
monoclonal antibodies. cECs are characterised by the presence of CD146. Anti-CD146 
antibodies are mixed with blood. Anti-CD146 binds to cells with CD146 antigen. The 
mixture is placed in front of a magnet. Cells bound to the beads are separated by the 
magnet. The magnet is washed to remove unbound cells. The bound cells can be labelled 
with endothelial specific fluorescent markers like Ulex europaes lectin 1 and counted 
under a fluorescent microscope (Boos et al., 2006).  
 
Flow cytometry is more extensively used to enumerate cECs. The procedure is currently 
not standardised. Multiple markers are used to identify cECs. cECs are characterised by 
the presence of endothelial cell surface markers like CD144 and absence of 
haematopoietic (e.g., CD45) and progenitor cell markers (e.g., CD133). CD144 is 
important for maintaining endothelium integrity through the cell to cell adhesion (Goon et 
al., 2006). The absence of CD133 has been used to distinguish it from EPCs. Published 
studies have used surface markers like CD31, CD62e, CD54, CD146, CD141, CD106, 
CD105, vWF and eNOS to identify cECs. CD34 is also present on EC (Table 8). However, 
there is a lack of consensus regarding a precise antigen for cECs identification (Boos et 
al., 2006; Burger and Touyz, 2012; Flores-Nascimento et al., 2015).  
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References cEC markers 
(Lampka et al., 2010) CD146+, CD45−, CD31+ 
(Li et al., 2013) CD146+, CD45−, Hoechst 
33342+, CD31+, and 
CD133−FWD/SSC 
(Mourino-Alvarez et al., 2013)  CD45−, CD31bright, CD34+, CD 
133−, and FWD/SSC 
(Flores-Nascimento et al., 2015)  CD45-, CD133-, CD144+, 
CD146+, VEGFR2+ 
(Ozdogu et al., 2007)  CD34-, CD117-, CD146+, CD144+ 
(Machalinska et al., 2010)  CD133-, CD144+ 
(Shaffer et al., 2006)  CD146+, CD146+CD31+, 
CD146+CD34+, 
CD146+CD34+CD31+, 
CD34+CD31+CD133- 
(Lombardo et al., 2012)  CD45-, CD31+CD146+ 
CD106 
 
Table 8: Overview of markers used in various publications regarding cECs.  
 
Various studies have described endothelial cells as resting and activated. Clinical and 
research significance of the activated or resting EC remains to be evaluated. Activated 
ECs have increased procoagulant activity, increased leukocyte adhesion and 
phagocytosis. These cells produce markers of oxidative stress like nitric oxide, 
prostacyclin and oxygen radicals. Activated ECs have been shown to express CD54 
(intracellular adhesion molecules), CD62e (E-selectin), CD106 (vascular cell adhesion-1) 
and CD105 (endoglin) (Mancuso et al., 2001; Khan et al., 2005).  
 
cECs have been shown to reflect endothelial status. Thus, the increase in cECs reflects 
increased vascular damage.  
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4.2.2 cECs in vascular disease 
 
Several studies have consistently demonstrated that cECs levels are high in patients 
with myocardial infarction and unstable angina (Mutin et al., 1999; Makin et al., 2004). 
cECs levels have been shown to be 400% higher in patients with MI than healthy 
control (Damani et al., 2012).  In stable angina, levels are either normal or minimally 
raised (Mutin et al., 1999; Lee et al., 2005a). Levels of cECs correlate with markers of 
endothelial dysfunction (Makin et al., 2004).  
 
Similarly, patients with an active peripheral vascular disease had higher ECs levels 
when compared to healthy controls or patients with symptoms of intermittent 
claudication (Makin et al., 2004; Shaffer et al., 2006). cECs levels are raised in patients 
with acute stroke when compared with healthy controls (Freestone et al., 2005; Nadar 
et al., 2005; Woywodt et al., 2006). Levels of cECs correlated with makers of 
endothelial function like (vWF or plasma tissue factor or E-Selectin) (Makin et al., 2004; 
Nadar et al., 2005). It is interesting to note that patients with hypertension have been 
shown to have normal cEC levels (Nadar et al., 2005). It is likely that appropriate 
vascular insult is needed for release of EC. This is evidenced by the fact that stable 
vascular diseases like stable angina or intermittent claudication did not result in an 
increase in cECs (Lee et al., 2005 and Makin et a., 2004).   
 
Other conditions like pulmonary hypertension (Smadja et al., 2009), acute and chronic 
heart failure have shown to be associated with higher cEC levels when compared to 
healthy control (Chong et al., 2006).  
 
cECs have been shown to predict cardiovascular events in high-risk groups. Koc et al. 
2005 demonstrated that high cEC levels predicted future CV events in haemodialysis 
patients (Koc et al., 2005). Similarly, Lee and co-workers 2005 demonstrated that high 
cECs levels at 48 hours predicted future coronary events and mortality in patients with 
ACS (Lee et al., 2005a). High cECs levels have been shown to predict increased 
mortality in a non-cardiac condition like septic shock (Mutunga et al., 2001).  
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4.2.3 cECs and diabetes mellitus  
 
Relationship of DM on cECs are discussed more in depth in the discussion. Briefly, 
cECs levels have been shown to be high in both T1DM and T2DM compared to healthy 
control. Table 9 provides a summary of available evidence published regarding DM 
and cECs.  
 
Reference Population studied Number of cECs 
(Asicioglu et al., 2010)  T1DM vs HC 7.5+/-5.4 vs 2.1+/-1 
(McClung et al., 2005)  T2DM vs HC 69+/-30 vs 10+/-5 
(Lombardo et al., 
2012)  
T2DM with or without 
complication vs. HC 
3427+/-3901 (3400% higher 
than HC) 
vs 2483+/-1828 (2500% higher 
than HC) 
 vs 99+/-76  
 
Table 9: cECs and available evidence in patients with diabetes mellitus. 
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4.2.4 Method 
 
We have discussed method for enumeration and compensation of cEC in section 
4.1.9.1 and 4.1.9.2. 
 
4.2.4.1 Optimisation of gating strategy for flow cytometric analysis of circulating 
Endothelial Cells (cEC) 
 
BD FACSDiva™ software was used to quantify cEC events. cEC events are defined 
as: CD45dim, CD133-, CD34+, and CD144+ events (West et al 2015, Ahmed et al 
2016). Lymphocytes and monocytes were gated on the side vs. forward-scatter plot. 
CD45dim population were gated on side-scatter vs. CD45. CD45dim events were further 
gated to obtain CD45dim, CD133-, CD34+ population. Then the remaining events were 
gated for CD144+ (Figure 36). 
 
 
Figure 31: Gating strategy to identify cEC population. 
A. Lymphocytes and monocytes were gated on side vs. forward-scatter plot; B. CD45 dim population 
were gated on side-scatter vs. CD45, gate was done by tracing demarcation seen between CD45dim 
and CD45+ population; C. events were further gated to obtain CD45dimCD133-CD34+ population; D. 
the remaining events were gated for CD144+. 
 
4.2.4.2 Determination of cECs per ml 
 
cECs per ml were calculated using the following formula: 
𝐸𝑣𝑒𝑛𝑡𝑠
𝑚𝑙
=
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑎 𝑐𝑒𝑟𝑡𝑎𝑖𝑛 𝑔𝑎𝑡𝑒
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 
×
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠
𝑣𝑜𝑙𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑚𝑙)
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4.2.5 Specific aim 
 
In this section, we aimed to evaluate if metformin improved the numbers of cECs in 
type 1 diabetes when controlled for glycaemic changes. 
 
4.2.6 Results 
 
Data is presented in Figure 37.  
 
4.2.6.1 Treatment group (Pre metformin) versus Healthy control 
 
cECs were significantly higher (74.6%) in TG compared with HC (TG V1 vs HC; median 
(IQ): 74.4 (46.4-221) vs. 42.6 (12.7-65.9) per ml; p=0.006). 
 
4.2.6.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin): 
 
Eight-week metformin treatment significantly decreased cECs in TG by more than 36% 
(TG V1 vs. TG V2; median (IQ): 74.4 (46.4-221) vs. 47.6 (21.8-76.7) per ml; p=0.009). 
 
4.2.6.3 Treatment group (Post metformin) versus Healthy control 
 
Metformin treatment decreased the cECs number in TG group and normalised the 
levels of the cECs count when compared to HC (TG V2 vs. HC; median (IQ): 47.6 
(21.8-76.7) vs. 42.6 (12.7-65.9) per ml). After treatment, the cECs count is only 11.7% 
higher in TG when compared to HC versus 74.6% lower in TG pre-metformin treatment 
when compared to HC. After metformin treatment, significance disappeared (p=0.7).  
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4.2.6.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, cECs were similar in TG and the SG (TG V1 vs. standard group SG V1; 
median (IQ): 74.4 (46.4-221) vs. 99.8 (59.4-210.5) cells per ml; p=0.68). 
 
4.2.6.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
the cEC count (SG V1 and SG V2: median (IQ): 99.8 (59.4-210.5) vs. 119.5 (80.5-
212.6 cells per ml; p=0.46). 
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Figure 32:  cEC comparing all groups. Results are given as per ml. Line denotes in each box as 
median and + in each box denotes mean value. 
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4.2.6.6 Subgroup analysis – Effect of metformin in smokers and patients taking 
ACE/Statins 
 
Smokers in TG had 66% (155 (65-497) vs 51.4 (15.6-151) per ml) reduction of cECs. 
Whilst in TG, individuals on ACE and/or statin led to only 26.6% reduction.  
 
4.2.6.7 Correlation 
 
In TG at baseline, cECs were not correlated with HbA1c (r=-0.23 p>0.05). In TG, at 
baseline, cECs number were inversely correlated with PAC numbers and PAC 
adhesion function (r=-0.48; p<0.05; r=-0.51; p<0.05). In TG, changes in cECs were 
inversely correlated with changes in CFU-Hill colonies (r=-0.6; p<0.01). 
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4.2.7 Discussion 
 
Markers of vascular damage were assessed at baseline and after eight weeks of 
metformin treatment. These were compared with healthy volunteers. Similar markers 
were evaluated in T1DM cohort group to explore if any changes in above-mentioned 
markers can be observed with routine follow up without any treatment with metformin.  
Individual findings will be discussed first followed by a summary of overall findings. 
 
4.2.7.1 Higher cEC in type 1 diabetes 
 
4.2.7.1.1 Main findings 
 
Our main findings were: 
1. cECs were significantly higher in T1DM when compared to healthy controls. 
2. In TG, PAC numbers and PAC adhesion function at the baseline was inversely 
correlated with cECs levels. 
 
4.2.7.1.2 Novelty/importance 
 
To our knowledge, this is the first study to date quantifying both cEC and PAC numbers 
and function in the same patient population. PACs play an important role in 
vascular/endothelial repair. Lower PAC numbers and reduced function may infer that 
there is reduced endothelial/vascular repair leading to the shedding of cECs.   
 
4.2.7.1.3 Prior work 
 
Our finding is in line with another group (Asicioglu et al., 2010). However, in contrast 
to Asicioglu et al. (2010), our study did not show any correlation between HbA1c and 
cECs (Appendix A-page 346). This difference could be due to better diabetic control 
and subject characteristics with more CVD risk factors such as longer duration of 
diabetes, older age group and higher BMI in our study. Higher BMI in our subjects 
could lead to slightly higher insulin resistance, thereby causing inflammation mediated 
endothelial damage. Indeed, patients with type 2 diabetes have been shown to have 
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higher cEC with no correlation with the level of HbA1c. However, this is speculative 
and needs further work to confirm.  
 
4.2.7.1.4 Mechanisms 
 
Endothelial damage and generation of cEC in individuals with diabetes mellitus are 
multifactorial. EC exposed to the diabetic environment results in an increase in reactive 
oxygen species (ROS) and advanced-glycated end-product (AGE) production (Yao 
and Brownlee, 2010). Hyperglycaemic conditions have been shown to decrease eNOS 
expression (Srinivasan et al., 2004).  These can result in EC injury causing detachment 
of EC. Thus, we can infer that in our study, increased level of cEC in T1DM could be 
mediated by a similar mechanism. 
 
4.2.7.2 Metformin reduces cEC numbers 
 
4.2.7.2.1 Main findings 
 
Our main findings were: 
1. Metformin therapy improved the cECs count in T1DM. 
2. There was an inverse correlation between changes in cECs and CFU-Hill 
colonies after metformin treatment.  
 
4.2.7.2.2 Novelty/importance 
 
Our study for the first time showed that metformin therapy improved the cECs count in 
T1DM and brought it closer to the matched HC. Even though cECs improved 
significantly, we believe that our study did not show the full effect of metformin on cECs, 
as some of our patients were using cardio-protective drugs already: statins and ACE 
inhibitors. Indeed, in TG subjects on ACE inhibitors and/or statins, less reduction of 
cECs was observed. In addition, our findings of an inverse correlation between 
changes in cECs and CFU-Hill colonies after metformin treatment demonstrated that 
changes in markers of vascular/endothelial damage are linked inversely with a marker 
of CVD risk (CFU-Hill-colonies). 
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4.2.7.2.3 Prior work 
 
To date, no prior study has explored the in vivo effect of metformin on cECs in T1DM. 
Previous work has explored the effect of metformin on cECs in in vitro conditions. 
However, in these studies supra-physiological levels of metformin was used. In both 
studies, metformin improved cEC function via increased availability of eNOS.  
 
4.2.7.2.4 Mechanisms 
 
Metformin has shown to improve vascular health in both T2DM and T1DM (Mather et 
al., 2001; Pitocco et al., 2013b). This is thought to be mediated by AMPK activation by 
metformin. Calvert et al. (2008) has shown that metformin has cardio-protective 
properties through AMPK activation (Calvert et al., 2008). Davies et al. (2006) 
demonstrated that metformin-mediated AMPK activation increases NOS activity and 
NO bioavailability through increased phosphorylation of eNOS. Metformin at supra-
physiological concentration inhibits glucose-mediated activation of respiratory chain 
complex and mitochondrial permeability transition pore (mPTP) in EC. Thereby,  
limiting ROS dependent damage and apoptosis of EC (Detaille et al., 2005). The 
additional mechanism includes the reduction of AGE-related damage mediated 
through the reduced expression of receptor of AGE (RAGE) and Lectin-like oxidized 
low-density lipoprotein (LDL) receptor-1 (LOX-1) receptors in EC (at supra-
physiological concentration of metformin) (Ouslimani et al., 2005). Metformin has been 
shown to reduce monocyte adhesion to EC (at physiological concentration) (Mamputu 
et al., 2003). Given the above-mentioned evidence, we can infer that a similar 
mechanism likely mediated improvement in cEC after metformin treatment in type 1 
diabetes. 
 
4.2.8 Conclusion 
 
In conclusion, we have demonstrated that metformin treatment in T1DM reduced cEC 
numbers. This could likely be mediated via reduced EC injury or increased EC repair. 
Future studies are needed to explore the mechanism and specific pathways modulated 
by metformin at physiological concentrations in T1DM.  
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4.3 Microparticles 
 
Microparticles (MPs) are enucleated submicron vesicles released from the plasma 
membrane of various cells in response to different stimuli causing activation and/or 
apoptosis (Jimenez et al., 2003). The outer membrane of the MP is characterised by 
the presence of phosphatidylserine (PS) as well as surface antigens they inherit from 
their parental cells like platelet, endothelial, leukocytes, erythrocytes, etc. (Piccin et al., 
2006). 
 
4.3.1 Historical perspective 
 
Particles shed from activated platelets was first described in 1967 by Wolf using 
electron microscopy. These particles had procoagulant activity and were called 
‘platelet dust’ (Wolf, 1967). Prior to this, it was known that there are circulating plasma 
factors which play a role in coagulation. Chargaff and West in 1946 described 
prolonged plasma coagulation if plasma was centrifuged at high speed. Coagulation 
time reduced when centrifuged pellet was added (Chargaff and West, 1946). Further 
work over time provided evidence about the generation of membrane particles 
released from various cells like endothelial cells, leukocytes, erythrocytes, etc. In an in 
vitro study, Warren and Vales in 1972 demonstrated that there was generation of MPs 
when the activated platelets  interacted with the vascular wall (Warren and Vales, 
1972). Khan and colleagues showed for the first-time involvement of MPs in a disease 
process. There was an increase in platelet fragments in patients with idiopathic 
thrombocytopenic purpura (Kahn I, 1975). Subsequently, circulating MPs of different 
cellular origins have been demonstrated including in healthy volunteers (Berckmans et 
al., 2001; Dignat-George and Boulanger, 2011). 
 
4.3.2 Nomenclature 
 
Defining circulatory vesicles have been problematic. International Society for 
Extracellular Vesicles (ISEV) has been trying to reach consensus 
(ISEV: www.isev.org/). However, it has not been possible to develop a uniform method 
to describe vesicles (van der Pol et al., 2012). Broadly, circulatory vesicles can be 
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classified by the cellular origin or mechanism of biogenesis or size. Examples of 
cellular classification are; prostasomes are vesicles released from prostate epithelium 
(Aalberts et al., 2013), dexosomes originated from dendritic cells (Delcayre et al., 
2005); adiposomes derived from adipocytes (Muller et al., 2010) etc.  
 
Circulatory vesicles can be classified based on their properties (size, density, lipid 
composition, subcellular origin-intracellular or membrane-derived and protein marker). 
These vesicles can be classified as exosomes, apoptotic bodies, exosomes like 
vesicles and MPs (Table 10) (Mattson et al., 2012).  
 
Vesicles Size Features Markers 
Exosomes 0.05-0.1 µm • Generated by 
budding 
• Intracellularly 
derived 
• Contain cytosolic 
component 
• Phospholipid 
bilayer 
LAMP-1, CD9, 
CD63 and CD81 
 
 
Apoptotic bodies 1-5 µm • Released by 
blebbing 
• Externalise 
phosphatidylserine 
 
• Increased 
membrane 
permeability 
• Contain nuclear 
material 
 
Annexin V +ve 
 
Stains with PI 
 
Microparticles 50nm to 1µm • Phospholipid 
bilayer 
• Budding/ 
Shedding 
• Intracellular and 
membrane derived 
Cell surface 
marker of cell 
origin 
 
Annexin V +ve 
 
 
Table 10: Features of vesicles. Adapted from (Dignat-George and Boulanger, 2011; György et al., 
2011)  
 
Vesicles are a group of extracellular particles which are diverse and heterogeneous in 
nature. Above mentioned terminologies have been used interchangingly in many 
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published literatures. However, for the purpose of this thesis microparticle (MP) will be 
used unless stated otherwise.  
 
4.3.3 Microparticle generation 
 
In vivo formation of MPs are not clearly understood. Most of our understanding comes 
from in vitro experiments (Schock et al., 2013). Eukaryotic cells contain a semi-
selective permeable membrane consisting of a double layer of phospholipid with 
various embedded proteins. Under normal micro-environment, there is the 
asymmetrical distribution of phospholipid (Mohandas et al., 2002). Phosphatidylcholine 
and sphingomyelin are located on the external layer whereas aminophospholipid PS 
and phosphatidylethanolamine is located on the internal layer (Devaux and P, 1984).  
 
Maintenance of this phospholipid membrane asymmetry is ensured by the balance 
between three main transmembrane enzymes; flippase, floppase and scramblase. 
Flippase, an ATP-dependent protein transports PS and phosphatidylethanolamine 
back to the inner layer from the external layer through amino-phospholipid 
translocation (Schock et al., 2013). Floppase, another ATP-dependent protein is 
responsible for disruption of membrane asymmetry when cells are activated by 
dynamic outward translocation of PS from internal to the external layer (Bevers et al., 
1999). Scramblase is a lipid transporter which plays an important role in lipid 
randomisation across the plasma membrane. Activation of scrambalase results in a 
bidirectional flow of phospholipid across the membrane; that is a movement of the 
internal layer phospholipid to external layer and vice versa (Bevers et al., 1999; Schock 
et al., 2013).  
 
MP release is dependent on Ca2+ mediated enzyme activation and inhibition. Stimuli 
causing cellular activation or apoptosis leads to a rapid increase in cellular Ca2+ 
concentration. The increase in Ca2+ concentration results in kinase and caplain 
activation and phosphatase inhibition. Furthermore, there is activation of floppase and 
inhibition of flippase activity. Caplain is a Ca2+ dependent proteases involved in 
cytoskeleton reorganisation. Above mentioned process leads to externalisation of PS, 
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blebbing and release of MP into the microenvironment (Yano et al., 1993; Schock et 
al., 2013) (Figure 38).  
 
Rho activation has been shown to play an important role in endothelial microparticle 
(EMP) formation (Tramontano et al., 2004). This can be mediated through activation 
of caspases. Under apoptotic signals, ROCK I, a Rho kinase isoform is activated by 
caspase 3 mediated cleavage. This leads to myosin light chain phosphorylation 
induced cell membrane contraction and MP formation. Non-apoptotic stimuli like 
thrombin have been shown to cause caspase 2 mediated ROCK II (Rho-kinase) 
activation. Rho kinase inhibitors like fluvastatin and Y26732 has been shown to reduce 
EMP formation (Sebbagh et al., 2001; Tramontano et al., 2004). 
 
As mentioned above, one of the steps in the formation of MP is externalisation of PS. 
PS on MP membrane serves essential processes. It plays an important role in the 
procoagulant activity of MP through binding of the coagulation factor II, Va and Xa 
(Furie et al., 2004). One of the properties of PS is binding to Annexin V via Ca-
dependent manner (Gerke and Moss, 2002; Dignat-George and Boulanger, 2011). 
Annexin V can be used to quantify a total number of circulatory MP. Annexin V will not 
discriminate MP into differential cell origin and stimuli. MP surface protein can be used 
to discriminate cellular origin and stimuli leading to the generation of MP.  
 
Initially, it was thought that all MPs were Annexin V positive. However, the presence 
of Annexin V negative MPs are now well established. Connor et al. demonstrated that 
more than 80% of platelets derived microparticles (PMPs) in healthy volunteers are 
Annexin V negative. Importantly, these Annexin V negative MPs lack procoagulant 
activity (Connor et al., 2010). It is not fully clear why MPs are Annexin V negative.  
1
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4.3.4 Microparticle characterization 
 
Circulatory MPs can be characterised by the cells they originate from. These MPs have 
markers which are cell specific. In this thesis, we will be discussing following circulatory 
MPs.  
 
4.3.4.1 Platelet-derived microparticles (PMP)  
 
The majority of circulatory MPs in healthy individuals are derived from platelets. It 
accounts for 70 to 90% of circulatory MPs (Berckmans et al., 2001). PMPs play an 
important role in physiological and pathological function (Figure 39). Physiological 
function includes endothelial repair, angiogenesis, blood clotting, inflammatory 
response and intracellular signal transduction. PMPs are involved in the pathogenesis 
of atherosclerosis via playing a role in adhesion, inflammation, pro-coagulation and 
lipid deposition (Thushara et al., 2015). PMPs deliver the growth factor which may 
promote angiogenesis. PMP levels are increased in diseases Table 12. Therefore, it 
can be used as a biomarker.  
 
The PMPs have been identified by the presence of glycoprotein receptor like PECAM 
(CD31) and intergrinα11bB3 (CD41) (Piccin et al., 2006). PMP derived from activated 
platelets have been shown to express P-selectin-CD62P (Table 11) (Flaumenhaft et 
al., 2009). It was thought that most of CD41+ MP were derived from activated platelet. 
However, Flaumenhaft et al. in 2009 demonstrated that CD41+ MP is also derived from 
megakaryocytes. Megakaryocyte-derived MP does not express CD62P or LAMP1 (a 
marker of granule fusion) or cytoskeletal degradation (filamin A) (Flaumenhaft et al., 
2009).  
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Surface marker  Available literature 
CD31+CD41+ (Amabile et al., 2005)  
CD31+CD42+ (Jung et al., 2012)  
CD41+ (Dignat-George et al., 2002) 
CD42a (Connor et al., 2010)  
CD61+ (Connor et al., 2010)  
 
Table 11: Surface markers for platelets microparticles.  
 
Disease Available literature 
T2DM (Nomura et al., 1995; Omoto et al., 2002; 
Ogata et al., 2005)  
T1DM (Dignat-George et al., 2002; Salem et al., 
2015)  
ESRF (Amabile et al., 2005)  
Uraemia (Ando et al., 2002)  
Sleep apnoea (Maruyama et al., 2011)  
CAD (Bernal-Mizrachi et al., 2003; Jung et al., 
2012) (Porto et al., 2012) 
Atrial fibrillation (Choudhury et al., 2007; Azzam and 
Zagloul, 2009)  
Pulmonary embolism (Bal et al., 2010) 
Cerebrovascular disease (Jung et al., 2009)  
Obesity (Esposito et al., 2006)  
 
Table 12: Raised platelets microparticles and some of available evidence.  
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Figure 34: Physiological and pathological role of platelet microparticle.  
Adapted from (Thushara et al., 2015)
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4.3.4.2 Endothelial-derived microparticles (EMP)  
 
EMPs, as the term implies, are released by endothelial cells as a result of various 
stimuli causing endothelial cell activation or apoptosis. EMP levels are much lower in 
a healthy individual when compared to PMPs (Berckmans et al., 2001). EMP plays 
many biological processes medicated via active surface markers and transportation of 
biologically active molecules.  
 
EMP are associated with vascular disease and levels reflect endothelial dysfunction 
(Amabile et al., 2005; Nickenig et al., 2006). Increased EMP levels are associated with 
cardiovascular disease and cardiovascular risk factors (Amabile et al., 2014). It has 
been shown that even second-hand smoking in healthy volunteers result in increased 
EMP levels and impaired endothelial function (Heiss et al., 2008). Thus, EMPs are 
potential biomarkers of vascular health. In addition to being a biomarker of 
cardiovascular disease, EMP has been shown to have prognostic properties (Dignat-
George and Boulanger, 2011). Levels of EMP have been demonstrated to predict 
cardiovascular outcome in renal failure patients (Amabile et al., 2012). In heart failure 
patients, circulatory EMP levels predicted future cardiovascular events (Nozaki et al., 
2010).  
 
EMP plays an important role in vascular disease pathogenesis and progression. This 
is mediated via pro-inflammatory, pro-angiogenic and pro-coagulant effects (Dignat-
George and Boulanger, 2011). EMPs have been shown to play an important role in the 
development and progression of atherosclerosis (Schiro et al., 2014).  
 
EMPs are identified by the surface marker. They express PECAM (CD31), VE-
Cadherin (CD144), MCAM (CD146), VCAM-1 (CD106), Endoglin CD105) and E-
Selectin (CD62E). These cell surface markers have been used to count the levels of 
EMPs. Researchers have used different marker combinations for EMP evaluation 
(Table 13). This is due to the fact that most markers are not exclusive to EMPs. CD62e 
and CD144 are specific for EMPs. Whereas, CD31 is expressed by platelets and 
leukocytes in addition to endothelial. Similarly, CD146 is expressed by activated T cell 
lymphocytes (Dignat-George and Boulanger, 2011).  
120 
 
As mentioned above, EMPs are generated either by activation or apoptosis of EC. It 
has been demonstrated EMP constitutive markers are distinct in activation versus 
activation. Exploring phenotypical distinctive EMP will yield further insight into the 
nature of endothelial injury in a disease process. Apoptosis leads to increase in 
expression of CD31 and CD105 while activation leads to increase in expression of 
CD54 or CD106 and CD62E. In order to distinguish between activation or apoptosis, 
researchers have studied the ratio of CD62E/CD31 population of EMPs instead of 
absolute numbers. A ratio of ≤ 1 is suggestive of apoptosis whereas a ratio of ≥ 10 is 
suggestive of activation. EMP phenotype in ACS is suggestive of EC apoptosis 
whereas in the acute phase of thrombotic thrombocytopenic purpura (TTP) the 
phenotype is indicative of EC activation. In diabetes mellitus levels of CD31+, CD105+ 
and CD106+ EMP are significantly higher. This EMP phenotype in diabetes mellitus is 
reflective of EC apoptosis.  
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EMP surface markers References 
CD31 (Mallat et al., 2000; Bernal-Mizrachi et 
al., 2003; Jung et al., 2009)  
CD31+/CD41- (Amabile et al., 2005; Amabile et al., 
2008)  
CD31+/CD42- (Pirro et al., 2006; Giugliano et al., 
2011)  
CD144 (Amabile et al., 2008; Gunduz et al., 
2013; Amabile et al., 2014)  
CD31+/CD144+ (Berezin et al., 2016)  
CD51 (Bernal-Mizrachi et al., 2003; Zielinska 
et al., 2005; Chironi et al., 2009; Hu et 
al., 2014)  
CD31+/CD51+ (Zielinska et al., 2005) 
CD62E (Amabile et al., 2008; Amabile et al., 
2009; Tramontano et al., 2010)  
CD105 (Chironi et al., 2009; Tramontano et al., 
2010; Breen et al., 2014)  
CD146 (Mallat et al., 2000; Gunduz et al., 2013)  
CD105+CD41a-CD45- (Simak et al., 2006)  
CD105+CD144+ (Simak et al., 2006)  
CD105+CD54+CD45- (Simak et al., 2006)  
CD105+PS+CD41a- (Simak et al., 2006)  
CD106 (Jimenez et al., 2003; Tramontano et 
al., 2010)  
 
Table 13: Surface markers for endothelial microparticles.  
 
EMP levels are associated with vascular injury and cardiovascular risk factors. Table 
14 provides some available evidence of elevated EMPs levels in various 
cardiovascular pathological conditions.   
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Cardiovascular pathology Reference 
T1DM (Dignat-George et al., 2002)  
T2DM (Dignat-George et al., 2002; 
Tramontano et al., 2010; Jung et al., 
2011; Berezin et al., 2016)  
Hypertension (Preston et al., 2003; Wang et al., 
2008a)  
Metabolic syndrome (Arteaga et al., 2006)  
Erectile dysfunction (Esposito et al., 2006; Heiss et al., 
2008)  
Hypertriglyceridemia (Ferreira et al., 2004)  
Hypercholesterolemia (Pirro et al., 2006)  
Renal failure (Amabile et al., 2005; Faure et al., 2006; 
Gurgoze et al., 2009)  
Obesity (Giugliano et al., 2011; Gunduz et al., 
2013)  
Coronary calcification (Jayachandran et al., 2008)  
Acute coronary syndrome (Mallat et al., 2000; Bernal-Mizrachi et 
al., 2003)  
Stable coronary artery disease (Bernal-Mizrachi et al., 2003)  
Carotid atherosclerosis (Chironi et al., 2009)  
Acute stroke (Simak et al., 2006; Jung et al., 2009)  
Pulmonary hypertension (Amabile et al., 2008)  
 
Table 14: Raised endothelial microparticles and some of available evidence. 
 
4.3.4.3 Other microparticles 
Circulatory cell like leucocytes and red blood cells also generate MPs. Leucocyte-
derived microparticles (LMPs) are generated from lymphocytes, granulocytes or 
monocytes (Angelillo-Scherrer, 2012). In healthy individual levels of LMP are very low. 
CD45 is the main marker used to identify LMPs (Nieuwland et al., 2000; Gelderman 
and Simak, 2008; Ayers et al., 2009; Macey et al., 2011). It has been shown that CD45 
is not expressed on all LMPs (Macey et al., 2011). Granulocytes, monocytes and 
lymphocyte fraction of LMPs express markers from their parental cells (Table 15). 
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Cellular Origin of MPs Markers 
Granulocytes CD15 
CD64 
CD66b 
CD66e 
Monocytes CD14 
CD11A 
CD18 
Lymphocytes CD2 
CD4 
CD8 
CD19 
CD20 
 
 Table 15: Markers of leukocyte-derived microparticles. (Adapted from Angelilo-Scherrer 2012) 
 
Levels of LMP are raised in inflammatory conditions like rheumatoid arthritis 
(Berckmans et al., 2002). LMP plays a role in the development of atherosclerosis 
plaques. Levels of LMP are raised at the site of plaque formation (Leroyer et al., 2007). 
LMP levels are raised by three-fold in diabetes mellitus (Dignat-George et al., 2002).  
 
Red blood cell-derived microparticles (RBC-MPs) are present in a small amount in 
healthy individuals. Levels of RBC-MP are elevated in condition causing haemolysis of 
RBCs like Sickle cell disease (Shet et al., 2003). Other condition includes nephrotic 
syndrome (Gao et al., 2012) and patients with graft-versus-host disease after 
haematopoietic stem-cell transplantation (Rank et al., 2011). CD235a (monoclonal 
antibody against glycophorin A), a membrane spanning protein is used to detect RBC 
MP (Amabile et al., 2005).   
4.3.5 Microparticle clearance 
 
Our knowledge regarding the mechanism of microparticle clearance is very limited. It 
is speculated that the MP levels depends on the rate of clearance. In vitro work has 
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demonstrated that MPs are cleared by phagocytosis (Distler et al., 2005). Currently, it 
is thought that liver or spleen is involved in clearance of MP. It is speculated that 
phagocytic cells directly bind to PS or opsonisation proteins on the MP (Flaumenhaft, 
2006; Davila et al., 2008). In vivo animal study by Willekens et al. 2004 demonstrated 
that RBC-MPs are engulfed by phagocytic cells of the liver, that is the 
reticuloendothelial system (Willekens et al., 2004). Rand et al. 2006 demonstrated that 
infused PMPs are rapidly cleared after being injected in the rabbit (Rand et al., 2006). 
In mice, it is shown to be cleared in 30 minutes (Flaumenhaft, 2006). In humans, 
procoagulant PMPs and EMPs are cleared within one hour. It was noted that RBC- 
MPs were not cleared to the same proportion to other MPs. It was speculated that other 
MPs, being more procoagulant needed to be cleared rapidly due to thrombotic risk 
(Augustine et al., 2013).  
 
EC is also thought to play a role in MP clearance. An in vitro experiment demonstrated 
that PMPs are endocytosed and internalised by cultured EC (Faille et al., 2011). An 
EC-associated protein called developmental endothelial locus-1 (Del-1) plays a major 
role in this process. In vitro and in vivo animal experiments have shown that inhibition 
of Del-1 reduced internalisation of PMP by EC (Dasgupta et al., 2012).   
 
4.3.6 Microparticle function  
 
Depending on the mode of generation and the microenvironment, MPs play various 
physiological and pathophysiological functions. MPs can act locally or circulate and act 
as a vehicle for intercellular communication and exchange via the transfer of biological 
signals and genetic information, membrane-associated receptor, the release of protein 
and bioactive lipids. In addition to the physical transfer of information, MPs can act a 
circulatory signalling molecules. Bioactive membrane molecular can induce a specific 
response in a target cell. An example includes, MPs with exposed CD40L can promote 
intraplaque neovascularization and plaque vulnerability via endothelial cell proliferation 
(Leroyer et al., 2008). All these processes can result in a multifaceted response of MPs 
including inflammation, thrombosis and bleeding and endothelial dysfunction (VanWijk 
et al., 2003) (Figure 40).  
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Figure 35: Schematic presentation of microparticle function. (Adapted from (VanWijk et al., 2003) 
 
4.3.7 Pre-analytical and analytical protocols for microparticle characterization 
 
Understanding in the role of MPs in the physiology and pathology of a disease process 
has been gaining interest. However, MP isolation and characterization has remained 
problematic due to lack of standardisation. Various studies have used multiple 
methods. These variations have shown to affect MP analysis and quantification 
(Jayachandran et al., 2012). There has been a call by International Society on 
Thrombosis and Haemostasis (ISTH) to address these issues. However, significant 
variation still remained in the pre-analytical and analytical (Lacroix et al., 2013). 
 
It has been recognised that it is important to prevent the production of MP generation 
after blood collection by preventing ex vivo activation. It has been recommended to 
use a large bore needle ranging 19-22 Gauge and to avoid prolonged use of a 
tourniquet. First, few millilitres of blood should be discarded (Yuana et al., 2010).  
 
Sodium citrate (3.2% or 3.8%) is the most common anticoagulant used for blood 
collection. Other anticoagulation used are ethylenediaminetatraacetic acid (EDTA), 
heparin and Acid-Citrate-Dextrose (ACD) (Yuana et al., 2010). Annexin V positive MPs 
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has been shown to be higher in samples collected in heparin than blood collected in 
sodium citrate or EDTA (Jayachandran et al., 2012). The blood should be processed 
immediately after collection to prevent generation of MP (Lacroix et al., 2013).  
 
Next important step is plasma isolation. It is important to remove platelets from plasma 
to avoid generation of MP via cellular activation. Two-step centrifugation method has 
been proposed to collect platelet-free plasma (PFP).  As seen in Table 16, various 
studies have used a different protocol. Standardising this step is important. Higher 
centrifugation rate can be too vigorous leading not only to depletion of platelets but 
also some MP. A lower centrifugation rate will result in a plasma sample still containing 
platelets (Lacroix et al., 2013). The samples should be centrifuged at room temperature 
(20-25), especially for citrated blood. Lower temperature can activate citrated blood 
leading to elevated levels of factor VII and factor VIII. Unfortunately, this has not been 
investigated adequately (Yuana et al., 2010). Therefore, there is a need to explore the 
effect of temperature on MP during centrifugation.  
 
It is ideal to use freshly isolated PFP for MPs measurement (Yuana et al., 2010). 
However, it is not feasible in most cases to perform MP enumeration at the same time. 
Similar was the case in our study. We had to plan for blood sampling logistics, transport 
time and most importantly processing of different assays like cell culture. We used 
available evidence and directly froze our samples at -800C (Yuana et al., 2010). 
However, other publications suggested to snap freeze the plasma first in liquid nitrogen 
followed by storing the samples at -800C (Lacroix et al., 2013).  
 
There is concern that freezing-thawing of plasma can affect the enumeration of MPs. 
Mobarrez et al. (2010) have demonstrated that freezing and thawing can increase PMP 
count by ten folds. However, samples used was platelet-poor plasma (Mobarrez et al., 
2009). Studies using PFP have shown no major effect on MP count due freezing and 
thawing of the PFP samples (Jayachandran et al., 2012). 
 
Various qualitative and quantitative methods have been reported in the available 
literature. All these methods vary widely and have their benefits and limitations. The 
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commonly used method is flow cytometry. It allows for the enumeration of MP numbers 
and also exploring the cellular origins including the subtypes. Furthermore, the analysis 
is quicker (Yuana et al., 2010). In order to improve defining MP population by size, 
beads of 1 um in diameter are used to define the upper limit of MPs. This helps in 
differentiating MP from bigger plasma constituents like platelets (Kim et al., 2002). 
However, use of flow cytometry needs to be done with understanding the limitations of 
this technique. The variable includes the use of laser, antibody, instruments and its 
calibration (Yuana et al., 2010). Our analysis was repeatedly interrupted by the 
maintenance of the instrument. We were unable to analyse one of our group due to 
changes in the machine.  
 
Other methods include electron and fluorescence confocal laser scan microscopy, 
capture based assay, proteomic analysis, impedance-based flow cytometry, dynamic 
light scattering and nanoparticle tracking analysis and atomic force microscopy. Each 
method has some advantages and limitations. Therefore, the research question should 
guide the choice of technique. (Yuana et al., 2010). 
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4.3.8 Microparticle in healthy individuals and physiological variation 
Level of MPs are lower in healthy individuals when compared to individuals with the 
metabolic or cardiovascular disease. PMPs form around 70% of the circulating MPs 
(Berckmans et al., 2001). It is important to note that MPs in healthy individuals have 
an anticoagulant function. It was hypothesised that PMP causes low levels thrombin 
generation leading to activation of protein C (Berckmans et al., 2001).  MP levels are 
higher in women when compared to men. The level of MPs is modulated with the 
menstrual cycle (Toth et al., 2007). In contrast to this, Nielsen et al. 2014 showed that 
men had higher MP levels (especially EMP and MMP) than women (Nielsen et al., 
2014). Women in Nielsen et al. (2014) were older and in peri-menopausal range. 
Furthermore, there was the methodological difference in the analysis of MP. These 
differences could explain the conflicting results. Post-menopausal women have lower 
PMP levels than pre-menopausal women. EMP levels are similar in both pre and post-
menopausal women (Rank et al., 2012). During pregnancy, MP levels increase 
gradually during each trimester. MPs are the highest in the third trimester (Radu et al., 
2015). 
 
Few studies have analysed differences in MP levels due to age. Forrest et al. (2019) 
demonstrated lower EMP levels in elderly whereas levels of PMP, RBC-MP or total MP 
were similar (Forest et al., 2009). (Emmerechts et al., 2012) results were in agreement 
with Forrest et al. 2010. They did not evaluate EMP levels.  
 
Moderate and strenuous exercise has been shown to alter MP levels. PMP and LMP 
levels are increased in strenuous exercise (Chaar et al., 2011). Acute exercise has 
shown to increase EMPs in men and CD34+MP in women (Lansford et al., 2015). 
Sossdorf et al. 2010 demonstrated that there was a difference in MP kinetic and 
dynamic release and the clearance between trained and untrained individuals. At 
baseline levels of MP and their pro-coagulant activity was similar. An acute bout of 
exercise raised levels of PMP, EMP and LMP in trained individuals but levels returned 
to normal after 2 hours. In an untrained individual, only PMP levels increased 
significantly. Furthermore, levels did not return to the baseline (Sossdorf et al., 2010).  
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4.3.9 Microparticle and diabetes mellitus  
 
It is well established that MP levels are altered in DM. From the available evidence, we 
can infer that MP levels are elevated in diabetes mellitus. Though, studies have 
reported different MP profile in DM. We could only identify two studies conducted in 
patients with T1DM (Dignat-George et al., 2002; Salem et al., 2015). T1DM and T2DM 
have a different profile of altered MP levels. In T2DM, only total microparticle (TMP) 
levels are raised. However, TMP, PMP and EMP are raised in T1DM (Dignat-George 
et al., 2002). MP levels have been shown to correlate with diabetes-related 
complications like nephropathy or retinopathy or foot disease (Nomura et al., 2004; 
Ogata et al., 2005; Tsimerman et al., 2011). EMP levels have been shown to be an 
independent predictor of CAD in patients with DM (Koga et al., 2005).  Table 17 
summarise finding of studies in diabetes mellitus. 
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4.3.10 Method 
 
4.3.10.1 Platelet-free plasma isolation 
 
After an overnight fast, peripheral blood was collected in citrate vacutainer tubes. Blood 
samples were processed within four hours of collection. Samples were centrifuged for 
15 minutes at 500 xg. The upper, clear fraction (platelet rich plasma, PRP) was 
collected without disturbing the bottom cellular layer and transferred to 1.5mL 
polypropylene tubes. These PRP samples were further centrifuged for 5 minutes at 
13000 x g in a microcentrifuge. After centrifugation, the clarified platelet-free plasma 
(PFP) was transferred to fresh 1.5mL polypropylene tubes and stored at -80ºC for 
subsequent analysis. The platelet pellet was discarded.  
 
4.3.10.2 Flow cytometry protocol for enumeration of microparticles 
 
BD LSR II instrument with five customised lasers (blue 488nm, red 635nm, violet 
405nm, green 532nm and UV 355nm) was used for MPs enumeration.  
 
PFP was thawed and went for ultracentrifugation at 13000g x 5 minutes before 
antibody incubation. Two sets of Trucount tubes, each containing 200µl of the PFP 
was stained with Antibodies set 1 (Table 18) for EMP and PMP and Antibodies set 1 
(Table 19) for PC-derived MP and EPC MP. Both tubes underwent 30 minutes 
incubation in the dark. 
 
Specimen: Platelet-free plasma 
Antibodies Fluorochrome Volume added Manufacturer 
Annexin V PE 5µl BD Biosciences 
CD31 AlexaFlour 647 20µl BD Biosciences 
CD41a PerCPCy5.5 20µl BD Biosciences 
CD144 FITC 20µl BD Biosciences 
CD62e BV421 5µl BD Biosciences 
 
Table 18: Antibodies set 1 for EMP and PMP. 
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Specimen: Platelet-free plasma 
Antibodies Fluorochrome Volume added Manufacturer 
Annexin V PE 5µl BD Biosciences 
CD45 V500 5µl BD Biosciences 
CD34 PerCPCy5.5 20µl BD Biosciences 
CDVEGFR2 (KDR) FITC 20µl R&D systems 
 
Table 19: Antibodies set 2 for PC-derived MP (CD34+ MP), EPC MP and LMP.  
 
Prior to analysing the study samples, optimisation was carried out. Compensation 
and gating strategy for were refined with support from flow cytometry department, 
which is discussed below. 
 
4.3.10.3 Optimising compensation strategy for enumeration of 
microparticles 
 
The MP gate was established via preliminary experiment using 1 micron fluorescent 
beads plotted on forward and side scatter. Threshold was set up to acquire Annexin 
V+ events.  True events for MPs were defined as particles that were positive for 
Annexin V and less than 1 µm in diameter. Compensation was done to make sure 
there is no overlap of the florescence channels (e.g., FITC can spill over into the PE 
channel). Once the compensation was achieved using each florescence antibody with 
Annexin V than all the fluorochromes were added and analysed together. Adequate 
compensation was deemed once each fluorochromes florescence was similar to 
fluorochromes florescence run separately. 
 
Samples were run with stopping gate for atleast 20,000 <1micron events. Analysis 
was also performed using BD FACS DIVA™ software, with EMP events defined as: 
Annexin-V+CD31+CD41a-. Annexin-V+CD31+, Annexin-V+CD62e+ and Annexin-
V+CD144+ events were also gated for EMP phenotype study. PMP were defined as 
Annexin-V+CD31+CD41a+. PC-derived MP and EPC MP events were defined as 
Annexin-V+CD34+, and Annexin-V+CD34+VEGFR2+. Lymphocyte derived MPs were 
defined as Annexin-V+CD45+.  
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Gating strategy to define above mentioned MP population is presented in Figure 41 
and 42. 
 
MP enumeration for standard group (SG) was not performed due to changes in the 
setting and lasers of BD LSR II instrument. If we had analysed the sample then we 
would not have been able to compare SG data with TG and/or HC. 
 
4.3.10.4 Determination of MP per µl 
 
Events per µl were counted using the following formula: 
𝐸𝑣𝑒𝑛𝑡𝑠
µ𝑙
=
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑎 𝑐𝑒𝑟𝑡𝑎𝑖𝑛 𝑔𝑎𝑡𝑒
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 
×
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (µ𝑙)
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Figure 36: Gating strategy for EMP and PMP quantification. 
A. 0.88 micron latex beads were ran to estimate the gating for <1µm events; B. <1µm events gated; C. 
threshold were set for Annexin V positive events and were gated for CD31+; D and E. Endothelial MPs 
(EMP) events were further gated for CD144+  and CD62e+; F and G. Annexin V+, CD31+ and CD41a+ 
showing platelet-derived MPs (PMP) contributing to majority of microparticle events and events positive 
for Annexin V and CD31 were gated for CD41a- to exclude PMP population.  
 
A 
D 
C B 
E F 
G 
AnnVCD31+CD41a- 
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Figure 37: Gating strategy for EMP and PMP quantification. 
A. 0.88 micron latex beads were ran to estimate the gating for <1µm events; B. <1µm events gated; C. 
threshold were set for Annexin V positive events and were gated for CD45+ (Lymphocytic MP); D CD34+ 
events were further gated; E. Annexin V positive events and were gated for CD45-; F. AnnexinV+CD45+ 
was plotted against CD34 to gate for CD34+ events; G. AnnexinV+CD45+CD34+ was plotted against 
CD34 and VEGFR2 and gated for AnnexinV+CD45+CD34+VEGFR2+. 
 
 
 
 
A B C 
D E F 
G 
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4.3.11 Specific aim 
 
In this section, we aimed to evaluate if metformin improved the following in type 1 
diabetes when controlled for glycaemic changes: 
1. Numbers of EMP, 
2. Numbers of PMP, 
3. Numbers of LMP, and 
4. Numbers of CD34+ and EPC MP. 
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4.3.12 Results 
 
All the EMP phenotypes (AnnexinV+CD31+, AnnexinV+CD31+CD41-, 
AnnexinV+CD62e+ and AnnexinV+CD144+), PMPs (AnnexinV+CD31+CD41+), LMP 
(AnnexinV+CD45+), AnnexinV+CD34+ and AnnexinV+CD45dimCD34+VEGFR2+ were 
significantly higher in treatment group (TG V1) at baseline when compared to healthy 
control. In treatment group eight weeks of metformin treatment did not change any of 
the EMP phenotypes, PMPs, LMPs, AnnexinV+CD34+ and 
AnnexinV+CD45dimCD34+VEGFR2+. After metformin treatment, EMP phenotypes, 
PMPs, LMPs, AnnexinV+CD34+ and AnnexinV+CD45dimCD34+VEGFR2+ remained 
significantly higher when compared to healthy control (Table 20).   
 
 TG V1 TG V2 
TG v1 
vs 
TG V2 
p-value 
HC 
HC 
vs 
TG V1 
p-value 
HC 
vs 
TG V2 
p-value 
AnnexinV+CD31+ 
per µl mean+/-SE 
3.2+/-0.3 3+/-0.35 0.5 0.8+/-0.15 <0.0001 <0.0001 
AnnexinV+CD31+CD
41- 
per µl median (IQ) 
0.24 (0.17-
0.75) 
0.17 (0.1-
0.3) 
0.3 
 
0.08 
(0.06-0.1) 
<0.0001 0.0003 
AnnexinV+CD62e+ 
per µl mean+/-SE 
3.7+/-0.4 3.4+/-0.4 0.4 0.9+/-0.2 <0.0001 <0.0001 
AnnexinV+CD144+ 
per µl mean+/-SE 
3.9+/-0.5 3.6+/-0.4 0.4 0.9+/-0.15 <0.0001 <0.0001 
AnnexinV+CD31+C
D41+ 
per µl mean+/-SE 
2.9+/-0.3 2.7+/-0.3 0.4 0.7+/-0.2 <0.0001 <0.0001 
AnnexinV+CD45+ 
per µl mean+/-SE 
5.9+/-0.8 5.5+/-0.8 0.7 2+/-0.4 0.0003 0.0001 
AnnexinV+CD34+ 
per µl mean+/-SE 
5.8+/-0.8 5.5+/-0.8 0.7 2.2+/-0.4 0.0001 0.0008 
AnnexinV+CD45di
mCD34+VEGFR2+ 
per µl median+/-SE 
0.09 
(0.03-0.3) 
0.09 
(0.03-0.2) 
0.4 0.07 
(0.035-
0.09 
0.1 0.3 
 
Table 20: Microparticle comparing treatment group pre-metformin (TG V1), post-treatment and healthy 
control (HC). Results are given as per µl.  
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4.3.12.1.1 CD62e+ to CD31+ ratio 
 
The ratio of CD62E+/CD31+ EMP populations has been used to identify if generation 
of EMPs were caused via activation versus apoptosis. A ratio ≥10 identifies activation 
while ratio ≤1.0 identifies apoptosis (Tramontano et al., 2010). CD62e+ to CD31+ ratio 
was similar in TG and healthy control (1.3+/-0.1, 1.2+/-0.02 and 1.4+/-0.1 respectively: 
TG V1 vs. HC: p=0.1; TG V1 vs. TG V2: p=0.4; TG V2 vs. HC: p=0.2). 
 
4.3.12.1.2 EMP to cEPC ratio (AnnexinV+CD31+CD41- to 
CD45dimCD34+VEGFR2+ ratio) 
 
The ratio of EMP to cEPC ratio (AnnexinV+CD31+CD41- to CD45dimCD34+VEGFR2+ 
ratio) provides information regarding balance between vascular injury and repair (Pirro 
et al., 2006). Increased ratio is associated with early atherosclerosis (Pirro et al., 2006). 
EMP to cEPC ratio was significantly higher in treatment group (TG V1) at baseline 
when compared to healthy control (TG V1 vs HC: 2.3+/-0.5 vs 0.3+/-0.04 per µl: 
p=0.0005). In treatment group eight weeks of metformin treatment significantly 
reduced EMP to the cEPC ratio (TG V1 vs. TG V2: 2.3+/-0.5 vs. 1.3+/-0.5 per µl; 
p=0.04). Even after reduction of EMP to the cEPC ratio in the treatment group after 
eight weeks of metformin, EMP to cEPC ratio remained significantly higher when 
compared to healthy control (TG V2 vs. HC: 1.3+/-0.5 vs. 0.3+/-0.04 per µl: p<0.05). 
 
4.3.12.2 EPC microparticles to cEPC ratio 
 
The ratio of EPC MP to cEPC (AnnexinV+CD45dimCD34+VEGFR2+ to 
CD45dimCD34+VEGFR2+ ratio) provides information regarding proportion of cEPC 
destruction. EPC to cEPC ratio were significantly higher in treatment group (TG V1) at 
baseline when compared to healthy control (TG V1 vs. HC: 0.6 (0.17-1.6) vs. 0.14 
(0.08-0.35) per µl: p=0.002). In treatment group, eight weeks of metformin treatment 
reduced the EPC MP to cEPC ratio significantly (TG V1 vs. TG V2: 0.6 (0.17-1.6) vs. 
0.4 (0.07-0.9) per µl; p=0.009). After metformin treatment, EPC MP to cEPC ratio 
phenotypes became non-significant when compared to healthy control (TG V2 vs. HC: 
0.09 (0.03-0.2) vs. 0.07 (0.035-0.09) per µl: p=0.17).  
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4.3.12.3 Correlation  
 
In this section, we will only present important correlation data discussed below. Full 
correlation data is presented in Appendix A.  
At baseline, CD34+ EMP was directly associated with CD31+ EMP (r=0.5; p<0.05) and 
PMP in TG (r=0.54; p<0.01). 
At baseline, PMP was directly associated with LMP in TG (r=0.54; p<0.01).  
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4.3.13 Discussion 
 
Markers of vascular damage were assessed at baseline and after eight weeks of 
metformin treatment. These were compared with healthy controls. MPs were not 
evaluated in standard treatment group-SG to explore if any changes in above-
mentioned markers could be observed with the routine follow up without any treatment 
with metformin. Individual findings will be discussed first followed by a summary of 
overall findings. 
   
4.3.13.1 Increased EMP phenotypes, PMPs and EMP/cEPC ratio in type 1 
diabetes  
 
We assessed different EMP phenotypes (AnnexinV+CD31+, Annexin V+CD31+CD41-
, Annexin V+CD144+ and Annexin V+CD62e+ MP), PMP (Annexin V+CD34+CD41+ 
MP), LMP (Annexin V+CD45+ MP) and PC-MP and EPC-MP (Annexin V+CD34+, 
Annexin V+CD45dimCD34+VEGFR2+ MP) in TG and HC. 
 
4.3.13.1.1 Main findings 
 
Main findings were:  
1. All EMP phenotypes, PMPs, LMPs and EMP/cEPC ratio were higher in TG 
when compared to healthy control.  
2. Progenitor cell MPs in T1DM were higher when compared to healthy controls. 
Though, EPC MP levels in T1DM were similar to healthy controls. However, 
EPC MPs and the cEPC ratio were significantly higher in type 1 diabetes than 
in healthy controls.  
3. AnnexinV+CD34+ MPs were directly associated with AnnexinV+CD31+ and 
PMPs in TG (Appendix A). 
4. PMPs were directly associated with AnnexinV+CD45+ MPs in TG. 
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4.3.13.1.2 Novelty 
 
For the first time, we have studied an extensive array of MPs including phenotypes of 
EMP, PMP, LMP, PC-MP, EPC MP in T1DM and compared with HC. This make our 
study unique in providing broad information regarding MP levels in T1DM. We have 
shown for the first time that EPC MP levels were similar in T1DM and HC. However, 
the ratio of EPC MP and cEPC was significantly higher demonstrating an increased 
generation of EPC MP in T1DM when compared to HC.  
 
4.3.13.1.3 Prior work 
 
Our data was consistent with the previous report of Sabatier et al. (2002) who showed 
increased EMPs and PMPs in type 1 diabetes. Different studies in diabetes have 
shown that not all the different phenotypes of EMP were higher. However, all of these 
studies included type 2 diabetes patients. It had been shown that different phenotypes 
of MPs were elevated in type 1 and type 2 diabetes (Dignat-George et al., 2002). This 
difference in EMP phenotype might show that there were different mechanisms of MP 
production in T1DM. 
 
PMP and LMP have been shown to be higher in T1DM (Dignat-George et al., 2002; 
Salem et al., 2015). PMPs have been shown to be higher in patients with diabetes-
related microvascular complication and microalbuminuria. Furthermore, PMP levels 
are directly related to the severity of diabetic retinopathy. 
 
4.3.13.1.4 Mechanism 
 
High EMP levels in T1DM as shown in our study not only demonstrated ongoing 
endothelial damage but put these patients at risk of developing vasculopathy as 
demonstrated by the extensive available evidence in diabetes and other conditions 
(Table 10 and 15). EMPs are associated with increased macroangiopathy in type 2 
diabetes (Jung et al., 2011) and positively correlated with CV risk factors (Amabile et 
al., 2014). Furthermore, high Annexin V+CD31+ MPs are linked with increased CV 
events in stable CAD patients (Sinning et al., 2011). Annexin V+CD31+CD41- MPs is 
an independent predictor of CV mortality in ESRF (Amabile et al., 2012). Annexin 
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V+CD144+ MP is negatively associated with impaired FMD (Tushuizen et al., 2007). 
Annexin V+CD62e+ numbers are negatively correlated with endothelial function in 
Kawasaki disease (Ding et al., 2014). Annexin V+CD62e+ levels are linked with poor 
outcome in pulmonary hypertension and stroke (Amabile et al., 2009; Lee et al., 2012).  
 
It has been shown that apoptosis is an important mechanism in production of EMPs  in 
T2DM (Tramontano et al., 2010). However, our data did not show that apoptosis was 
the major factor in MP production. High CD31+ and CD62e+ in our study suggested 
that in addition to apoptosis, activation played an important role.  
 
MPs in poorly controlled T1DM patients have a higher pro-coagulant activity. This may 
account for increased thrombogenicity in T1DM.  HbA1c has been positively 
associated with the pro-coagulant activity of MP (Dignat-George et al., 2002). Our 
T1DM patients had good overall diabetes control. There is a need to explore if good 
diabetes control has an effect on pro-coagulant activity of MP in T1DM.  
 
We have shown that PMP and LMP were higher in T1DM than in HC.  It has been 
proposed that PMPs can stimulate coagulation cascade by increasing adhesion of 
leukocytes and endothelial cells (Ogata et al., 2005). Our data showed that PMPs are 
directly associated with AnnexinV+CD45+ MP. The interaction between activated 
platelets, PMPs, LMPs and endothelial cells are important in the early stages of 
atherosclerosis (Puddu et al., 2010). Patients with carotid atherosclerotic plaques have 
been shown to have higher PMP (Michelsen et al., 2009). In children and adolescents 
with T1DM, PMPs are directly related to CIMT (Salem et al., 2015).  
 
EMPs are not only related to endothelial dysfunction but also has been shown to have 
an effect on EPC. In an in vitro condition, it has been demonstrated that EMPs from 
patients with hypercholesterolemia significantly increased EPCs apoptosis and 
reduced colony forming capacity (Pirro et al., 2006). Similarly, EMPs from hypertensive 
with microalbuminuria/microalbuminuria reduced EPC function and increased EPC 
death/apoptosis (Huang et al., 2010a).  EMPs and PMPs have been shown to be 
inversely related to EPCs (Pirro et al., 2006). This is in contrast to our finding of no 
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correlation between EMP and PMPs with cEPC in T1DM. Even though there was no 
correlation, our data of high EMPs and low cEPCs complements Pirro et al. (2006) 
finding in patients with CVD risk factor. Thereby, causing an imbalance between 
endothelial repair and damage. Furthermore, we have shown that increased EPC MP 
to cEPC ratio in T1DM than in HC. This finding demonstrated an increased 
microparticle production from cEPCs and progenitor cells. 
 
4.3.13.2 Metformin has no effect on EMPs, PMP and cEPC MPs but 
decreases EMP to cEPC and EPC MP to cEPC ratio 
 
4.3.13.2.1 Main findings 
 
Eight weeks of metformin treatment  
1. Did not decrease EMP and their phenotypes, PMP, LMPs and EPC-derived 
MPs in T1DM.  
2. Showed a significant reduction in EMP to cEPC ratio in TG.  
 
4.3.13.2.2 Novelty 
 
For the first time, we explored the effect of metformin treatment on the array of MPs in 
T1DM independent of glycaemic control. Our data provided evidence that eight weeks 
of metformin treatment in T1DM shifted the focus towards vascular repair from vascular 
damage. However, future studies need to explore if this yield long term CV benefit in 
T1DM.  
 
4.3.13.2.3 Prior work 
 
Our results are similar to Esposito et al. 2011 who showed that 24 weeks of metformin 
treatment in newly diagnosed type 2 diabetes did not improve EMPs. However, no 
change in the cEPC count was also noted (Esposito et al., 2011). As mentioned above, 
we demonstrated a significant increase in cEPC numbers. So far, no study has 
explored the effect of metformin on the wide array of MPs in T1DM. 
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4.3.13.2.4 Mechanism 
 
Our study was not powered to explore MPs. This is the most likely reason we did not 
see the difference in MPs in our study. Other reasons for no change in EMPs after 
metformin treatment can be explained by the method of MP enumeration and the 
retrospective nature of MP assessment. We gated all our MPs on Annexin V. This 
meant that we did not enumerate Annexin V negative MPs. It has been shown 
previously that not all MP are Annexin V positive. It is speculated that some MPs do 
not externalise phosphatidylserine or not bind Annexin V (Shet et al., 2003). MP can 
be altered at any stage of enumeration including centrifugation, storage and thawing 
(Piccin et al., 2006). It has been shown that freezing and storage duration can effect 
MP numbers and phenotypes (van Ierssel et al., 2010). Centrifugation, storage 
condition and thawing was similar during pre- and post-treatment. Each patient 
samples pre- and post-treatment were analysed together. The difference in the 
duration of storage between pre- and post-treatment is eight weeks. We believe that 
stages of enumeration cannot completely explain our results of no effect of metformin 
on EMP numbers.    
 
In our study, cEPC numbers increased significantly after metformin treatment. As a 
consequence, EMP to cEPC ratio showed a significant reduction. Thereby, shifting the 
balance from endothelial damage to improved repair capacity. A previous intervention 
study in type 2 diabetes patients had demonstrated that pioglitazone decreased EMP 
to the cEPC ratio (Esposito et al., 2011). Furthermore, our assessment of cEPC MP to 
cEPC ratio showed a significant reduction. We can infer from these finding that 
metformin not only increased cEPC numbers but also reduced MP generation from 
EPCs.   
 
4.3.14 Conclusion 
 
In conclusion, MPs numbers are higher in T1DM except for EPC-MP. Metformin 
treatment did not change the levels of MP in T1DM. It may be the metformin can have 
an effect on MP biological function by shifting the focus from vascular damage to repair. 
However, this theory needs to be robustly investigated. This can include in vitro 
experiment exploring if MP from metformin-treated patients can improve endothelial 
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cell survival. Further extension of this work can include an animal model to assess if 
MP from metformin-treated endothelial cells can improve angiogenesis and 
mobilisation of MPs.  
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4.4 Summary 
 
In this section strengths, limitations and clinical/research implications will be discussed.  
 
4.4.1 Strengths 
 
In our knowledge, this is the first study exploring all of the above-mentioned markers 
in one group of patients with type 1 diabetes. This is a major strength of our work. Most 
of the studies on type 1 diabetes have looked at one or two specific markers (Sibal et 
al., 2009a; Esposito et al., 2011).  Our data gives a much better overview of underlying 
vascular repair and damage imbalance in patients with type 1 diabetes. Our study has 
corroborated finding of previous studies that the markers of vascular damage are 
significantly higher, and markers of vascular repair are significantly lower in type 1 
diabetes compared to healthy match control (Sibal et al., 2009a; Asicioglu et al., 2010; 
Salem et al., 2015).  
 
4.4.2 Limitations 
 
Our work in this section could have been further strengthened if we had randomised 
equal numbers of SG and TG. In SG, we were not able to study MPs due to changes 
made to BD LSR II laser. This would have made comparing TG and SG impossible. 
Our data showed that overall diabetes control as assessed by HbA1c did not have any 
effect on the results of all the above markers in TG and SG. Glucose variability 
remained unchanged in TG. However, we did not study glucose variability in SG. If we 
had studied glucose variability in SG, it would have provided a better design to explore 
the effect of glucose variability on above-discussed markers.  
 
4.4.3 Clinical and research implication 
 
We demonstrated that in patients with relatively well-controlled type 1 diabetes mellitus 
(mean HbA1c 7.3% or 56.4 mmol/mol), metformin therapy improved markers of 
vascular damage (cECs) and repair (cEPCs). Further evidence that our patients might 
benefit from metformin comes from the fact that CFU-Hills’ colonies, PACs number and 
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adhesion properties improved significantly. It is well established that CFU-Hill colonies 
number are inversely related to Framingham risk score, and therefore CFU-Hill 
colonies are yet another predictor of CVD (Hill et al., 2003b).  In addition, PACs 
adhesion function is an important factor in cEPCs homing, cell-cell contact and 
transmigration events for neovascularisation and vascular repair (Urbich and 
Dimmeler, 2004b). Metformin not only improved the level of cEPCs but also brought 
PACs number/ adhesion and CFU-Hill colonies closer to HC levels. In addition, an 
inverse correlation between changes in cECs and CFU-Hill colonies shows that 
changes in markers of vascular/endothelial damage are linked inversely with a marker 
of CVD risk (CFU-Hill-colonies).  
 
EMP levels did not improve with metformin treatment. Our results are similar to another 
study on type 2 diabetes patients (Esposito et al., 2011). However, in contrast to 
Esposito et al. (2011), the EMPs/EPC ratio after metformin treatment reduced 
significantly. This could reflect a shift in balance towards endothelial repair capacity 
from endothelial damage. We also noted the reduction in cEPC MP numbers relative 
to increase in cEPC numbers. This could either mean increased consumption or 
decreased the production of cEPC MP. Increased consumption of cECP MP can be 
due to increase in interaction with EC. Thereby, increasing vascular repair and leading 
to reduction in cECs. However, this is speculative and needs further work to 
understand the mechanism of relative reduction of cEPC MPs.  
 
Data in chapter 4 yields important information regarding the effect of metformin on 
cardiovascular markers. Our work can be meaningfully expanded to design a 
randomised controlled trial to further evaluate above studied markers. Our data can be 
used to calculate the number of subjects needed for the study to have adequate power. 
Furthermore, future work should define the upstream and downstream pathways 
effected by the physiological dose of metformin leading to changes in above-studied 
CV markers.   
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4.4.4 Conclusion 
 
We believe that this study may have positive clinical implication for patients with T1DM. 
Metformin treatment may provide potential CVD benefit by rebalancing the emphasis 
in their management from limiting damage alone to also improving vascular repair. 
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5 Chapter 5: Effect of metformin on microRNA 
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5.1 Introduction 
 
MicroRNAs (miR) are a family of small highly conserved endogenous non-coding 
single-stranded RNA that is produced in every animal and plant cells (Ambros, 2004; 
David et al., 2004). They are approximately 22 (19-24) nucleotides in length (David et 
al., 2004; Bhaskaran and Mohan, 2014). They play a significant role in the regulating 
post-transcriptional gene expression. miR binds the complementary target on 
messenger RNA leading to their degradation on inhibition of transcription. Also, this 
results in dysregulation of subsequent protein production. However, the exact 
mechanism is unknown (Bhaskaran and Mohan, 2014).  miRs are thought to regulate 
approximately 30% of mRNA (Filipowicz et al., 2008).  
 
Before 1993, our understanding of protein synthesis was limited to transcription of DNA 
into RNA. This was then translated into protein. In 1993, the first miRNA lin-4 was 
discovered, and the importance of miR was revealed (Lee et al., 1993). 
 
Rasalind Lee and Rhonde Finbaum from Ambros laboratories discovered the first 
miRNA, Lin-4 in the nematode, Caenorhabditis elegans. Lin-4 controlled the larval 
transition from stage 1 and stage 2 thus affecting larval development. Lin-4 was not 
transcribed into mRNA, thus did not code for any protein. Lin-4 is transcripted into two 
single strands of 61 nucleotides (nt) and 21 nt lengths. Ambrose together with Ruvkun’s 
laboratory demonstrated that Lin-4 transcripts were complementary in the 3’ UTR of 
Lin-14. Lin-4 is a negative regulator of Lin-14 and reduces the amount of Lin-14 
proteins (Lee et al., 1993). 
 
Finding of this new regulatory product spurred new research in this area of molecular 
biology. However, it took seven years till the second miR; Let-7 was discovered 
(Reinhart et al., 2000). Let-7 controlled the larval transition from stage 4 to the adult 
stage. Let-7 miR family was found in other species including humans (Reinhart et al., 
2000). The presence of miR in other species resulted in a revolution in miR research. 
It was estimated that more than 800 miR genes are present in humans (Bentwich et 
al., 2005). So far, 2588 miRs have been identified in humans as per miRbase database 
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(http://www.mirbase.org/) in their latest version 21 released in June 2014.  Across all 
species so far, 28645 miRs have been discovered (Kozomara and Griffiths-Jones, 
2014).  
 
The reason behind the rapid expansion in numbers of miRNA is the fact that miRNA is 
now thought to play a pivotal role in a disease like cancer, CV disease, autoimmune 
disease, neurodegenerative disease and diabetes mellitus, etc. As a result of rapid 
expansion, there was the need to develop a database. This has led to multiple 
databases being set up like miRbase (Griffiths‐Jones, 2004), Pictar (Krek et al., 2005), 
microRNA.org (Betel et al., 2008), Target Scan (Agarwal et al., 2015), etc. To facilitate 
miRNA target prediction and interpretation of their role in disease, tools and software 
like miRanda (John et al., 2004), DIANA Tool (Kiriakidou et al., 2004), etc  have been 
developed.  
 
5.1.1 microRNA nomenclature 
 
So far a large number of microRNA has been discovered. Naming and identification of 
microRNA could have been a problem. However, to have consistent naming technique, 
researchers have agreed on a guideline (Ambros et al., 2003). 
 
Each microRNA is identified by a number attached to prefix miR like miR-126, miR-
129, etc. Three or four-letter prefixes are used to identify the organism (example hsa 
in homa sapiens). Therefore, microRNA in humans will be named as hsa-miR-126. 
microRNA (miRNA) is named after the manuscript is accepted for publication. So for 
example, at the time of acceptance of manuscript last published, miRNA was miR-
1011. Then the new miRNA in the manuscript will be named miR-1012. In case, a 
miRNA has been discovered in more than one species than it is advised that the 
numbers are kept the same (Ambros et al., 2003).  
 
‘miR’ is used to designate mature miRNAs. In some case, a letter is attached after the 
unique number. This letter suffixes relationship between mature sequence (example 
has-miR-133a is related to miR-133b). The miRNA gene is also named in a similar 
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way, but they can have three letter prefix ‘mir’ written in italics, capitalization or 
hyphenated (like MIR-156 or mir-156) (Ambros et al., 2003). 
 
In some cases, two miRNA sequences are identified. The functional sequence is 
assigned as miR, and the non-functional sequence is identified as miR*. However, in 
certain cases, it is not clear which sequence is functional. 5p and 3p suffixes are added 
after unique numbers to identify 5’ and 3’ arm respectively (Ambros et al., 2003).  
 
5.1.2 miRNA Biogenesis 
 
miRNA biogenesis starts in the nucleus and continues in the cytoplasm of the cells 
(Lee et al., 2002; Lee et al., 2004; Borchert et al., 2006) (Figure 51 and 52).  
 
miRNA gene is transcribed into primary miRNA transcript called primary miRNA (pri-
miRNA). These pri-miRNA can produce multiple miRNAs (Lee et al., 2002). However, 
it has been demonstrated that a pri-miRNA transcribed from a genome containing 
miRNA coding cluster can only express single miRNA (Ramalingam et al., 2013).  
 
Next step is processing of Pri-miRNA by a microprocessor into 70 nucleotide hair-pin 
like structure called Pre-miRNA. The microprocessor is a multiprotein complex 
consisting of Dorsha; RNase III enzyme and DiGeorge Syndrome Critical Region 8 
(DGCR8/Pasha) (Lee et al., 2003). DGCR8 is a double-stranded blinding protein also 
known as Pasha (Diederichs et al., 2009).  
 
Pre-miRNA is exported from the nucleus by nuclear transport domain called Expotin 5 
and RAN-GTP to the cytoplasm (Diederichs et al., 2009).  
 
In the cytoplasm, pre-miRNA is spliced by an enzyme called Dicer. It is another RNase 
III. The resulting product is 22nt RNA duplexes called miRNA duplex (miRNA and 
miRNA*). Dicer forms complex with the double-stranded RNA-binding protein (TRBP), 
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a protein activator of PKR (PACT) and Argonaute (Ago) 2. This is called RICS loading 
complex (RLC) (Diederichs et al., 2009).  
 
Next step is splitting and unwinding of the duplex. This is mediated through an enzyme 
called helicase. However, the specific enzyme has not been identified. In theory, both 
strands of the duplex can result in a functional miRNA. However, in most cases, strand 
bound to Ago leads to a functional mature miRNA. Whereas other strand is degraded. 
Depending on the strand’s stability, one strand of the duplex is loaded with Ago protein. 
Strand with the least stable 5’ region is incorporated into Ago protein. In most cases, 
another strand (passenger strand-miRNA*) is degraded. In some tissues, both strands 
are retained. In this case, both, mature miRNA and passenger miRNA may have a 
functional role (Ro et al., 2007).   
 
miRNA once incorporated into Ago protein has a long half-life. Nearly 97% of miRNA 
in cells are tightly bound to RISC. Binding to RISC not only provides stability but also 
is the first step towards the functional activity of miRNA (Diederichs et al., 2009).  
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Figure 38: Biogenesis of miRNA. 
 
 
Adapted from (Diederichs et al., 2009) 
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Figure 39: Simplified mechanism of miRNA biosynthesis. 
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5.1.3 miRNA target recognition 
 
miRNA interacts with its target mRNA through RNA-RNA base pairing. The miRNA 
guides RISC to the target messenger RNA and downregulates gene expression. This 
was first observed by (Wightman et al., 1993) between 3’UTRs of the target mRNA 
(lin14) and 5’ end of lin4 (miRNA).  
 
The mechanism by which gene regulation is downregulated depends on the 
complementarity. Full complementarity between miRNA and mRNA results in 
suppression of gene expression through mRNA cleavage (Zeng and Cullen, 2003). 
RISC is important in mRNA cleavage. Ago 2 have mRNA splicing property. Perfect 
complementarity is rare in animals. However, in animal/humans, most of the 
complementarity are imperfect. As a result, there is translational repression instead of 
miRNA cleavage. Thus, protein synthesis is inhibited (Guo et al., 2010). Two 
translational repression models have been suggested. In first proposed model, 
translation is repressed at a later stage after initiation of translation (Mathonnet et al., 
2007). In the second model, initiation is suppressed. These theories are still under 
investigation (Behm-Ansmant et al., 2006). (Figure 53). 
 
Recently, it has been found that miRNA can also activate translation of target mRNA. 
(Vasudevan et al., 2007) demonstrated that miR-369-3 could upregulate translation of 
TNF-α. Similarly, (Place et al., 2008) showed that miR-373 acts as gene promoter and 
increases expression of E-cadherin and CSDC2. 
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Figure 40: microRNA mechanism of action. 
A: mRNA transcripts are translated into protein. B: miRNA represses translation, thereby inhibiting 
protein synthesis. C: miRNA can cause mRNA degradation, thereby inhibiting protein synthesis.  
Adapted from (Romaine et al., 2015) 
 
 
 
 
 
 
 
 
 
160 
 
5.1.4 miRNA and cardiovascular disease 
 
With advances in miRNA field, we are now able to detect miRNA in plasma (Mitchell 
et al., 2008). This has opened many possibilities including the role of miRNA as a 
biomarker of cardiovascular disease. Creatinine kinase and troponin T are used as 
biomarkers for diagnosis of the acute cardiac ischaemic injury. microRNA have 
emerged as a new potential biomarker not only for diagnosis but also for prognosis of 
acute cardiac ischaemic injury (Devaux et al., 2015).  
 
Even in stable coronary artery disease, miRNA levels have been noted to be affected. 
miR-126 and cluster miR-17-90 have been demonstrated to be reduced while miR-
133a and miR-208 levels were increased (Fichtlscherer et al., 2010). In a prospective 
population-based study, (Zampetaki et al., 2012) found that miR-126, miR-197 and 
miR-223 could predict future ischaemic cardiac events in asymptomatic adults over a 
period of 10 years follow up.  
 
miRNA during post-ischemia phase have been noted to play an important role. miR-
21 is cardio-protective (Gu et al., 2015), miR-133 and miR-21 is anti-apoptotic (Xu et 
al., 2007; Cheng et al., 2010c), miR-1 is antiarrhythmic (Yang et al., 2007) and miR-1 
and miR-320 is apoptotic (Xu et al., 2007; Ren et al., 2009). However, our 
understanding is limited and further work needs to be carried out to understand 
mechanisms by which microRNA play a role in cardiovascular disease. 
 
5.1.5 microRNA and diabetes 
 
The role of miRNA in diabetes has been acknowledged recently. miR-126 has been 
identified as major miRNA associated with type 2 diabetes. miR-126 levels were 
inversely related to blood glucose levels during glucose tolerance test. miR-126 levels 
are inversely correlated with the future development of peripheral vascular disease in 
diabetes mellitus (Zampetaki et al., 2010). miR-21, miR-218 and miR-211 has been 
shown to dysregulated in patients with diabetes induced atherosclerosis (Zhang et al., 
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2016). Thus, these miRs in future might serve as a novel biomarker of vascular 
dysfunction in diabetes patients. However, this will need to be confirmed.  
 
There is limited evidence regarding role of miRNAs in type 1 diabetes. Evidence is 
pointing towards distinct dysregulation of miRNAs in the blood. (Osipova et al., 2014) 
demonstrated that plasma miR-21 and miR-210 was upregulated in plasma and urine 
of individuals with type 1 diabetes mellitusas miR-126 levels were reduced. miR-126 
levels correlated negatively with HbA1c. In individuals with newly diagnosed type 1 
diabetes, twelve miRNAs were demonstrated to be upregulated (miR-152, miR-30a-
5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, 
miR-25, miR-200a). Plasma miR-25 was directly related to HbA1c (Nielsen et al., 
2012).  
 
Role of miRNA as a biomarker for diabetes related complication in type 1 diabetes is 
still being explored. Osipova et al. (2014) concluded that urinary miR-21 might help 
identify patients with renal injury. As mentioned above, urinary miR-21 was elevated in 
type 1 diabetes patients. miR-21 has been known to cause fibrosis in kidney (Chau et 
al., 2012). This has been demonstrated in type 1 and type 2 diabetes animal model 
(Dey et al., 2011a; Zhong et al., 2013). Levels of urinary miRNAs varies with different 
stage of diabetes related nephropathy in type 1 diabetes (Argyropoulos et al., 2013). 
 
Our understanding of the mechanism of action of miR in diabetes is limited. Further 
work still needs to be conducted to explore the role of miR in development of CVD in 
DM.   
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5.2 Method 
 
5.2.1 Platelet-free plasma isolation 
 
After an overnight fast, peripheral blood was collected in EDTA vacutainer tubes. Blood 
samples were processed within four hours of collection. Samples were centrifuged for 
15 minutes at 500 xg. The upper, clear fraction (platelet rich plasma, PRP) was 
collected without disturbing the bottom cellular layer and transferred to 1.5mL 
polypropylene tubes. These PRP samples were further centrifuged for 5 minutes at 
13000 x g in a microcentrifuge. After centrifugation, the clarified platelet-free plasma 
(PFP) was transferred to fresh 1.5mL polypropylene tubes and stored at -80ºC for 
subsequent analysis. The platelet pellet was discarded.  
 
5.2.2 Quantifying microRNAs by reverse transcription quantitative real-time 
polymerase chain reaction (RT-qPCR) 
 
miRNA levels were assayed directly from PFP using the Taqman real-time RT-PCR 
platform (Life Technologies). Control samples (RT control) for each miRNA were 
prepared in parallel for each patient, where the reverse transcriptase enzyme was 
omitted from the reaction mix to discount false-positive results due to DNA 
contamination. The PFP were thawed on ice then diluted 1:3 with nuclease-free water 
(Ambion). The diluted PFP were heated to 95C for 10 minutes then cooled to 4C. 
MicroRNA-specific primer (Life Technologies) was added (3µL) and the mixture 
incubated at 65C for 5 minutes then cooled to 4C to allow primer annealing. Reaction 
mastermix (reverse transcription buffer, 1mM dNTPs, RNase inhibitor, reverse 
transcriptase and nuclease-free water) (Table 21) was added to the primer/PFP mix to 
a final volume of 15µLand incubated at 16C for 30 minutes followed by 42C for 30 
minutes and 85C for 5 minutes. The RT mixture was then cooled to 4C.  
 
Aliquots of 2µL of the reverse transcription reaction product was combined with 18µL 
of PCR master mix (10µL 2x Taqman Fast Advanced mastermix, 1µL 20x miRNA 
Assay, 7µL nuclease-free water) in a 96-well reaction plate (Life Technologies) (Table 
22). No template controls were included for each miRNA to discount false-positive 
results due to DNA contamination. Each sample was amplified in triplicate. The 
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amplification reactions were performed using the Applied Biosystems® 7900HT Fast 
Real-Time PCR system as follows: 50C for 2 minutes, 95C for 20 seconds followed 
by 50 cycles of 95C for 1 second and 60C for 20 seconds. Amplification was 
monitored by the SDS 2.3 software (Life Technology).  
 
 
 
 
 
 
 
 
 
Table 21: Master Mix reagents volumes required for single sample of RT and RTC reactions. Reverse 
transcription: RT; Reverse transcription negative control: RTC. 
 
 
Reagent Volume (µl) 
2x TaqMan fast master mix 10.0 
20x miRNA assay mix 1.00 
Nuclease-free H2O 7.00 
Total 18.0 
 
Table 22: Master Mix reagents volumes required for single sample of PCR. 
 
 
 
 
 
 
 
 
 
Reagent RT RTC 
Volume (µl) Volume (µl) 
10x RT buffer 1.50 1.50 
100mM dNTPs 0.15 0.15 
RNase inhibitor 0.19 0.19 
Multiscribe RT 1.00  
Nuclease-free H2O 4.16 5.16 
Total 7.00 7.00 
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5.2.3 Plasma microRNA determination 
 
MicroRNA levels were determined using the PCR kinetics equation described in 
Equation 1. 
 
Equation 1   Nc = N0  x 2c 
where NC is the template quantity at cycle C, N0 is the initial template quantity prior to 
amplification and C is the amplification cycle. 
This is rearranged to give the initial level of target in a sample (Equation 2). 
 
Equation 2   N0 = Nc  x 2-C 
In real-time PCR, the quantity of target template at the quantification cycle is directly 
proportional to the emitted fluorescence at that point. Therefore, by substituting N for 
fluorescence, F, and C for quantification cycle, Cq, the starting levels of microRNA can 
be determined using equation 3. 
 
Equation 3  F0 = FCq  x 2-Cq 
The parameters required to quantify target genes using this equation, namely FCq and 
Cq, were obtained from multiparameter models fit to the fluorescence data using the 
programming package, qpcR, designed for the R statistical programming environment 
(version 2.15.1., GNU General Public Lisence). The fluorescence data were exported 
following completion of amplification and the model-fitting process executed in R. The 
calculated amplification parameters were used to determine the initial microRNA levels 
as given by Equation 3.  
 
C. elegans miR-39 was tried as endogenous control in our assay. However, after 
repeated experiments, we found that C. elegans could not be used in experiment as it 
interfered with levels of microRNAs that we measured. Thus, the obtained miRs results 
were controlled for plasma volume. 
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5.2.4 Choice of miRNA to be analysed 
 
We decided to explore twenty miRNAs in the first instance. These miRNAs were 
chosen based on available evidence with regards to their role in endothelial function, 
atherosclerosis, angiogenesis and anti-angiogenic properties. miR-34a, miR-133a, 
miR-125b, miR-126, miR-21, miR-10a, miR-155, miR-130a, miR-145, miR-223, miR-
33a, miR-210, miR-195, miR-503, miR-320, miR-222, miR-92a, miR-221 and miR-296 
were studied (Table 23). 
  
miRNA Function Evidence 
miR-21 Anti-angiogenic  (Sabatel et al., 2011)  
miR-222 Anti-angiogenic 
 
Neointimal formation 
(Poliseno et al., 2006) 
(Suárez et al., 2007) 
(Liu et al., 2009)  
miR-195 Anti-angiogenic in cancer 
Anti neointimal formation 
(Wang et al., 2013b) (Wang et 
al., 2012)  
miR-210 Angiogenic (Fasanaro et al., 2008; 
Pulkkinen et al., 2008)  
miR-126 Angiogenic (Fish et al., 2008) 
(Wang et al., 2008b)  
miR-320 Anti-angiogenic (Wang et al., 2009)  
miR-92a Anti-angiogenic (Bonauer et al., 2009; Fang 
and Davies, 2012)  
miR-223 Anti-angiogenic (Shi et al., 2013) 
miR-34a Anti-angiogenic (Arunachalam et al., 2014a) 
miR-133 Anti-angiogenic (Soufi-Zomorrod et al., 2016) 
miR-125b Anti-angiogenic (Muramatsu et al., 2012) 
miR-10a Angiogenic (Hassel et al., 2012) 
miR-155 Neointimal formation (Nazari-Jahantigh et al., 2012) 
miR-130a Angiogenic (Chen and Gorski, 2008) 
miR-145 Neointimal formation (Santovito et al., 2013) 
miR-503 Angiogenic (Caporali et al., 2011) 
miR-296 Angiogenic (Würdinger et al., 2008) 
miR-33a Neointimal formation (Rayner et al., 2011) 
 
Table 23: Studied miRNAs and some available evidence regarding their function. 
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5.3 Result 
 
5.3.1 Choice of miRNA based on Cq value 
 
We evaluated if we can measure twenty miRNAs (miR-34a, miR-133a, miR-125b, miR-
126, miR-21, miR-10a, miR-155, miR-130a, miR-145, miR-223, miR-33a, miR-210, 
miR-195, miR-503, miR-320, miR-222, miR-92a, miR-221 and miR-296) reliably in our 
plasma samples. We used five recruit samples to study plasma levels of twenty 
miRNAs. Cq values of eight miRNAs (miR-126, miR-21, miR-223, miR-210, miR-195, 
miR-503, miR-320, miR-222 and miR-92a) was <35 (Figure 54). Therefore, these eight 
miRNAs could be reliably measured in the plasma.   
 
Cq values for miR-125b, miR-130a, miR-34a, miR-133a, miR-33a, miR-10a, miR-145, 
miR-221, miR-155, miR-503, and miR-296 were high (>35.00) (Figure 55) Therefore, 
plasma levels of above mentioned twelve miRNAs were not measured reliably by the 
method mentioned above. High Cq values indicated that plasma levels of these 
miRNAs are very low and cannot be reliably measured in plasma. This also resulted in 
high coefficient of variation (CV%). For example, CV% for miR-125b was 43.01%.  
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Figure 41: Amplification plot demonstrating Ct value of miR-92a. 
 
 
 
Figure 42: Amplification plot demonstrating Ct value of miR-125b. 
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5.3.2 Coefficient of variation 
 
Our previous unpublished work on miRNA evaluation demonstrated that miR-92a, 
miR-126, miR-222, and miR-320 had coefficient of variation (CV%) of 8.0%, 6.1%, 
4.9%, 6.8% respectively.  
 
Intra-assay coefficient of variation for eight miRNAs was < 20% except for miR-210 
(21.7% CV). We aimed to evaluate miRNA with CV of <25%.  
 
5.3.3 Statistical analysis 
 
We have discussed statistical analysis in section 3.2. We have analysed eight miRNAs. 
We took advice from the statistician regarding correcting for multiple testing. The 
statistician advised us that based on the aims and objectives of the study, multiple 
testing is not recommended. MERIT study’s aim was to evaluate and discover 
biomarkers of interest. Significant biomarkers will be needed to be studied further to 
confirm the finding. Furthermore, small numbers of hypothesis were tested (less than 
ten).    
 
Based on the advice, we have not performed correction for multiple testing.  
 
5.3.4 Specific aims 
 
We aimed to evaluate if metformin treatment, independent of glycaemic control in type 
1 diabetes  
1. Increased levels of angiogenic circulatory miRNAs, and 
2. Decreased levels of anti-angiogenic circulatory miRNAs 
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5.3.5 miRNA 21a 
 
Results presented in Figure 56. 
 
5.3.5.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-21a levels were significantly higher in TG when compared 
with HC (TG V1 vs HC) mean+/-SE:  1.8x10-7+/-1.6x10-8 vs 8.9x10-7+/-6x10-9: 
p=0.0001. 
  
5.3.5.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment significantly reduced plasma miR-21a levels in TG; 
(TG V1 vs TG V2) mean+/-SE: 1.8x10-7+/-1.6x10-8 vs 1.3x10-7+/-1.3x10-8: p=0.0012. 
 
5.3.5.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-21a levels in TG V2 remained significantly 
higher when compared to HC (TG V2 vs HC); mean+/-SE: 1.3x10-7+/-1.3x10-8 vs 
8.9x10-7+/-6x10-9: p=0.02. 
 
5.3.5.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-21a levels were similar in TG when compared with SG 
(Treatment group pre-metformin TG V1 vs standard group SG V1 (pre-observation); 
mean+/-SE; (TG V1 vs ST V1): 1.8x10-7+/-1.6x10-8 vs 1.6x10-7+/-3.6x10-8; p=0.5. 
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5.3.5.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-21a remained unchanged (standard 
group pre-observation (SG V1) and standard group post-observation (SG V2): mean+/-
SE (SG V1 vs SG V2): 1.6x10-7+/-3.6x10-8 vs 1.7x10-7+/-4x10-8: p=0.6.  
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Figure 43: Comparing miR-21a level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), 
standard group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.6 miRNA 222 
 
Results presented in Figure 57. 
 
5.3.6.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-222 levels were significantly higher in TG when compared 
with HC (TG V1 vs HC) mean+/-SE:  8.9x10-8+/-8.6x10-9 vs 5.8x10-8+/-3.5x10-9: 
p=0.009. 
 
5.3.6.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment significantly reduced plasma miR-222 levels in TG; 
(TG V1 vs TG V2) mean+/-SE: 8.9x10-8+/-8.6x10-9 vs 7x10-8+/-5.8x10-9: p=0.007. 
 
5.3.6.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-222 levels were similar in TG and HC. (TG V2 
vs HC); mean+/-SE: 7x10-8+/-5.8x10-9 vs 5.8x10-8+/-3.5x10-9: p=0.2. 
 
5.3.6.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-222 levels were similar in TG when compared with SG pre-
observation mean+/-SE; (TG V1 vs. ST V1): 8.9x10-8+/-8.6x10-9 vs. 8x10-8+/-1.8x10-8; 
p=0.5. 
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5.3.6.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-222 remained unchanged in standard 
group (SG V1 and SG V2): mean+/-SE (SG V1 vs. SG V2): 8x10-8+/-1.8x10-8 vs. 
8.4x10-8+/-1.8x10-8: p=0.99.  
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Figure 44: Comparing miR-222 level (per ml) in plasma in all groups. Results are presented as 
mean±SE.  Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), 
standard group pre-observation (SG V1) and standard group post-observation (SG V2). 
 
 
173 
 
5.3.7 miRNA 195 
 
Results presented in Figure 58. 
 
5.3.7.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-195 levels were significantly higher in TG when compared 
with HC (TG V1 vs. HC) mean+/-SE:  6.6x10-7+/-1.2x10-7 vs. 7.1x10-8+/-1.1x10-8: 
p<0.0001. 
 
5.3.7.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment significantly reduced plasma miR-195 levels in TG; 
(TG V1 vs. TG V2) mean+/-SE: 6.6x10-7+/-1.2x10-7 vs. 4.4x10-7+/-8x10-8: p=0.002. 
 
5.3.7.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-195 levels remained significantly higher when 
compared to HC (TG V2 vs. HC); mean+/-SE: 4.4x10-7+/-8x10-8 vs. 7.1x10-8+/-1.1x10-
8: p<0.0001. 
 
5.3.7.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-195 level was significantly higher in TG when compared with 
SG: mean+/-SE; (TG V1 vs. SG V1): 6.6x10-7+/-1.2x10-7 vs. 2.8x10-7+/-8x10-8; p=0.03. 
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5.3.7.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-195 remained unchanged in the 
standard group (SG V1 and SG V2): mean+/-SE (SG V1 vs. SG V2): 2.8x10-7+/-8x10-
8 vs. 2.8x10-7+/-7.2x10-8: p=0.97.  
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Figure 45: Comparing miR-195 level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), 
standard group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.8 miRNA 210 
 
Results presented in Figure 59. 
 
5.3.8.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-210 levels were significantly higher in TG when compared 
with HC (TG V1 vs. HC) mean+/-SE:  1.3x10-8+/-1.2x10-9 vs. 7.9x10-9+/-8.9x10-10; 
p=0.003. 
 
5.3.8.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment significantly reduced plasma miR-210 levels in TG; 
(TG V1 vs. TG V2) mean+/-SE: 1.3x10-8+/-1.2x10-9 vs. 9.7x10-9+/-1.2x10-9: p=0.004. 
 
5.3.8.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-210 levels in TG became similar to HC (TG V2 
vs. HC); mean+/-SE: 9.7x10-9+/-1.2x10-9 vs. 7.9x10-9+/-8.9x10-10: p=0.4. 
 
5.3.8.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-210 level was similar in TG and SG: mean+/-SE; (TG V1 vs. 
SG V1): 1.3x10-8+/-1.2x10-9 vs. 1.3x10-8+/-1.9x10-9; p=0.98. 
 
5.3.8.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-210 remained unchanged in the 
standard group (SG V1 and SG V2): mean+/-SE (SG V1 vs. SG V2): 1.3x10-8+/-1.9x10-
9 vs. 1.2x10-8+/-1.7x10-9: p=0.5.  
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Figure 46: Comparing miR-210 level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), standard 
group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.9 miRNA 223 
 
Results presented in Figure 60. 
 
5.3.9.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-223 levels were significantly higher in TG when compared 
with HC (TG V1 vs. HC) mean+/-SE:  1.1x10-6+/-1.4x10-7 vs. 3.8x10-7+/-3.4x10-8; 
p<0.0001. 
 
5.3.9.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment did not change plasma miR-223 levels in TG; (TG 
V1 vs. TG V2) mean+/-SE: 1.1x10-6+/-1.4x10-7 vs. 9.9x10-7+/-1.5x10-7: p=0.4. 
 
5.3.9.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-223 levels in TG remained significantly higher 
when compared to HC (TG V2 vs. HC); mean+/-SE: 9.9x10-7+/-1.5x10-7 vs. 3.8x10-7+/-
3.4x10-8: p<0.0001. 
 
5.3.9.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-223 level was similar in TG and SG: mean+/-SE; (TG V1 vs. 
SG V1): 1.1x10-6+/-1.4x10-7 vs. 7.9x10-7+/-1.6x10-7; p=0.18. 
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5.3.9.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-223 remained unchanged in the 
standard group: mean+/-SE (SG V1 vs. SG V2): 7.9x10-7+/-1.6x10-7 vs. 1.2x10-6+/-
2.8x10-7: p=0.09.  
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Figure 47: Comparing miR-223 level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), standard 
group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.10 miRNA 320 
 
Results presented in Figure 61. 
 
5.3.10.1 Treatment group (pre metformin) versus healthy controls 
 
At baseline, plasma miR-320 levels were significantly higher in TG when compared 
with HC (TG V1 vs HC) mean+/-SE:  3.6x10-7+/-3.8x10-8 vs 2.6x10-7+/-2x10-8: p<0.05. 
 
5.3.10.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment non-significantly reduced plasma miR-320 levels in 
TG; (TG V1 vs TG V2) mean+/-SE: 3.6x10-7+/-3.8x10-8 vs 3x10-7+/-2.8x10-8: p=0.06. 
 
5.3.10.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-320 levels in TG V2 were similar to HC (TG V2 
vs HC); mean+/-SE: 3x10-7+/-2.8x10-8 vs 2.6x10-7+/-2x10-8: p=0.6. 
 
5.3.10.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-320 levels were similar in TG and SG; mean+/-SE; TG V1 vs 
SG V1: 3.6x10-7+/-3.8x10-8 vs 5.5x10-7+/-7.8x10-8, p=0.03. 
 
5.3.10.5 Standard group (pre-observation) versus Standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-320 remained unchanged in standard 
group: mean+/-SE (SG V1 vs SG V2): 5.5x10-7+/-7.8x10-8 vs 5.5x10-7+/-6.8x10-8: 
p=0.98.  
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Figure 48: Comparing miR-320 level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), 
standard group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.11 miRNA 126 
 
Results presented in Figure 62. 
 
5.3.11.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-126 levels were non-significantly higher in TG when 
compared with HC (TG V1 vs HC):  1.4x10-7 +/- 1.7x10-8 vs 9.4x10-8 +/- 7.3x10-9: 
p=0.06). 
 
5.3.11.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment did not change plasma miR-126 levels in TG; (TG 
V1 vs TG V2) mean+/-SE: 1.4x10-7 +/- 1.7x10-8 vs 1.37x10-7 +/- 1.7x10-8: p=0.8). 
  
5.3.11.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-126 levels remained not significantly higher in 
TG V2 when compared to HC (TG V2 vs HC); mean+/-SE: 1.37x10-7 +/- 1.7x10-8 vs 
9.4x10-8 +/-7.3x10-9: p=0.14. 
 
5.3.11.4 Treatment group (pre metformin) versus standard group (Pre-
observation) 
 
At baseline, plasma miR-126 levels were similar in TG and the SG (Treatment group 
pre-metformin TG V1 vs standard group SG V1 (Pre-observation); mean+/-SE; (TG V1 
vs ST V1: 1.4x10-7 +/- 1.7x10-8 vs 1.7x10-7+/- 3.3x10-8; p=0.45). 
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5.3.11.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-126 remained unchanged (standard 
group pre-observation (SG V1) and standard group post-observation (SG V2): mean+/-
SE (SG V1 vs SG V2: 1.7x10-7+/- 3.3x10-8 vs 2.1x10-7 +/- 4.5x10-8: p=0.3).  
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Figure 49: Comparing miR-126 level (per ml) in plasma in all groups. Results are presented as 
mean±SE. Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), 
standard group pre-observation (SG V1) and standard group post-observation (SG V2). 
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5.3.12 miRNA 92a 
 
Results presented in Figure 63. 
 
5.3.12.1 Treatment group (pre metformin) versus healthy control 
 
At baseline, plasma miR-92a levels were non-significantly higher in TG when 
compared with HC (TG V1 vs HC) mean+/-SE: 9.7x10-7+/-1.1x10-7 vs 7.6x10-7+/-8x10-
8: p=0.33. 
 
5.3.12.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eight-weeks metformin treatment did not change plasma miR-92a levels in TG; (TG 
V1 vs TG V2) mean+/-SE: 9.7x10-7+/-1.1x10-7 vs 7.5x10-7+/-9x10-8: p=0.16. 
 
5.3.12.3 Treatment group (post metformin) versus healthy control 
 
After metformin treatment, plasma miR-92a levels were not significantly different 
between TG V2 and HC (TG V2 vs HC); mean+/-SE: 7.5x10-7+/-9x10-8 vs 7.6x10-7 +/-
8x10-8: p=0.7. 
 
5.3.12.4 Treatment group (pre metformin) versus standard group (pre-
observation) 
 
At baseline, plasma miR-92a levels were similar in TG and the SG (TG V1 vs SG V1; 
mean+/-SE; (TG V1 vs ST V1: 9.7x10-7+/-1.1x10-7 vs 1.3x10-6+/-2.3x10-7; p=0.18). 
 
5.3.12.5 Standard group (pre-observation) versus standard group (post-
observation) 
 
After eight weeks of observation, plasma miR-92a remained unchanged in standard 
group: mean+/-SE (SG V1 vs SG V2): 1.7x10-7+/- 3.3x10-8 vs 2.1x10-7 +/- 4.5x10-8: 
p=0.96).  
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Figure 50: Comparing miR-92 level (per ml) in plasma in all groups. Results are presented as mean±SE. 
Treatment group pre-metformin (TG V1), treatment group post-metformin (TG V2), standard group pre-
observation (SG V1) and standard group post-observation (SG V2). 
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5.3.13 Correlation 
 
Correlation is presented in Appendix A. Below, we are presenting important 
correlations.  
• In TG, there was a direct correlation between changes in plasma miR-222 and 
cECs levels (r=0.42; p<0.05).  
• In TG at baseline, there was direct correlation between numbers of cECs and 
miR-320 levels (r=0.51; p<0.05). 
• In TG at baseline, there was an inverse correlation between weight and miR-
195 levels (r=-0.43; p<0.05). 
• In TG, there was a direct correlation between levels of miR-126 and HDL 
cholesterol (r=-0.53; p<0.05).  
• In TG, there was no correlation between circulating miR-126 and HbA1c and/or 
glucose variability in our type 1 diabetes patients. 
• In TG, there was an inverse correlation of EMPs and plasma miR-92a r=-0.52; 
p<0.05). 
• In TG, four miRNAs (miR-21a, miR-222, miR-320 and miR-195) except miR-
223 were positively correlated with each other. 
• In TG, we did not demonstrate correlation between plasma miR-210 levels and 
anti-angiogenic miRNAs. 
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5.4 Discussion  
 
We focused on eight miRNAs which has emerged to play a major role in the 
pathogenesis of CVD and diabetes-related complication. Plasma miRNA levels were 
assessed at baseline and after eight weeks of metformin treatment. These were 
compared with healthy controls. Furthermore, miRNA plasma levels were evaluated in 
type 1 diabetes cohort group (standard treatment group-SG) to explore if any changes 
in above mentioned markers can be observed with routine follow up without any 
treatment with metformin.   
 
The discussion is divided into two main sections. The first section discusses each 
miRNA separately. The second section summarises those findings of our work and its 
significance. 
 
5.4.1 Plasma miRNA levels in type 1 diabetes and effect of metformin 
 
This section discusses the studied plasma miRNA levels in type 1 diabetes and 
compares the levels with healthy controls. Effect of eight weeks of metformin on each 
studied miRNA levels in type 1 diabetes is assessed. SG underwent similar follow-up 
except for treatment with metformin. At baseline, all the miRNA levels were similar in 
treatment and standard group. Plasma levels of all the measured miRNA did not 
change after eight weeks of follow-up in the standard group.  
 
5.4.1.1 miR-21 
 
5.4.1.1.1 Main finding 
 
We have demonstrated the plasma levels of miR-21 were significantly higher in type 1 
diabetes when compared to healthy volunteers. We have for the first time shown that 
metformin decreased miR-21 levels in the plasma of type 1 diabetes independent of 
glycaemic control. 
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5.4.1.1.2 Novelty 
 
miR-21 is an anti-angiogenic miR. Decrease in miR-21 by metformin can result in the 
reduction of anti-angiogenic signal. Thereby, indirectly promoting angiogenesis and 
vascular repair. However, this is speculative and will need to be confirmed in future 
studies. Prior to our work, no study has explored the effect of metformin in type 1 or 
type 2 diabetes.  
  
5.4.1.1.3 Prior work 
 
Our data complements another study by Osipova and group who demonstrated the 
circulatory miR-21 was higher in patients with type 1 diabetes (Osipova et al., 2014).  
Increased miR-21 levels in type 1 diabetes served as an indicator for established 
vascular damage or ongoing vascular damage (Osipova et al., 2014). Levels of plasma 
miR-21 in type 2 diabetes patients were shown to be lower when compared to healthy 
controls (Zampetaki et al., 2010). Thus, type 1 diabetes and type 2 diabetes have been 
shown to have different plasma miR-21 levels.  
 
5.4.1.1.4 Mechanism 
 
miR-21 has been shown to be involved in the pathogenesis of vascular disease like 
atherosclerosis (Raitoharju et al., 2011; Cengiz et al., 2015). It has been shown in an 
animal model that miR-21 levels were five-fold higher in balloon injured carotid arteries 
(Ji et al., 2007).  Up-regulation of miR-21 inhibits PTEN (Ji et al., 2007) and PDCD4 
(Lin et al., 2009), thereby inhibiting apoptosis and promoting vascular smooth muscle 
proliferation. Similarly, in endothelial cells under stress, increased miR-21 expression 
decreases apoptosis through PTEN and the PI3K/Akt survival pathway and enhanced 
NO production (Weber et al., 2010). This is suggestive that increased miR-21 should 
decrease endothelial cell and VSMC apoptosis. Decreased vascular repair with 
ongoing damage is involved in the pathogenesis of atherosclerosis. It has been shown 
that inhibiting effect of miR-21 decreases neointimal lesion formation after angioplasty 
(Ji et al., 2007). Overexpression of miR-21 promotes inflammation by directly targeting 
and downregulating peroxisome proliferators activated receptor-α (PPAR-α) (Zhou et 
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al., 2011). miR-21 has been shown to reduce RhoB mediated endothelial cell 
proliferation, migration and tube formation (Sabatel et al., 2011).  
 
In vivo and in vitro data has suggested an inhibitory effect of miR-21 on EPC 
proliferation and angiogenesis function. miR-21 levels in CAD patients was directly 
correlated with impaired EPC migratory capacity. Inhibition of miR-21 improved EPC 
migratory function (Fleissner et al., 2010). Another recent study showed increased 
expression of miR-21 in EPC of patients with atherosclerosis. There was an elevation 
of miR-21 when EPCs were exposed to hypoxia. Inhibiting miR-21 reversed hypoxia 
induced growth arrest in EPC. This has been shown to be mediated by TGF-β (Zuo et 
al., 2015). Furthermore, suppression of miR-21 improved EPC survival via suppressing 
high-mobility group A2 (hmga2) (Zhu et al., 2013).  miR-21 expression in EPC of type 
2 diabetes is much higher in patients with previous major CV event (Domenico et al., 
2015). Above mentioned data infers an inhibitory effect of miR-21 on angiogenesis and 
vascular repair.  However, in contrast, a study involving type 2 diabetes patients 
without CVD showed reduced expression of miR-21 in the PAC (Meng et al., 2012). 
There is no published evidence regarding miR-21 expression in cultured EPCs in type 
1 diabetes.  
 
Salas-Perez and group demonstrated that miR-21 levels were reduced in PBMC 
collected from type 1 diabetes patients compared with healthy controls. Incubating 
PBMCs at different glucose concentrations increased miR-21 expression. However, 
when compared to healthy control, miR-21 expression in type 1 diabetes was still lower 
(Sala-Perez et al. 2013). It was hypothesised that reduced miR-21 expression in PBMC 
of T1DM could lead to increased survival of PBMC due to decreased apoptosis of these 
cells. This might lead to a continued pro-inflammatory environment maintained by 
apoptosis resistant PBMC (Salas-Pérez et al., 2013).   
 
miR-21 can have tissue specific effects. miR-21 dysregulation plays an important role 
in diabetes-related complication, especially renal impairment. In type 1 diabetes animal 
models, hyperglycaemia induced increased expression of miR-21 in mesangial cells 
(Dey et al., 2011b). This had been shown in vitro studies where high glucose-induced 
increased expression of miR-21 by endothelial cells (Zeng et al., 2013). miR-21 plays 
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an important role in renal fibrosis and inflammation by upregulating TGF-β and NF-κB 
signalling pathway (Dey et al., 2011b). Urinary miR-21 levels are elevated in type 1 
diabetes (Osipova et al., 2014). This is indicative of ongoing fibrotic renal damage in 
young type 1 diabetes population. Ongoing inflammatory process with direct 
correlation of CPR and urinary miR-21 is speculated to play a role in kidney damage 
(Osipova et al., 2014). miR-21 may have a functional role in wound healing in patients 
with diabetes mellitus. miR-21 has shown to be highly expressed in diabetes skin. In 
contrast to the inhibitory effect of miR-21 on endothelial cell migration, it has been 
demonstrated that miR-21 promotes fibroblast migration in the skin (Madhyastha et al., 
2011).  
 
From the above-mentioned evidence, we can see that miR-21 expression in different 
cells may have a contrasting response. However, miR-21 expression in different cells 
is likely playing a role in the development of vascular disease (e.g. high miR-21 
expression in EPC correlating with impaired migration capacity or lower expression of 
miR-21 in PBMCs pf type 1 diabetes individuals). We believe that high plasma miR-21 
levels in our type 1 diabetes cohort may be suggestive of an ongoing process of 
diabetes-related vascular complication.  
 
Based on the upper mentioned evidence, reduced expression of miR-21 is suggestive 
of decreased ongoing vascular damage. We hypothesised that decreased expression 
of plasma miR-21 could improve endothelial cell functions of proliferation, migration 
and tube formation. This effect can be mediated through attenuating RHO-kinase 
activity (Liu et al., 2014a). Furthermore, metformin has been shown to reduce TGF-β 
signalling pathway (Xiao et al., 2010). Metformin has been demonstrated to inhibit 
NFκB signalling pathway in endothelial cells (Hattori et al., 2006). Both are upregulated 
by increased expression of miR-21. Reduced expression of miR-21 in vascular smooth 
muscle will lead to increased expression of PTEN (Ji et al., 2007). Metformin has been 
shown to activate AMPK induced expression of PTEN leading to decreased 
inflammation in vascular smooth muscle cells. However, metformin concentrations 
used were higher than clinically relevant and increased the expression of PTEN 
regulated inflammatory response of vascular smooth muscle (Kim and Choi, 2012). 
Based on the current available evidence, we can infer that metformin can reduce the 
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inflammatory response and improve vascular repair through reducing miR-21 
expression. 
 
The flow diagram below gives a pictorial proposed pathway of action miR-21 in the 
development of vascular pathogenesis in type 1 diabetes (Figure 64A). We have 
shown that metformin reduced circulatory miR-21 levels thereby attenuating pathways 
leading to the development of diabetes-related complication (Figure 64B). However, 
this will need to be confirmed. 
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Figure 51: A- Flowchart proposing the effect of miR-21 on the development of vascular pathology in 
type 1 diabetes patients. B- Effect of metformin on circulatory miR-21 levels. Green colour represents 
downregulation and red represent upregulation.  
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5.4.1.2 miR-222 
 
We studied plasma levels of miR-222 in type 1 diabetes patients. We also investigated 
miR-221. miR-222 and miR-221 are located on the same gene separated by only a 
distance of 726 base pair (Chistiakov et al., 2015). They both play a vital role in 
vascular haemostasis. Most of the studies have evaluated miR-221 and miR-222 
together. However, in our study miR-221 coefficient of variation was high. Therefore, 
we have only evaluated miR-222.  
 
5.4.1.2.1 Main finding 
 
We demonstrated that plasma levels of miR-222 were higher in type 1 diabetes when 
compared to healthy controls. We also demonstrated that 8 weeks of metformin 
treatment significantly reduced the plasma miR-222 levels in type 1 diabetes. 
 
5.4.1.2.2 Novelty 
 
We have shown for the first time that miR-222 levels were significantly higher in type 
1 diabetes than HC. In addition, we have shown that metformin treatment can reduce 
miR-222. miR-222 is an anti-angiogenic miRNA. Decrease in miR-222 by metformin 
can result in the reduction of anti-angiogenic signal. Thereby, indirectly promoting 
angiogenesis and vascular repair. However, this is speculative and will need to be 
confirmed in future studies. 
 
5.4.1.2.3 Prior work 
 
Our findings of higher miR-222 in type 1 diabetes is similar to Ortega et al. 2014, who 
showed that miR-222 levels were elevated in type 2 diabetes. It is likely that metabolic 
factors like insulin resistance in type 2 diabetes play a role in miR-222 levels. In our 
study, TG cohort were overweight. Thus, insulin resistance may have played a role in 
higher miR-222 levels in type 1 diabetes. However, insulin resistance was not 
evaluated in our study. Therefore, future studies should evaluate if changes in insulin 
resistance have any effect of miR-222 levels.  
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We demonstrated that eight weeks of metformin reduced miR-222 levels in type 1 
diabetes. Our findings complement another study on type 2 diabetes which showed 
how metformin treatment reduced miR-222 levels in the internal mammary artery 
(Coleman et al., 2013). Coleman and team measured miR-222 levels in the smooth 
muscle cells and endothelial cells (Coleman et al., 2013). Therefore, from our work and 
Coleman et al, 2013, we can infer that metformin can have an effect on miR-222 levels 
in plasma and at cellular level.  
 
5.4.1.2.4 Mechanism 
 
miR-222 is pro-atherogenic and anti-angiogenic properties and plays a role in 
endothelial dysfunction.  miR-222 is highly expressed in EPC of CAD patient (Chang 
et al., 2014), vascular smooth muscle cells (Liu et al., 2012) and endothelial cells (Liu 
et al., 2012). miR-222 mechanism of action has been shown to be variable and 
dependent on the tissue. miR-222 in VSMC stimulates proliferation, migration and 
attenuates apoptosis (Liu et al., 2012). At the site of vascular injury, platelets and EC 
releases platelet derived growth factor (PDGF) (McNamara et al., 1996). PDGF 
induces expression of miR-222 and miR-221. Increased expression of miR-222/miR-
221 reduced levels of p27kip1 (Liu et al., 2012). p27kip1 is known to attenuate 
atherosclerosis development (Shahzad et al., 2011). Reduced expression of p27kip1 
leads to the development of atherosclerotic plaque (DÍEZ-JUAN and ANDRÉS, 2001; 
Akyürek et al., 2010).  
 
Metformin has been observed to reduce miR-222 expression in EC in vitro in type 2 
diabetes (Coleman et al., 2013). Our data showed that metformin reduced miR-222 
levels in type 1 diabetes plasma. miR-222 levels were reduced to levels similar to 
healthy volunteers. We have shown a positive correlation between changes in plasma 
miR-222 and cECs levels). We can postulate that metformin may decrease EC damage 
through improving miR-222 levels. However, further functional studies need to be 
conducted to confirm this finding and elucidate this mechanism. Firstly, in vitro work 
should be conduction studying the effect of metformin at the physiological 
concentration on miR-222. This should be extended further to study downstream 
pathways e.g. eNOS pathway. Further work using miR-222 gain and loss of function 
in culture microenvironment should be conducted to evaluate downstream pathways. 
194 
 
The flow diagram below gives a pictorial proposed pathway of action miR-222 in the 
development of vascular pathogenesis in type 1 diabetes (Figure 65A). We have 
shown that metformin reduced circulatory miR-222 levels thereby attenuating 
pathways leading to the development of diabetes-related complication (Figure 65B). 
However, this will need to be confirmed. 
 
 
 
Figure 52: A- Flowchart proposing the effect of miR-222 on the development of vascular pathology in 
type 1 diabetes patients. B- Effect of metformin on circulatory miR-222 levels. Green colour represents 
downregulation and red represent upregulation.  
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5.4.1.3 miR-195 
 
5.4.1.3.1 Main Finding 
 
Main findings of our study included: 
1. Plasma levels of miR-195 were significantly higher in type 1 diabetes individual 
when compared to healthy controls. 
2. There was an inverse correlation between weight and miR-195 levels in type 1 
diabetes. 
3. Eight weeks of metformin reduced miR-195 levels in plasma significantly in type 
1 diabetes mellitus. However, the level of plasma miR-195 remained 
significantly higher than healthy volunteers. 
 
5.4.1.3.2 Novelty 
 
So far, no study has specifically found evidence regarding dysregulation of miR-195 in 
type 1 diabetes. We have for the first time demonstrated that miR-195 levels were 
higher in type 1 diabetes when compared to HC. In addition, metformin lowered miR-
195 levels after eight weeks of metformin treatment. It is for the first time, we have 
shown that anti-angiogenic miR-195 is reduced along with miR-21a. Thereby, reducing 
anti-angiogenic signals.  
 
5.4.1.3.3 Prior work 
 
In contrast to our data, miR-195 levels in plasma were observed to be significantly 
lower in type 2 diabetes (Ortega et al. 2014). This might be due to the different disease 
population in our study and Ortega et al. (2014). Furthermore, plasma collection 
protocol was different (500g for 15 minutes followed by 13000g for 5 minutes (our 
protocol) vs 1000g for 15 minutes followed by 2000g for 5 minutes (Ortega et al. 2014). 
Type 2 diabetes has more of metabolic disturbance whereas type 1 diabetes is mainly 
due to insulin deficiency and less metabolic dysfunction. There may be different 
mechanisms and factor causing miR-195 dysregulation. Higher weight or BMI does 
increase insulin resistance even in type 1 diabetes. Lower miR-195 expression in type 
2 diabetes and our data of inverse correlation between weight and BMI is suggestive 
of insulin resistance playing an important role in miR-195 dysregulation.   
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5.4.1.3.4 Mechanism 
 
miR-195 is a marker of vascular injury. It is raised in patients with acute myocardial 
ischemia (Long et al., 2012). There is developing evidence that miR-195 plays a role 
in vascular repair and damage. It has been shown in the model of balloon-injury carotid 
artery model that miR-195 reduced proliferation, migration and pro-inflammatory 
biomarkers (Wang et al., 2012).  
 
In diabetes animal model, miR-195 has been linked with diabetes-related complication. 
In type 1 diabetes animal model, miR-195 has been shown to play a major role in 
microvessels damage in diabetic retinopathy through it downregulating SIRT1 
(Mortuza et al., 2014).  miR-195 has been shown in the diabetic animal model to 
augment myocardial hypertrophy, decrease coronary blood flow and reduce 
myocardial function (Zheng et al., 2015). miR-195 plays a role in oxidative damage, 
apoptosis and reducing angiogenesis. miR-195 has been shown to be anti-angiogenic 
through reducing the expression of VEGF (Wang et al., 2013b). miR-195 has been 
demonstrated to play an important role in palmitate-induced cardiomyocytes apoptosis 
and sepsis-induced apoptosis, and multi-organ injury though its effect on SIRT1 (Zhu 
et al., 2011). miR-195 has also been shown to downregulate HMGA-1 expression. 
Downregulation of HMGA-1 expression is involved in isoprenaline-induced 
cardiomyocyte hypertrophy (You et al., 2014).  Based on the evidence mentioned 
above, we can infer that high miR-195 levels in type 1 diabetes can be linked with the 
development of diabetes-related complication and CVD.  
 
Based on above mentioned result, metformin effect in reducing miR-195 expression 
may lead to a partial decrease in risk of development of diabetes-related complication 
in type 1 diabetes. We hypothesised that SIRT-1 will play a role in this.  We know that 
hyperglycaemia has been shown to decrease SIRT1 expression. Restoring SIRT1 
expression has been demonstrated to play a protective role in diabetes vasculopathy 
(Orimo et al., 2009). Metformin has been shown to attenuate hyperglycaemia related 
endothelial senescence due to partly restoring SIRT-1 expression (Arunachalam et al., 
2014b).  Concentration of metformin in Arunachalam and group is higher than 
physiological concentration of metformin (50mM). Therefore, effect of physiological 
concentration of metformin on miR-195 and SIRT-1 will need to be confirmed.  
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The flow diagram below gives a pictorial proposed pathway of action miR-195 in the 
development of vascular pathogenesis in type 1 diabetes (Figure 66A). We have 
shown that metformin reduced circulatory miR-195 levels thereby attenuating 
pathways leading to the development of diabetes-related complication (Figure 66B). 
However, this will need to be confirmed. 
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Figure 53: A-Flowchart proposing the effect of miR-195 on the development of vascular pathology in 
type 1 diabetes patients. B-Effect of metformin on circulatory miR-195 levels. Green colour represents 
downregulation and red represent upregulation.  
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5.4.1.4 miR-210 
 
5.4.1.4.1 Main finding 
 
We demonstrated that miR-210 plasma levels were higher in type 1 diabetes when 
compared to healthy controls. Furthermore, for the first time, we have shown that 
metformin significantly reduced miR-210 levels. However, after metformin treatment, 
levels remained significantly higher in type 1 diabetes individual when compared to 
healthy volunteers. 
 
5.4.1.4.2 Novelty 
 
As the only study looking at effect of metformin in type 1 diabetes, we have shown that 
eight weeks of metformin treatment significantly reduced miR-210 in type 1 diabetes. 
This provides novel information which can be used to elucidate the mechanistic 
pathways affected by metformin.  
 
5.4.1.4.3 Prior work 
 
Our results are similar to Osipova et al. (2014), who also showed increased levels of 
miR-210 in plasma and urine of individuals with type 1 diabetes. Circulating levels of 
miR-210 is also upregulated even in children with newly diagnosed type 1 diabetes 
(Nielsen et al., 2012). To the best of our knowledge, there is currently no evidence on 
the effect of metformin in type 1 or type 2 diabetes.  
 
5.4.1.4.4 Mechanism 
 
miR-210 has been established as hypoxia responsive “master” miRNA (Kulshreshtha 
et al., 2008; Huang et al., 2010b). There is an extensive body of evidence developing 
regarding the role of miR-210 in tumour initiation (Huang et al., 2009c) and 
progression. Rapidly expanding tumours are known to have hypoxic microenvironment 
(Huang et al., 2010b). miR-210 is increased in patients with malignancy (Giannakakis 
et al., 2007; Camps et al., 2008).  miR-210 can serve as potential biomarkers in renal 
cell carcinoma (Zhao et al., 2013a). Based on cancer work, (Huang and Zuo, 2014) 
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summarised miR-210 functions, which included promoting angiogenesis, protection 
from apoptosis, a regulator of cell cycle progression, repressing DNA damage and 
regulating mitochondrial metabolism. Hypoxia induced factor-α (HIF-α) has been 
identified as an important regulator of miR-210. HIF-α is upregulated under hypoxic 
condition. HIF-α is involved in regulating gene expression associated with promoting 
angiogenesis and preventing apoptosis under hypoxic condition, thereby promoting 
protection (Huang et al., 2010b). HIF-1α and HIF-2α, both have been shown to be 
involved in regulating miR-210 (Camps et al., 2008; Huang et al., 2009c; Zhang et al., 
2009b). However, in comparison to HIF-2α, HIF-1α plays a major role in increasing 
expression of miR-210 (Crosby et al., 2009; Huang et al., 2009c).  
 
miR-210 promotes angiogenesis and cell migration in EC even in normoxic condition. 
miR-210 is up-regulated in response to hypoxia in EC. This is mediated through HIF-
1α activation (Fasanaro et al., 2008). miR-210 has been shown to protect EC and 
cardiomyocytes from apoptosis (Cicchillitti et al., 2012). miR-210 levels have been 
shown to remain elevated even after disappearance of hypoxia (Fasanaro et al., 2008). 
This means that miR-210 protective response is maintained to improve cell survival. 
Angiogenic and cell migration signal by miR-210 in response to hypoxia is modulated 
through downregulating EFNA3 (Fasanaro et al., 2008). Growth factors like VEGF 
upregulated miR-210 in CD34+ cells (Alaiti et al., 2012). miR-210 has been shown to 
enhance ex vivo angiogenesis in normoxic condition when there was no VEGF in the 
medium. Silencing miR-210 attenuated VEGF mediated angiogenesis (Alaiti et al., 
2012). miR-210 has been demonstrated to improve cardiomyocyte survival in murine 
ischaemic models (Hu et al., 2010).  
 
The above-mentioned properties of miR-210 are interesting in the light of our results 
and other evidence of high miR-210 plasma levels in type 1 diabetes patients (Osipova 
et al., 2014). Diabetes microenvironment has been shown to increase vascular 
damage. In vitro studies have demonstrated increased miR-210 expression due to high 
glucose (Greco et al., 2012).  Increased miR-210 levels could be a response to ongoing 
vascular injury leading to counter-regulatory enhanced vascular repair and endothelial 
protection through promoting angiogenesis and preventing apoptosis. However, this 
could also be a marker of increased vascular injury. miR-210 is a marker of 
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atherosclerosis (Li et al., 2011b). The miR-210 expression has been shown to be 
higher in atherosclerotic plaque (Raitoharju et al., 2011). It is hypothesised that 
increased angiogenic signal of miR-210 affects VSMC phenotypes and plays a critical 
role in atherosclerosis (Li et al., 2011b). (Chen et al., 2015b) demonstrated that 
oxidised LDL resulted in HIF-1α mediated increase in miR-210. miR-210 inhibits 
sprouty-related EVH1 domain 2 (SPRED2) expressions. SPRED2 inhibition is linked 
with the development of vascular disease. HIF-1α is associated with the development 
of atherosclerosis by regulating development of foam cells (Vink et al., 2007). 
Expression of HIF-1α is directly correlated with diabetic retinopathy progression (Yan 
and Su, 2014). The HIF-1α expression is an independent risk factor of coronary artery 
calcification in patients with type 2 diabetes (Li et al., 2014). In an animal model, the 
HIF-1α expression has been shown to mediate diabetes-related kidney disease (Nayak 
et al., 2016).  
 
In summary, HIF-1α mediated miR-210 expression is important in vascular repair. 
However, excess expression of HIF-1α and downstream target (e.g. miR-210) may 
lead to the development of a vascular disease like atherosclerosis.  
 
As mentioned above, metformin treatment reduced miR-210 in type 1 diabetes. 
Reduction in miR-210 after eight weeks of metformin treatment could be due to a 
reduction in ongoing vascular damage and/or less inflammatory microenvironment. 
Metformin effect on plasma miR-210 levels could be mediated through HIF-1α. 
Metformin is known to reduce HIF-1α expression (Wheaton et al., 2014). HIF-1α 
inhibition has been shown to prevent development and progression of diabetic 
retinopathy in type 1 diabetes animal model (Chen et al., 2013). Plasma miR-210 levels 
in our type 1 diabetes patient after eight weeks of metformin treatment did not reach 
levels similar to healthy volunteer’s levels. As mentioned above, the excess angiogenic 
signal can lead to the development of atherosclerosis and diabetes-related 
complication. Therefore, reduction of miR-210 levels by metformin may be rebalancing 
excess angiogenic signal to a more balanced vascular repair. Plasma miR-210 levels 
were still significantly higher in type 1 diabetes than healthy control suggesting 
presence of microenvironment causing vascular damage and increased need for 
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vascular repair and.  This hypothesis needs to be confirmed by designing in vitro and 
in vivo studies.  
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5.4.1.5 miR-223 
 
5.4.1.5.1 Main finding 
 
We have for the first time shown that plasma miR-223 levels were significantly higher 
when compared to healthy controls. Eight weeks of metformin treatment did not have 
any effect on miR-223 levels.  
 
5.4.1.5.2 Novelty 
 
Our result of raised miR-223 in type 1 diabetes when compared to healthy control is 
unique to our study. We need to explore and elucidate the role of miR-223 in 
pathogensis of  diabetes-related complication.  
 
5.4.1.5.3 Prior work 
 
Our findings of raised miR-223 levels in type 1 diabetes were in contrast to studies 
exploring plasma miRNA levels in type 2 diabetes (Zampetaki et al., 2010), patients 
with coronary heart disease (Finn et al. 2013) and risk of ischaemic heart disease 
(Zampetaki et al., 2012). Zampetaki et al. 2010 demonstrated that plasma miR-223 
levels were not only lower in type 2 diabetes, but reduced levels could be detected well 
before the presentation of type 2 diabetes. This could in part be explained by levels of 
EMPs and PMPs. miR-223 is known to be transported through MP (Finn et al., 2013). 
It has been shown previously that EMPs and PMPs are significantly higher in type 1 
diabetes when compared with healthy control (Dignat-George et al., 2002). Whereas 
in type 2 diabetes, EMPs and PMPs are similar to healthy volunteers (Dignat-George 
et al., 2002). This can explain why plasma miR-223 levels were raised in our type 1 
diabetes cohort. Additionally, in type 2 diabetes, decreased miR-223 could be due to 
decreased loading in MPs.  
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5.4.1.5.4 Mechanism 
 
miR-223 levels vary depending on the disease process. It has been established that 
miR-223 expression is dysregulated in malignancy. It belongs to a class of miRNA 
called OncomiRs (Taïbi et al., 2014). In the breast, gastric and ovarian cancer, the 
miR-223 expression is upregulated and promotes invasiveness of malignancy (Laios 
et al., 2008; Li et al., 2011c; Yang et al., 2011). However, miR-223 levels are reduced 
in other cancers like hepatocellular carcinoma and AML (Wong et al., 2008; Eyholzer 
et al., 2010). Thus, up- or downregulation of miR-223 in different cancers have been 
shown to promote carcinogenesis and metastasis. It is only in 2013 when Shi et al. 
published their work in Circulation Research, miR-223 became recognised for its 
significant role in the development of vascular pathophysiology (Thum, 2013). (Shi et 
al., 2013) demonstrated that miR-223 attenuated EC angiogenic potential. 
Furthermore, miR-223 inhibited growth factors (VEGF and bFGF), mediated EC 
proliferation, migration and sprouting. This is partly mediated through downregulation 
of β1integrin. Similarly, (Pan et al., 2014)  demonstrated that platelet-derived miR-223 
promoted EC apoptosis. It has been demonstrated that miR-223 increased osteoblast 
apoptosis. miR-223 mediated this effect through downregulating insulin life growth 
factor receptor 1 (Qin et al., 2016).  
 
We can infer from the above-mentioned evidence that miR-223 is antiangiogenic. High 
levels of miR-223 in our type 1 diabetes patients are a further proof suggestive of the 
antiangiogenic signal in this group of patients.  
 
Metformin has shown to have no effect on plasma miR-223 levels. This could be due 
to unchanged MP levels in our TG after eight weeks of metformin treatment. Our result 
is similar to previous work which showed that metformin has no effect on miR-223 
plasma levels in type 2 diabetes (Ortega et al. 2014). miR-223 overexpression does 
not affect AMPK or PIK3 pathway (Lu et al., 2010). Both of these pathways are 
activated by metformin (Pernicova and Korbonits, 2014). Thus, it is likely that 
metformin mediates its effects through other mechanisms without affecting miR-223 
expression. However, this needs to be further confirmed through in vitro and in vivo 
studies using metformin for a longer duration of time.  
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5.4.1.6 miR-320 
 
5.4.1.6.1 Main finding 
 
We have demonstrated that plasma miR-320 was significantly higher in type 1 diabetes 
patients when compared to healthy controls. Eight weeks of metformin treatment non-
significantly reduced plasma miR-320 levels in type 1 diabetes. However, after 
metformin treatment, plasma miR-320 levels in type 1 diabetes and healthy controls 
were not significantly different.  
 
5.4.1.6.2 Novelty 
 
We have for the first time demonstrated that miR-320 was significantly higher in type 
1 diabetes. Our data provides additional evidence that anti-angiogenic signals plays 
an important role in type 1 diabetes. Our data can be used to understand the miR-320 
upstream and downstream pathways in type 1 diabetes. 
 
5.4.1.6.3 Prior work and mechanism 
 
Plasma miR-320 levels have been shown to be lower in type 2 diabetes (Zampetaki et 
al., 2010). Similarly, in vitro animal model data has demonstrated that high glucose 
concentration would result in a reduction of miR-320 expression in EC and kidney 
(Feng and Chakrabarti, 2012). Therefore, it is likely that there is another mechanism 
other than hyperglycaemia resulting in differential expression of miR-320 in type 2 
diabetes. miR-320 plasma levels are reduced in other metabolic condition like PCOS 
(Sørensen et al., 2014). However, there is conflicting evidence regarding miR-320 
levels in metabolic syndrome associated with type 2 diabetes (Karolina et al., 2012). It 
was demonstrated that miR-320 levels were high in patients with metabolic syndrome 
with type 2 diabetes (Karolina et al., 2012). 
 
miR-320 levels have been demonstrated to be high in patients with acute myocardial 
ischemia (Devaux et al., 2015). Similarly, miR-320 levels are upregulated in patients 
with coronary artery disease or high-risk individuals (Chen et al., 2015a). In vitro and 
in vivo experiments have revealed that miR-320 played a role in the development of 
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atherosclerosis through inhibiting EC proliferation and inducing apoptosis (Chen et al., 
2015a).  Furthermore, miR-320 expression in cardiomyocytes has been shown to be 
detrimental to their survival during ischemia/reperfusion injury (Ren et al., 2009; Song 
et al., 2014). Therefore, increased plasma miR-320 levels in type 1 diabetes is an 
additional factor suggestive of a microenvironment not favourable for endothelial 
repair. 
 
Metformin reduced the plasma miR-320 levels in type 1 diabetes to levels similar to 
healthy controls. However, this reduction was not statistically significant. Is this 
reduction clinically significant? We have demonstrated a positive correlation between 
changes in plasma miR-320 levels with markers of endothelial injuries (cECs). 
Currently, available evidence and our data point towards a protective effect of this 
reduction in plasma miR-320. In vitro and in vivo experiments have demonstrated that 
blocking miR-320 during ischemia in cardiomyocytes was protective (Ren et al., 2009; 
Song et al., 2014). This will need to be confirmed by studying the effect of metformin 
on miR-320 and its downstream pathways.  
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5.4.1.7 miR-126 
 
5.4.1.7.1 Main finding 
 
Our main finding includes: 
1. We demonstrated that plasma miR-126 levels were non-significantly higher in 
type 1 diabetes when compared to healthy volunteers.  
2. Plasma miR-126 levels were directly correlated with HDL cholesterol.  
3. Eight weeks of metformin treatment did not change plasma miR-126 levels. 
 
5.4.1.7.2 Novelty 
 
There is a lot of focus on miR-126 due to its angiogenic properties. We for the first time 
had demonstrated that metformin did not have any effect on circulatory miR-126 levels.  
 
5.4.1.7.3 Prior work and mechanism 
 
Plasma miR-126 levels have been demonstrated to be lower in type 2 diabetes patients 
(Zampetaki et al., 2010). Reduced plasma miR-126 levels have been shown to be 
present many years prior to the occurrence of type 2 diabetes (Zampetaki et al., 2010). 
Plasma miR-126 levels are lower in patients with impaired fasting glucose and 
impaired glucose tolerance (Liu et al., 2014b). In healthy individuals, plasma miR-126 
levels increase with age. However, this effect is lost in type 2 diabetes. Levels are 
lower in patients with poorly controlled diabetes. This has been demonstrated in vitro 
where high glucose reduced miR-126 expression in EC (Domenico et al., 2015). 
Treatment with diet or insulin improved plasma miR-126 levels in type 2 diabetes (Liu 
et al., 2014b). Circulatory angiogenic cells in type 2 diabetes also expressed low levels 
of miR-126 (Domenico et al., 2015). In contrast to type 2 diabetes, patients with type 1 
diabetes has shown similar levels of plasma miR-126 levels when compared to healthy 
controls (Osipova et al. 2014 and Nielsen et al. 2012). However, urinary miR-126 levels 
are lower and correlated negatively with HbA1c in type 1 diabetes (Osipova et al. 
2014). Cultured PAC from type 1 diabetes demonstrated an increased miR-126 
expression (Garcia de la Torre et al., 2015).  
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Our data of non-significantly raised miR-126 levels in our type 1 diabetes patients is in 
line with another study on type 1 diabetes (Osipova et al. 2014). However, our and 
Osipova et al. (2014) results are in contrast with type 2 diabetes studies. In type 2 
diabetes studies (Liu et al., 2014b; Domenico et al., 2015), it has been proposed that 
hyperglycaemia may be a factor in dysregulation of plasma miR-126 levels. Both type 
1 diabetes and type 2 diabetes patients are exposed to hyperglycaemia. However, we 
have not shown any correlation between circulating miR-126 and HbA1c and/or 
glucose variability in our type 1 diabetes patients. Thus, there is likely another 
mechanism for the dysregulation of miR-126 levels in type 2 diabetes.  
 
Our patients with type 1 diabetes had higher HDL cholesterol when compared to 
healthy volunteers. This could be due to some of our patients being treated with statins. 
Circulatory miR-126 is known to be transported on HDL particles (Wagner et al., 2013). 
This could explain a slight non-significantly higher plasma miR-126 levels in our 
patients.  
 
Eight weeks of metformin treatment did not change plasma miR-126 levels. This is in 
line with data from type 2 diabetes study. Three months of metformin treatment did not 
alter the expression of miR-126 plasma levels (Ortega et al. 2014). Therefore, we can 
conclude that metformin most likely has no effect on plasma miR-126 levels.  
 
miR-126 has been shown to have angiogenic properties and essential for vascular 
haemostasis. It has been proved in in vitro and in vivo experiments. miR-126 mediates 
its effect through repressing SPRED-1 expression which in turn activate MAP kinase 
pathway. In addition to SPRED-1, miR-126 inhibits PIK3 pathway. This, in turn, 
activates VEGF-mediated angiogenesis (Fish et al., 2008). This is most likely the 
mechanism in non-diabetic individuals. As mentioned above, miR-126 levels are lower 
in type 2 diabetes. This reduced the functions of EPC through affecting VEGF-
mediated pathway (Wu et al., 2016). In contrast to this, (van Solingen et al., 2011) had 
shown that damaged endothelium had lower miR-126 expression leading to increase 
in SDF-1 and VCAM-1 levels. This resulted in the increased mobilisation of EPC. 
However, increased PIK3 activity due to reduced miR-126 can lead to EPC-mediated 
intimal hyperplasia (Zhang et al., 2013). This can contribute to atherogenesis. 
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Therefore, miR-126 levels are necessary to keep an equilibrium between 
angiogenesis, mobilisation of EPC and vascular repair. 
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5.4.1.8 miR-92a 
 
miR-92a is a proatherogenic and anti-angiogenic miRNA. It is essential for endothelial 
cell function (Iaconetti et al., 2012). We demonstrated that plasma miR-92a levels were 
similar in type 1 diabetes and healthy volunteers. This is in line with other available 
evidence that miR-92a expression does not change in both type 1 diabetes and type 2 
diabetes (Nielson et al. 2012 and Ortega et al. 2014). Furthermore, eight weeks of 
metformin treatment did not significantly reduce the plasma levels in type 1 diabetes. 
Limited evidence from a type 2 diabetes study demonstrated similar results where 
three months of metformin treatment did not change plasma miR-92a levels (Ortega et 
al. 2014).  
 
miR-92a is thought to be endothelial in origin (Fichtlscherer et al., 2010; Ren et al., 
2013). miR-92a is upregulated in EMPs of CAD patients (Ren et al. 2013). However, 
circulatory levels are not significantly higher in our cohort despite increased levels of 
EMPs. Furthermore, we have demonstrated an inverse correlation of EMPs and 
plasma miR-92a (Appendix A). This is suggestive that most of the miR-92a are not 
carried by MP in type 1 diabetes. Indeed, our data is in line with current evidence which 
is suggestive that most of the circulatory miR-92a are outside vesicles. MP isolated 
from patients with diabetes did not show any differential expression of miR-92a 
(Jansen et al., 2016). Hyperglycaemia did not demonstrate any change in expression 
of miR-92a from EC (Jansen et al. 2016).  
 
Our data is suggestive that plasma miR-92a may not play a major role in the 
pathogenesis of vascular disease and endothelial dysfunction in type 1 diabetes. 
Furthermore, evidence from our data and type 2 diabetes have shown that metformin 
does not regulate miR-92a expression.  
 
 
 
 
211 
 
5.4.2 Summary 
 
We have studied eight microRNAs. These can be divided into two major groups: 1) 
angiogenic and 2) antiangiogenic. miR-126 and miR-210 are angiogenic miRNAs 
whereas miR-21a, miR-222, miR-320, miR-92a, miR-223 and miR-195 are anti-
angiogenic miRNAs. We have shown that miR-21a, miR-222, miR-320, miR-223 and 
miR-195 are significantly raised in type 1 diabetes when compared to age- and gender-
matched healthy volunteers. Four miRNAs (miR-21a, miR-222, miR-320 and miR-195) 
except miR-223 positively correlated with each other. Thus, it is suggestive that 
microenvironment in type 1 diabetes patients increases the release of antiangiogenic 
and proapoptotic miRNAs in the plasma.  
 
These changes in plasma miRNA levels could be reflective of a clinical condition in the 
microenvironment of our type 1 diabetes patients. Circulating miRNAs have been 
reported as biomarkers for diagnosis and prognosis in patients with CVD. Each 
disease process provides a unique feature which may cause differences in the profile 
of circulating microRNAs. Furthermore, expression/levels may differ in each tissue.  
 
In addition to being a biomarker and reflecting clinical condition, circulating miRNAs 
has been shown to play a role in gene expressions of exposed tissues.  Multiple studies 
have shown the functional capacity of circulating miRNAs in either development of the 
disease or vascular repair. Raised antiangiogenic miRNA levels in patients with type 1 
diabetes individuals provide an environment leading to impaired vascular repair.  
 
We explored which pathways will be affected by raised antiangiogenic miRNAs 
(Vlachos et al., 2015). We analysed the pathway using DIANA TOOLS mirPATH v.3 
online software. The analysis of the pathway demonstrates that angiogenesis, 
proliferative, migration, adhesion, cell cycle and apoptosis pathways are dysregulated. 
Few of the pathways which are dysregulated includes PIK3-AkT signalling, focal 
adhesion, TGF-β signalling, cell cycle and p53 pathways, etc (Figure 67).  
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One of the angiogenic miRNAs (miR-210) was significantly raised in patients with type 
1 diabetes. We have complemented findings of a previous study showing raised 
circulating miR-210 in type 1 diabetes. This could represent a compensatory 
mechanism trying to mount a regenerative response to ongoing vascular damage. 
However, it is important to note that plasma miR-210 levels do not correlate with any 
of the anti-angiogenic miRNAs.  miR-210 is an angiogenic miRNA. It may be that as a 
part of reparative response, there is an excess expression of miR-210. We have 
discussed previously that excess expression of miR-210 has been shown to play a role 
in the development of diabetes complication and development of atherosclerosis. The 
role of excess miR-210 expression needs to be studied in the presence of anti-
angiogenic miRNAs in vitro and in vivo studies. Similarly, miR-126, another angiogenic 
miRNA studied did not show increased plasma levels when compared to healthy 
controls. To our knowledge, there is no published evidence exploring the effect of the 
intervention on plasma miRNA in type 1 diabetes. Only one study explored the effect 
of metformin on plasma miRNA levels in patients with diabetes. This study included 
patients with type 2 diabetes (Ortega et al., 2014). In this study, circulatory levels of 
miR-222 and miR-140 were significantly decreased whereas circulatory levels of miR-
142 and miR-192 were significantly increased. Insulin resistance, weight and HbA1c 
decreased significantly. These factors could play a role in modifying levels of 
circulatory miRNAs levels. HbA1c and weight did not change in our study. Furthermore, 
glucose variability did not change after eight weeks of metformin treatment. Effect of 
glucose variability and HbA1c on plasma miRNA levels needs to be explored further.  
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miR-222, miR-21a, miR-320 and miR-195 are anti-angiogenic miRNAs. Reduction of 
these miRNA levels may provide an environment conducive to vascular repair. Effect 
of metformin on circulatory miR-210 levels is interesting. It seems that metformin is 
encouraging to normalise angiogenic signal towards normal. This could be 
compensatory as anti-angiogenic miRNA are being reduced. Alternatively, this could 
represent the effect of metformin on excess angiogenic signal and balance the repair 
process. This will need to be explored further in in-vitro and in vivo studies. Before this 
could be done, further work needs to be done in improving the validity of the miR-210 
analysis. 
 
We explored which pathways will be affected by improvement of two significantly 
reduced (miR-21a and miR-195) antiangiogenic miRNAs (Vlachos et al. 2015). The 
analysis of the pathway demonstrates that reduction in plasma levels of these miRNA 
will improve angiogenesis, proliferation, migration, adhesion and cell cycle (Figure 68).  
 
Our data has yielded important information regarding angiogenic and antiangiogenic 
signal in the plasma. Our work can be meaningfully extended by exploring miRNA, 
miRNA targets and downstream protein expression. Gain of function and loss of 
function experiment (in vitro and in vivo) experiments will yield information regarding 
individual miRNA and their functions. This will be important in not only generating 
circulatory biomarkers but also prognostic markers and future treatment. 
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6 Chapter 6: Effect of metformin on cytokines 
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6.1 Introduction 
 
Cytokines are a diverse group of mediators released by inflammatory cells or tissues. 
Cytokines play a vital role in physiological and pathological processes.  Cytokines are 
involved in inflammatory, vascular, immune (innate and adaptive) and haematopoiesis 
response. The effects of cytokines are mediated by binding to specific cell surface 
receptors and modulating intracellular transduction pathways (Kofler et al., 2004). This 
can ultimately lead to activation of transcription mediators like NF-κB and STAT 
(Kishimoto et al., 1994; O'Shea et al., 2002).  
 
Cytokines play an integral role in vasculopathy. Cytokines act on EC via paracrine and 
autocrine manner. Circulatory cytokines like TNF-α act on EC, leading to EC activation. 
Activation of a transcription mediator like NF-κB leads to increased production of pro-
inflammatory cytokines like IL-6, IL-1 and TNF-α by EC (Kofler et al., 2004). Cytokines 
like IL-6 and TNF-α have been shown to cause endothelial dysfunction (Wassmann et 
al., 2004; Zhang et al., 2009a). Cytokines cause vascular cell activation, increased 
adhesion molecule expression, leukocyte activation, foam cell formation and oxidative 
stress. All these are steps in the formation of atherosclerotic plaque (Figures 69 and 
73). Cytokines also contribute to atherosclerotic plaque rupture and thrombosis by 
increasing macrophages and smooth muscle cell (SMC) apoptosis, inhibition of 
collagen synthesis, increased MMP activity, reduced TIMP-1 activity and increased 
coagulation activation (Ait-Oufella et al., 2011).  
 
Figure 56: Role of cytokines in atherosclerosis development and plaque disruption.  
(Reproduced from Ait-Oufella et al. 2011). 
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Cytokines play a major role in the development of complications in patients with 
diabetes mellitus. Hyperglycaemia is a major issue in both type 1 and type 2 diabetes. 
Even with good control, intermittent glucose excursion cannot be controlled. Therefore, 
hyperglycaemia results in a modulating myriad of metabolic and haemodynamic 
changes leading to diabetic vasculopathy. Hyperglycaemia-induced inflammation and 
oxidative stress is a major mechanism in the pathophysiology of development of a 
diabetes-related complication. The release of inflammatory cytokines and chemokines 
contributes to a vicious cycle of continued vascular damage (King, 2008; Elmarakby 
and Sullivan, 2010) (Figure 70).  
.  
 
Figure 57: Role of hyperglycaemia and in type 1 and type 2 diabetes-related complications. 
Elmarakby and Sullivan 2010 
 
Below we discuss selected cytokines which have been shown to play a role in the 
pathogenesis of atherosclerosis and diabetes-related complication.  
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6.2 TIMP-1 
 
TIMP-1 or tissue inhibitor of metalloproteinases-1 is one of the four inhibitors that 
control the activity of matrix metalloproteinases (MMP). TIMP-1 plays a role in 
extracellular matrix turnover via its effect on MMP (Brew and Nagase, 2010).  The role 
of MMP and TIMP-1 in EPC mobilisation is still being elucidated. Based on current 
evidence, we understand that MMP most likely plays a role in the mobilisation of EPC 
from bone marrow through the release of cKIT. cKIT, in turn, facilitate the release of 
EPC (Huang et al., 2009b). Increased TIMP activity will reduce MMP function (Brew 
and Nagase, 2010), thereby limiting EPC mobilisation (Figure 71).  
 
TIMP-1 levels are higher in type 1 and type 2 diabetes than in thehealthy control 
(Maxwell et al., 2001; Lee et al., 2005b).  Higher TIMP-1 is associated with CVD and 
albuminuria in type 1 diabetes and type 2 diabetes (Peeters et al., 2015). TIMP-1 and 
its target, MMPs, is speculated to be involved in diabetic nephropathy (Dimas et al., 
2015). High glucose concentration has been shown to increase TIMP-1 levels and 
decrease MMP levels in renal tissues (Bai et al., 2006). This can lead to glomeruli 
basement membrane abnormality. miR-21 has been shown to increase TIMP-1 levels 
and is speculated to play a role in renal fibrosis (Wang et al., 2013a).   
 
Currently, there is no in vivo evidence on effect of the metformin on TIMP-1 levels in 
type 1 diabetes. Most of the experiments have been done in vitro using a 
supraphysiological dose of metformin (Hwang et al., 2010).  
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Figure 58: Mobilisation of EPC from bone marrow. Effect of TIMP-1 on MMP-9. 
Adapted from (Liu and Velazquez, 2008) 
 
6.3 Inflammatory cytokines 
 
6.3.1 Tumour necrosis factor alpha (TNFα) 
 
TNFα is a proinflammatory cytokine involved in acute phase reaction (Moller, 2000). 
Levels of TNFα are elevated in type 1 and type 2 diabetes (Swaroop et al., 2012; West 
et al., 2015). Circulatory TNFα is implicated in endothelial dysfunction. This effect can 
be mediated via its action on the endothelium causing increased expression of 
adhesion molecules. This can lead to an increase in cell infiltration. TNFα reduces the 
availability of NO. TNFα acts on NO synthase and reduces the production of NO 
(Zhang et al., 2009a). Furthermore, removal of NO is increased (Gao et al., 2007).  
TNFα increases the production of reactive oxygen species (ROS). This effect is 
mediated via multiple mechanisms. In diabetes mellitus, TNFα increases the activity of 
NADPH oxidase, leading to increased production of ROS (Guzik et al., 2002).  
 
The effect of TNFα on EPC levels is of considerable interest. It is speculated that the 
TNFα myelosuppressive effect potentially plays a role in reduced levels of cEPC in 
patients with CVD (Agnoletti et al., 1999). Anti- TNFα treatment in RA have been shown 
to improve cEPC numbers (Spinelli et al., 2013).  
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Furthermore, our group has shown that improvement in cEPC numbers was inversely 
related to levels of TNFα at baseline (West et al. 2015). This might be due to TNFα 
direct myelosuppressive effect or due to TNFα effect on levels of NO. There is a need 
to explore the effect of inflammation on cEPC numbers.  
 
In vitro studies have shown that metformin decreases TNFα levels (Huang et al., 
2009a; Arai et al., 2010; Hyun et al., 2013). Huang et al., 2009 demonstrated that 
metformin exposure reduced the production of TNFα by EC. A similar effect was noted 
when human monocytes were incubated in a metformin treated medium (Arai et al., 
2010).  However, this effect has not been replicated in in vivo studies. Metformin 
treatment has been shown to have no effect on TNFα levels in type 2 diabetes (Lithell 
et al., 1998; Hsieh et al., 2007).  
 
6.3.2 IL-6 
 
IL-6 belongs to the IL-6 cytokines family and is considered to be a pro-inflammatory 
cytokine. However, we now understand that IL-6 is a pleiotropic cytokine with both 
pathological and protective properties in type 1 and type 2 diabetes mellitus. IL-6 acts 
on cells with the gp130 receptor and can modulate the JAK/STAT and MAPK pathway. 
These pathways play a role in proliferation, differentiation, survival and apoptosis 
(Kristiansen and Mandrup-Poulsen, 2005).  
 
IL-6 is considered a biomarker of vascular inflammation and CVD (Hou et al., 2008). 
IL-6 levels have been shown to predict high-risk mortality in older patients with CVD 
(Tsutamoto et al., 1998). Levels of IL-6 have been demonstrated to be higher in 
individual with obesity and those who go on to develop  T2DM and MI (Ridker et al., 
2000b; Pradhan et al., 2001). In addition to being a biomarker, IL-6 plays a central role 
in the pathogenesis of CVD (Hou et al., 2008).  
 
IL-6 has been shown to play a role in endothelial dysfunction via increased production 
of ROS. This is mediated via increased expression of the Angiotensin 1 receptor (AT-
222 
 
1) (Wassmann et al., 2004). Overexpression of AT-1 exacerbates oxidative stress 
leading to endothelial dysfunction. Furthermore, Ang-II mediated vasoconstriction may 
be accentuated (Wassmann et al., 2004). IL-6 levels are associated with endothelial 
dysfunction in healthy individuals (Esteve et al., 2007). Given the available evidence, 
IL-6 is involved in the pathogenesis of atherosclerosis (Schuett et al., 2009). 
 
In vitro studies have demonstrated that metformin reduces IL-6 levels in ECs (Libby et 
al., 2006). This is likely mediated via PI3K-dependent AMPK phosphorylation (Libby et 
al., 2006). Effect of metformin in patients with PCOS has produced conflicting results. 
Lin et al., 2011 reported that IL-6 levels were reduced significantly after 12 weeks of 
metformin treatment (Lin et al., 2011). However, Mohlig et al., 2004 and Jakubowska 
et al., 2008 demonstrated that plasma IL-6 levels did not change after 6 months of 
metformin therapy (Mohlig et al., 2004; Jakubowska et al., 2008). IL-6 levels have been 
shown to be higher in type 1 and type 2 diabetes (Sibal et al., 2009). There is limited 
evidence on the effect of metformin on plasma levels of IL-6 in type 2 diabetes. 
Metformin treatment did not reduce IL-6 levels in obese patients with type 2 diabetes 
(Ersoy et al., 2008). 
 
6.3.3 CRP 
 
CRP is an acute phase reactant and is associated with the inflammatory process 
contributing to CVD. Levels of CRP are elevated in patients with obesity, impaired 
glucose tolerance, and type 1 and type 2 diabetes. CRP levels are not only elevated 
in patients with CVD but they are also a strong predictive marker for future 
cardiovascular risk in patients without overt CV disease (Tracy et al., 1997; Koenig et 
al., 1999; Ridker  et al., 2002).  
 
CRP is not only a biomarker for CV disease or risk but may also may play a role in the 
pathogenesis of atherosclerosis (Verma et al., 2004b; Amit Kumar Shrivastava, 2015). 
The causal relationship between CRP and CVD is controversial. Even with a wealth of 
evidence, we are still debating whether CRP plays a role in development of CVD or is 
a by-product of the inflammatory process which causes the development of CVD. It 
acts not only on EC but also on vascular smooth muscle cells (VSMCs). CRP inhibits 
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eNOS activity, stimulates endothelin-1 and IL-6 production and increases adhesion 
molecules expression in EC (Pasceri et al., 2000; Verma et al., 2002a; Verma et al., 
2002b). CRP acts on macrophages and augments their ability to take up LDL 
cholesterol and develop into form cells (Amit Kumar Shrivastava, 2015). CRP has been 
shown to augment Ang-1 activity in VSMC and promote ROS production and 
neointimal formation (Wang et al., 2003). CRP has been shown to upregulate NF-κB 
activity, leading to pro-atherosclerotic genes transcription (Verma et al., 2003). 
Furthermore, CRP has shown to reduce EPC survival and differentiation (Verma et al., 
2004a).  
 
Metformin has been shown to reduce CRP levels in PCOS, individuals at high risk of 
type 2 diabetes (Chakraborty et al., 2009; Shi et al., 2014). CRP levels have been 
shown to be influenced by weight and glycaemic control (Goldberg et al., 2014). In a 
randomised trial, it was demonstrated that the effect of metformin on CRP can be 
explained by changes in the weight and glycaemic control (Goldberg et al., 2014). To 
the best of our knowledge, there is no evidence on the effect of metformin on CRP in 
type 1 diabetes. What we know is that CRP levels are higher in patients with type 1 
diabetes (Sibal et al., 2009). Our work explored the effect of metformin on CRP in 
patients with type 1 diabetes.    
 
6.3.4 IL-8 
 
IL-8 is a chemokine and is also known as a neutrophil chemotactic factor. It is produced 
by many cells including endothelial cells. It is stored in Weibel-Palade bodies in ECs 
(Utgaard et al., 1998). IL-8 levels are elevated in both type 1 and type 2 diabetes. Being 
a potent chemoattractant, IL-8 plays a critical role in the development of 
atherosclerosis (Shin et al., 2002). IL-8 plays an important role in the recruitment of IL-
8 at the site of vascular injury. Furthermore, IL-8 facilitates the transmigration of 
inflammatory cells into subendothelial space (Gerszten et al., 1999). IL-8 plays a role 
in initial leukocytes adhesion to the EC (DiVietro et al., 2001). However, experimental 
IL-8 elimination resulted in the prevention of atherosclerosis (Boisvert et al., 1998). The 
monocyte chemoattractant protein-1 (MCP-1) plays an important role alongside IL-8. 
Levels of IL-8 have been noted to be high in the atherosclerotic arterial wall (Rus et al., 
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1996). Macrophages have been identified as the main source of IL-8 in atherosclerotic 
plaques (Apostolopoulos et al., 1996). 
 
Currently, there is no evidence on the effect of metformin in type 1 diabetes. Evidence 
on the effect of metformin on IL-8 in type 2 diabetes is limited.  We could only find one 
study exploring the effect of metformin in type 2 diabetes. This study demonstrated 
that metformin treatment reduced IL-8 levels in type 2 diabetes (Lavrenko et al., 2012). 
In vitro studies have shown that metformin reduced IL-8 production in EC, smooth 
muscle cells, macrophages and endometriotic stromal cells (Libby et al., 2006; 
Takemura et al., 2007). Metformin reduced IL-8 production in a dose dependent 
manner. This was shown to be significant at physiological concentration of metformin 
(Takemura et al., 2007).  
 
6.3.5 INF-γ 
 
INF-γ is a pro-inflammatory cytokine and belongs to the INF cytokine family (Mire-Sluis 
A., 1998). It has been established that INF-γ plays a role in the progression of 
atherosclerosis (McLaren and Ramji, 2008) (Figure 72). However, it is debated 
whether it is pro-atherosclerotic or anti-atherosclerotic (Muhl and Pfeilschifter, 2003).  
INF-γ increases the production of chemokines like MCP-1, leading to increased 
recruitment of macrophages and T-lymphocytes (Valente et al., 1998). INF-γ, itself 
increases recruitment of immune cells. INF-γ increases expression of adhesion 
molecules in EC (Chung et al., 2003). INF-γ has been shown to potentiate the adhesion 
factor expression by other inflammatory cytokines like TNF-α (Zhang et al., 2011). INF-
γ activates monocytes to macrophages and promotes the development of form cells 
(Schroder et al., 2004). In an animal model, INF-γ promotes SMC proliferation and 
differentiation (Tellides et al., 2000). INF-γ plays a role in apoptosis of foam cells and 
plaque disruption (Harvey and Ramji, 2005). In contrast, INF-γ functions have some 
anti-atherogenic properties. INF-γ has been shown to reduce oxidation of LDL and 
uptake of oxiLDL by macrophages (Fong et al., 1994). INF-γ increases the production 
of NO via upregulation of iNOS (Chung et al., 2010). Most INF-γ action is mediated by 
activating the JAK/STAT pathway (Darnell et al., 1994). 
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Limited information is available on the effect of metformin in INF-γ. In animal model 
mimicking inflammatory condition like multiple sclerosis, metformin has been shown to 
suppress expression of INF-γ (Nath et al., 2009).   
 
 
 
Figure 59: Role of INF-γ in atherosclerosis. 
Adapted from Harvey and Ramji, 2005 
 
6.3.6 IL-10 
 
IL-10 is a potent anti-inflammatory and anti-atherogenic cytokine (Han and Boisvert, 
2014). IL-10 acts directly on macrophages to control lipid modulation and inhibition of 
MMP and tissue factor (TFT) production (Kamimura et al., 2005; Han et al., 2010). IL-
10 inhibits the release if pro-inflammatory cytokines like IL-8, TNF-α and IL1β (de Waal 
Malefyt et al., 1991). Furthermore, it reduces the release of chemokines like MCP-1. 
IL-10 inhibits the action of IL-12 (Uyemura et al., 1996). This leads to reduced 
activation of the immune cell-like macrophages. IL-10 is present in atherosclerotic 
plaques. IL-10 plays a vital role in plaque stability. IL-10 inhibits the production of iNOS, 
thereby protecting the cell in the plaques from increased cell death (Mallat et al., 1999). 
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In hyperlipidemic mice models, overexpression of IL-10 reduced atherosclerosis (Han 
et al., 2010). 
 
Levels of IL-10 have been demonstrated to be lower in patients with diabetes mellitus 
(Yaghini et al., 2011). IL-10 levels are associated with improved clinical outcomes in 
patients with CVD (Heeschen et al., 2003b).  
 
Metformin has been shown to increase IL-10 production from activated macrophages. 
(Kelly et al., 2015). The effect of metformin in type 1 diabetes has not been studied so 
far. Metformin has been shown to increase IL-10 levels in type 2 diabetes (Chen et al., 
2016). However, this effect was noted after one year of metformin treatment.  
 
 
Figure 60: Role of cytokines in atherosclerosis. 
Adapted from (Pérez Fernández and Kaski, 2002) 
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6.3.7 IP-10 
 
IP-10 is also known as interferon gamma-induced protein 10 or C-X-C motif chemokine 
10 (CXCL-10) (Heller et al., 2006). IP-10 secretion from ECs and inflammatory cells 
are induced by INF-γ (Luster and Ravetch, 1987). IP-10 plays a major role in 
atherosclerosis. This effect is mediated by VSMC proliferation and inflammatory cell 
infiltration (Wang et al., 1996). IP-10 has been shown to be expressed in 
atherosclerotic lesions IP-10 acts as a chemokine and attract immune cells to the site 
of vascular injury (Niki et al., 2015). In an animal model, blocking IP-10 action has been 
shown to inhibit atherosclerosis formation (Heller et al., 2006; Zuojun et al., 2011). IP-
10 levels are elevated in individuals with type 1 and type 2 diabetes (Shimada et al., 
2001; Xu et al., 2005). IP-10 is associated with endothelial dysfunction in type 2 
diabetes (Kajitani et al., 2010). Increased IP-10 levels have been demonstrated in CAD 
patients and seemed to precede cardiac events (Herder et al., 2006).  
 
There is paucity of evidence regarding the effect of metformin on IP-10. Our group has 
demonstrated that metformin in physiological concentration reduced the expression of 
IP-10 in CD34+ cells in a model of the diabetic state combined with hypoxia 
(Bakhashab et al., 2016).  
 
6.4 Vascular injury and adhesion markers 
 
6.4.1 P-Selectin and E-Selectin 
 
P-Selectin and E-Selectin belong to the selectin family (Blankenberg et al., 2003). P-
Selectin is stored in granules of platelets and ECs. P-Selectin is immediately released 
once platelets and ECs are activated by an inflammatory response. This response is 
short lived. However, with continued inflammatory stimuli like TNF-α, P-Selectin is 
formed and expressed on the cell surface (McEver, 2002). E-Selectin is present on 
ECs. E-Selectin is not found in resting ECs. Once ECs are activated by the 
inflammatory response, E-selectin is formed by the ECs and expressed on the cell 
surface (Wang and Huo, 2010). P-Selectin and E-Selectin play a major role in the initial 
stages of atherosclerosis. P-Selectin and E-Selectin are involved in leukocyte capture 
and rolling on activated ECs (McEver, 2002) (Figure 74).  
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Levels of P-Selectin and E-Selectin are elevated in patients with diabetes mellitus 
(Jilma et al., 1996; Albertini et al., 1998; Yngen et al., 2001). E-Selectin has been 
demonstrated to be associated with increased risk of diabetes (Song et al., 2007). P-
Selectin is associated with an increased risk of future CVD (Ridker et al., 2001). E-
Selectin has been demonstrated to be elevated in individuals with CV risk factors 
(Demerath et al., 2001). P-Selectin levels are elevated in patients with CAD including 
AMI (Ikeda et al., 1994; Aref et al., 2005).  
 
Currently, there is no evidence regarding the effect of metformin on P-Selectin and E-
Selectin levels in type 1 diabetes. Most of the work has been done in type 2 diabetes 
and on E-Selectin. Improvement in glycaemic control and lipid profile has been shown 
to improve E-Selectin levels (Albertini et al., 1998; Yki-Järvinen and Hannele, 2001). 
Short-term (16 weeks) metformin treatment in type 2 diabetes improved E-Selectin 
levels (De Jager et al., 2005). However, this finding can be explained by improvement 
in glycaemic control and lipid profile. When this group was followed for over 4 years, 
metformin treatment did not lead to any change in E-Selectin levels in type 2 diabetes 
(de Jager et al., 2014).  
 
There is a paucity of evidence on the effect of metformin in diabetes mellitus.  An in 
vitro and animal study has demonstrated that P-Selectin expression is lower in 
activated platelets (Xin et al., 2016). Further work is needed to elucidate the effect of 
metformin on P-Selectin in type 1 diabetes.  
 
6.4.2 Immunoglobulin superfamily 
 
Intercellular adhesion molecules 1 (ICAM-1), ICAM-2, ICAM-3 and Vascular cell 
adhesion molecules 1 (VCAM-1) belong to the immunoglobulin superfamily. ICAM-1 is 
expressed by leukocytes and ECs. ECs express VCAM-1 (Blankenberg et al., 2003). 
ICAM-1 and VCAM-1 plays a major role in the pathogenesis of atherosclerosis. ICAM-
1 and VCAM-1 mediate the adhesion of inflammatory cells to EC and are involved in 
the transmigration of inflammatory cells into intimal space (Wang and Huo, 2010) 
(Figure 74).  
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ICAM-1 and VCAM-1 can be measured in plasma and referred to as soluble ICAM-1 
(sICAM-1) and soluble VCAM-1 (sVCAM-1). sICAM-1 and sVCAM-1 have been shown 
to be elevated in children with diabetes mellitus, obesity and hypertension (Glowinska 
et al., 2005). However, our group has previously demonstrated that ICAM-1 and 
VCAM-1 were not elevated in patients with type 1 diabetes (Sibal et al., 2009a). In type 
2 diabetes, ICAM-1 and VCAM-1 have been demonstrated to be elevated in patients 
with microalbuminuria (Bruno et al., 2008). Similar findings have been described in 
type 1 diabetes (Clausen et al., 2000). sICAM-1 has been shown to have strong 
predictive value for future CAD in healthy individuals (Hwang et al., 1997; Ridker, 
1998), whereas sVCAM-1 has been shown to predict future CV events in patients with 
CAD and diabetes mellitus (Jager et al., 2000; Malik et al., 2001). sICAM-1 has been 
shown to demonstrate atherosclerotic disease (Pradhan et al., 2002), whereas 
sVCAM-1 demonstrates disease severity (De Caterina et al., 1997; Blankenberg et al., 
2003).  
 
 
Figure 61: Role of Selectin and immunoglobulin family due atherosclerosis. 
Adapted from (Weber et al., 2007) 
 
Metformin has been shown to reduce sICAM and sVCAM in type 2 diabetes over short 
and long-term treatment. This effect was shown to be mediated independent of 
glycaemic control (De Jager et al., 2005; De Jager et al., 2014). Jager et al., 2014 in 
their double blind randomised controlled trial estimated that sVCAM together with 
another maker of endothelial dysfunction accounted for 34% reduction of CV morbidity 
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and mortality. The glucose independent reduction of the above-mentioned markers 
provides important information that needs to be explored in type 1 diabetes.  
 
6.4.3 Thrombomodulin (TM) 
 
TM is a cell surface protein expressed on ECs. It plays an important role in the 
coagulation cascade. It binds thrombin and forms the TM-thrombin complex. This 
complex activates protein C. The complex and protein C have anti-inflammatory and 
anti-coagulation properties (Li et al., 2012b).  
 
TM levels are elevated in patients with type 1 and type 2 diabetes (Gabat et al., 1996) 
and atherosclerotic disease (Seigneur et al., 1993). However, (Iwashima et al., 1990) 
in their study demonstrated that patients with diabetes mellitus without complication 
have similar TM levels to healthy individuals. Patients with microalbuminuria or renal 
disease due to diabetes mellitus have been shown to have increased TM levels. The 
prognostic value of TM in healthy individuals and individuals with diabetes mellitus 
related complication is different. It has been shown that in healthy individuals, higher 
levels of TM were associated with lower risk of CV events (Salomaa et al., 1999). 
However, this is not the case in patients with diabetes mellitus. Higher levels of TM in 
patients with diabetes mellitus with microalbuminuria have been shown be linked to 
poor prognostic outcomes (von Scholten et al., 2016). Therefore, levels of TM in 
diabetes mellitus reflect endothelial injury and progression of atherosclerotic disease 
(Blann et al., 1997).  
 
To our knowledge, no evidence is available regarding the effect of metformin on 
thrombomodulin levels in vivo and in vitro.  
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6.5 Growth factors 
 
6.5.1 basic Fibroblast growth factor (bFGF) 
 
bFGF is produced by ECs, VSMC and macrophages (Cordon-Cardo et al., 1990). It is 
released as a response to EC injury (Gajdusek and Carbon, 1989). bFGF has 
mitogenic and angiogenic properties (Lindner et al., 1991; Peyrat et al., 1992). bFGF 
action is mediated in a paracrine and autocrine manner (Sigala et al., 2010). bFGF 
plays an important role in the pathogenesis of atherosclerosis. In vitro and animal 
studies have shown that short-term exposure to bFGF may have an anti-
atherosclerotic effect (Six et al., 2004). However, the major effect of bFGF is neointimal 
formation. This is mediated via SMC migration and proliferation (Lindner et al., 1991; 
Sato et al., 1991). Furthermore, bFGF is involved in plaque instability. This is due to 
increased plaque size (SMC migration and proliferation) and weakness (inhibition of 
collagen synthesis) (Flugelman et al., 1993; Kennedy et al., 1995). This effect is 
mediated by the bFGF dependent downstream pathway: MAPK and NF-κB pathways 
(Sigala et al., 2010). 
 
bFGF levels have been shown to be high in patients with CVD and diabetes mellitus 
especially those with complications (Zimering and Eng, 1996; Zimering et al., 2010; 
Zimering et al., 2013). Incubation of cardiomyocytes with metformin have been shown 
to reduce bFGF production (Wang et al., 2010). To the best of our knowledge, there is 
no in vivo study exploring the effect of metformin in diabetes mellitus.  
 
6.5.2 Vascular endothelial growth factor (VEGF) 
 
VEGF is an important growth factor and plays a vital role in the maintenance of 
endothelium. The VEGF family consists of VEGF-A, VEGF-B, VEGF-C and VEGF-D. 
These four factors act via three receptors: VEGFR-1, VEGFR-2 and VEGFR-3 
(Ferrara, 1999; Rutanen et al., 2003). VEGF has pro-angiogenic and anti-thrombotic 
properties. It acts on EC and promotes proliferation and migration. This is crucial for 
endothelium maintenance and renewal. It also reduces EC apoptosis. It acts on SMC 
and has an anti-proliferative effect (Waltenberger, 2009). 
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VEGF effect is pleiotropic in diabetes mellitus. It is important for maintaining vascular 
repair. However, it plays a role in diabetes-related complication (Duh and Aiello, 1999). 
Levels of VEGF have been shown to be increased in type 1 diabetes with nephropathy 
when compared to patients with type 1 diabetes without complication (Chiarelli et al., 
2000; Hovind et al., 2000). High VEGF levels have been shown to predict future 
diabetes-related nephropathy (Santilli et al., 2001).  
 
VEGF-A has been demonstrated in atherosclerotic plaques and levels of VEGF-A 
increased with progression of atherosclerotic disease. VEGF-A has been 
demonstrated in macrophages in atherosclerotic plaque (Rutanen et al., 2003).  In 
animal studies, high levels of VEGF-A have been shown to induce development of 
atherosclerotic lesions (Celletti et al., 2001). Rutanen and colleague (2003) 
demonstrated that VEGF-D was expressed in the normal endothelium. However, levels 
of VEGF-D decreased in complicated lesions. Interestingly, VEGF-D levels in the 
macrophages at the lesion site increased leading to plaque neovascularisation. Thus, 
in addition to an overprotective effect, VEGF-A and VEGF-D are involved in the 
pathogenesis of atherosclerosis (Rutanen et al., 2003). 
 
We have demonstrated that VEGF-A levels are increased by hyperglycaemia, hypoxia 
and by metformin in CD34+ cells. However, hyperglycaemia reduces VEGFR-2 
expression, thereby reducing VEGF signalling in CD34+ cells (Bakhashab et al., 2016). 
The effect of metformin in in vivo experiments has not produced consistent results. 
One study did not show any effect on VEGF (Watanabe et al., 2001), whereas another 
study demonstrated that metformin reduced VEGF levels in obese patients with type 2 
diabetes (Ersoy et al., 2008). 
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6.6 Method 
 
6.6.1 Platelet-free plasma isolation 
 
Cytokines were evaluated in TG, HC and SG. After an overnight fast, peripheral blood 
was collected in citrate vacutainer tubes. Blood samples were processed within 4 hours 
of collection. Samples were centrifuged for 15 minutes at 500 xg. The upper, clear 
fraction (platelet rich plasma, PRP) was collected without disturbing the bottom cellular 
layer and transferred to 1.5mL polypropylene tubes. These PRP samples were further 
centrifuged for 5 minutes at 13000 x g in a microcentrifuge. After centrifugation, the 
clarified platelet-free plasma (PFP) was transferred to fresh 1.5mL polypropylene tubes 
and stored at -80ºC for subsequent analysis. The platelet pellet was discarded.  
 
6.6.2 Cytokines 
 
Cytokines were measured using a Mesoscale Discovery (MSD) kit as it offers high 
sensitivity and reproducibility. The protocol is simple and validated. Furthermore, 
technical support was provided in the form of an adviser during the experiments. 
Initially, pre-configured V-Plex panels and TIMP-1 kit were used (Table 24).  
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 Table 24: MSD panel used for cytokine analysis. 
 
 
All the MSD assays were conducted according to the manufacturer’s instructions. MSD 
plate reader was used to analyse the plates. MSD software was used to evaluate the 
levels of cytokines.  
 
Plasma samples were diluted according to the manufacturer’s instruction (Table 25). 
 
Cytokine panel Dilution 
Vascular injury panel 1 1X 
Vascular injury panel 2 1000X 
Cytokine panel 1 2X 
Pro-Inflammatory panel 1 2X 
Angiogenesis panel 2X 
Chemokine 4X 
TIMP-1 100X 
 
Table 25: Dilution of plasma for each panel. 
 
1 
Vascular injury panel 1 
E-Selectin, P-Selectin, sICAM-3 and thrombomodulin 
2 
Vascular injury panel 2 
CRP, SAA, sICAM-1, sVCAM-1 
3 
Cytokine panel 1 
GM-CSF, IL-12p40, IL-15, IL-16, IL-1α, IL-5, IL-7, TNF-β, VEGF 
4 
Pro-Inflammatory panel 1 
INF-γ, IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α 
5 
Angiogenesis panel 
bFGF, PIGF, sFIT-1, Tie-2, VEGF, VEGF-C, VEGF-D 
6 
Chemokine 
Eotaxin, Eotaxin-3, IL-8, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-
1alpha, MIP-1β, TARC 
7 TIMP-1 
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Initially, 46 cytokines were evaluated. However, 17 cytokines could be reliably 
assessed in all the samples. For 29 cytokines, not all the samples were in the detection 
range (Figure 75). Only cytokines, where all the samples were in detection range were 
evaluated (Figure 76). Therefore, we have presented 17 cytokines in our final analysis. 
These are given in Table 26. Data were analysed using MSD Discovery Workbench 
version 2.0 software. 
  
 
Table 26: Final list of cytokines studied. 
 
 
 
 
 
 
 
 
1 
Vascular injury panel 1 
E-Selectin, P-Selectin, sICAM-3 and thrombomodulin 
2 
Vascular injury panel 2 
CRP, sICAM-1, sVCAM-1 
3 
Pro-Inflammatory panel 1 
INF-γ, IL-10, IL-6, IL-8, TNF-α 
4 
Angiogenesis panel 
bFGF, VEGF, VEGF-D 
5 
Chemokine 
IP-10 
6 TIMP-1 
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Figure 62: GM-CSF detection curve (blue line). Red dots are the sample detection values. 
 
 
Figure 63: sICAM-1 detection curve (blue line). Red dots are the sample detection values. 
 
 
 
 
237 
 
6.6.2.1 TIMP-1 
 
25µl of diluent 2 was placed in each well. The plate was then sealed with an adhesive 
seal. The plate was incubated for 30 minutes with vigorous shaking at room 
temperature. 25 µl of samples and calibrator were placed in appropriate wells. The 
plate was again incubated for 2 hours with vigorous shaking at room temperature. The 
plate was washed 3 times with phosphate-buffered saline with 0.05% Tween-20 (PBS-
T). 25 µl of detection antibody was dispensed into each well. The plate was incubated 
for 2 hours with vigorous shaking. The plate was washed 3 times again with PBS-T. 
150 µl of 2X Read Buffer T was added to each well. The plate was read with MSD 
Sector Imager 2400.  
 
6.6.2.2 Pro-inflammatory panel 1  
 
50 µl of samples and calibrator were added to appropriate wells. The plate was sealed 
with an adhesive plate and incubated with shaking for 2 hours. The plate was washed 
3 times with at least 150 µl per well of wash buffer. 25 µl of detection antibody solution 
was added to each well. The plate was sealed and incubated at room temperature with 
shaking for 2 hours. The plate was washed 3 times again with wash buffer. 150 µl of 
2X Read Buffer T was added to each well. The plate was read with MSD Sector Imager 
2400.  
 
6.6.2.3 Vascular injury panel 1 
 
Blocker A solution (150 µl) was added to each well. The plate was incubated at room 
temperature for 1 hour on a plate shaker. The plate was then washed 3 times with 
PBS-T (200 µl per well). 40 µl of Diluent 10 was added. 10 µl of samples and calibrator 
were added to appropriate wells and incubated for 2 hours with shaking. The plate was 
then washed 3 times with PBS-T. 25 µl of 1X detection antibody was added to each 
well and incubated for 1 hour at room temperature with shaking. The plate was then 
washed 3 times with PBS-T. 150 µl of 1X Read Buffer T was added to each well. The 
plate was read with MSD Sector Imager 2400.  
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6.6.2.4 Vascular injury panel 2 
 
The plate was washed 3 times with 150 µl per well of wash buffer. 25 µl of diluted 
samples and calibrator were added to appropriate wells. The plate was sealed with an 
adhesive seal and incubated for 2 hours at room temperature with shaking. The plate 
was washed 3 times again with wash buffer. 25 µl of detection antibody was added to 
each well. The plate was sealed and incubated for 1 hour at room temperature with 
shaking. The plate was washed 3 times again with wash buffer. 150 µl of 1X Read 
Buffer T was added to each well. The plate was read with MSD Sector Imager 2400.  
 
6.6.2.5 Angiogenesis panel 1 
 
150 µl of Blocker A solution was added to each well. The plate was sealed with an 
adhesive seal and incubated at room temperature for 1 hour with shaking. The plate 
was washed 3 times with 150 µl per well of wash buffer. 50 µl of diluted samples and 
calibrator were added in appropriate well. The plate was sealed with an adhesive plate 
and incubated for 2 hours with shaking. The plate was again washed with wash buffer. 
25 µl of detection antibody solution was added to each well. The plate was sealed with 
an adhesive plate and incubated at room temperature for 2 hours with shaking. The 
plate was washed 3 times with wash buffer and 150 µl of Read Buffer T was added to 
each well. The plate was read with MSD Sector Imager 2400.  
 
6.6.2.6 Chemokine panel 1 (IP-10) 
 
50 µl of samples and calibrator were added to appropriate wells. The plate was sealed 
with an adhesive plate and incubated with shaking for 2 hours. The plate was washed 
3 times with at least 150 µl per well of wash buffer. 25 µl of detection antibody solution 
was added to each well. The plate was sealed and incubated at room temperature with 
shaking for 2 hours. The plate was washed 3 times again with wash buffer. 150 µl of 
2X Read Buffer T was added to each well and incubated at room temperature for 10 
minutes. The plate was read with MSD Sector Imager 2400.  
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6.7 Specific aim 
In type 1 diabetes, when changes in glycaemia are accounted for, metformin will: 
1. Increase cytokines related to EPC mobilisation and angiogenesis.    
2. Decrease cytokines representative of vascular injury markers and  
           inflammatory cytokines. 
 
6.8 Statistical analysis 
 
General statistical analysis has been discussed in section 3.2. We took advice from 
the statistician regarding correcting for multiple testing. We were advised that data 
should be interpreted without multiple corrections due to the discovery nature of the 
study. However, as we had studied more than 10 cytokines, we were advised that we 
should present both non-corrected and corrected p values with the results. After 
Bonferroni correction, the p value of <0.003 was assumed to be significant. 
Nevertheless, for discussion in our thesis, a p value of <0.05 was assumed to be 
significant.  
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6.9 Results 
 
6.9.1 TIMP-1 
 
Result is presented in Figure 77. 
 
6.9.1.1 Treatment group (Pre metformin) versus Healthy control 
 
TIMP-1 levels were significantly higher in TG when compared with HC (Treatment 
group pre-metformin (TG V1) vs HC; mean+/-SE: 179665+/-9452 vs 156202+/-4097 
pg/ml; p=0.02; after Bonferroni correction: p=0.32). 
 
6.9.1.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly reduced TIMP-1 levels in TG (TG V1 vs 
TG V2; mean+/-SE: 179665+/-9452 vs 158503+/-5424 pg/ml; p=0.018; after 
Bonferroni correction: p=0.3). 
 
6.9.1.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, TIMP-1 levels in TG group became similar to HC ((TG V2 
vs HC); mean+/-SE: 158503+/-5424 vs 156202+/-4097 pg/ml; p=0.7).   
 
6.9.1.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, TIMP-1 levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 179665+/-9452 vs 
174529+/-10010 pg/ml; p=0.8). 
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6.9.1.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of standard, TIMP-1 levels remained unchanged (standard treatment 
group pre (SG V1) and standard treatment group post (SG V2): mean+/-SE: 174529+/-
10010 vs 180589+/-7919 pg/ml; p=0.6). 
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Figure 64: TIMP-1 levels comparing groups. Results given as pg/ml. 
TGV1: Treatment group pre metformin; TGV2: Treatment group post metformin; HC: Healthy control; 
SGV1: Standard group pre observation; SGV2: Standard group post observation.  
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6.9.2 TNF-α 
 
Result is presented in Figure 78. 
6.9.2.1 Treatment group (Pre metformin) versus Healthy control 
 
TNF-α levels were significantly higher in TG compared with HC (Treatment group pre-
metformin (TG V1) vs HC; median (intraquartile range (IQ): 1.97 (1.5-2.5) vs 1.5 (1.28-
1.6) pg/ml; p=0.0004; after Bonferroni correction: p=0.064). 
 
6.9.2.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in TNF- levels 
(Treatment group pre-metformin (TG V1) vs treatment group post metformin (TG V2); 
median (IQ): 1.97 (1.5-2.5) vs 1.91 (1.5-2.4) pg/ml; p=0.2). 
 
6.9.2.3 Treatment group (Post metformin) versus Healthy control 
 
TNF-α level remained significantly higher in TG after metformin treatment when 
compared to HC (TG V2 vs HC); median (IQ): 1.91 (1.5-2.4) vs. 1.5 (1.28-1.6) pg/ml; 
p=0.0003; after Bonferroni correction: p=0.0048.  
 
6.9.2.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, TNF-α level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 1.97 (1.5-2.5) vs 1.64 (1.5-1.7) 
pg/ml; p=0.07). 
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6.9.2.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
TNF-α level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): median (IQ): 1.64 (1.5-1.7) vs 1.8 (1.5-1.96) pg/ml; p=0.2). 
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Figure 65: TNF-α levels comparing all groups. Results given as pg/ml. 
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6.9.3 IL-6 
 
Result is presented in Figure 79. 
6.9.3.1 Treatment group (Pre metformin) versus Healthy control 
 
IL-6 levels were significantly higher in TG compared with HC (Treatment group pre-
metformin (TG V1 vs HC; median (intraquartile range (IQ): 0.6 (0.34-1) vs 0.33 (0.22-
0.4) pg/ml; p=0.0056; after Bonferroni correction: p=0.09). 
 
6.9.3.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly reduced IL-6 levels in TG: (TG V2 vs 
TGV1; median (IQ): 0.6 (0.34-1) vs 0.44 (0.36-0.4) pg/ml; p=0.0093; after Bonferroni 
correction: p=0.15). 
 
6.9.3.3 Treatment group (Post metformin) versus Healthy control 
 
Metformin treatment reduced IL-6 levels in TG group and brought it closer to HC ((TG 
V2 vs HC); median (IQ): 0.44 (0.36-0.4) vs. 0.33 (0.22-0.4) pg/ml). After metformin 
treatment, significance disapperred (p=0.053).  
 
6.9.3.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, IL-6 level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 0.6 (0.34-1) vs 0.54 (0.3-0.8) 
pg/ml; p=0.6). 
 
6.9.3.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in IL-
6 level (standard treatment group pre (SG V1) and standard treatment group post (SG 
V2): median (IQ): 0.54 (0.3-0.8) vs 0.54 (0.3-0.9) pg/ml; p=0.7). 
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Figure 66: IL-6 levels comparing all groups. Results given as pg/ml. 
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6.9.4 CRP 
 
Result is presented in Figure 80. 
6.9.4.1 Treatment group (Pre metformin) versus Healthy control 
 
CRP levels were significantly higher in TG when compared with HC (Treatment group 
pre-metformin (TG V1) vs HC; median (intraquartile range (IQ): 1.9X106 (1.1X106 – 
2.4X106) vs 632829 (374400 – 1.7X106) pg/ml; p=0.0003; after Bonferroni correction: 
p=0.005). 
 
6.9.4.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not change CRP levels (TG V1 vs TG V2); 
median (IQ): 1.9X106 (1.1X106 – 2.4X106) vs 1.9X106 (1.5X106 – 2.5X106) pg/ml; 
p=0.98). 
 
6.9.4.3 Treatment group (Post metformin) versus Healthy control 
 
CRP levels in TG after metformin treatment remained similar when compared to HC 
(TG V2 vs HC); median (IQ): 1.9X106 (1.5X106 – 2.5X106) vs. 632829 (374400 – 
1.7X106) pg/ml; p=0.0008; after Bonferroni correction: p=0.013.  
 
6.9.4.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, CRP level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 1.9X106 (1.1X106 – 2.4X106) vs 
913450 (387014 – 3.2X106) pg/ml; p=0.4). 
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6.9.4.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
CRP level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): median (IQ): 913450 (387014 – 3.2X106) vs 1.3X106 (349435 – 3X106) pg/ml; 
p=0.8). 
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Figure 67: CRP levels comparing all groups. Results given as pg/ml. 
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6.9.5 IL-8 
 
Result is presented in Figure 81. 
6.9.5.1 Treatment group (Pre metformin) versus Healthy control 
 
IL-8 levels were significantly higher in TG compared with HC (Treatment group pre-
metformin (TG V1) vs HC; mean+/-SE: 4.6+/-0.4 vs 3+/-0.15 pg/ml; p<0.0001; after 
Bonferroni correction: p<0.01).  
 
6.9.5.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in IL-8 levels (TG 
V1 vs. TG V2; mean+/-SE: 4.6+/-0.4 vs 4.6+/-0.4 pg/ml; p=0.9). 
 
6.9.5.3 Treatment group (Post metformin) versus Healthy control 
 
IL-8 level remained significantly higher in TG after metformin treatment when 
compared to HC (TG V2 vs HC; mean+/-SE: 4.6+/-0.4 vs. 3+/-0.15 pg/ml; p<0.0001; 
after Bonferroni correction: p<0.01).   
 
6.9.5.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, IL-8 level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); mean+/-SE: 4.6+/-0.4 vs 4.9+/-0.5 pg/ml; 
p=0.5). 
 
6.9.5.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in IL-
8 level (standard treatment group pre (SG V1) and standard treatment group post (SG 
V2): mean+/-SE: 4.9+/-0.5 vs 5.6+/-0.4 pg/ml; p=0.4). 
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Figure 68:IL-8 levels comparing all groups. Results given as pg/ml.  
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6.9.6 INFγ 
 
Result is presented in Figure 82. 
6.9.6.1 Treatment group (Pre metformin) versus Healthy control 
 
INFγ levels were similar in TG when compared with HC (Treatment group pre-
metformin (TG V1) vs HC; median (intraquartile range (IQ): 3.9 (3.2 – 6) vs 4.7 (2 – 
6.3) pg/ml; p=0.9). 
 
6.9.6.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in INFγ levels ( (TG 
V1 vs TG V2); median (IQ): 3.9 (3.2 – 6) vs 4.7 (2 – 6.3) pg/ml; p=0.9). 
 
6.9.6.3 Treatment group (Post metformin) versus Healthy control 
 
INFγ levels in TG after metformin treatment remained similar when compared to HC 
(TG V2 vs HC); median (IQ): 3.8 (2.9 – 3.8) vs. 4.7 (2 – 6.3) pg/ml; p=0.8.  
 
 
6.9.6.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, INFγ level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 3.9 (3.2 – 6) vs 3.7 (2.7 – 7.8) 
pg/ml; p=0.97). 
 
6.9.6.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
INFγ level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): median (IQ): 3.7 (2.7 – 7.8) vs 3.2 (2.5 – 7.9) pg/ml; p=0.7). 
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Figure 69: INFγ levels comparing all groups. Results given as pg/ml. 
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6.9.7 IL-10 
 
Result is presented in Figure 83. 
6.9.7.1 Treatment group (Pre metformin) versus Healthy control 
 
IL-10 levels were significantly higher in TG compared with HC (Treatment group pre-
metformin (TG V1) vs HC; median (intraquartile range (IQ): 0.34 (0.24-0.76) vs 0.19 
(0.14-0.23) pg/ml; p=0.0003; after Bonferroni correction: p=0.005). 
 
6.9.7.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in IL-10 levels (TG 
V1 vs TG V2); median (IQ): 0.34 (0.24-0.76) vs 0.33 (0.23-0.5) pg/ml; p=0.3). 
 
6.9.7.3 Treatment group (Post metformin) versus Healthy control 
 
IL-10 level remained significantly higher in TG after metformin treatment when 
compared to HC (TG V2 vs HC; median (IQ): 0.33 (0.23-0.5) vs. 0.19 (0.14-0.23) pg/ml; 
p=0.0001; after Bonferroni correction: p=0.0016).  
 
6.9.7.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, IL-10 level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 0.34 (0.24-0.76) vs 0.22 (0.16-
0.34) pg/ml; p=0.06). 
 
6.9.7.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in IL-
10 level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): median (IQ): 0.22 (0.16-0.34) vs 0.29 (0.16-0.38) pg/ml; p=0.7). 
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Figure 70: IL-10 levels comparing all groups. Results given as pg/ml.  
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6.9.8 IP-10 
 
Result is presented in Figure 84. 
6.9.8.1 Treatment group (Pre metformin) versus Healthy control 
 
IP-10 levels were non-significantly higher in TG when compared with HC (Treatment 
group pre-metformin (TG V1) vs HC; median (intraquartile range (IQ): 245.5 (144-369) 
vs 232 (151-324) pg/ml; p=0.8). 
 
6.9.8.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly reduced IP-10 levels in TG (TG V1 vs 
TG V2); median (intraquartile range (IQ): 245.5 (144-369) vs 192 (127-298) pg/ml; 
p=0.028; After Bonferroni correction: p=0.45). 
 
6.9.8.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, IP-10 levels in TG group became non-significant when 
compared to HC ((TG V2 vs HC); median (intraquartile range (IQ): 192 (127-298) vs 
232.3 (151-324) pg/ml; p=0.35).  
 
6.9.8.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, IP-10 levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre observation); median (intraquartile 
range (IQ):  245.5 (144-369) vs 260.4 (204.2-357) pg/ml; p=0.8). 
 
6.9.8.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of observation, IP-10 levels remained unchanged (standard 
treatment group pre observation (SG V1) and standard treatment group post 
observation (SG V2): median (intraquartile range (IQ):  260.4 (204.2-357) vs 239 
(217.2-404) pg/ml; p=0.3). 
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Figure 71: IP-10 levels comparing all groups. Results given as pg/ml. 
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6.9.9 P-Selectin 
 
Result is presented in Figure 85. 
6.9.9.1 Treatment group (Pre metformin) versus Healthy control 
 
P-Selectin levels were non significantly higher in TG when compared with HC 
(Treatment group pre-metformin (TG V1) vs HC; mean+/-SE: 43671+/-2882 vs 
36167+/-2757 pg/ml; p=0.06). 
 
6.9.9.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment did not change P-Selectin levels in TG ( (TG V1 vs 
TG V2); mean+/-SE: 43671+/-2882 vs 41845+/-2715 pg/ml; p=0.2). 
 
6.9.9.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, P-Selectin levels in TG group remained non significantly 
different when compared to HC (TG V2 vs HC); mean+/-SE: 41845+/-2715 vs 36167+/-
2757 pg/ml; p=0.1).  
 
6.9.9.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, P-Selectin levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 43671+/-2882 vs 
40478+/-2982 pg/ml; p=0.5). 
 
6.9.9.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of standard, P-Selectin levels remained unchanged (standard 
treatment group pre (SG V1) and standard treatment group post (SG V2): mean+/-SE: 
43671+/-2882 vs 46317+/-5511 pg/ml; p=0.2). 
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Figure 72: P-Selectin levels comparing all groups. Results given as pg/ml. 
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6.9.10 E-Selectin 
 
Result is presented in Figure 86. 
6.9.10.1 Treatment group (Pre metformin) versus Healthy control 
 
E-Selectin levels were similar in TG when compared with HC (Treatment group pre-
metformin (TG V1) vs HC; mean+/-SE: 15592+/-1438 vs 16697+/-1240 pg/ml; p=0.45). 
 
6.9.10.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment did not change E-Selectin levels in TG (Treatment 
group pre-metformin (TG V1 vs TG V2; mean+/-SE: 15592+/-1438 vs 14691+/-1259 
pg/ml; p=0.1). 
 
6.9.10.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, E-Selectin levels in TG group remained similar when 
compared to HC ((TG V2 vs HC); mean+/-SE: 14691+/-1259 vs 16697+/-1240 pg/ml; 
p=0.24).  
 
6.9.10.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, E-Selectin levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 15592+/-1438 vs 
18154+/-1299 pg/ml; p=0.15). 
 
6.9.10.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of standard, E-Selectin levels remained unchanged (standard 
treatment group pre (SG V1) and standard treatment group post (SG V2): mean+/-SE: 
18154+/-1299 vs 17503+/-1145 pg/ml; p=0.4). 
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Figure 73: E-Selectin levels comparing all groups. Results given as pg/ml. 
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6.9.11 sICAM-1 
 
Result is presented in Figure 87. 
6.9.11.1 Treatment group (Pre metformin) versus Healthy control 
 
sICAM-1 levels were non-significantly higher in TG when compared with HC 
(Treatment group pre-metformin (TG V1) vs HC; mean+/-SE: 323952+/-29749 vs 
235393+/-17173 pg/ml; p=0.1). 
 
6.9.11.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment did not change sICAM-1 levels in TG (Treatment 
group pre-metformin (TG V1) vs treatment group post metformin (TG V1 vs TG V2; 
mean+/-SE: 323952+/-29749 vs 319008+/-25289 pg/ml; p=0.9). 
 
6.9.11.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, sICAM-1 levels in TG group were significantly higher when 
compared to HC ((TG V2 vs HC); mean+/-SE: 319008+/-25289 vs 235393+/-17173 
pg/ml; p=0.04; after Bonferroni correction: p=0.64).  
 
6.9.11.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, sICAM-1 levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 323952+/-29749 vs 
294829+/-27450 pg/ml; p=0.6). 
 
6.9.11.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of standard, sICAM-1 levels remained unchanged (standard 
treatment group pre (SG V1) and standard treatment group post (SG V2): mean+/-SE: 
294829+/-27450 vs 235574+/-19386 pg/ml; p=0.07). 
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Figure 74: sICAM-1 levels comparing all groups. Results given as pg/ml. 
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6.9.12 sVCAM-1 
 
Result is presented in Figure 88. 
6.9.12.1 Treatment group (Pre metformin) versus Healthy control 
 
sVCAM-1 levels were non-significantly higher in TG when compared with HC 
(Treatment group pre-metformin (TG V1) vs HC; mean+/-SE: 898854+/-285166 vs 
445233+/-18518 pg/ml; p=0.95). 
 
6.9.12.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment non-significantly reduced sVCAM-1 levels in TG (TG 
V1 vs TG V2); mean+/-SE: 898854+/-285166 vs 438643+/-65548 pg/ml; p=0.5). 
 
6.9.12.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, sVCAM-1 levels in TG group became similar to HC ((TG V2 
vs HC); mean+/-SE: 438643+/-65548 vs 445233+/-18518 pg/ml; p=0.12).  
 
6.9.12.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, sVCAM-1 levels were similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 898854+/-285166 vs 
625900+/-58664 pg/ml; p=0.5). 
 
6.9.12.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
After eight weeks of standard, sVCAM-1 levels remained unchanged (standard 
treatment group pre (SG V1) and standard treatment group post (SG V2): mean+/-SE: 
625900+/-58664 vs 503733+/-25669 pg/ml; p=0.1). 
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Figure 75: sVCAM-1 levels comparing all groups. Results given as pg/ml. 
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6.9.13 Thrombomodulin  
 
Result is presented in Figure 89. 
6.9.13.1 Treatment group (Pre metformin) versus Healthy control 
 
Thrombomodulin levels were non significantly higher in TG when compared with HC 
(Treatment group pre-metformin (TG V1) vs HC; mean+/-SE: 4180+/-227.2 vs 3827+/- 
174.4 ng/ml; p=0.2). 
 
6.9.13.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
Eight-week metformin treatment significantly decreased thrombomodulin levels in TG 
(Treatment group pre-metformin (TG V1) vs treatment group post metformin (TG V2); 
mean+/-SE: 4180+/-227.2 vs 3854+/-174.4 ng/ml; p=0.0002; After Bonfferoni 
correction: p=0.0032). 
 
6.9.13.3 Treatment group (Post metformin) versus Healthy control 
 
Metformin treatment decreased thrombomodulin levels in TG group and normalised 
the levels of thrombomodulin levels when compared to HC ((TG V2 vs HC); mean+/-
SE: 3854+/-186.8 vs 3827+/-174.4 ng/ml; p=0.92).  
 
6.9.13.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, thrombomodulin levels were similar in TG and the SG (Treatment group 
pre-metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 4180+/-227.2 vs 
4243+/-240.1 ng/ml; p=0.9). 
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6.9.13.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
Thrombomodulin levels remained unchanged after eight weeks of standard follow-up 
(standard treatment group pre (SG V1) and standard treatment group post (SG V2): 
mean+/-SE: 4180+/-217 vs 4018+/-282.5 ng/ml; p=0.14). 
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Figure 76: Thrombomodulin levels comparing all groups. Results given as pg/ml. 
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6.9.14 bFGF 
 
Result is presented in Figure 90. 
6.9.14.1 Treatment group (Pre metformin) versus Healthy control 
 
bFGF levels were similar in TG and HC (Treatment group pre-metformin (TG V1) vs 
HC; median (intraquartile range (IQ): 2.92 (1.98-4.55) vs 2.11 (1.15-3.54) pg/ml; 
p=0.2). 
 
6.9.14.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week of metformin treatment did not result in any change in bFGF levels 
(TG V1 vs TG V2; median (IQ): 2.92 (1.98-4.55) vs 2.15 (1.6-4) pg/ml; p=0.2). 
 
6.9.14.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment bFGF levels remained similar in TG and HC (TG V2 vs HC); 
median (IQ): 2.15 (1.6-4) vs. 2.11 (1.15-3.54) pg/ml; p=0.4.  
 
6.9.14.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, bFGF level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); median (IQ): 2.92 (1.98-4.55) vs 3.34 (0.75-5) 
pg/ml; p=0.9). 
 
6.9.14.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
bFGF level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): median (IQ): 3.34 (0.75-5) vs 4.37 (2.5-9.8) pg/ml; p=0.5). 
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Figure 77: bFGF levels comparing all groups. Results given as pg/ml. 
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6.9.15 VEGF 
 
Result is presented in Figure 91. 
6.9.15.1 Treatment group (Pre metformin) versus Healthy control 
 
VEGF levels were non-significantly higher in TG when compared with HC (Treatment 
group pre-metformin (TG V1) vs HC; mean+/-SE: 58+/-11.4 vs 39+/-1.8 pg/ml; p=0.09). 
 
6.9.15.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in VEGF levels (TG 
V1 vs TG V2; mean+/-SE: 58+/-11.4 vs 50+/-5 pg/ml; p=0.9). 
 
6.9.15.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, VEGF levels remained non-significantly higher in TG when 
compared to HC (TG V2 vs HC); mean+/-SE: 50+/-5 vs 39+/-1.8 pg/ml; p=0.08.  
 
6.9.15.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, VEGF level was similar in TG and the SG (Treatment group pre-metformin 
TG V1 vs standard group SG V1 (Pre); mean+/-SE: 58+/-11.4 vs 44.2+/-5.1 pg/ml; 
p=0.55). 
 
6.9.15.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up resulted in significant increase in 
VEGF level (standard treatment group pre (SG V1) and standard treatment group post 
(SG V2): mean+/-SE: 44.2+/-5.1 vs 61.7+/-8.8 pg/ml; p=0.034; after Bonferroni 
correction: p=0.5). 
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Figure 78: VEGF levels comparing all groups. Results given as pg/ml. 
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6.9.16 VEGF-D 
 
Result is presented in Figure 92. 
6.9.16.1 Treatment group (Pre metformin) versus Healthy control 
 
VEGF-D levels were significantly higher in TG when compared with HC (Treatment 
group pre-metformin (TG V1) vs HC; mean+/-SE: 634.7+/-30 vs 498+/-33.6 pg/ml; 
p=0.003; after Bonferroni correction: p=0.048). 
 
6.9.16.2 Treatment group (Pre metformin) versus Treatment group (Post 
metformin) 
 
In TG eight-week metformin treatment did not result in any change in VEGF-D levels 
(Treatment group pre-metformin (TG V1) vs treatment group post metformin (TG V2); 
mean+/-SE: 634.7+/-30 vs 629.8+/-30.8 pg/ml; p=0.64). 
 
6.9.16.3 Treatment group (Post metformin) versus Healthy control 
 
After metformin treatment, VEGF-D levels remained significantly higher in TG when 
compared to HC (TG V2 vs HC); mean+/-SE: 629.8+/-30.8 vs 498+/-33.6 pg/ml; 
p=0.005; after Bonferroni correction: p=0.08.  
 
6.9.16.4 Treatment group (Pre metformin) versus Standard group (Pre 
observation) 
 
At baseline, VEGF-D level was similar in TG and the SG (Treatment group pre-
metformin TG V1 vs standard group SG V1 (Pre); mean+/-SE: 634.7+/-30 vs 628.2+/-
74.6 pg/ml; p=0.6). 
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6.9.16.5 Standard group (Pre observation) versus Standard group (Post 
observation) 
 
In standard group, eight weeks of standard follow-up did not result in any change in 
VEGF-D level (standard treatment group pre (SG V1) and standard treatment group 
post (SG V2): mean+/-SE: 628.2+/-74.6 vs 617.3+/-54.7 pg/ml; p=0.86). 
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Figure 79: VEGF levels comparing all groups. Results given as pg/ml. 
 
 
 
 
 
 
 
 
 
 
272 
 
6.9.17 Correlation 
 
In TG, TIMP-1 was inversely correlated with cECs (r=-0.59; p<0.01) and positively 
correlated with the PAC adhesion function (r=0.52; p<0.01). We have demonstrated a 
positive correlation between CRP and sICAM-1 (r=0.77; p<0.01) and an inverse 
correlation of CRP and the PAC adhesion function (r=-0.43; p<0.05). IP-10 levels in 
our TG correlated with INF-γ (r=0.42; p<0.05) and TNF-α (r=0.53; p<0.01). In TG, there 
was no correlation between HbA1c and IP-10 levels. In TG, there was a positive 
correlation between HbA1c and E-Selectin (r=0.49; p<0.05) and P-Selectin (r=0.64; 
p<0.01). We have shown a direct correlation between CRP and sICAM-1 levels 
(r=0.82; p<0.01). 
 
In TG, there was no correlation between changes in TIMP-1 and cEPCs levels (r=-
0.23; p>0.05). There is a positive correlation between changes in HDL levels and 
TIMP-1 levels (r=0.48; p<0.05). 
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6.10 Discussion 
 
This section of the thesis discusses the effect of metformin on plasma cytokine levels 
in individuals with type 1 diabetes. Plasma cytokine levels were assessed at baseline 
and after 8 weeks of metformin treatment. These were compared with healthy 
volunteers. Furthermore, plasma cytokine levels were evaluated in the type 1 diabetes 
cohort group (standard treatment group,SG) to explore whether any changes in above-
mentioned markers can be observed with routine follow up without any treatment with 
metformin.  The diabetes control remained unchanged over 8 weeks in both the TG 
and SG groups.  
 
Our work focused on pro-inflammatory, anti-inflammatory, pro-angiogenic, anti-
angiogenic and vascular injury markers.  We have broken the discussion down into 
four major sub-sections: 1) extracellular matrix modulator; 2) inflammatory; 3) vascular 
and 4) growth factors. The extracellular matrix modulator only includes TIMP-1. The 
inflammatory cytokines discussed are CRP, IL-6, IL-8, IL-10, TNF-α, IP-10 and INF-γ. 
The vascular markers studied included sVCAM-1, sICAM-1, P-Selectin, E-Selectin and 
thrombomodulin. The growth factors studied included bFGF, VEGF and VEGF-D.  
 
We were advised by a statistician to present both non-corrected and corrected data to 
to interpret the data in a more critical manner. However, as our study was designed to 
identify markers of interest for future research, we were advised that our discussion 
should be based on non-corrected data. 
 
The discussion is divided into two main parts. The first section discusses each sub-
section separately. The second section summarises the findings of our work and its 
significance. 
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6.10.1 TIMP-1 
 
We have shown that TIMP-1 levels are higher in individual with type 1 diabetes when 
compared to healthy volunteers. Our data is in line with most of the available evidence 
describing elevated TIMP-1 levels in patients with type 1 diabetes and type 2 diabetes 
(Maxwell et al., 2001 and Lee et al., 2005).  
 
TIMP-1 is an important regulator of matrix metalloproteinases (MMP). MMP plays a 
major role in angiogenesis. It degrades the extracellular matrix thereby facilitating new 
vessel formation and expansion (Hiraoka et al., 1998). MMP also plays a role in the 
mobilisation of EPCs (Heissig et al., 2002; Aicher et al., 2003). In vitro studies have 
shown increased expression of TIMP-1 in response to hyperglycaemia and hypoxia 
(Bakhashab et al., 2016). Elevated TIMP-1 levels in type 1 diabetes can be interpreted 
as a factor limiting vascular repair. Elevated TIMP-1 levels can be postulated to inhibit 
MMP action thereby resulting in decreased EPC mobilisation and increased basement 
membrane thickening. It would have been ideal to have measured MMP levels. 
However, shortage of funding limited us to only measuring TIMP-1.  MMP levels are 
altered in patients with diabetes. In type 1 diabetes patients MMP9 and TIMP-1 levels 
are elevated (Maxwell et al., 2001), whereas in patients with type 2 diabetes MMP2 
and TIMP-1 levels are elevated (Lee et al., 2005). Another study demonstrated an 
elevated level of MMP9 and TIMP-1 in type 2 diabetes (Tayebjee et al., 2004). 
Therefore, elevated TIMP-1 levels in type 1 diabetes patients could also be due to 
increased MMP levels. Another smaller study showed that only MMP2 and MMP9 
levels are altered and that there is no change in TIMP-1 levels in type 1 diabetes 
(Kolset et al., 2009). MMP has been shown to have dual action. In addition to its pro-
angiogenic action, it has been shown to suppress angiogenesis through the generation 
of angiostatin (Chung et al., 2006). This imbalance between MMP and TIMP-1 is 
thought to play a major role in the development of vascular complications in patients 
with diabetes mellitus.  
 
We have shown that TIMP-1 was inversely correlated with cECs and positively 
correlated with the PAC adhesion function (Appendix A). These findings are in contrast 
to our hypothesis and the available evidence. TIMP-1 has been shown to inhibit 
endothelial cell migration in in vitro studies. This is mediated through MMP dependent 
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and MMP independent pathway (Akahane et al., 2004).  These need to be assessed 
in a larger cohort of patients with type 1 diabetes. 
 
There is increasing evidence that TIMP-1 plays a major role in the development of 
diabetic nephropathy. miR-21 is speculated to be involved in the pathogenesis of 
diabetic nephropathy via the down-regulation of MMP and upregulation of TIMP-1 
(Wang et al., 2013a).  
 
In a large population-based study, TIMP-1 levels have been shown to be elevated in 
individuals with CVD risk factors. Furthermore, TIMP-1 is associated with increased 
left ventricular mass, thickness and reduced function. TIMP-1 levels are elevated in 
patients with CAD and it is linked with poor prognosis in patients with established CVD 
(Lubos et al., 2005; Cavusoglu et al., 2006). TIMP-1 is related to CV mortality and 
strokes in elderly men (Hansson et al., 2011).  
 
Given the above evidence, high TIMP-1 levels in type 1 diabetes can be inferred as a 
marker of ongoing vascular dysfunction. Further work needs to be conducted to 
explore whether the reduction of TIMP-1 leads to a decrease in the development of 
diabetes-related complications. ACE-inhibitors have been shown to reduce TIMP-1 
levels in patients with hypertension (Laviades et al., 1998). Improvement in metabolic 
control has been shown to improve levels of TIMP-1 (Tayebjee et al. 2004). Around 
half of our patients have been on a statin, ACE inhibitors and aspirin. Thus, this may a 
give lower baseline TIMP-1 level in our TG. Insulin has been shown to have no effect 
on TIMP-1 levels. 
 
We have for the first time shown that 8 weeks of metformin treatment reduced TIMP-1 
levels in type 1 diabetes patients to levels similar to healthy volunteers. This may be 
important as it rebalances vascular repair signals. We have shown that a physiological 
dose of metformin reduced TIMP-1 levels in vitro under the condition of 
hyperglycaemia and hypoxia combined. In addition, there is increased tube formation. 
This effect is not replicated under euglycaemic or euglycaemia and hypoxia condition 
(Bakhashab et al., 2016). Interestingly, there is an inverse correlation between 
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changes in levels of TIMP-1 and the PAC adhesion function. Thus, a greater decrease 
in TIMP-1 levels results in an increased PAC adhesion function. Furthermore, there is 
a positive correlation between changes in HDL levels and TIMP-1 levels. As mentioned 
before, HDL levels decreased significantly after metformin treatment. There is some 
evidence linking high HDL cholesterol with a higher risk of a coronary event. This is an 
evolving area and further research is needed to get clearer evidence. Other high-risk 
markers including increased inflammatory markers like CRP and interleukins are 
discussed below.  
 
Given all the evidence, we believe that the reduction of TIMP-1 levels after 8 weeks of 
metformin treatment alters the balance more towards vascular repair and 
angiogenesis. This is independent of glycaemic control. We believe our current work 
and previously published research (Bakhashab et al., 2016) will be validated in in vivo 
settings. Furthermore, there is a need to design outcome studies to explore 
whethersustained reduction of TIMP-1 levels can lead to reduced diabetes-related 
complications.  
 
6.10.2 Inflammatory cytokines 
 
6.10.2.1 hs-CRP 
 
CRP is an acute phase protein raised in an inflammatory condition (Amit Kumar 
Shrivastava, 2015). A hyperglycaemic state in diabetes mellitus leads to the 
development of an inflammatory microenvironment. CRP levels are higher in patients 
with diabetes when compared to non-diabetic individuals (Mahajan et al., 2009). In our 
study, median levels of plasma hs-CRP are significantly higher in type 1 diabetes 
patients.  Our data is similar to a previous type 1 diabetes study showing elevated CRP 
levels in adults with known type 1 diabetes.  
 
CRP levels have been demonstrated to be related with HbA1c and BMI (King et al., 
2003; Kao et al., 2009). We have also shown a positive association between CRP 
levels and BMI. Indeed, it is established that CRP is higher in overweight and obese 
when compared to normal weight controls (Kao et al., 2009). Weight loss has been 
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shown to reduce CRP levels (Selvin et al., 2007). CRP levels have been shown to rise 
prior to the onset of type 1 diabetes, type 2 diabetes and gestational diabetes (Pradhan 
et al., 2001; Wolf et al., 2003; Chase et al., 2004). Despite the body of evidence 
demonstrating high CRP levels in type 1 diabetes patients, (Erbagci et al., 2002) 
showed that CRP levels in children with type 1 diabetes are non-significantly higher 
when compared to the control group. This could be due to lower BMI and insulin 
resistance in type 1 diabetes as compared to type 2 diabetes. 
 
CRP is a marker of ongoing low-grade vascular inflammation. It is established as a 
novel risk marker of development of CVD in healthy individuals (Ridker  et al., 2002; 
Ridker et al., 2003). CRP is a prognostic marker in patients with ischaemic heart 
disease (Pietllä et al., 1996). Evidence that CRP plays a role in the development of 
CVD in addition to be a marker of inflammation remains controversial. It is not clear 
whether CRP causes the development of vascular damage or is a byproduct of ongoing 
vascular damage. In young individuals with type 1 diabetes increased CRP levels are 
linked to early stages of carotid atherosclerosis (Hayaishi-Okano et al., 2002).  
 
CRP has been demonstrated to increase expression of other inflammatory cytokines 
like IL-6, IL-8 and TNF-α (Ballou and Lozanski, 1992). CRP has been shown to 
increase the expression of vascular injury markers like sICAM-1, sVCAM, etc (Pasceri 
et al., 2000). We have demonstrated a very strong positive correlation between CRP 
and sICAM-1. CRP is involved in extenuating infiltration of monocytes into the vessel 
wall (Torzewski et al., 2000). In vitro studies have shown that CRP impairs EC and 
EPC function, and increases cEC and EMP numbers (Verma et al., 2004a; Devaraj et 
al., 2011). Our data showed an inverse correlation between CRP and PAC adhesion 
function (Appendix A). However, ex vivo experiment have not shown similar results. 
(Fasing et al., 2014) demonstrated that in healthy individuals CRP levels do not 
correlate with the ability of EPC to form colonies, migrate, undergo apoptosis and 
release angiogenic factors. Therefore, there is a need to explore and clarify if CRP 
levels play a role in EPC function in vivo.  
 
We explored whether metformin treatment will reduce CRP levels in type 1 diabetes. 
We showed that metformin did not have any effect on CRP levels in type 1 diabetes. 
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This could be due to the shorter duration of the treatment and it may be that a longer 
duration of therapy is needed. Furthermore, our study was not powered to explore the 
effect of metformin in type 1 diabetes. In a randomised controlled trial using 850mg BD 
of metformin, Stocker and team (Stocker et al., 2007) demonstrated unchanged CRP 
levels after 24 weeks of metformin treatment in type 2 diabetes. It was possible that 
CRP levels could have been reduced if a full dose of metformin (2 grams per day) had 
been used.  In their meta-analysis, Shi et al., 2014 concluded that metformin reduced 
CRP levels in type 2 diabetes. We have no evidence of the effect of metformin in 
T1DM. Therefore, a longer duration of study is needed to to establish whether 
metformin can reduce CRP levels in T1DM.  
 
6.10.2.2 TNF-α and Interleukins 
 
Diabetes mellitus is associated with chronic low-grade inflammation. This is in part 
linked to insulin resistance and metabolic syndrome, especially in type 2 diabetes. 
Hyperglycaemia plays an important role in the development of chronic inflammation. 
We demonstrated that levels of TNF-α, IL-6 and IL-8 were higher in type 1 diabetes 
when compared with healthy controls. This is in line with previous evidence showing 
increased inflammatory markers in type 1 diabetes.  
 
We explored the effect of metformin on inflammatory cytokines. To our knowledge, this 
is the first study exploring the effect of metformin on inflammatory markers in type 1 
diabetes. Metformin treatment did not improve  IL-8, TNF-α and IL-10 levels in type 1 
diabetes. The major finding in our study is a significant reduction of IL-6 after 8 weeks 
of metformin treatment. 
 
Our data has demonstrated an increased ongoing inflammatory process in type 1 
diabetes. We have shown all three markers to be elevated in individual with type 1 
diabetes even with good diabetes control. Sibal et al. (2009) showed an increase in 
CRP and IL-6, whereas TNF-α levels were unchanged in young individuals with type 
1 diabetes. IL-6 and TNF-α levels have been shown to be high in T1DM (Targher et 
al., 2001; West et al., 2015).  The EURODIAB study showed increased circulatory IL-
6 and TNF-α levels in type 1 diabetes with complications (Schram et al., 2003b). 
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Similarly, IL-8 levels have been shown to be higher in type 1 diabetes when compared 
to the healthy control (Lo et al., 2004). In contrast, (Purohit et al., 2015) in a large 
population study, demonstrated that IL-8 levels are lower in type 1 diabetes. TNF-α, 
IL-6 and IL-8 are implicated in the pathogenesis of diabetes related complications 
(Şavli et al., 2002; Gonzalez-Clemente et al., 2005; Navarro et al., 2006; Zorena et al., 
2007; Lee et al., 2008; Shelbaya et al., 2012).  
 
Elevated inflammatory markers are linked to CVD and CVD risk. (Dragut et al., 2014) 
demonstrated that increased IL-6 and TNF-α are linked with increased CVD risk in 
patients with metabolic syndrome and type 2 diabetes. (Tuomisto et al., 2006) 
concluded that TNF-α is an independent predictor of CVD in men only. IL-6 and TNF-
α are associated with poor prognosis in patients with CAD (Ridker et al., 2000a; Su et 
al., 2013). Similarly, IL-8 has been shown to be elevated in patients with CAD (Romuk 
et al., 2002). TNF-α, IL-6 and IL-8 have been linked with the development of 
atherosclerosis (Apostolopoulos et al., 1996; Ait-Oufella et al., 2011). IL-6 has been 
associated with endothelial dysfunction in type 1 diabetes (Sibal et al., 2009a). 
Similarly, TNF-α has been shown to play a role in the development of endothelial 
dysfunction (Picchi et al., 2006). Our data complemented the above-mentioned studies 
and demonstrated a positive association between IL-6 and the markers of endothelial 
injury, sVCAM-1 and EMPs.  
 
In summary, our data complement the available evidence showing increased 
inflammatory markers in patients with type 1 diabetes.  
 
IL-10 is well established as an anti-inflammatory cytokine (Murray, 2005). It has been 
shown to have anti-atherogenic properties especially in animal models (Mallat et al., 
1999). Given the increased inflammatory markers in type 1 diabetes, one can 
hypothesise that levels of the anti-inflammatory cytokine, IL-10 will be lower. Contrary 
to our hypothesis, we have demonstrated increased circulatory IL-10 levels in type 1 
diabetes when compared with healthy volunteers.  
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IL-10 has been shown to be lower in patients with type 2 diabetes (van Exel et al., 
2002). Levels of IL-10 have been shown to be even lower in patients with 
microalbuminuria (Pestana, 2016). In contrast, IL-10 levels are similar in patients with 
type 1 diabetes and healthy controls, whereas patients with type 1 diabetes and 
nephropathy had increased IL-10 levels (Mysliwska et al., 2005). The difference 
between the results of our study and that of Mysliwska et al., 2005 can be explained 
by the assay used and data interpretation. Mysliwska et al., 2005 included data even 
when it was below the threshold and unmeasurable. The MSD assay used in our study 
was able to measure IL-10 in all the subjects.  Higher IL-10 levels in our study could 
be a compensatory response to increased inflammatory conditions to counteract high 
IL-6, TNF-α, IL-8 and CRP. IL-10 has been shown to counteract the effect of IL-6 and 
TNF-α (Fiorentino et al., 1991). Similarly, Fichtlscherer et al., 2004 demonstrated that 
higher IL-10 levels improved EF in patients with CAD and counteracted ongoing 
inflammatory activity (Fichtlscherer et al., 2004).  
 
Against the background of pro-inflammatory melluli in type 1 diabetes, we 
demonstrated that, IL-6 levels were reduced by metformin treatment in type 1 diabetes. 
However, metformin did not reduce TNF-α, IL-8 and IL-10 in type 1 diabetes. Our 
results could be explained by the sample size. Our study was not powered to assess 
the effect of the above mentioned inflammatory cytokines. Our data could be 
meaningfully expanded to design a study with an appropriate sample size to answer 
whether metformin has any effect on TNF-α, IL-6, IL-8 and IL-10.  
 
Metformin has shown contradictory effects on inflammatory cytokines in PCOS and 
type 2 diabetes. (Mohlig et al., 2004; Kim et al., 2007a; Lund et al., 2008b; Pradhan et 
al., 2009; Lin et al., 2011; Xu et al., 2014). In vitro studies have shown the anti-
inflammatory effect of metformin. Metformin has been shown to increase IL-10 in an in 
vitro study (Kelly et al., 2015). As mentioned above, IL-10 levels in our study were 
significantly higher than healthy controls.  Therefore, there may not be enough capacity 
to increase IL-10 further.  
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6.10.2.3 Interferon-γ and Interferon gamma-induced protein 10 (IP-10) 
 
We have demonstrated that interferon-γ (IFN-γ) and IP-10 levels were similar in type 
1 diabetes and healthy volunteers. Eight weeks of metformin treatment did not change 
IFN-γ and IP-10 concentration in our treatment group.  
 
Levels of INF-γ in type 1 diabetes depends on the duration of diabetes. Levels of INF-
γ have been shown to be higher in patients with recent-onset type 1 diabetes (Hussain 
et al., 1996), whereas, INF-γ levels in patients with established type 1 diabetes have 
been shown to be similar to healthy controls (Hussain et al., 1996). IFN-γ is involved 
in the development of type 1 diabetes through β cell destruction. IFN-γ plays a role in 
progression or remission of type 1 diabetes. High levels of IFN-γ are associated with 
disease progression whereas low levels are associated with remission of diabetes 
(Alizadeh et al., 2006). Patients in our group hade type 1 diabetes for more than 20 
years. Therefore, complete β cell destruction had already occurred. Furthermore, 
glycaemic control was good. It is likely that IFN-γ levels reflect completed β cell 
destruction and good glycaemic control. Furthermore, it is likely that IL-10 mediated 
suppression of Th1 immune response. As discussed above, IL-10 levels were 
significantly higher in type 1 diabetes when compared to controls.  
 
IFN-γ acts on many types of cells, including monocytes, neutrophils and ECs, and 
induces production of IFN-γ inducible protein 10 (IP-10) (Luster and Ravetch, 1987; 
Cardozo et al., 2003). Other inflammatory cytokines like TNF-α can also induce the 
release of IP-10 (Gasperini et al., 1999; Narumi et al., 2001; Berthier-Vergnes et al., 
2005). IP-10 levels in our TG correlated with INF-γ and TNF-α.  
 
IP-10 is a pro-inflammatory chemokine that enhances adhesion of inflammatory cells 
to ECs. It has been shown to have anti-angiogenic properties (Yates-Binder et al., 
2012) IP-10 has been shown to inhibit EC migration and induces vessel regression 
(Bodnar et al., 2006; Bodnar et al., 2009). IP-10 levels are higher in patients with type 
1 diabetes. This conflicts with our data which showed no difference between circulatory 
IP-10 concertation in individuals with type 1 diabetes and healthy volunteers. The 
difference between our data and other studies could be mainly due to the duration of 
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diagnosis of type 1 diabetes. Most studies have been conducted on patients with a 
recent diagnosis of type 1 diabetes, whereas our cohort in the TG had an average 
duration of diagnosis of more than 20 years. IP-10 plays a role in the pathogenesis of 
type 1 diabetes. It could be that inflammatory mediated β cell destruction had waned 
completely in our TG. Furthermore, diabetes control in our TG was good. There is no 
correlation between HbA1c and IP-10 levels.  
 
IP-10 levels were associated with weight in our TG. This is consistent with the available 
evidence, which demonstrates increased IP-10 levels in patients with obesity. 
Circulatory levels have been shown to be higher in patients with diabetes mellitus 
patients with increased BMI (Dalmas et al., 2011). IP-10 levels have been associated 
with diabetes-related complications. Urinary IP-10 levels are associated with a decline 
in renal function. However, IP-10 levels are not associated with microalbuminuria 
(Wolkow et al., 2008).  
 
Eight weeks of metformin treatment non-significantly reduced IP-10 levels in type 1 
diabetes. Analysing the data, we could appreciate that data analysis may have yielded 
better information if our study was powered to explore the effect of metformin on IP-10 
levels. Therefore, there is a need to design a study with an adequate sample size and 
power to explore the effect of metformin on IP-10 levels in type 1 diabetes   
 
The mechanism for lowering IP-10 levels in type 1 diabetes by metformin needs to be 
explored. We hypothesise that NF-κB plays a role in regulating IP-10 release. NF-κB 
activity is increased in patients with diabetes (Andreasen et al., 2011). Increased NF-
κB activity is involved in macro- and microvascular complications in type 2 diabetes 
(Kassan et al., 2013). Metformin inhibits NF-κB activation by other pro-inflammatory 
cytokines like TNF-α (Hattori et al., 2006). NF-κB plays a role in hyperglycaemia 
induced IP-10 release. A decrease in activity of NF-κB attenuates IP10- release due 
to hyperglycaemia (Devaraj and Jialal, 2009).  
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6.10.3 Vascular injury markers 
 
Endothelial dysfunction is well established in young patients with type 1 diabetes 
before the development of overt CVD (Sibal et al., 2009). We explored plasma markers 
of ED in type 1 diabetes. The aim was to study the effect of metformin on plasma 
markers of EF in well-controlled type 1 diabetes mellitus. The biomarkers studied 
included sICAM-1, sVCAM-1, P-Selectin, E-Selectin and thrombomodulin. sICAM-1 is 
also a marker of low-grade inflammation. 
 
The major finding of our study was that none of the markers of ED were significantly 
higher in type 1 diabetes when compared to healthy controls. The circulatory level of 
P-Selectin, sICAM-1, sVCAM-1 and thrombomodulin were higher in type 1 diabetes 
but did not achieve statistical significance.  
 
We for the first time demonstrated that 8 weeks of metformin treatment improved 
thrombomodulin levels in type 1 diabetes. This finding is unique to our study.  
 
There is some conflicting data regarding P-Selectin and E-Selectin. Sibal et al., (2009) 
demonstrated elevated E-Selectin levels in young individuals with type 1 diabetes. 
However, Yngen et al., 2004 (Yngen et al., 2004) demonstrated that P-Selectin and E-
Selectin are not elevated in patients with type 1 diabetes without any microvascular 
insult. The difference between Yngen et al., 2004 and Sibal et al., 2009 data could be 
explained by diabetes control. Patients in Yngen et al., 2004 had tighter control as 
evidenced by HbA1c (Yngen et al., 2004 vs. Sibal et al., 2009: 6.5% vs. 8.5%). Our 
patients had tighter control, with HbA1c of 7.1%. In addition, our individuals with type 
1 diabetesshowed a positive correlation between HbA1c and E-Selectin and P-
Selectin. However, type 1 diabetes patients with good glycaemic control but with 
microvascular disease have elevated levels of P-Selectin and E-Selectin (Yngen et al., 
2004). Sibal et al., 2009 showed a direct correlation between E-Selectin and ED. Thus, 
it is likely that levels of E-Selectin and P–Selectin are not raised in individuals with type 
1 diabetes without overt endothelial dysfunction and microvascular complications.  
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Circulatory sICAM-1 and sVCAM-1 levels in type 1 diabetes have been shown to be 
similar to healthy volunteers (Clausen et al., 2000). Our data is complementary to the 
available evidence. Furthermore, biomarkers of ED have been shown to be associated 
with increased risk of CVD mortality in individuals with type 2 diabetes (de Jager et al., 
2006). sICAM-1 levels are associated with the development of diabetic nephropathy in 
type 1 diabetes.  It is important to note that overall glycaemic control in these patients 
was inferior to our patients (8.7% vs. 7.1%) (Lin et al., 2008). Similarly, this putative 
ED is associated with the development of diabetic nephropathy in type 2 diabetes 
(Koga et al., 1998; Bruno et al., 2008).  
 
The expression of ICAM-1 and VCAM-1 has been shown to be upregulated by 
inflammatory cytokines like CRP and TNF-α. An in vitro study has shown that CRP 
induces expression of adhesion molecules (ICAM-1 and VCAM-1) (Pasceri et al., 
2000). We have shown a direct correlation between CRP and sICAM-1 levels.  
 
Short-term metformin treatment (16 weeks) has been shown to reduce sVCAM-1 in 
type 2 diabetes (De Jager et al., 2005). When metformin was continued for more than 
4 years, the same group demonstrated that sICAM and sVCAM levels decreased 
significantly (De Jager et al., 2014). This effect on the above-mentioned biomarkers 
was independent of changes in glycaemic control and weight. In our study, metformin 
treatment did not change the levels of sICAM and sVCAM. This could be due to the 
shorter duration of treatment with metformin (8 weeks).  Our data suggests that 
metformin used in the short-term treatment of type 1 diabetes may not affect markers 
of ED. Longer-term treatment may show improvement in markers of ED. However, this 
will need to be evaluated in a longer trial.  
 
We have demonstrated that thrombomodulin levels were non-significantly higher in our 
type 1 diabetes and healthy volunteer group. This is in contrast to previous data which 
showed that thrombomodulin levels are elevated in type 1 diabetes and type 2 diabetes 
(Gabat et al., 1996). Levels were higher in individuals associated with diabetes-related 
complications (Oida et al., 1990). Higher levels in Gabat et al., 1995 could be explained 
by the fact that levels of thrombomodulin were higher in patients with increasing 
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numbers of diabetes related complications. In our study, the subjects studied did not 
have any evidence of diabetes-related complications. 
 
Thrombomodulin levels were directly associated with the EPC and 
CD45dimCD34+CD133+ numbers.  This is in line with available evidence that 
thrombomodulin is released by EPCs (Li et al., 2011a).  
 
We have for the first time demonstrated that 8 weeks of metformin treatment reduced 
thrombomodulin levels. The reduction in thrombomodulin levels could reflect 
decreased endothelial damage. (Strijbos et al., 2008)  demonstrated a direct 
correlation between cEC numbers and plasma levels of thrombomodulin. However, we 
have not shown any correlation between thrombomodulin levels or changes in 
thrombomodulin levels with any markers of endothelial damage. This could be due to 
the small number of subjects in our TG. This will need to be explored further in a larger 
trial.  
 
The reduction in thrombomodulin levels after 8 weeks of metformin treatment could be 
due to improvement in insulin sensitivity. Levels of thrombomodulin were related to 
insulin sensitivity in type 2 diabetes (Aso et al., 2001). The improvement in insulin 
sensitivity after metformin treatment in type 1 diabetes is likely to be small when 
compared to type 2 diabetes. However, the mechanisms by which metformin may 
reduce thrombomodulin levels in type 1 diabetes needs to be confirmed. 
 
6.10.4 Growth factors 
 
In our study, we have shown that in patients with type 1 diabetes with good glycaemic 
control, 1) VEGF and FGF levels are similar in type 1 diabetes and healthy volunteers, 
2) VEGF-D levels are significantly higher in type 1 diabetes when compared to healthy 
volunteers, and 3) metformin treatment did not result in any change in growth factor 
levels.  
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VEGF is a potent angiogenic growth factor involved in endothelial cell growth and 
proliferation (Waltenberger, 2009). VEGF levels are  elevated in type 2 diabetes (Lim 
et al., 2004). In patients with type 1 diabetes , VEGF levels are not elevated (Malamitsi-
Puchner et al., 1998). Our data is similar to Malamitsi-Puchner et al. 1998. However, 
levels of another family of VEGF, VEGF-D were elevated in our patients in the TG 
when compared with healthy control. In vitro work by our group has shown that VEGF 
receptors are downregulated in hyperglycaemic environments. This results in a 
compensatory increase in VEGF levels (unpublished data). VEGF-D acts on VEGFR-
3. VEGFR-3 is expressed by ECs. Therefore, we can speculate that VEGFR-3 is 
downregulated in the ECs of our TG participants, leading to increase an in VEGF-D.  
 
It has been shown that elevated levels of VEGF are involved in the pathogenesis of 
diabetes-related complications like retinopathy and nephropathy (Adamis et al., 1994; 
Santilli et al., 2001). Elevated VEGF levels in young type 1 diabetes patients without 
complications predict future development of microalbuminuria (Santilli et al., 2001). 
Plasma VEGF levels increase with worsening glycaemic control. Improving glycaemic 
control improved VEGF levels (Kakizawa et al., 2004). VEGF reduced in type 2 
diabetes after multifactorial intervention only in patients with CVD (Lim et al., 2004). 
Ersoy et al., 2008 demonstrated that metformin treatment for 12 weeks improved 
VEGF levels in obese patients with type 2 diabetes. In this study, HbA1c and BMI 
improved significantly but were not associated with VEGF (Ersoy et al., 2008). We 
have shown in an in vitro study that hyperglycaemia raised VEGF-A levels (Bakhashab 
et al., 2016). However, metformin exposure did not lead to a reduction in VEGF-A 
levels. Metformin treatment in our type 1 diabetes group did not decrease VEGF levels. 
 
So, in summary, VEGF-A levels are non-significantly higher in our group. Furthermore, 
VEGF-D levels are significantly higher in our TG. Thus, we can infer that our TG were 
at risk of development of a diabetes-related complication. Furthermore, our in vitro 
study (Bakhashab et al., 2016) and current work demonstrate that metformin may not 
affect VEGF levels.  
 
FGF levels are low in healthy volunteers (Larsson et al., 2003). FGF levels are elevated 
in patients with type 2 diabetes with microalbuminuria (Zimering et al., 1996) and are 
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a marker of CVD risk in type 2 diabetes (Zimering et al., 2013). Levels of FGF can be 
a marker of increased risk for CAD in type 2 diabetes patients (Zimering et al., 2011). 
Levels of FGF are increased in CVD (Katinioti et al., 2002). In young patients with type 
1 diabetes, levels of FGF are not elevated (Malamitsi-Puchner et al., 1998). Similarly, 
in our study levels of FGF were not elevated. It is likely that in individuals with type 2 
diabetes without complications, FGF levels are not elevated. However, this will need 
to be confirmed in a trial looking at FGF levels in patients with type 1 diabetes and 
diabetes-related complications. 
 
We also demonstrated that metformin did not have any effect on FGF levels in type 1 
diabetes. It is likely that our cohort had lower FGF levels. Thus, metformin may not be 
able to reduce it further. In addition, it is likely that metformin may not have any effect 
on FGF levels. This will need to be confirmed in in vitro and in vivo studies.  
 
6.11 Summary  
 
We evaluated sixteen cytokines in our study. They can be divided into the matrix 
metalloprotease inhibitor (TIMP-1), inflammatory cytokines, vascular injury cytokines 
and growth factors. TNF-α, IL-6, CRP, IL-8, INF-γ, IL-10 and IP-10 play an important 
role in inflammatory processes. Except for IL-10, all the cytokines are pro-
inflammatory. IL-10 has anti-inflammatory properties. The vascular injury markers 
studied included E-Selectin, P-Selectin, sVCAM, sICAM and thrombomodulin. The 
growth factors studied included bFGF, VEGF, VEGF-D. TIMP-1 is an inhibitor of MMP, 
thereby playing an important role in EPC mobilisation.  
 
Increased levels of inflammatory cytokines, VEGF-D and TIMP-1 levels in type 1 
diabetes 
Our study complemented previous work and demonstrated that inflammatory cytokines 
(IL-6, TNF, CRP and IL-8) were significantly elevated in patients with type 1 diabetes. 
Even after Bonferroni correction, levels of CRP and IL-8 were significantly elevated. 
The presence of chronic inflammation in type 1 diabetes would lead to vascular 
damage and development of vascular disease. 
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We demonstrated that levels of vascular markers (E-Selectin, P-Selectin, sICAM, 
sVCAM and thrombomodulin) were not elevated. Our finding complemented previous 
work demonstrating similar levels of vascular markers in patients with good overall 
glycaemic control (Yngen et al., 2004). With sub-optimal control, it has been shown 
that E-Selectin was elevated in patients with type 1 diabetes (Sibal et al., 2009).  
 
We have demonstrated that bFGF and VEGF levels were similar in type 1 diabetes 
and healthy controls. Interestingly, we demonstrated that VEGF-D levels were higher 
in type 1 diabetes when compared to healthy control.  We speculated that VEGF-D in 
our type 1 diabetes was elevated due to down-regulation of VEGF-D receptors 
(VEGFR-3). This will need to be confirmed by analysing whether VEGFR-3 levels are 
lower in type 1 diabetes.  
 
TIMP-1 levels were elevated in our patients with type 1 diabetes when compared to 
healthy controls. This could lead to poor recruitment of EPCs from bone marrow (Liu 
and Velazquez, 2008). In addition, increased TIMP-1 levels will decrease MMP activity 
(Brew and Nagase, 2010). This will lead to thickning of the basement membrane and 
development of diabetes related complications (Bai et al., 2006). However, there is a 
need to explore the effect of TIMP-1 in type 1 diabetes. 
 
Metformin treatment reduced IL-6, IP-10, TIMP-1 and thrombomodulin levels in 
type 1 diabetes 
We evaluated the effect of metformin on a wide array of cytokines in type 1 diabetes. 
We demonstrated that 8 weeks of metformin treatment significantly reduced TIMP-1, 
IP-10, IL-6 and thrombomodulin levels in type 1 diabetes. From our results, we can 
infer that metformin may have an effect in reducing inflammatory conditions in type 1 
diabetes. This could potentially lead to reduced vascular damage. We demonstrated 
that thrombomodulin, a marker of vascular damage, was also reduced after metformin 
treatment. Other markers of vascular damage, sICAM, sVCAM and E-Selectin, were 
not reduced. In addition, we demonstrated that metformin significantly reduced TIMP-
1 levels. We could infer that reduction in TIMP-1 levels may lead to increased EPC 
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mobilisation. We have demonstrated that cEPC levels were higher after metformin 
treatment. However, there was no correlation between changes in TIMP-1 and cEPC 
levels. We also evaluated our data after Bonferroni correction. Only the reduction in 
thrombomodulin levels after metformin treatment retained significance. This could be 
due to the smaller sample size. Our study was not powered to evaluate the effect of 
metformin on cytokines in type 1 diabetes. This is one of the limitations which should 
be taken into consideration in evaluating our data.  Therefore, our data could be 
meaningfully used to design a study with adequate power to explore the effect of 
metformin on cytokines in type 1 diabetes.  
 
Our work has added important information regarding the effect of metformin on 
cytokines independent of glycaemic control. We have identified cytokines that may play 
a role in the pathways which may be modified by metformin. Future studies are needed 
to explore the effect of metformin on inflammatory pathways. 
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7 Chapter 7: Effect of metformin on gene expression of peripheral 
blood mononuclear cells 
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7.1 Introduction 
 
Peripheral blood mononuclear cells (PBMCs) consist of a group of blood cells which 
are characterised by a round nucleus. PBMCs consist of two major cells type: 
lymphocytes and monocytes. Lymphocytes include T lymphocytes (T cells), natural 
killer cells (NK cells) and B lymphocytes (B cells) (Saša Končarević, 2014). Both 
lymphocytes and monocytes play an important role in providing immunity (Saša 
Končarević, 2014). NK cells provide cell-mediated and innate immunity (Paust and von 
Andrian, 2011). T cells provide cell-mediated and adaptive immunity. B cells provide 
antibody driven adaptive immunity (Walter et al., 2002a). Monocytes are the largest 
PBMC and play an important role in both the innate and adaptive immune responses. 
Monocytes can differentiate into macrophages (Leon and Ardavin, 2008; Parihar et al., 
2010).  
 
PBMCs play a central role in providing body protection. They mount an immune 
response to destroy pathogens. However, in addition to this protective role, PBMCs 
can contribute to the damage of the human body. PBMCs are central to driving the 
inflammatory response needed for the development and progression of 
atherosclerosis.  The old dogma for the development of atherosclerosis included the 
passive deposition of lipids in blood vessel walls (Libby et al., 2002). We now know 
that in addition to lipids, inflammation plays a major role in the development of 
atherosclerosis. Both lymphocytes and monocytes are involved in the pathogenesis of 
vascular damage and atherosclerosis (Moore and Tabas, 2011; Hedrick, 2015).  
 
7.1.1 Role of monocytes in development of atherosclerosis 
 
A number of different stimuli such as hyperglycaemia can lead to endothelial cells (EC) 
injury and activation of ECs. ECs produce adhesion molecules like E- and P-Selectin 
(Blankenberg et al., 2003). Activated ECs produce chemoattractants like MCP-1, 
endothelin-1, etc. and pro-inflammatory cytokines like TNF-alpha, IL-6 and IL-8 (Lucas 
and Greaves, 2003; Bobryshev, 2006). This leads to recruitment of monocytes at the 
site EC injury. Monocytes attach to the damage EC via selectin adhesion molecules. 
Firm attachment of monocytes requires another family of adhesion molecules: VCAM-
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1 and ICAM-1. Monocytes transmigrate across the endothelium into sub-endothelial 
space (Mestas and Ley, 2008; Moore and Tabas, 2011).  
 
Once the monocytes are in sub-endothelial space, they can differentiate into 
macrophages and dendritic cells (Johnson and Newby, 2009; Paulson et al., 2010). 
Macrophages can accumulate lipid especially LDL cholesterol and develop into foam 
cells (Brown et al., 1980). Lipid-rich foam cells and dendritic cells accumulate in the 
area of EC damage leading to the progression of atherosclerosis. Continued 
accumulation leads to the development of fibrous plaque. The central area of the 
plaque leads to the formation of the necrotic core due to increased cell death. Cellular 
debris and lipid continue to accumulate within the core, thereby increasing the size. 
Atherosclerotic plaques continue to grow due to continued recruitment of monocytes 
and differentiation to foam cells (Reviewed by (Bobryshev, 2006; Moore and Tabas, 
2011) (Figure 93).  
 
 
Figure 80: Role of monocytes in development and progression of atherosclerosis.  
Adapted from Moore and Tabas 2012 
 
 
 
293 
 
7.1.2 Role of lymphocytes in atherosclerosis 
 
Lymphocytes encompass three major cells. T lymphocytes, B lymphocytes and natural 
killer cells (NK). They play a major role in atherosclerosis (Wigren et al., 2012).  
 
B lymphocytes have a pleiotropic function. B lymphocytes have been shown to be anti-
atherogenic. In a splenectomy mouse model, increased atherosclerosis has been 
demonstrated. The spleen is a reservoir of B lymphocytes (Caligiuri et al., 2002). B 
lymphocyte-deficient mice model has shown that hypercholesterolaemia increased 
development of atherosclerosis (Major et al., 2002). B lymphocytes mount antibody 
response preventing the development of atherosclerosis. In addition, IgM antibody 
against oxidised LDL have been shown to be anti-atherogenic (Tsimikas et al., 2007). 
However, recently B lymphocytes have been shown pro-atherosclerotic properties (Ait-
Oufella et al., 2010; Kyaw et al., 2010). B lymphocytes role in atherosclerosis is still 
under investigation (Tsiantoulas et al., 2015). 
 
The role of T lymphocytes in atherosclerosis appears to be more complex. A subset of 
T lymphocytes are pro-atherogenic (Th1 and Th17) and another subset anti-
atherogenic. (Th2 and Treg). Th1 cells related cytokines like INF-γ have been shown 
to be in greater quantity in atherosclerotic plaque (Frostegård et al., 1999). Th1 have 
been shown to increase atherosclerosis (Buono et al., 2005).  The role of Treg has 
been well established in atherosclerosis especially in an animal model. Decrease in 
Treg has been shown to increased development of atherosclerosis (Mallat et al., 2003; 
Ait-Oufella et al., 2010). Similarly, NK cells have been shown to have pro-
atherosclerotic properties (Li et al., 2015).  
 
 
7.1.3 Role of PBMC in diabetes-related complications 
 
Diabetes mellitus is associated with increased risk of vascular complications. In 
addition, inflammation has been shown to play a vital role in the pathogenesis of 
diabetes-related complications. PBMC, as discussed above plays a critical role in the 
development of atherosclerosis. There is increasing evidence that PBMCs are involved 
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in the generation of the inflammatory condition. Hyperglycaemia has been shown to 
mediate the increase in monocyte adhesion to EC (Kim et al., 1994). Diabetes mellitus 
patients have shown to have increased adhesion of monocytes to EC (Carantoni et al., 
1997). Monocytes adhesion to EC has been demonstrated be related to the diabetes 
control (Cipolletta et al., 2005). The proatherogenic activity of monocytes has been 
shown to be increased in diabetes mellitus (increased superoxide anion, IL1β and 
increased adhesion) (Devaraj and Jialal, 2000).  
  
Macrophages and lymphocytes have been shown to be increased in glomeruli in 
diabetes mellitus patients (Lim, 2014). T cell infiltration in type 1 diabetes was 
correlated with albuminuria and renal function (Moriya et al., 2004). In an animal model, 
T-reg cell (anti-inflammatory cells) has been shown to protect against the development 
of albuminuria (Eller et al., 2011).  
 
Hyperglycaemia have been shown to effect PBMC cytokine production and function. 
PBMC’s from patients with type 1 diabetes has been shown to be in inflammatory state 
when cultured. TNF and IL-10 levels were higher in supernatant of PBMC culture from 
patients with type 1 diabetes when compared to healthy control (Foss-Freitas et al., 
2009). Interestingly, PBMC’s from patients with type 1 diabetes had poor response to 
activation by LPS compared to healthy control (Foss et al., 2007). This meant that 
PBMC’s in patients with type 1 diabetes have poor immune response leading to 
increased incidence of infection.  
 
There is no evidence on the effect of metformin on PBMC in patients with type 1 
diabetes. In individual with pre-diabetes, eight weeks of metformin treatment increased 
expression of genes involved in regulation of longevity, thereby counteract accelerated 
ageing (Vigili de Kreutzenberg et al., 2015). However, metformin treatment increased 
insulin sensitivity and decreased weight significantly. Therefore, metabolic factor could 
have played a part in modulation of gene expression (Vigili de Kreutzenberg et al., 
2015). This will need to be confirmed in future studies. Most in vitro studies have used 
supra-physiological doses of metformin in their experiment. Metformin in supra-
physiological concentrations reduced production of pro-inflammatory cytokines. 
Similarly, metformin (supra-physiological concentration) did not have any effect on 
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proliferation of non-stimulated PBMC (Djordjic et al.).  Our group explored the effect of 
metformin on CD34+ cell (extracted from PBMCs). We demonstrated that metformin 
at physiological concentration had an inhibitory effect on genes of pro-inflammatory 
factors like IL-6 and IL-8 (Bakhashab et al., 2017). 
 
7.2 Specific aim 
 
We aimed to evaluated if eight weeks of metformin treatment had an effect on the 
kinase and inflammatory gene expression of PBMCs in patients with type 1 diabetes 
when compared to healthy control.  
 
7.3 Methods 
 
7.3.1 Selection of subjects for gene expression 
 
We only selected subjects from TG and HC. SG was not included. This was due to 
limitation of funding. In TG, we aimed to select samples from patients not taking any 
medications for primaryprevention. Statin and ACE inhibitors have been shown to have 
an effect on gene expression of PBMCs (Wibaut-Berlaimont et al., 2005). Subjects in 
HC group were selected based on them being matched with TG. Subject’s clinical and 
metabolic characteristics are presented in Table 27.  
 
7.3.2 Total RNA extraction 
 
PBMCs were isolated after ficoll preparation. Ficol preparation was discussed earlier. 
Cells were plated for PAC. The cells which were left were used for RNA extraction. 
Approximately, 5 X 106 cells were lysed using the Qiazol lysis reagent (Catalogue 
number: 79306). 700 µl was used to lyse the cells. The sample was vortexed and kept 
in the dark for 5 minutes to make sure that the samples were completely lysed. Lysed 
samples were stored at -800c. 
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The RNeasy® Mini kit was used for extraction of total RNA from the lysate. Ten μl β-
mercaptoethanol (β-ME) was added to 1 ml Buffer RLT. Buffer RLT with β-ME or DTT 
can be stored at room temperature for up to 1 month. Four volumes of ethanol (96–
100%) were added to Buffer RPE for a working solution. 
 
1 volume of 70% ethanol was added to the lysate and mixed well by pipetting. 700 μl 
of the sample, including any precipitate, was added to an RNeasy Mini spin column 
placed in a 2ml collection tube. The sample was centrifuged for 15 s at ≥ 8000 x g. 
Flow-through was discarded. 350 μl Buffer RW1 was added to the RNeasy spin 
column. The sample was centrifuged for 15 s at ≥8000 x g. Flow-through was 
discarded.  
 
10 μl DNase I stock solution was added to 70 μl Buffer RDD. This was mixed gently by 
inverting the tube. The mixture was centrifuged briefly. 500 μl Buffer RPE was added 
to the RNeasy spin column. This was then centrifuged for 15 s at ≥8000 x g. Flow-
through was discarded. 500 μl Buffer RPE was added to the RNeasy spin column. This 
was then centrifuged for 2 min at ≥8000 x g. RNeasy spin column was placed in a new 
2 ml collection tube. It was than Centrifuge at full speed for 1 min to dry the membrane. 
 
The RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 μl RNase-
free water was added directly to the spin column membrane. We then centrifuged for 
1 min at ≥8000 x g to elute the RNA. 
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7.3.3 nCounter gene expression 
 
nCounter Gene Expression assay is a highly novel multiplexed method which is 
sensitive and reproducible. It is based on Nanostring Technology. This includes digital 
detection and direct molecular barcoding of target molecules. Colour coded probe pairs 
are used. Probe pair consist of colour coded reporter probe (colour codes at 5’ end) 
and a capture probe (biotin on the 3’ end). Reporter probe carries the molecular code 
for detection. The capture probe is used for immobilisation. Both probes have 35-50 
base long target specific region. Once paired probe is added to the sample for 
evaluation of molecular target, data is collected using nCounter digital analyser. On 
reporter probe, seven positions are available for four colours to be used as barcodes. 
This gives availability of thousands of combinations (Figure 94).  
 
Figure 81: nCounter gene expression. Reporter and Capture probe. (Taken from Kyle Green 
presentation) 
 
Gene expression using the nCounter system was performed according to the 
manufacturer’s recommendations. Each sample was run as duplicates. The first step 
was hybridization of the code set to RNA. Reporter probe was added to the extracted 
total RNA. Capture probe set was added. The mixture was briefly spun down. The 
sample was placed on pre-heated 650C thermocycler and incubated overnight 
(minimum 12 hours and maximum 36 hours). Then the sample was loaded to the 
nCounter Prep Station. This step removes excess reporter, binds the reporter to the 
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surface and immobilises and aligns reporter probe. Next step was to load the 
processed sample to the nCounter Digital Analyzer for imaging and data analysis 
(Figure 95).  
 
Inflammatory and kinase Nano string panels were used.   These two-panel covered 
genes involved in pathways that play an important role in inflammation, vascular 
dysfunction and vascular repair. 
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7.3.4 Data Analysis  
 
Data was analysed using nSolver software and R. As per NanoString recommendation; 
the resultant data set was normalised. We used the code sets already present as 
internal positive controls. This was conducted to eliminate variability unrelated to 
sample. Inflammatory and kinase panels were analysed individually. However, only 3 
and nine genes were differentially expressed on the inflammatory and kinase panel, 
respectively in the treatment group (TG V1 vs. TG V2).  
 
We evaluated our data more globally and included both the kinase and inflammatory 
panels together in nSolver software. 28 genes overlapped between the two panels 
(Figure 96). Ten genes with lowest %CV from the overlapping genes were selected as 
housekeeping genes (Figure 97). Inflammatory and kinase datasets were normalised 
using housekeeping genes. Then we manually combined the datasets and calculated 
the fold change (FC) between treatment group (TGV1 vs TGV2) and between 
treatment group and healthy control (TGV1 vs HC and TGV2 vs HC). 
 
One treatment group pre-treatment sample gave an error during normalisation step. 
Therefore, we excluded the sample (both pre and post treatment) from the analysis 
(Figure 98 and 99). After exclusion of this sample, all other samples passed the quality 
control (QC) parameters. QC was performed by nSolver software using following 
parameters:   
• Imaging QC – A measure of the percentage of each lane that was successfully 
scanned. 
• Binding Density QC – A measure of barcode density on the scan surface. 
 
• Positive (POS) control linearity QC – A measure of how well the 6 synthetic POS 
control spike-ins form a dilution series. 
• POS control Limit of Detection QC – A measure of whether Positive control  
spike  in  E(POS  E)  is statistically detectable above the NEG control probes. 
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Figure 83:28 genes common in both kinase and inflammatory panel. 
 
 
 
Figure 84:10 gene used to normalise data in both kinase and inflammatory panel. 
Gene Name Accession #
CCL2 NM_002982
CLTC NM_004859
GAPDH NM_002046
GUSB NM_000181
HPRT1 NM_000194
MAP2K1 NM_002755
MAP2K4 NM_003010
MAP2K6 NM_002758
MAP3K1 NM_005921
MAP3K5 NM_005923
MAP3K7 NM_145333
MAP3K9 NM_033141
MAPK14 NM_001315
MAPK3 NM_001040056
MAPKAPK2 NM_004759
MAPKAPK5 NM_003668
MKNK1 NM_003684
PGK1 NM_000291
PRKCA NM_002737
PRKCB NM_212535
PTK2 NM_005607
RAF1 NM_002880
RIPK1 NM_003804
RIPK2 NM_003821
ROCK2 NM_004850
RPS6KA5 NM_004755
TGFBR1 NM_004612
TUBB NM_178014
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Figure 85: Inflammatory normalisation: 13 pre-treatment failed normalisation (high content 
normalisation) 
 
 
  
 
Figure 86:Kinase normalisation: TG V1 13 pre-treatment failed normalisation (high content 
normalisation) 
 
 
7.4 Statistical analysis 
 
We took advice from the statistician. We were advised that data should be corrected 
for multiple corrections using Benjamini-Hochberg (BH), False discovery rate (FDR). 
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7.5 Results 
 
This section discusses the results of the expression of 768 genes (519 kinase gene 
panel and 249 inflammatory gene panel). The results are presented in three main 
sections. The first section discusses the pre-treatment group (TG V1) compared to 
healthy control (HC). The second section discusses TG V1 compared to TG V2 (post 
treatment). The third section discussed TG V2 compared to HC.  
 
7.5.1 Treatment group (pre-metformin) versus healthy control 
 
Without FDR, seventy-one genes are differentially expressed in TG V1 when 
compared to HC. Gene list of p values and fold changes are provided in Table 28. 
Figure 100 depicts a volcano plot. Figure 101 shows a heat map of significant genes. 
Except for nine genes, all the significant genes are overexpressed in TG V1 when 
compared to HC.  
 
After analysing the data for multiple correction using FDR, none of the genes were 
differentially expressed.  
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Figure 87: Volcano plot comparing pre-treatment (TG V1) with HC. Horizontal line depicts p-value of 
0.05. Any gene above the line has a p value of <0.05 (non-corrected). Two vertical lines depicted fold 
change (-1.5 and +1.5). Significantly expressed genes are coloured in blue.  
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 Figure 101: Heat Map showing up and downregulation of genes between TG V1 vs. HC
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7.5.1.1 Ingenuity Pathway Analysis  
 
The complement system, the role of macrophages, fibroblast and endothelial cell, NF-
kB signalling complex and CCR3 signalling were upregulated significantly in TG V1 
when compared with HC. The Z score was more than 2 and these were above the 
threshold. Figure 102 demonstrates top 20 canonical pathway.  
 
ATP-γ-S, Lipopolysaccharide, interferon-α, ING-γ, BQ123 pathways were significantly 
upregulated (P<0.05). Lipopolysaccharide and Interferon-γ were predicted to be 
activated in TG V1 when compared with HC (Figure 103). 
 
The analysis predicted that there would be a significant increase in levels of LDH, CRP, 
Creatinine and alkaline phosphatase in TG V1 compared with HC (p<0.05) (Figure10 
4).  
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The major regulatory networks affected in TG V1 were CD40LG and NF-κB complex 
when compared with HC.  The affected networks increased activation of phagocytes. 
The analysis predicted that CD40LG, NF- κB, TNF and STAT-1 were activated (Figure 
105). Analysis of these networks predicted activation of PBMC chemotaxis, homing 
and phagocytosis (Figure 106). 
  
  
 
Figure 91: CD40LG, NF-kB, TNF and STAT1 was predicted to be upregulated in TG V1 vs. HC.  
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Analysis demonstrated that TNF, INF-γ, CD40L and CSF2 cytokines were significantly 
upregulated in TG V1 when compared to HC. The Inhibitor of Kappa Light Polypeptide 
Gene Enhancer In B-Cells (IKBKB) was also activated significantly in TG V1 compared 
with HC (Z-score ≥ 2) (Figure 107).  
 
In TG V1, the inflammatory response, post-translational modification, cell death and 
survival, cellular movement and cell to cell signalling and interaction, immune cell 
trafficking, cell-mediated immune response, humoral immune response were 
significantly upregulated when compared with HC. It was predicted that TG V1 had 
increased adhesion of immune cell, inflammatory response, leukocytes chemotaxis 
and immune response of leukocytes. (Figure 108 to 111).
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Figure 94: Adhesion of immune cells upregulation in TG V1 compared to HC. 
 
Figure 95: Chemotaxis of leukocytes upregulation in TG V1 compared to HC. 
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Figure 96: Inflammatory response upregulation in TG V1 compared to HC. 
 
 
Figure 97: Immune response of leukocytes upregulation in TG V1 compared to HC. 
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Below figure 112 to 116 demonstrate heat maps of cellular function. Orange 
demonstrates upregulation. Blue demonstrates downregulation and grey 
demonstrates no pattern of predicted regulation. 
 
 
 
Figure 98: Inflammatory response heat map. 
 
 
Figure 99: Immune cell trafficking heat map. 
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Figure 100: Cell mediated immune response. 
 
 
Figure 101: Cell movement heat map. 
 
 
Figure 102: Cell to cell signalling heat map. 
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We performed analysis for links with disease markers and cellular function. Based on 
the z-score (≥2), TG V1 had increased chemotaxis, homing, movement, adhesion and 
activation of PBMC compared to HC (Figure 117). 
 
 
Figure 103: Disease and function annotation. Only Z score of greater than 2 is included. 
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7.5.2 Treatment group (pre metformin) versus treatment group (post 
metformin) 
 
Eleven genes were differentially expressed in TG V2 when compared to TG V1 (Table 
29). The list of genes with p values and fold changes are provided in Table 7. Figure 
118 depicts volcano plot. Figure 119 shows a heat map of significant genes. Except 
for three genes, all the significant genes were overexpressed in TG V2 when compared 
to TG V1. After analysing the data for multiple correction using FDR, none of the genes 
were differentially expressed.  
 
 
 
Figure 104: Volcano plot is comparing post-treatment (TG V2) with pre-treatment (TG V1). Horizontal 
line depicts p-value of 0.05. Any gene above the line has a p value of <0.05. Two vertical lines 
depicted fold change (-1.5 and +1.5). Significantly expressed genes are coloured in blue.  
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Gene 
Name 
Post 
vs. 
Pre 
FC 
Post vs. 
Pre p-
val 
q value 
RAPGEF2 -1.15 0.003285 2.3 
SPEG -2.35 0.008645 3 
STK3 1.45 0.015063 3.5 
KNG1 -3.02 0.024251 4.2 
CCR7 -1.46 0.032895 4.6 
CXCL9 2.26 0.033285 3.9 
MAP3K9 -1.47 0.034378 3.4 
MAFK -1.5 0.0373 3.2 
IFNG 1.31 0.037935 2.9 
MAPKAPK2 -1.27 0.047785 3.3 
DDIT3 -1.99 0.049269 3.1 
 
Table 29: Significant gene expression in TG V2 when compared with TG V1; q value represents false 
discovery rate corrected values. 
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7.5.2.1 Ingenuity Pathway Analysis  
 
The critical canonical pathways significantly affected by metformin in TG were 
communication between innate and adaptive immune cells, p38 Mitogen-activated 
protein kinase (MAPK) signalling, crosstalk between dendritic cells and NK cells (figure 
120). However, the z-score did not point toward upregulation and downregulation 
(Figure 121).  
 
Metformin treatment significantly affected INF-γ, p38 MAPK, RELA, SOD2 and TLR9. 
However, none of the upstream regulators could predict if there was activation or 
deactivation based on the Z-score. The maximum activation score was 0.468 (Figure 
122) (Activation: Z score should be ≥ 2; Deactivation: Z score should be ≤ -2).  
 
Metformin treatment significantly affected the inflammatory response, cellular 
movement, cell morphology, cell death and survival, cell to cell signalling, cell-
mediated immune response and immune cell trafficking. However, the Z score was not 
greater or less than 2. The genes affected by metformin treatment could not predict 
activation of any specific network or pathway.  
 
It was predicted that metformin treatment in TG reduced chemotaxis whereas 
phosphorylation of protein was increased (Figure 123 and 124 respectively).  
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Figure 109: Predicted decreased chemotaxis of PBMC in TG V2 vs. TG V1.  
 
 
Figure 110: Predicted increased phosphorylation of protein in TG V2 vs. TG V1.  
(Orange is upregulation and blue is down-regulation) 
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7.5.3 Treatment group (post metformin) versus healthy controls 
 
Thirty-one genes were differentially expressed in TG V2 when compared to healthy 
controls. The list of genes with p values and fold changes are provided in Table 30. 
Figure 125 depicts a volcano plot. Figure 126 shows a heat map of significant genes. 
Except for ten genes, all the significant genes were under expressed in TG V2 when 
compared to HC.  
 
After analysing the data for multiple correction using FDR, none of the genes were 
differentially expressed.  
 
 
 
Figure 111: Volcano plot is comparing post-treatment (TG V2) with healthy control (HC). Horizontal 
line depicts p-value of 0.05. Any gene above the line has a p value of <0.05. Two vertical lines 
depicted fold change (-1.5 and +1.5). Significantly expressed genes are coloured in blue. 
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Gene 
Name 
Post vs. Ctl 
FC 
Post vs. Ctl p-
val 
q 
value 
LMTK2 -1.49 0.001836 1.27581 
DYRK1A -1.36 0.002171 0.75435 
PAK2 -1.18 0.00439 1.01697 
STK17A -1.36 0.005414 0.94076 
PDIK1L -1.32 0.006547 0.9101 
IL15 1.44 0.006633 0.76838 
CD55 1.9 0.006789 0.67403 
PRKD3 -1.44 0.007045 0.612 
CDK7 -1.33 0.007262 0.56081 
PSKH2 5.74 0.008233 0.57218 
TIE1 3.36 0.009365 0.59172 
STK4 -1.24 0.010795 0.6252 
MST4 -1.46 0.01132 0.6052 
ITK -1.26 0.01204 0.59768 
HPRT1 -1.24 0.016025 0.7425 
RIOK3 -1.52 0.018937 0.82256 
SNRK -1.52 0.024433 0.99887 
PLA2G4A 1.79 0.027556 1.06397 
MAP3K6 2.79 0.033321 1.21886 
PXK 1.3 0.034712 1.20624 
NRBP1 -1.17 0.037039 1.22581 
GNB1 -1.18 0.038726 1.22339 
HDAC4 1.39 0.04169 1.25975 
BRD4 -1.2 0.042494 1.23056 
TLR2 1.54 0.043047 1.19669 
MARK4 -1.19 0.044631 1.19303 
NEK6 1.74 0.044851 1.1545 
CPNE3 -1.24 0.045624 1.13246 
PEAK1 -1.17 0.048384 1.15955 
WEE1 -1.41 0.04917 1.13911 
RYK -1.23 0.049959 1.12004 
 
Table 30: Significant genes in TG V2 compared with HC; q value represents false discovery rate 
corrected values. 
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7.5.3.1 Ingenuity Pathway Analysis  
 
eNOS and B cell receptor signalling were affected significantly in TG V2 when 
compared to HC (p<0.05) (Figure 127). There was a trend towards reduced B cell 
receptor signalling TG V2 when compared with HC. Even though eNOS activity was 
significantly affected, no activity pattern could be elucidated (Figure 128).  
 
IL-10 was significantly up-regulator in TGV2 compared to HC. TNF, INF-γ and IL1B 
were significantly downregulated in TG V2 when compared with HC. However, none 
of the Z-score reached ≥ 2 (Figure 129).  
 
The inflammatory response, post-translational modifications, cell death and survival, 
cellular assembly and organisation, cellular function and maintenance and cell to cell 
signalling and interaction were significantly different in TG V2 when compared with HC. 
There was a trend towards negative Z scores. However, none of the Z-scores for the 
relevant cellular functions reached ≥ 2or ≤ -2 (Figure 130).  
 
The heat map demonstrated a decreased inflammatory response, immune cell 
trafficking, cell-mediated immune response, cell to cell signalling in TG V2 when 
compared with HC. Post-translational modification was upregulated in TG V2 when 
compared with HC. (Figure 131 to 135). Orange demonstrates upregulation, blue 
demonstrates downregulation, grey demonstrates no pattern of predicted regulation. 
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Figure 116: Disease and function annotation. 
    
 
 
Figure 117: Inflammatory response heatmap. 
 
 
Figure 118: Immune cell trafficking heatmap. 
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Figure 119: Cell-mediated immune response especially cellular movement heatmap. 
 
 
Figure 120: Cell to cell signalling heatmap. 
 
Figure 121: Post-translational modification heatmap. 
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It was predicted that EC death, immune cells adhesion, leukocytes chemotaxis, the 
inflammatory response and synthesis and quantity of ROS would be decreased and 
angiogenesis increased in TG V2 compared to HC. (Figure 136 to 143- Blue depicts 
downregulation and orange depicts upregulation).  
 
Figure 122: Predicted downregulation of cell death of EC. 
 
 
Figure 123: Predicted upregulation of angiogenesis in TG V2 when compared with HC.  
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Figure 124: Predicted down-regulation of adhesion of immune cell in TG V2 compared to HC.  
 
 
 
Figure 125: Predicted downregulation of chemotaxis of leukocytes in TG V2 when compared with HC.  
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Figure 126: Predicted down-regulation of the immune response of leukocytes in TG V2 compared with 
HC.  
 
 
Figure 127: Predicted down-regulation of the inflammatory response in TG V2 compared with HC. 
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Figure 128: Predicted down-regulation of synthesis of reactive oxygen species in TG V2 compared 
with HC. 
 
Figure 129: Predicted down-regulation of the quantity of reactive oxygen species in TG V2 compared 
with HC. 
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7.5.4 MAP kinase pathway 
 
Multiple pathways can be analysed to provide predicted up- or down-regulation of 
genes using KEGG pathway. R software (The statistical programming software) was 
used to provide prediction of activation or suppression of the pathway. MAP kinase 
was chosen as it was predicted to be affected. Furthermore, the MAP kinase pathway 
plays an important role atherosclerosis (Fisk et al., 2014).  
 
We analysed the effect of significantly expressed genes in group TG (TG V2 vs. TG 
V1) on MAP kinase pathway. 
 
Metformin treatment was predicted to downregulate genes in both the classical and 
p38 MAP kinase pathways in TG (Figure 144).  
 
 
Figure 130: Predicted MAP kinase regulation comparing TG V2 vs. TG V1. Blue means down-
regulation and red means upregulation.  
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7.6 Discussion 
 
PBMCs from selected TG and matched HC were analysed using the nCounter 
technology to explore the differential gene expression profile. RNA from the treatment 
group PBMC were analysed before and after metformin treatment (TG V1 and TG V2) 
to study the effect of metformin on PBMC gene expression. After FDR, none of the 
genes were differentially expressed. Non-corrected analysis showed that seventy 
genes were differentially expressed in TG V1 compared to HC. All but nine genes were 
overexpressed. Metformin treatment altered gene expression of eleven genes in TG. 
Out of this, three were downregulated. After metformin treatment, thirty-one genes 
were differentially expressed when compared to HC. Out of these, ten genes were 
under-expressed.  
 
After correcting for multiple testing (Benjamini-Hochberg -BH: FDR), none of the 
differential gene expression was significant. We did not set a limit on the fold changes 
(FC) greater than or equal to +/-1.5. Our TG group had good diabetes control as 
defined by HbA1c levels and these did not change with metformin treatment. 
Therefore, we needed to study PBMC gene expression in larger number of TG and 
HC. 
  
It is of great interest to evaluate if metformin can alter gene expression in T1DM 
individuals with good diabetes control and to this end we used IPA to evaluate and 
analyse predicted targets and pathways. In TG at baseline, differentially expressed 
genes predicted the activation of INF-γ, NF-κB, TNF-α and IKBKB. All of these 
processes increased chemotaxis, adhesion, migration and the inflammatory response 
of the PBMC in T1DM compared to HC. Our cytokines data of increased CRP and 
TNF-α levels in TG V1 compared to HC complimented our gene expression analysis. 
Our gene expression data has demonstrated that in T1DM, the PBMC has an 
increased tendency towards inflammation. The increase in inflammation has been 
reported to play an important part in vascular damage and atherosclerosis (Libby et 
al., 2002).  
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NF-κB was also predicted to be upregulated in TG V1. NF-kB plays a vital role in 
inflammation, angiogenesis and apoptosis (Ghosh and Hayden, 2008). We have 
shown that the CD40 ligand (CD40L) was predicted to be upregulated. CD40L is known 
to activate NF-kB pathway (Coope et al., 2002).  Activation of NF-κB pathway has been 
shown to increase expression of proinflammatory cytokines, such as IL-6, IL-8 and 
TNF-alpha and anti-inflammatory cytokines IL-10 (Monaco et al., 2004; Pamukcu et 
al., 2011). We have shown that all of these cytokines are increased in the plasma of 
our TG at baseline. NF-kB has also been shown to increase adhesion molecules in EC 
(Chen et al., 1995). These are important in driving the inflammatory response and the 
development of atherosclerosis. In vitro studies have demonstrated that the NF-κB 
pathway is activated by hyperglycaemia (Yerneni et al., 1999). NF-κB plays a role in 
diabetes-related complications such as retinopathy and nephropathy (Patel and 
Santani, 2009). The NF-κB pathway has been shown also to be activated in IHD 
patients (Liuzzo et al., 2007). NF-κB pathway activation has been shown to be involved 
in the pathogenesis of atherosclerosis from a very early stage (de Winther et al., 2005). 
Animal studies have shown that inhibition of the NF-κB pathway may reduce the 
inflammatory response and EC adhesion expression (Ferrante et al., 2006). Inhibition 
of the NF-κB could provide a novel mechanism in preventing the development of 
atherosclerosis.  
 
Evaluation of gene expression after metformin treatment predicted a decrease in 
leukocytes chemotaxis and increased protein phosphorylation. Phosphorylation of 
proteins in the AMPK pathway leads to activation of this pathway. This is one of the 
known effects of metformin. Metformin treatment in TG did demonstrate alteration in 
the MAP kinase pathway. However, IPA pathway analysis did not support either 
positive or negative regulation.  MAP kinase is discussed in next section. 
 
Comparison of gene expression between TG V2 and HC predicted reduced 
inflammatory and increased angiogenic responses, as demonstrated by increased IL-
10 expression. IPA pathway analysis predicted reduced inflammatory response, 
reduced oxidative stress and increased angiogenesis.  
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If we compare TG V1 vs. HC and TG V2 vs. HC, it can be seen that individuals with 
T1DM have increased inflammatory signals when compared to HC. Metformin 
treatment shifts this focus towards reduced inflammation and improved angiogenesis.  
 
We evaluated 14 subjects for gene analysis (8 from TG and 6 from HC). If we had 
included more subjects, than we could have increased the power of our analysis. 
Furthermore, we did not evaluate upstream and downstream markers effected by the 
genes. However, our data can be used to evaluate specific genes and their upstream 
and downstream effectors.  
 
7.6.1 Predicted KEGG pathway affect in PBMCs by metformin treatment: MAP 
kinase  
 
KEGG pathway analysis demonstrated that metformin treatment reduces the MAP 
kinase pathway activity in PBMC in TG. This may have potential implications in the 
reduced inflammatory activity of PBMCs. MAP kinase pathway is known to increase 
pro-inflammatory cytokine activity by increasing production of IL-1 and TNF-α (Lee et 
al., 1994). It may be that decreased activity of MAP kinase pathway reduced the PBMC 
mediated vascular damage. Also, the MAP kinase pathway has been implicated in the 
differentiation of monocytes into macrophages (Ayala et al., 2000). Furthermore, it 
plays a critical role in the transformation of macrophages into foam cells (Zhao et al., 
2002). Furthermore, the fraction of PBMC constitutes potential EPCs. MAP kinase 
activity is implicated in the survival of EPC. Inhibition of MAP kinase has been shown 
to increase EPCs survival. Furthermore, inhibition of MAP kinase activity in EPCs has 
been shown to increase angiogenesis in an ex vivo ischaemic animal model (Seeger 
et al., 2005).  
 
7.6.2 Overall assessment 
 
We have shown that PBMCs in type 1 diabetes patients has the increased tendency 
towards inflammation compared to healthy control. NF-kB pathway likely plays an 
important role in increasing the inflammatory signals. 
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Metformin treatment in type 1 diabetes patients with good glycaemic control likely 
moves the focus towards reduced inflammation. In addition, inhibition of MAP kinase 
in PBMCs by metformin may play a significant role in decreased vascular damage by 
PBMC.  
 
Our results need to be confirmed by exploring the effect of physiological concentration 
of metformin on MAP kinase activity in the PBMCs. This can be extended further by 
exploring the effect of metformin-treated PBMCs on EC.
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8 Chapter 8: General discussion and recommendation 
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8.1 General discussion  
 
MERIT Study is an open-label observation study aiming to explore the effect of 
metformin on circulatory biomarkers in individuals with T1DM independent of the 
glycaemic control. Metformin is one of the first oral DM medications with cardio-
protective properties. However, limitedresearch has been conducted to evaluate its 
cardio-protective effects in T1DM. Our study addressed an unmet area of research and 
evaluated early response to metformin on established biomarkers of CVD risk in 
patients with T1DM. So far, no study has addressed if metformin has clinical efficacy 
on biomarker established to prevent the development of early CVD in patients with 
T1DM. Recently, REMOVAL trial has demonstrated that metformin might reduce the 
progression of atherosclerosis in type 1 diabetes. Unfortunately, REMOVAL study was 
underpowered to demonstrate positive effect of metformin on CIMT in type 1 diabetes 
(Petrie et al., 2017). However, REMOVAL study has not addressed if metformin can 
affect early biomarkers of vascular damage and repair. Our proof of concept study’s 
primary outcome is an evaluation of the effect of metformin on cEPCs (biomarkers of 
vascular repair). The secondary outcome of MERIT study included exploring the 
influence of metformin on circulatory biomarkers representative of vascular repair and 
damage. Below, we summarise our major findings based on our hypothesis. 
 
 
 
We showed that cEPCs were lower in T1DM compared with HC. Metformin treatment 
significantly increased cEPCs.  
 
 
 
We showed that cECs were higher in T1DM compared with HC. Metformin treatment 
significantly decreased cECs in TG.  
 
 
Hypothesis 1: Metformin therapy improves the number and function of EPCs in 
T1DM when controlled for euglycaemia. 
 
Hypothesis 2: Metformin improves cECs in T1DM when controlled for 
euglycaemia. 
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We demonstrated that EMPs, PMPs, LMPs, CD34+ and cEPC MPs were higher in 
T1DM compared with HC. All the MPs remained unchanged after metformin treatment. 
 
 
 
 
We evaluated two angiogenic miRNAs: miR-126 and miR-210. miR-126 levels were 
similar in TG and HC. Plasma miR-126 levels remained unchanged after metformin 
treatment.  
 
Plasma miR-210 levels were significantly higher in TG when compared to HC. 
Metformin treatment reduced plasma miR-210 levels in TG.  
 
 
 
We evaluated plasma miR-21a, miR-92a, miR-195, miR-222, miR-223 and miR-320 
levels in our participants.  
Plasma miR-222 levels were significantly higher in TG when compared to HC. 
Metformin treatment reduced plasma miR-222 levels in TG.  
Plasma miR-195 levels were significantly higher in TG when compared to HC. 
Metformin treatment reduced plasma miR-195 levels in TG.  
Plasma miR-223 levels were significantly higher in TG when compared to HC. Plasma 
miR-21a levels in TG remained unchanged after metformin treatment.  
Plasma miR-320 levels were significantly higher in TG when compared to HC. Plasma 
miR-320 levels in TG remained unchanged after metformin treatment.  
Hypothesis 3: Metformin improves circulatory MPs in T1DM when controlled for            
euglycaemia. 
 
Hypothesis 4: Metformin increases angiogenic miRNA when controlled for 
euglycaemia. 
 
Hypothesis 5: Metformin decreases anti-angiogenic miRNA when controlled for 
euglycaemia. 
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miR-92a levels were similar in TG and HC. Plasma miR-92a levels remained 
unchanged after metformin treatment.  
 
 
 
We evaluated plasma TIMP-1 levels in our participants. TIMP-1 levels were higher in 
TG when compared to HC. Metformin treatment significantly reduced TIMP-1 in TG. 
 
 
 
We measured E-Selectin, P-Selectin, sICAM-1, sVCAM-1, sICAM-3 and 
thrombomodulin in plasma of our participants. All the marker levels were similar in TG 
and HC. Only thrombomodulin reduced significantly in TG after metformin treatment.  
 
 
 
We measured CRP, TNF-α, IL-6, IL-8, IP-10, INF-γ and IL-10 in plasma of our 
participants. Except for IP-10 and INF-γ, all other inflammatory markers were raised in 
TG when compared to HC. Metformin treatment reduced plasma IL-6 and IP-10 levels 
significantly while CRP, TNF-α, IL-8, INF-γ and IL-10 remained unchanged in TG.  
 
 
 
We measured bFGF, VEGF and VEGF-D in plasma of our participants. Plasma bFGF 
and VEGF levels were similar in TG and HC. VEGF-D levels were higher in TG when 
compared to HC. Plasma levels of these growth factors did not change after metformin 
treatment.  
 
Hypothesis 9: Metformin increases angiogenic cytokines when controlled for 
euglycaemia. 
controlled for euglycaemia. 
 
Hypothesis 8: Metformin decreases inflammatory cytokines when controlled for 
euglycaemia. 
controlled for euglycaemia. 
 
Hypothesis 7: Metformin decreases cytokines representative of vascular injury 
markers when controlled for euglycaemia. 
 
controlled for euglycaemia. 
 
Hypothesis 6: Metformin increases cytokines related to EPC mobilisation when 
controlled for euglycaemia 
 
350 
 
 
 
 
 
 
 
Nanostring gene expression analysis of PBMCs demonstrated that metformin 
treatment did not alter the gene expression of inflammatory and kinase gene in type 1 
diabetes. Analysis of non-corrected data had shown that individuals with T1DM had 
increased tendency toward inflammation. Furthermore, metformin treatment 
demonstrated a tendency toward reduced inflammatory signal in PBMC in TG. This is 
likely to be mediated via MAP kinase.  
 
Data generated from MERIT Study demonstrated that metformin may have positive 
clinical implication in preventing CVD in patients with T1DM by rebalancing the 
emphasis in their management from limiting damage alone to also improving vascular 
repair. cEPC, a marker of vascular repair increased significantly. In addition, there was 
a significant reduction in cEC numbers (vascular injury marker). Metformin treatment 
not only improved the level of cEPCs in T1DM but also brought PACs number/ 
adhesion and CFU-Hill colonies closer to the HC levels. We have been able to 
demonstrate this in T1DM individual with good overall diabetes control. Furthermore, 
this effect is generated without improvement in a variable of glycaemic control i.e. 
HbA1c and glucose variability.  
 
Improvement in cEPC numbers could be mediated via increased survival, 
differentiation and/or mobilisation from bone marrow. It is likely all these processes 
contribute to this. We have shown that PAC adhesion function improved significantly. 
It is likely that similar mechanism is involved in increased survival. KEGG pathway 
analysis of gene expression data of PBMC demonstrated reduction in activity of MAP 
kinase pathway. PACs are a very small fraction of cells of PBMC. Similarly, cEPCs are 
Hypothesis 10: Gene expression profile of PBMC from T1DM patient 
demonstrates increased inflammatory signals compared to healthy volunteer. 
 
Hypothesis 11: Metformin will shift the gene expression profile of PBMC in T1DM 
towards decreased inflammation.  
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a cells derived from PBMCs. It is likely, reduced activity of MAP kinase by metformin 
treatment improved cEPC and PAC survival and function. Indeed, inhibition of MAP 
kinase activity has been shown to improve PAC survival and angiogenesis function 
(Seeger et al., 2005).  Our data provides an insight into the differentiation of CD34+ 
cells into cEPCs. 4 weeks of metformin treatment increased CD34+ cells, cEPC 
numbers did not increase. However, at 8 weeks CD34+ cell numbers reduced back to 
baseline whilst cEPC numbers increased. It may be that there was increased 
differentiation of CD34+ cells into cEPCs. Improvement in cEPC numbers is also likely 
due to increase in cEPC mobilisation. The possible mechanism may be mediated by 
reduction of TIMP-1 as seen in our study. TIMP-1 is known to inhibit matrix 
metalloproteinases in bone marrow, thereby limiting EPC mobilisation. Reduction in 
TIMP-1 would allow bone marrow matrix to allow for EPC mobilisation. However, this 
will need confirmation. 
 
We have assessed EMPs, PMPs, LMPs, CD34+ MPs and cEPC MPs in our 
participants except for SG (due to change in assay). Metformin treatment did not result 
in change in MP concentration in TG. It might be that metformin did not have any effect 
on MP generation. It could be that metformin may shift the focus of MP function toward 
maintaining vascular homeostasis. There is extensive evidence that MPs play an 
important role in inflammation, coagulation and endothelial dysfunction. It is important 
to note that MPs can have both deleterious and beneficial effects on vascular 
haemostasis (Figure 145). MPs are a conduit for exchange of biological information. In 
addition, MPs can serve as protective mechanism whereby harmful products like 
oxidative stress markers produced by cells are released via generation of MPs. If these 
oxidative stress markers remained in the cells, it will cause damage. In vitro experiment 
had shown that ECs exposed to statin at physiological relevant concentration released 
more EMPs. However, more EC remained viable when exposed to statin. It was noted 
that oxidative stress marker (Caspase 3) laden MPs were increased (Diamant et al., 
2008). Thus, there is a need to explore if metformin changes the MPs content rather 
than numbers or move the balance toward vascular homeostasis.  
We explored selected angiogenic and anti-angiogenic plasma miRNA levels. Major 
finding is significant reduction of anti-angiogenic plasma miRNA levels after metformin 
treatment. It may be likely those anti-angiogenic signals are reduced by metformin, 
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thereby shifting the focus towards angiogenesis. Metformin treatment did not affect 
plasma miR-126 levels. However, there was significant reduction in plasma miR-210 
levels. Both, miR-126 and miR-210 have angiogenic properties. High miR-210 levels 
have been linked with development of atherosclerosis. Reduction in miR-210 levels 
after metformin treatment is suggestive of reduced signals for development of 
atherosclerosis. However, this hypothesis is speculative. Further work is needed to 
understand the effect on angiogenic and anti-angiogenic miRNAs and its upstream 
regulator and downstream regulators.  
PBMC plays a critical role in development of atherosclerosis. This is mediated via 
multiple mechanisms including increased generation of inflammation. Metformin 
treatment shifted predicted gene expression profile towards reduced inflammatory 
tendency. In contrast, plasma inflammatory cytokines except for IL-6 did not decrease 
with 8 weeks metformin treatment. There is a need to explore the effect of metformin 
on inflammation and vascular damage over longer duration. 
 
 
Figure 131: Proposed role of microparticle in vascular homeostasis. 
Adapted from (Tushuizen et al., 2011) 
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8.1.1 Limitations of our study 
 
In this section, we will discuss overall limitations of our work. Major limitation of MERIT 
study was that it was a non-randomised trial. MERIT study was designed as an open 
label proof of concept study. Therefore, there is a need to design a randomised 
controlled trial to explore the effect of metformin on primary CVD outcomes in type 1 
diabetes. At this current moment, no randomised trial has been conducted in patients 
with type 1 diabetes exploring the effect of metformin on primary CV outcomes. Data 
generated from our work can be used to design randomised trials of longer duration in 
order to repurpose this widely used T2DM drug, for patients with T1DM (Bromage and 
Yellon, 2015). Our work can be supplemented by exploring the effect of metformin 
treatment on oxidative stress markers in T1DM.   
 
MERIT study was limited by small sample size. However, it was adequately powered 
to evaluate the primary outcome. Our participants had heterogeneous features with a 
wide range of diabetes duration and age. This can also be seen as an advantage to 
improve generalisability of the results of our study. CGMS was not perfomed in SG. 
This can introduce bias as we could not access glucose variability. However, SG 
overall glycaemic control did not change as assessed by HbA1c. Furthermore, glucose 
variability should not be affected as SG was not given any treatment. Furthermore, 
home blood glucose readings were evaluated to make sure that overall profile 
remained unchanged. In TG, CGMS was performed at the beginning and middle of the 
study and not at the end of the study. However, CGMS in the middle of the treatment 
phase was done at the maximum dose of tolerated metformin. Therefore, it is 
representative of metformin effect on blood glucose levels. 
 
MPs and gene expression was not undertaken in SG. MPs could not be analysed in 
SG due to changes made in the LSR machine. This meant that data from SG could not 
be compared reliably with TG and HC data. Lack of funding prevented us from 
analysing gene expression in SG group.  
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8.2 Future work 
 
8.2.1 Animal study 
 
As discussed earlier that DM is associated with bone marrow dysfunction. It is 
speculated that it leads to impaired mobilisation of EPCs from bone marrow to vascular 
tissue. We propose to conduct an animal study to answer two important questions: 
1. Is diabetes associated with impaired mobilisation of EPCs from bone marrow to 
vascular tissues? 
2. Does metformin improve mobilisation of EPC from bone marrow to vascular 
tissue? 
 
We propose to study type 1 diabetes mice model (C57BL/6), aged 8 to 9 weeks. There 
will be six different groups of mice with five animals in each group. The experiments 
will be performed in triplicates in order to validate the results. Therefore, the final 
number of animals studied in each group will be 15. Six groups (Table 6) are: 
1) Control non-diabetic mice,  
2) non-diabetic mice treated with metformin,  
3) control mice treated with vehicle (citrate buffer control for STZ injection),  
4) diabetic mice (streptozocin (STZ) induced),  
5) STZ mice treated with insulin (insulin will be used to aim for euglycaemia state).   
6) STZ mice treated with insulin + MF (we will use the same dose of MF of 40mg/kg/day 
and the dose of insulin will be adjusted so the level of glycaemia will be comparable 
with animal group  
 
STZ will be injected intraperitoneally in a single dose of 187.5 mg/kg dissolved in sterile 
citrate buffer. All animals will undergo validated (Home Office) clinical scoring system 
with tail tip blood glucose testing. Weekly IPGTT (1.5g/kg) fasting and stimulated 
samples will be done for sensitive insulin (ELISA). Mice with a blood glucose level > 15 
mmol/l will be considered diabetic. We will use glargine insulin (50u/kg) as previously 
described (Dong et al., 2011). 
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The dose of metformin will reflect the dose used in patients (40mg/kg/day). The initial 
study will be set up to establish with few mice (n=6) that low dose of metformin does 
not lower significantly glucose levels in control mice and that comparable euglycaemia 
is achieved between the diabetic animals using insulin and insulin and metformin. We 
anticipate that that low dose of metformin will not alter significantly glucose levels in 
mice treated with metformin alone and that the dose of insulin required may be reduced 
in STZ mice treated with insulin and metformin. 
 
EPCs defined as CD34/VEGFR+2, Lin – ( CD23, CD11b, Ter 119, and CD45) can be 
measured in bone marrow, peripheral circulation and aorta (by FACS) in all groups 
using protocols established by us and others (Sibal et al., 2009b; Shakoor et al., 2010) 
(Zengin et al., 2006; Khoo et al., 2009). 
 
Angiogenesis assay can be performed using aortic ring culture assay (Zengin et al., 
2006). Fragments of the aorta will be cut into 1 mm thick rings and embedded between 
two layers of special collagen gel (Invitrogen) (Zengin et al., 2006). Rings will be 
evaluated for angiogenesis every day using a phase contrast microscope. In 3 
experiments, rings will be fixed and embedded in paraffin for immunohistochemistry. 
The immunohistochemical analysis will be performed before and after the ring assay 
using antibodies recognising endothelial and precursor cell markers CD34, CD31, 
CD45, CD105, CD133, CD68, von Willebrand Factor, TIE2 VEGFR2, VEcadherin, 
smooth-muscle-actin. 
 
Cytokines like SDF-1, VEGF, VEGFR, leptin, adiponectin, MM9, TIMP-1 and 
inflammatory cytokines in blood at the end of the experiment and compare with EPC 
number and angiogenesis in all groups of animals (MSD multiplex assay/ELISA). We 
anticipate that MF will have additional effect on cytokine secretion to the effect of STZ 
and influence angiogenesis.   
 
Plan mentioned above is summarised in Table 31. 
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Animal group/assay Control Control 
& MF 
Mice & 
citrate 
STZ  
DM 
mice 
STZ DM 
mice & 
Insulin 
STZ  
DM &  
insulin 
& MF 
EPCs in BM x x x x x x 
EPCs in blood x x x x x x 
EPCs in aorta x x x x x x 
angiogenesis (aorta) x x x x x x 
Insulin/glucose/cytokines x x x x x x 
 
Table 31: Plan of animal experiments; streptozocin-treated (STZ), metformin (MF), diabetic (DM) mice. 
 
 
8.2.2 Clinical study 
 
In our proof of concept MERIT study, we have established important preliminary data.  
Our work can meaningfully be extended to design a randomised controlled trial. Any 
work should include plans to explore mechanistic pathways. We propose a randomised 
controlled trial that will answer following questions: 
1. Do cEPCs improve significantly with metformin treatment? 
2. Does metformin improve endothelial function? 
3. Does change of cEPC correlate with changes in endothelial function? 
4. Do changes in cytokines determine the response of cEPCs? 
5. Do changes in miRNAs determine the response of cEPCs? 
6. Do cECs improve significantly with metformin treatment? 
7. Does change of cECs correlate with changes in endothelial function? 
8. Does metformin changes microparticles constituents? 
 
We propose a multicentre, double-blind randomised placebo controlled trial using 
metformin versus placebo. Participants are to be randomised to receive either 
metformin or placebo for duration of 12 months. Inclusion and exclusion criteria are 
similar to MERIT Study (Table 1). The only difference will be the inclusion of T1DM 
patients with an HbA1c of ≤ 82 mmol/mol.  
The study design is explained in Figure 146. Briefly, the participant will go through 8 
weeks running in phase. Clinical, vascular and biomarkers will be assessed at 0, 6 and 
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12 months post randomisation. Further clinical assessment will be undertaken at 1, 4 
and 7 months.   
 
Protocol for enumeration of cEPC and cEC is well established by our group. 
Enumeration of microparticles will need further development. Cytokine array will be 
measured in plasma by MSD platform. miRNA will be assessed using NGS (Exiqon). 
We had a problem with the machine continuously. Endothelial function assessment 
can be conducted via pulse wave velocity (aortic stiffness).  
 
This randomised controlled trial is aimed to confirm our proof of concept open label 
study and provide definitive data regarding the clinical efficacy of cEPCs in assessing 
early response to metformin treatment. This trial will also assess the size of effect whilst 
comparing with the functional improvement of endothelial function. Furthermore, we 
will be able to answer if metformin, an inexpensive drug can reduce early CVD in young 
T1DM individual. 
3
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8.3 Conclusions 
 
In summary, the data presented in this thesis has shown for the first time that metformin 
treatment may provide cardiovascular benefit by increasing markers of vascular repair 
(cEPCs, CFU-Hill Colonies, and PACs,) and reducing markers of vascular damage 
(cECs and anti-angiogenic miRNA). A pivotal study by Werner and colleagues (Werner 
et al., 2005) demonstrated that CVD events are lowest in the group with higher levels 
of cEPCs. We believe that a 75% rise in cEPCs number in T1DM patients, as 
mentioned in chapter 4 of this thesis, might equate to the reclassification of our T1DM 
patients into a lower CVD risk group. This might equate to an approximate reduction 
of CVD risk by 23% as presented by Werner and collegues  (Hazard Ratio of 0.77) 
(Werner et al., 2005). If this decrease in CVD risk can be achieved in T1DM patients 
with good control, we believe that metformin may further reduce the CVD risk in T1DM 
patients with suboptimal control. However, this will need to be confirmed by large 
randomised a controlled trial examining cardiovascular events.
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